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Abstract 
Exploring hyperbranched Polydendron Chemistry and Architecture for Nanomedicine 
Applications 
 
The introduction of amphiphilicity into hyp-polydendrons has been achieved for the first 
time through the use of tertiary amine functional dendritic chain-ends and branched 
hydrophobic polymer chains. Explorations into the chemistry and architectural 
components within the hyp-polydendron structure has been carried out, offering the 
opportunity to control both structural and chemical behaviour. These have included: 
variation of the chemical composition of the primary polymer chain; utilisation of 
different monomers within the polymerisation; variation of dendron surface and linker 
chemistry; variation of primary chain architecture to produce statistical and block 
copolymers; variation of the degree of polymerisation; and initiation by multiple 
initiators (dendron and non-dendron) to result in mixed surface groups on the hyp-
polydendron. The synthesis and aqueous nanoprecipitation of these branched materials is 
compared with their linear–dendritic polymer analogues, showing that the chemical and 
structural variables are all capable of influencing the ability to generate nanoparticles, 
the resulting nanoparticle diameter and dispersity, and subsequent response to changes 
in pH. 
 
The incorporation of the monomer, 2-(diethylamino)ethyl methacrylate, and a new acid-
cleavable brancher has resulted in the preparation of pH-responsive nanoparticles that 
undergo solubilisation upon the addition of acid. Additionally, the hydrolysis of 
aggregated nanoprecipitates into linear-dendritic polymer chains has been confirmed by 
gel permeation chromatography, and encouraging encapsulation and release studies 
demonstrate a promising platform for pH-responsive drug delivery vehicles. 
 
The co-nanoprecipitation of linear-dendritic hybrids with branched copolymers has 
produced stable nanoparticle dispersions. Comparative nanoparticle behavioural studies, 
and consequent response to changes in pH have been conducted between co-
nanoprecipitated nanoprecipitates in aqueous media to similarly composed hyp-
polydendron nanoprecipitates containing covalently-bound dendron chain-ends. 
 
The dye molecule fluoresceinamine has been selected as a model guest molecule for 
encapsulation (9 wt%) within certain nanoparticles which were stable under 
physiologically-relevant conditions. Cytotoxicity and transcellular permeability studies 
were carried out using Caco-2 cells, showing low cytotoxicity at the concentrations 
studied, enhanced permeation though the Caco-2 cell monolayer, and high accumulation 
in Caco-2 and ATHP-1 cells. 
 
Finally, the ring opening co-polymerisation of ε-caprolactone and 4,4’-bioxepanyl-7,7’-
dione using dendron initiators was explored. This resulted in stable ε-caprolactone 
nanoprecipitates formed in aqueous media, from biodegradable polyester hyp-
polydendrons. To the best of our knowledge, this is the first example of stabilised p(CL) 
nanoparticles in aqueous solution, without the need for additional stabilisers. 
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1.1?Human Immunodeficiency Virus 
Human immunodeficiency virus (HIV) currently affects approximately 38.1 million 
people in the world, with sub-Saharan Africa being the most severely affected, accounting 
for 70% of the people living with HIV worldwide (Figure 1.1). In the same year, 1.2 
million people died of acquired immunodeficiency syndrome (AIDS)-related illnesses.1 
Figure 1.1 Number of people estimated to be living with HIV in 2014, taken from ref. 1 
The HIV virus persists within cellular and tissue sanctuary sites that have poor drug 
permeation, such as macrophages.2 Failure to penetrate these sites is associated with 
discordance in viral kinetics and the evolution of resistant viruses. 
1.1.1 HIV infection 
HIV is a ribonucleic acid (RNA) retrovirus that exists in 2 forms – HIV-1 and HIV-2. Both 
are responsible for human AIDS, with the latter being almost entirely confined within 
West Africa. HIV interacts mainly with cytotoxic T lymphocytes (CD8* T cells) and 
CD4+ helper T lymphocytes. Cytotoxic T lymphocytes directly kill virally infected cells 
and produce and release antiviral cytokines. Once within the cell, HIV is integrated within 
the host deoxyribonucleic acid (DNA), undergoing transcription and generating new 
virions when the cell is activated. There are a large number of mutations daily at each site 
in the HIV genome, resulting in the virus escaping recognition by the original cytotoxic 
lymphocytes.3 This depletes the function of the T cells that act against all the mutations 
and, along with the death of the CD4+ helper cells, is what causes the immune system to 
fail. 
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1.1.2 Anti-Retroviral Therapy 
HIV therapy utilises anti-retroviral therapy (ART).4 This is a combination of drugs that 
penetrate cells through diffusion or active influx and, as effective as it is, requires at least 
three drugs including: nucleoside/nucleotide reverse transcriptase inhibitors, non-
nucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors and/or 
integrase inhibitors.5 ART combines several anti-retroviral drugs in order to slow the HIV 
virus making copies of itself (replication) in the body. 
 
The use of three or more anti-retroviral drugs, sometimes referred to as an anti-HIV 
"cocktail", is the standard treatment at present for HIV infection. This treatment provides 
the best chance of preventing HIV from multiplying, reducing the concentration of 
circulating virus (viral load)6 until it reaches a level that is undetectable with current blood 
tests and allowing the immune system to stay healthy. The dose frequency, pill burden 
and side effects7,8 are all limitations associated with ART, generating the desire for novel 
nano-carrier drug delivery vehicles to target HIV-infected macrophages via 
endocytosis/phagocytosis,9 as HIV-infected macrophages show greater phagocytic 
activity than uninfected cells.10  
 
1.2 Nanomedicine 
New drug carrier systems have been investigated thoroughly in order to overcome drug 
permeability issues and improve drug delivery.11 Important factors need to be taken into 
consideration when designing drug delivery vehicles such as: the capacities of the carrier 
to host an adequate drug payload; optimal release kinetics for each drug depending on 
mechanism and location(s) of release within the body; and the mode of excretion and 
reactivity of all side/end products that the carrier may degrade into.12 
 
The research and development of drug delivery vehicles has been comprehensive, with 
most attention focussed on cancer therapies and treatments.13 Only within the last 20 years 
have polymer-based medicines, which were once dismissed as interesting but impractical 
scientific curiosities, entered clinical practice. In recent years, research has extended from 
extensive manipulation of linear polymers14 to encompass the opportunities offered by 
perfectly branched macromolecules such as dendrimers.15 
Following the clinical approval of various polymer therapeutics, an explosion of interest 
in “nanotechnology” and the applications available in drug delivery has occurred. The 
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application of precisely engineered materials at the 10–1000 nm scale has been utilised to 
investigate new routes to novel therapeutics and diagnostic approaches.16,17 The vast 
selection of materials on offer on the nano-scale results in unequalled opportunities to 
modify fundamental therapy features; examples being solubility, diffusion rates, blood 
circulation half-life, drug release characteristics and immunogenicity; these advantages 
have stimulated immense interest.18,19 Within nanomedicine lies the potential to create 
new classes of drug delivery vehicles with a comprehensive combination of attributes. 
 
Rational design of “nanomedicines” began nearly 50 years ago and in 2010 there were 
>40 products listed as completing the complex journey from laboratory to routine clinical 
use.20 The fundamental elements that are relevant to the design of practical nanomedicines 
and the regulatory mechanisms designed to ensure safe and timely realisation of 
healthcare benefits have been discussed by researchers such as Ruth Duncan and Rogerio 
Gasper.20,21 These reviews critically evaluate nanomedicines in clinical use, emerging 
nano-sized drugs and drug delivery systems. They also discuss the vital considerations 
undertaken in designing nano-pharmaceuticals, if they are ever to succeed in translation 
to clinical use. 
 
The majority of current nanomedicine examples on the market (Table 1.1) are 
administered intravenously, apart from Renagel® and Welchol® which are taken orally 
to treat kidney disease and high blood cholesterol levels respectively. Estrasob™ used to 
treat hot flushes, and Bepanthen® used for skin irritation, are applied as topical emulsions. 
Over one third of the examples listed are used for cancer therapy and it is very apparent 
throughout the literature that this is where the main focus of nanomedicine research lies. 
 
To date, there are no clinically-available nanomedicines for the treatment of HIV. Not 
only is the need increasing as the number of infected patients continues to rise, but there 
is the essential task of developing a treatment avoiding intravenous administration. HIV 
is a chronic disease that requires decades of dosing and patient adherence to therapy. Lack 
of adherence leads to drug resistance. For patients to be adherent with such long dosing 
regimens they need to self administer and this cannot be through a daily injection. Oral 
dosing is, therefore, the only clinically-relevant admninistration option. 
 
Table 1.1 Examples of current nanomedicines available on the market. 
Nanomaterial Active ingredient Brand name  Approved Ref. 
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Polymer-protein conjugate Bovine serum 
albumin 
Adagen® 1990 (USA) 22 
Micelle Paclitaxel Taxol® 1992 (USA) 23 
Polymer-protein conjugate Asparaginase Oncaspar® 1994 (USA) 24 
Liposome Amphotericin B Abelcet® 1995 (USA) 25 
Liposome Doxorubicin Caelyx® 1995 (USA) 26 
Micelle Docetaxel Taxotere® 1995 (EU) 27 
Polymeric drug Glatiramer acetate Copaxone® 1996 (USA) 28 
Liposome Daunorubicin citrate DaunoXome® 1996 (USA) 29 
Liposome Amphoteracin B Ambisome® 1997 (USA) 30 
Liposome Cytarabine Depocyt® 1999 (USA) 31 
Liposome Doxorubicin Myocet® 2000 (EU) 32 
Polymer-protein conjugate IFN-α2b PEGINTRON® 2000 (EU) 33 
Polymeric drug Sevelamer HCl Renagel® 2000 (USA/EU) 34 
Liposome Verteporfin Visudyne® 2000 (USA/EU) 35 
Polymeric drug Colesevelam HCl Welchol® 2000 (USA) 36 
Polymer-protein conjugate PEGfilgrastim Neulasta® 2002 (USA/EU) 37 
Polymer-protein conjugate IFN-α2a PEGASYS® 2002 (USA/EU) 38 
Polymer-protein conjugate PEGvisomant Somavert® 2002 (EU) 39 
Micelle Estradiol 
hemihydrate 
Estrasob™ 2003 (USA/EU) 40 
Liposome Morphine sulphate Depodur® 2004 (USA) 41 
Polymer-aptamer conjugate siRNA Macugen® 2004 (USA) 42 
Albumin NP Paclitaxel Abraxane® 2005 (USA) 43 
Polymer-protein conjugate Epoetin β Mircera® 2007 (USA/EU) 44 
Polymer-protein conjugate Anti-TNF-α Cimzia® 2008 (USA) 45 
Liposome Mifamurtide Mepact® 2009 (EU) 46 
Polymer-protein conjugate Urate oxidase Krystexxa® 2010 (USA) 47 
Nanoemulsion Dexpanthenol Bepanthen® 
spray 
On market 48 
Liposome Vincristine sulphate Marqibo® On market (2012) 49 
 
1.2.1. Synthesis and application of solid-drug nanoparticles 
 
Nanoparticles (NPs) are defined as solid and soft-solid colloidal particles that include both 
nano-spheres and nano-capsules.50 Over the past two decades, a progressive increase in 
the number of commercially available NP-based therapeutic products has been witnessed. 
In 2006, the European Science and Technology Observatory conducted a survey and 
found that >150 companies were developing nano-scale therapeutics.51 They also showed 
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that 24 nanotechnology-based therapeutic products had been approved for clinical use, 
with liposomal drugs and polymer–drug conjugates accounting for >80 % of the total 
amount at that time. 
 
Generally, the classical methods for the preparation of NPs for medical use include: 
nanoprecipitation, emulsion–diffusion, double emulsification, emulsion-coacervation, 
polymer coating, layer-by-layer, milling and high pressure homogenisation. Solid drug 
NPs are produced from poorly water-soluble drugs and are stabilised by polymers and/or 
surfactants.52 These are also known as nano-suspensions53 and are formed by “top-down” 
attrition (milling) of powders and slurries, and more recently by the employment of oil-
in-water emulsions (high pressure homogenisation)54 and emulsion template freeze 
drying.55 Emulsion processing utilises water-soluble polymers and surfactants in an 
aqueous phase and water-immiscible organic solvent solutions of drugs in a dispersed 
phase.56  
 
The association of drug to polymer NPs, either covalently attached,57 encapsulated or 
stabilised, has been studied for many different polymer classes. The potential treatment 
mechanisms of pathophysiological conditions by NPs includes utilising the enhanced 
permeability and retention (EPR) effect, resulting in favourable delivery to tumours.58 
 
1.2.2 Polymer therapeutics 
Biologically active polymeric drugs59 (Figure 1.2A), polymer-protein conjugates60,61 
(Figure 1.2B), polymer-drug conjugates62,63 (Figure 1.2C), block copolymeric micelles64 
(Figure 1.2D; Section 1.2.3.1) and polyplexes65 (Figure 1.2E) have been designed and 
reported by an expansive multidisciplinary research effort, long before the term 
‘nanomedicine’ became fashionable. 
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Figure 1.2 Diagrammatic representation showing the families of polymer constructs called “polymer 
therapeutics”; A) Polymeric-drug; B) Polymer-protein conjugate; C) Block copolymeric micelle; D) 
Polymer-drug conjugate; E) Polyplex (polymer-DNA complex). 
Ruth Duncan has termed these complex multicomponent polymer-based drugs and 
delivery systems as ‘polymer therapeutics’ and this terminology has become widely 
accepted. There have been numerous reviews summarising progress in their 
application66,67 and concentrating on emerging issues relating to polymer safety, the 
increasing use of biodegradable polymers, design of technologies for combination therapy 
and potential biomarkers for individualised patient treatment. 
 
Self-assembled polymer−drug conjugates are often obtained from amphiphilic block 
copolymers of biodegradable or bioresorbable polymers. Polymeric-drugs are generally 
based on the Ringsdorf model,68 which describes the concept of targetable anti-cancer 
polymer–drug conjugates. This model lists features essential for effective design to limit 
cellular uptake via endocytic routes and produce long-circulating conjugates. It is 
important to note that although polymer-drug conjugates are nano-sized constructs 
(typically 2–25 nm), they are quite distinct from polymeric NPs. 
 
Polymer-drug conjugates have proven to reduce cellular uptake via endocytic routes as 
well as significantly prolonging the in vivo circulation time relative to unmodified drug 
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compounds. This encourages passive delivery of drugs to tissues with leaky blood vessels 
such as solid tumours and atherosclerotic plaques.69,70 There has been a large number of 
polymeric materials and architectures proposed as novel drug delivery carriers, however, 
very few linear architectures have succeeded in full translation to clinical practice. 
Challenges that have arisen include: toxicity, immunogenicity, nonspecific bio-
distribution, in vivo circulation stability, and low drug loading capacities with rapid drug 
release.71 Polyethylene glycol (PEG) was the first linear polymer accepted into clinical 
use in the early 1990s.72 PEG-conjugation has been shown to enhance the plasma stability 
and solubility of various drugs while simultaneously reducing immunogenicity. Today, 
there are several examples of “PEGylated” drugs in clinical practice, including 
PEGylated-anti-TNF Fab Cimzia20 for rheumatoid arthritis and the PEG-aptamer 
Macugen73 for age related macular degeneration. PEG has also been conjugated with 
Interferon α-2a (PEGASYS), used in the treatment of chronic hepatitis C, to successfully 
improve the half-life and efficacy of the drug.74 Additionally, the first synthetic polymer 
anticancer drug conjugate went into clinical trial in 1994,75 and many conjugates have 
subsequently followed. 
 
Polymer-drug conjugates are labelled as ‘new chemical entities’ rather than being 
considered as the drug within a delivery system or formulation that simply entraps, 
solubilises or controls drug release without the need for chemical conjugation. Examples 
include “simple” polymer–drug conjugate systems,76 including those containing 
doxorubicin/paclitaxel that have progressed to clinical trials (Figure 1.3A), receptor 
targeted polymer-drug conjugates, including recent examples containing galactosamine 
for liver targeting (Figure 1.3B),77,78 and combination therapies, such as those containing 
aminoglutethimide and doxorubicin (Figure 1.3C).79,80 
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Figure 1.3 Detailed chemical and general cartoon structure of polymer-drug conjugates. The polymer 
is shown in red, linker region in blue, drug in green and targeting residue in purple. A) A polymer-drug 
conjugate containing doxorubicin that has progressed to clinical trial; B) A multivalent receptor targeted 
conjugate containing galactosamine to promote liver targeting; C) Polymer combination therapy 
containing the aromatase inhibitor aminogluthethimide (orange) and doxorubicin (green). 
There has been a very large investment specifically in liposomal and antibody 
therapeutics; however, wider research in polymer therapeutics has progressed strongly in 
the past two decades through the overall interest in ‘nanomedicines’. Many challenges 
must be overcome in order to ensure the safe and rapid translation of polymer therapeutics 
into routine clinical use. There is a need for the far-sighted design of new conjugates, with 
cautious chemical characterisation before clinical trials, and careful safety assessment of 
all new polymeric carriers. 
 
1.2.3 Self-assembling diblock copolymers for drug delivery
Diblock copolymers are amphiphilic linear polymers comprising two polymer 
chemistries; often a hydrophilic A block and a hydrophobic B block, (Figure 1.4A, B and 
C). The assembly behaviour of the diblock copolymers is governed by the ratio of the 
hydrophilic to hydrophobic A and B block segments. Linear amphiphilic polymers of 
varying monomers and block length ratios have been extensively studied for the formation 
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of micelles,81 liposomes,82 polymersomes,83 worms and cylinders.84,85,86, 87, 88 
 
1.2.3.1 Preparation of micelles from diblock copolymers 
Micelles may be prepared from block copolymers with amphiphilic character that self-
assemble in aqueous media because of the large solubility difference between the 
hydrophobic and hydrophilic segments (Figure 1.4).89  
 
 
Figure 1.4 Diagrammatic representation of three different classes of functional micelles formed from 
A-B diblock copolymers containing a hydrophobic (green) and hydrophilic (blue) segment containing 
functionality (gold stars). The micelles are formed from i) micellisation and/or ii) cross-linking 
producing D) Core-crosslinked micelles formed from functionalisation of the hydrophobic block (A), 
E) Shell-crosslinked micelles formed from functionalisation of the hydrophilic block (B); and F) 
Surface functionalised micelles from functionalised chain end groups (C). 
 
It is well-known that A-B diblock copolymers aggregate to form micelles in solvents 
which are selective for either the A block segment or the B block.90,91,92,93 If the block 
segment chain length ratio is not too asymmetric, micelles or reverse (inverted) micelles 
from the same block copolymer can be obtained, as long as the appropriate solvents are 
selected. 
 
Armes and co-workers reported the first instance of a novel water-soluble A-B diblock 
copolymer, which was capable of forming both micelles (A block segment within the 
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core) and reverse micelles (B block segment within core) solely in aqueous media.94 The 
formation of these reverse micelles was driven by a variety of different parameters 
including the solution pH, electrolyte concentration, temperature and block symmetry.95 
 
Reported polymeric micelle-based drug carriers commonly comprise a biodegradable 
polyester core (e.g. p(ε-caprolactone)) and a biocompatible and nontoxic hydrophilic shell 
such as PEG.96 Drugs can be encapsulated within the core of stable micelles and release 
is mediated by the rate of drug diffusion from the assembled nanostructure.97 Due to the 
pH-dependent solubility of ionic drugs, release rates are often subject to change depending 
on the surrounding environment of the drug carriers.98 This introduces a major challenge 
when addressing systemic absorption via oral administration where achievable plasma 
concentrations are affected by exposure to significant fluctuations from the large pH 
variation in the gastrointestinal tract. 
 
pH-dependent release can be undesirable, especially for treatments necessitating steady 
plasma drug concentrations. Methods to overcome these issues have involved shell cross-
linking, core cross-linking and surface functionalisation of micelles99 (Figure 1.4D, E and 
F). Recent examples include micelles with charged channels on the surface in order to 
reduce the difference in drug release rate upon changes in pH.100 
 
Cross-linking of micelles (Figure 1.4D) provides stability at concentrations below the 
critical micelle concentration of the block copolymer and allows them to be isolated and 
re-dispersed as stable NPs. This extra stability means they are not as likely to disperse or 
fully dissolve in media such as the blood-stream, but rather lead to increased circulation 
times to allow the drugs to be released over long durations. Additionally, with shell-
crosslinking (Figure 1.4E), the permeability of the corona can be controlled and fine-tuned 
to suit a release rate that is desirable for different drug compounds. Functionalisation of 
the block copolymers (Figure 1.4C) contributes to targeting specific sites of interest within 
the body, therefore, also adding improved distribution control throughout the whole drug 
delivery process. 
 
Despite lacking the surface functionality associated with dendrimers (cf. Section 1.2.4), 
these colloidal carrier systems have received much attention due to their high loading 
capacity for drugs as well as their unique disposition characteristics in the body.101 
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1.2.3.2 Synthesis and pharmaceutical application of liposomes 
A liposome is composed of natural or synthetic amphiphilic lipid molecules (Figure 1.5A) 
that arrange themselves into a bi-layered membrane to create a spherical lipid vesicle 
(Figure 1.5B).102,103 Examples include phospholipids (Figure 1.5A) that spontaneously 
arrange themselves as liposomes when dispersed in aqueous media.104 The hydrophilic 
interaction of the charged head groups with water, results in the formation of multilamellar 
systems. 
Figure 1.5 A) Detailed chemical and cartoon structure of a phospholipid showing hydrophobic fatty 
acid tail (green), glycerol backbone (black) and hydrophilic phosphorylated alcohol (red); B) Cartoon 
representation of how the phospholipid spontaneously arranges in aqueous media to form a liposome. 
Liposomes have been extensively used as pharmaceutical carriers due to a number of 
distinctive capabilities. They are able to encapsulate hydrophobic and hydrophilic 
therapeutic agents, shield the encapsulated agent from the external environment and any 
unwanted effects that might occur in these conditions, and easily be tailored with specific 
ligands for targeting. Generally, their circulation half-life can be extended through coating 
of inert and biocompatible polymers and desired formulations can be formed depending 
on required properties such as composition, size and surface charge.105 
 
The first liposomal drug formulation approved by the Food and Drug Administration, 
USA was Doxil in 1995,106 for the treatment of Kaposi’s sarcoma. Doxil is a long-
circulating formulation of doxorubicin, in which doxorubicin hydrochloride is 
encapsulated within the PEGylated liposome. The encapsulated doxorubicin within the 
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liposome alters its pharmacokinetic and biodistribution profile, resulting in reduced 
cardiotoxicity,107 however major adverse side-effects of hand-foot syndrome have also 
been reported compared with free doxorubicin.26 This is a distinctive and relatively 
frequent dermatologic toxic reaction associated with certain chemotherapeutic agents,108 
and strategies investigating dose frequencies to minimise the effects are ongoing.109
 
1.2.4 Dendrimers 
 
Dendrimers (Figure 1.6B) comprise sub-units, known as dendrons (Figure 1.6A). 
Dendrimers are classified by generation (Gx), which refers to the number of repeated 
branching cycles that are performed during the synthesis. 
 
Figure 1.6 Diagrammatic representation of a dendron (A), the building block of a dendrimer (B) 
comprised of surface groups (red), branching groups (blue) and core (green). 
The first successful synthesis of dendrimers was carried out in the late 1970s,110 where the 
new potential of these highly branched, highly symmetrical macromolecules with 
maximised surface functionality began to be realised. The first synthetic example was 
reported by Vögtle and co-workers,111 achieved by a cascade approach via divergent 
growth. Following the initial development of well-defined branched macromolecules, the 
term “starburst polymers” was subsequently used to describe dendrimers in many of the 
first reports of their synthesis by Tomalia and co-workers.112 The various syntheses can 
offer fine control over molecular weight, levels of branching and numbers/chemistry of 
terminal end groups, making these perfectly branched macromolecules quite distinct from 
the more readily accessed, but less well-defined, hyperbranched polymers with irregular 
branching.  
 
Dendrimers are generally synthesised in one of two ways, convergent and divergent 
growth.113  
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1.2.4.1 Synthesis of Dendrimers via Divergent growth 
Divergent dendrimer growth strategies start by reacting a multifunctional molecule that 
eventually becomes the core of the dendrimer, with reagents that exhibit the surface 
functionality desired (Scheme 1.1).114,115 Subsequent reactions take place at the surface of 
the growing dendrimer and functionality is exponentially multiplied at each generation of 
growth. 
 
Scheme 1.1 Divergent growth starting with the core of the molecule (green) reacting with methyl 
acrylate via exhaustive Michael additions (1) followed by amidation with ethylenediamine (2) to 
produce amino surface groups (red) that eventually end up as branching points (blue) as the steps are 
repeated to produce a Generation 1 dendrimer. 
Polyamidoamine (PAMAM) dendrimers (Scheme 1.1), synthesised by Tomalia et al. via
divergent growth,112 are one of the most commercially available and widely used 
dendrimers in biology.116 They are made through a repetitive cycle of exhaustive Michael 
addition of amino groups with methyl acrylate, followed by amidation of the resulting 
esters with ethylenediamine. The broad applicability of PAMAM dendrimers has been 
demonstrated via modification of the surface amine groups in order to overcome various 
complications within living systems, including liver accumulation and toxicity seen with 
polycationic materials. This is often achieved by reacting the amine groups with neutral 
or anionic moieties.117,118  
1.2.4.2 Synthesis of Dendrimers via Convergent growth 
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Convergent growth begins by reacting molecules that will become the eventual dendrimer 
surface.119,120 A series of dendrons are formed from successive couplings to 
multifunctional branching molecules. Dendrons can react further to form larger generation 
materials or couple with a chosen core molecule at any generation of “growth”. 
 
The first example of convergent growth was conducted by Hawker and Fréchet in 1990.121 
They synthesised aryl ether dendrons up to G6 which were subsequently coupled to a 
trivalent core to produce the equivalent p(aryl ether) dendrimers based upon the 
“monomer” 3,5-dihydroxy-benzyl alcohol (Scheme 1.2). This method showed a greater 
control over the synthesis of dendrimers, with less imperfections arising and without the 
need for an excess of reagents. However, during the coupling step of the dendrons to the 
core molecule to form the final dendrimer, the yields declined dramatically with 
increasing dendrimer generation, achieving 76% and 51% for the G5 and G6 dendrimers 
respectively. This reduction in yield was due to steric hindrance of bulky dendron 
coupling with a small molecule core. 
 
Scheme 1.2 Convergent growth starting with the aryl ether surface groups of the molecule (red) 
producing benzyl branching points (blue) before eventual coupling around a trivalent core (green) to 
produce a Generation 2 dendrimer. 
The more globular shape of dendrimers offers several advantages over the random coil 
structures of most solvated linear polymers. This change in conformation assumes a lack 
of chain entanglements, and confers different solution and bulk properties compared to 
linear analogues. This topology is known to affect the interaction with biological 
substrates, leading to the discovery of interesting effects related to macromolecular 
architecture.122 
1.2.4.3 Dendrimers for biological applications 
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Dendrimers have been studied for several applications due to their controlled molecular 
size,123 distinct and tailored interior and exterior, ability to encapsulate guest molecules 
and micelle-like properties.124 In spite of such benefits, dendrimers have not currently 
been commercialised as nanomedicines due to their lengthy/expensive syntheses and 
purification, although several dendrimers are in commercial medically-related products 
and others are progressing through clinical trials.  
Much effort has been devoted to the preparation of dendrimers in order to prepare 
water-soluble and highly biocompatible materials.125 The dendritic architecture can 
provide several advantages for drug delivery applications in comparison to the features of 
conventional linear polymers.126 Dendrimer drug-delivery systems include encapsulation 
of guest molecules in the void interior dendrimer spaces (Figure 1.7A), dendrimer-drug 
networks (Figure 1.7B), attachment of a therapeutic agent to the dendrimer surface either 
covalently (Figure 1.7C) or non-covalently (Figure 1.7D) to produce a range of new 
prodrug structures.  
 
 
Figure 1.7 Diagrammatic representations of dendrimer drug-delivery systems. The orange oval 
represents an active drug substance: A) Encapsulated guest; B) Dendrimer-drug network; C) 
Covalently-bound prodrug; D) Non-covalently bound prodrug. 
Host-guest interactions of drug with dendrimers are well established,127 and examples 
include liposomal formulations including dendrimers entrapped and subsequently slowly 
releasing methotrexate,128 and prodrug design using 5-aminolevulinic acid residues on the 
surface of 2nd and 3rd generation dendrimers.129?Advantages such as the controlled multi-
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valency of dendrimers can allow several drug molecules to be attached at the molecular 
surface and surface groups can be tailored as targeting and solubilising groups on the 
periphery of the dendrimers in a controlled manner. G3-PAMAM dendrimers have been 
internalised and transported to endosomes and lysosomes following surface modification 
with lauroyl and propranolol chains.130
 
A water-soluble polyester dendrimer was found to be biocompatible in vitro and in vivo,131 
therefore introducing a promising aliphatic dendrimer backbone based on 2,2-
bis(hydroxymethyl) propionic acid for the development of anticancer delivery. There was 
an observed lack of accumulation in vital organs offering desirable behaviour; however, 
a longer circulatory half-life than the reported values is required to obtain passive tumour 
targeting via the EPR effect – a phenomenon observed when macromolecules of a certain 
size accumulate more in tumours than they do in healthy tissues.132 
VivaGel® is an innovative antimicrobial developed by StarPharma and partners133 in 
order to combat a range of sexual health issues such as bacterial vaginosis. Surface groups 
imparting the most potent inhibitory activity against HIV-1 and herpes simplex virus 
(HSV-2) were naphthalene disulfonic acid (DNAA) and 3,5-disulfobenzoic acid 
exhibiting the greatest anionic charge and hydrophobicity of the seven surface groups 
tested. Their anti-HIV-1 activity did not appreciably increase beyond a second-generation 
dendrimer while dendrimers larger than two generations were required for potent anti-
HSV-2 activity. Second generation (SPL7115) and fourth generation (SPL7013) (Figure 
1.8) DNAA dendrimers demonstrated broad-spectrum anti-HIV activity.134 
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Figure 1.8 Diagrammatic representation of a fourth generation (SPL7013) dendrimer with chemical 
structures for the benzhydrylamine-lysine core (green), lysine branching units (blue) and DNAA 
surface groups (red). 
SPL7013 was more active against HSV and showed increased blocking of HIV-1 envelope 
mediated cell-to-cell fusion and is the active ingredient in VivaGel®. Thirty-two 
naphthalene disulfonate moieties, attached via amide linkages, decorate the molecule’s 
surface. This polyanionic structure prevents HIV infections by binding to the gp120 
glycoprotein receptors on the virus surface. The interaction in turn prevents HIV from 
attaching to receptors on T cells in the body. Tsai and co-workers suggested a protective 
effect against HIV following investigations in a demanding animal model of HIV 
infection.135 
StarPharma have also developed the drug delivery vehicle DEP™ docetaxel, a poly-L-
lysine-based dendrimer-docetaxel conjugate, which is currently in Phase 1 clinical 
trials.136 Docetaxel is a leading chemotherapy drug that treats a range of tumours, 
including breast, lung and prostate cancer, and is marketed as Taxotere®. DEP™ 
docetaxel has demonstrated a significant enhancement of anticancer effects by eliminating 
neutropenia, the major dose-limiting toxicity for marketed formulations of docetaxel. It 
has also demonstrated higher accumulation in tumours and longer plasma half-life 
compared to Taxotere® alone. 
 
The synthetic preparation of high-generation dendrimers is time consuming and the 
increase in hydrodynamic volume in each generation growth step is often very small as a 
direct result of the globular architecture. It is, however, essential in order to improve the 
circulation half-life as larger molecules are eliminated from the body more slowly.137 In 
attempts to access different sizes and different dendritic polymer properties, one route that 
has seen much international research interest is the combination of dendrimers and linear 
polymers to produce hybrids of varying architectures. 
 
Concepts offered for the potential of dendrimer-based nanomedicines are emerging more 
than ever before.138 They offer substantial promise and benefits for many current 
nanomedicines and nano-therapies, inspired by the ‘global nanotechnology revolution’. 
The promise that polymers show in the development of anticancer drug delivery 
systems,75 encourages a greater research effort to establish applications of dendrimers in 
this area. The possibilities of various new polymer architectures provided by dendrimers, 
show great potential in relevant drug delivery needs. 
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1.2.5 Synthesis and application of dendronised polymers 
 
In recent years, many reports have shown the connection of large numbers of dendritic 
molecules to linear polymers, resulting in dendronised polymers.139 These predominantly 
host pendant dendrons at many repeat units along the chain backbone and, at high 
molecular weights, assume extended rod-like conformations.140 This consequently leads 
to cylindrical core-shell architectures with biological and physical properties different to 
conventional dendrimers, without losing the appealing multi-valent feature of the surface 
functionality. Thorough investigations into the control of composition and morphologies 
within dendronised polymers have been explored and are ongoing.141 There are 3 main 
routes to synthesise dendronised polymers (Figure 1.9).  
 
The “graft-from’ approach involves a step-growth process progressing from the polymer 
backbone (Figure 1.9A), with increasing dendron generation with each synthetic step. 
This method was first reported by Tomalia et al.,142 and targets a maximum degree of 
dendronisation, despite problems arising from structural defects. Subsequently, many 
examples exist within the literature including non-degradable p((4-hydroxy)styrene)143
and biodegradable substituted p(caprolactone).144 
 
 
Figure 1.9 Synthetic routes to dendronised polymers; A) “Graft-from” approach proceeds via a step 
growth process from the polymer backbone; B) Chemical and diagrammatic representation of the 
“graft-to” approach whereby a preformed dendron is coupled to a polymer that contains pendant groups 
for attachment; C) Macromonomer approach incorporates dendrons into the monomer. 
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The “graft-to’ approach (Figure 1.9B) involves conjugation of preformed dendrons to 
pendant groups on the chosen polymer backbone. Complete coverage of the backbone has 
proved problematic using G3 dendrons or larger; however, successful examples include 
Fréchet-type dendritic azides reacting with the pendant alkynes of p(vinylacetylene) 
(Scheme 1.3).145  
 
Scheme 1.3 Chemical example of the “graft-to” approach to produce a dendronised polymer via the 
reaction of dendritic azides with the pendant alkynes of p(vinylacetylene). 
 
The macromonomer approach (Figure 1.9C) involves incorporation of dendrons into a 
monomer structure. This ensures a perfect pendant dendron exists at each repeat unit; 
however, macromonomers containing high generation dendrons have been reported to 
reach only low degrees of polymerisation.146,147 
 
These molecules show interesting pharmacokinetic behaviour in bio-distribution studies 
that differ from that displayed by linear polymers with equivalent molecular weight.148 
They also show potential to act as drug delivery vehicles due to the long circulation half-
lives and many peripheral groups, which could be utilised for drug attachment, targeting 
and solubilising groups. 
 
1.2.6 Dendritic-like polymers 
1.2.6.1 Linear-dendritic polymers 
Dendrons, the central structural sub-units of dendrimers, have been combined with linear 
polymers to generate many new classes of polymer architectures.113 These include the 
placement of dendrons at linear polymer chain ends to form linear-dendritic polymer 
hybrids (Figure 1.10A), linear chains with dendrons at both ends (Figure 1.10B), linear 
chains conjugated to the periphery of a dendron (‘bow-tie’ hybrids; Figure 1.10C) and star 
polymers containing dendron chain end functionality (Figure 1.10D). 
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Figure 1.10 Diagrammatic representation of linear-dendritic polymers including: A) Linear-dendritic 
hybrid; B) Linear polymer chains with dendrons at both ends; C) ‘Bow-tie hybrid’ of dendron and linear 
polymers; and D) Star polymer containing dendron chain-end functionality. 
 
 
 
1.2.6.1.1 Synthesis of linear-dendritic polymer hybrids 
Linear-dendritic polymer hybrids have been synthesised using various strategies.149 The 
introduction of dendritic functionality to linear polymer chain ends, has led to numerous 
structural variations.150,151,152 The commercially available dendrons and dendrimers based 
on 2,2-bis(methylol)propionic acid have, overall, excelled as the leading molecule to 
prepare non-toxic, biocompatible materials for in vivo applications.153,154 Examples 
include star branched p(3-caprolactone) chains constructed from G4 dendrons, leading to 
successful micelle self-assembly and loading of doxorubicin.155 
Examples of ‘bow-tie’ hybrids include polyester dendrimers and PEG, with varying 
architectures and molecular weights, prepared by tuning the number of PEG arms and the 
targeted molecular weights.156 PEG was chosen as the linear polymer segment due to its 
high biocompatibility and the availability of low dispersity commercial materials,157
allowing hybrids with similar dispersity to dendrimers to be created. 
 
The demand of functionalisation and application continues to increase structural 
complexity, requiring more robust and versatile synthetic methods to vary the dendritic 
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functionality within linear-dendritic polymers. Developments in click chemistry have 
provided routes to prepare highly functionalised macromolecular architectures,158 with the 
consequent construction of dendritic polymers utilising Cu(I)-catalyzed azide–alkyne 1,3-
dipolar cycloadditions159 which results in the formation of an aromatic triazole. Reported 
examples include A-functionalities (azides) and B-functionalities (acetylenes) for 
eventual repeating triazole ring groups in the final dendritic structure, for subsequent post-
functionalisation.160 Other strategies have employed a range of commercially available 
acrylate monomers in multiple deprotection/functionalisation reactions with a xanthate 
dendron polymer chain end.161 The result is a range of complex polymer architectures with 
multiple reactive functional groups, from an efficient and facile one-pot reaction. 
 
1.2.6.1.2 Application of linear-dendritic polymer hybrids  
The conjugation of p[N-(2-hydroxypropyl)methacrylamide] to PAMAM dendrimers, 
followed by attachment of the anticancer drug doxorubicin to the polymer arms by a 
biodegradable peptide spacer, results in a star-like carrier.162 The star polymer has a highly 
dense architecture that results in slower rates of enzyme-mediated drug release, which 
decreases the cytotoxicity of the conjugate. 
Fréchet and co-workers proceeded to synthesise a number of linear-dendritic hybrids 
comprising PEG with polylysine (Figure 1.11A) or polyester dendrons.163 These have 
assembled to form pH-responsive micelles whose drug release rates have the potential to 
be tuned and whose disintegration into unimers has been demonstrated (Figure 1.11B). 
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Figure 1.11 Example of a linear-dendritic block copolymers. A) Chemical structure of linear-dendritic 
comprised of poly(ethylene oxide) and a polylysine dendron to develop a stable micelle system in 
neutral pH (B) that disintegrates into unimers upon the addition of acid (i). 
 
It is still a challenge to prepare dendritic polymers that circulate in the blood long enough 
to accumulate at target sites,164 and are able to be eliminated from the body at acceptable 
rates to avoid long-term accumulation. The tissue localisation of dendritic polymers is 
difficult to predict in advance and more studies are required to determine the effect of 
peripheral dendritic groups on these observations. The release of drugs from dendritic 
polymers has proved problematic due to the steric hindrance associated with the dense 
globular dendritic architecture, making the engineering of enzymatically cleavable 
linkages difficult.165,166,167 
1.2.6.2 Branched polymers producing dendrimer-like structures 
The on-going development of hyperbranched polymers168,169 has led to materials with 
increased degrees of branching and better control over the branching, molecular weight 
distribution and polymer architecture, bringing hyperbranched polymers closer to 
perfectly branched dendrimers (Figure 1.12).  
 
 
Figure 1.12 Diagrammatic representation of the preparation of A) a hyperbranched polymer; and C) a 
dendrimer; from an AB2 building block (B). 
Highly branched polymer molecules have been extensively synthesised using AB2 
molecules.170 The first approach to the synthesis of highly branched materials via self-
polymerisation was reported by Fréchet et al. in 1995171 and concerned the polymerisation 
of a vinyl monomer with a pendant group, which can be transformed into an initiating 
moiety (an inimer) (Scheme 1.4).172,173 
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Scheme 1.4 Polymerisation of a vinyl monomer with a pendant group (an inimer) producing an 
initiating moiety (B) following activated monomer production (A). 
 
This polymerisation was termed self-condensing vinyl polymerisation (SCVP) and was 
first demonstrated for the polymerisation of styrene and 3-(1-chloroethyl)-ethenylbenzene 
(3CEB). The 3CEB monomer consists of vinyl functionality and a pendant latent initiating 
functionality, which was activated by the addition of stannic chloride (Scheme 1.5).174 
The synthesis of branched polymers using A-B monomers through SCVP produced 
architectures similar to that of dendrimers, albeit with less control. Branching points arose 
from propagation of the A-B monomer and the introduction of new initiating centres with 
each propagation step.  
 
 
 
Scheme 1.5 Self-condensing vinyl polymerisation of 3-(1-chloroethyl)-ethenylbenzene (B) following 
activated monomer production (A). 
Despite continuous refinements, hyperbranched polymers are notorious for being 
typically imperfectly branched with high dispersities, but due to the simplistic one step 
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syntheses, many applications have become accepting of these imperfections resulting in a 
variety of hyperbranched polymers becoming commercially available.175 These 
applications range from additives to coatings, advanced technologies176 including sensors, 
high loading supports in combinatorial chemistry studies and homogeneous catalysts.177 
Two of the most widely recognised commercially available hyperbranched polymer 
systems are Perstorp’s Boltorn® 178,179 and DSM’s Hybrane® 180,181 (Figure 1.13). 
Hybrane® materials have been produced at multi-tonne scale, and the modification and 
combination of anhydrides has led to several types of end groups and consequently a large 
variety of structures. Hybrane® polymers are used as strainer candidates for extractive 
distillation processes, and Boltorn® polymers have been employed in a succession of 
industrial applications in chemical engineering such as coating agents and printing inks.182 
The distinctive dendritic properties such as lack of entanglements, large number of 
reactive end groups, and the possibility to interact with guest molecules has potentials to 
be fully exploited. 
 
Figure 1.13 An example of a typical structure of a hyperbranched Hybrane® macromolecule. 
 
Hyperbranched or highly branched polymers can also be synthesised via other 
polymerisation techniques including chain-growth polymerisation. 
 
1.3 Chain-growth Polymerisation 
Chain-growth polymerisation183 involves the successive addition of unsaturated 
monomers to the active site of growing polymer chains; the addition of each monomer 
unit regenerates the active site.184 Chain-growth fundamentally proceeds via three steps: 
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chain initiation, chain propagation and chain termination. Different types of chain-growth 
polymerisation include free radical polymerisation (Scheme 1.6), cationic 
polymerisation,185 that involves transfer of charge to a monomer from a cationic initiator, 
and anionic polymerisation,186 that involves a carbanion active species. 
 
Scheme 1.6 Free radical chain-growth polymerisation involving 1) Chain initiation; 2) Chain 
propagation and 3) Chain termination. 
 
Progressive developments over many years have led to varying degrees of control over 
the number average polymer chain length.187 This has predominantly been led by “living 
polymerisation” techniques, which essentially remove the potential for chain termination 
from chain growth polymerisation and controls the various rates of the key reactions 
within the polymerisation reaction.188 This results in the polymer chains growing at a more 
constant average rate until reaching the specific target degree of polymerisation as 
determined by the initiator to monomer ratio (Scheme 1.7).189 This attribute is desirable 
as it introduces precision and control over the primary polymer chain length, necessary 
when the properties of polymers are directed by variations in architecture and molecular 
weight. Examples include living anionic polymerisation,190 living cationic 
polymerisation,191 and free radical polymerisation (controlled radical polymerisation) 
(Figure 1.7). Many forms of controlled radical polymerisations (CRP) have emerged, all 
continually aiming to control polymerisation progression through an equilibrium of 
dormant/active chains. 
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Scheme 1.7 Example of a controlled radical polymerisation producing polymers containing the same 
number of monomer units ( ) following initiation by an initiator ( ). 
 
1.3.1 Controlled radical polymerisation 
CRP developments and methods have grown significantly over the past decades.192 All 
are based on establishing a rapid dynamic equilibrium between a large majority of a 
dormant species and a small concentration of reactive radical species. The dormant form 
of the radicals is controlled in a variety of ways, depending on the type of CRP technique 
used. Examples include reversible addition-fragmentation chain transfer 
polymerisation,193 nitroxide mediated polymerisation194 and degenerative transfer.195 The 
technique used within this work is atom transfer radical polymerisation (ATRP).196 
1.3.1.1 Atom transfer radical polymerisation 
The CRP method focussed on within this study is ATRP, which produces radicals via a 
transition metal catalysed reaction. ATRP has been reported on widely since initial 
publication in 1995 by Sawamoto and co-workers185 and Matyjaszewski and co-
workers.197 ATRP typically employs a transition metal complex (Mtn/L; Scheme 1.8) as 
the catalyst and an alkyl halide as the initiator (R-X; Scheme 1.8). The dormant species is 
activated by the transition metal complex to generate the radicals, simultaneously 
establishing a higher oxidation state (X-Mtn+1/L; Scheme 1.8). This reversible process 
rapidly produces an equilibrium between dormant and active species, with a predominated 
production of low radical concentrations. The number of polymer chains is determined by 
the number of initiators, and each growing chain has an equal probability to propagate and 
produce polymers with similar molecular weights with an overall narrow molecular 
weight distribution.198 
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Scheme 1.8 General ATRP mechanism involving an alkyl halide (R-X), a transition metal complex 
(Mtn/L) as the catalyst, establishing a higher oxidation state (X-Mtn+1/L) upon the generation of radicals 
(R.) and an equilibrium between dormant and active chains. 
This attractive radical polymerisation lends itself to a vast range of monomers containing 
substituents that can stabilise the propagating radicals; such as (meth)acrylates,199 
styrenics200 and (meth)acrylamides.201 Equally, the effect of various synthesis parameters 
on the rate of polymerisation have been thoroughly examined; such as the initiator,202 
ligand,203 metal catalyst204 and solvent choice.205 
 
1.3.1.1.1 Branched polymers via controlled radical polymerisation 
Free radical polymerisation produces high molecular weight polymer chains that easily 
cross-link,206 resulting in gelation, even at relatively low concentrations of brancher. The 
ATRP branching method has been reported to rely strongly on controlling the 
brancher:initiator ratio in order to prevent the formation of an insoluble three dimensional 
network207 as described in the Flory-Stockmayer theory.208 The Flory-Stockmayer theory 
predicts that gelation will occur when the number of cross-links per chain is equal to one, 
assuming that the reactivity of each vinyl group is the same and that no intramolecular 
cyclisation occurs. Therefore, a ratio brancher:initiator 0.95:1 or less will prevent gelation 
and produce high molecular weight, soluble polymers.209 ? 
In an attempt to overcome cross-linked polymer networks, Sherrington and co-workers 
introduced the “Strathclyde” route210,211,212,213 to free radical polymerisation of vinyl and 
divinyl monomers. This stated that gelation can be prevented by ensuring that less than 
one branching monomer is incorporated per primary polymer chain. The route was 
originally utilised in conventional free radical polymerisation and used bi-functional 
monomers, such as ethylene glycol dimethacrylate (EGDMA) in the presence of a chain 
transfer agent (CTA) to produce high levels of branching in any vinyl monomer 
polymerisation. The presence of a CTA avoids gelation by preventing every polymer 
chain from bearing a divinyl monomer. This method produced high molecular weight, 
soluble branched polymers via control of the primary polymer chain length. 
R-X + Mtn/L R + X-Mtn+1/L
kact
kdeact
kp kt
monomer
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The introduction of a low concentration of divinyl monomer (brancher) within various 
chain-growth polymerisation methods has led to the production of highly branched, 
soluble polymers with impressive molecular weights.209 Li and Armes have synthesised a 
number of branched copolymers using a branching agent containing a disulfide bond.214 
This allowed cleavage of each branch point to degrade the high molecular weight 
polymers into near monodisperse primary polymer chains and confirm the mechanism of 
branching; controlled polymerisation of linear chains prior to combination to produce the 
branched copolymer. Further studies of the ATRP branching mechanism have been 
reported by Bannister et al,215 uncovering a three-stage polymerisation mechanism 
constructed from their analysis of the evolution of the molecular weight distribution 
during polymerisation. Branching appeared to be negligible during the early stages of the 
co-polymerisation, with dispersities remaining low up to 70-80% monomer conversion, 
and substantial branching occurred in the later stages of the reaction via inter-chain 
reaction through pendant vinyl functional groups (Figure 1.15). 
 
 
Figure 1.15 Diagrammatic formation of a branched copolymer by ATRP via: A) initiation using an 
ATRP initiator ( ); B) propagation and C) latent branching involving statistical linking of monomer (
) and branching units ( ). 
 
1.3.1.1.2 Synthesis of hyperbranched polydendrons via ATRP 
In 2014, Hatton et al. reported the introduction of simultaneous branching during the 
propagation of the vinyl segment of a linear-dendritic hybrid, to form a new class of 
macromolecular architecture: hyperbranched polydendrons (hyp-polydendrons).216 The 
concepts associated with the previously mentioned free-radical “Strathclyde” 
polymerisation, were utilised and the presence of a dendron macroinitiator within the 
controlled radical co-polymerisation of a mixture of vinyl and divinyl monomers was used 
to form soluble, high molecular weight branched polymers (Scheme 1.9). 
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Scheme 1.9 Co-polymerisation of 2-hydroxypropyl methacrylate (2) and ethylene glycol 
dimethacrylate (3) initiated by a Generation 2 1,3-dibenzyloxy-2-propanol dendron ATRP initiator (1) 
in the presence of CuCl/bpy as the metal/catalyst to produce a hyp-polydendron. 
By combining dendritic surface functionality with chain-growth polymerisation, 
significant sample masses, high functionality and high molecular weights (> 2,000,000 g 
mol-1) were obtained within a relatively small number of synthetic steps. Naturally, the 
ideal branching concept throughout the macromolecule, compared to dendrimers, has 
been compromised. 
 
1.4 Stimuli-responsive materials. 
Stimuli-responsive materials are defined as materials that respond with drastic chemical 
or physical change after variation in external environmental conditions. They have been 
the subject of research for many groups over several decades due to their potential in a 
vast array of applications such as oil recovery,217 water decontamination,218 analytical 
chemistry,219 purification,220 anti-bacterial coatings221 and, more recently, textiles222 and 
biomedicine.223 Furthermore, applications in controlled release have contributed in further 
development of interest in stimuli-responsive polymers due to the opportunities for use in 
the pharmaceutical industry as new delivery systems for active agents.224  
 
The attractive characteristics affiliated with stimuli-responsive polymers, a desirable 
factor for drug carriers, is the ability to undergo reversible conformational changes in 
solution. These materials can adapt their solution behaviour in response to a range of 
stimuli such as temperature,225 pH,226 ionic strength,227 and light.228 
 
1.4.1 Temperature-responsive materials 
Temperature-responsive polymers undergo a volume phase transition at well-defined 
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temperatures, causing an immediate change in their solvation state.229 Polymers either 
become insoluble or soluble upon heating possessing either a lower critical solution 
temperature (LCST) or upper critical solution temperature (UCST) respectively. The 
volume phase transition occurs because of competing hydrogen-bonding properties 
depending on whether the intra- and intermolecular hydrogen bonding within the polymer 
is more favourable than the water-polymer interaction. The solubility in water arises when 
the interactions between the water and polymer are preferred. Thermodynamically, the 
miscibility of polymer and solvent occurs when the Gibbs free-energy of the system 
decreases i.e. when there are no interactions between the polymers (no enthalpy (ΔH=0)), 
there will be a preferred entropy of mixing with the solvent (ΔS>0), resulting in a decrease 
in Gibbs free-energy. These systems are not necessarily confined to aqueous solvent 
environments; however, aqueous conditions are of most interest in the field of biomedical 
applications. 
 
Complex multi-block responsive micelles230 have been prepared by Laschewsky and co-
workers,231 Wooley and co-workers232 and Rannard and co-workers.233 These examples 
include temperature-responsive micelles in aqueous media that form from the self-
assembly of amphiphilic A-B diblock copolymer unimers of p(alkylene oxide)s combined 
with p(styrene) and p(4-vinylpyridine).234,235 
 
Linear-dendritic PEG-based biocompatible copolymers have also been shown to act as 
thermo-responsive micelles that completely disrupt into unimers upon cooling below their 
LCST, with reversible self-assembly upon heating (Figure 1.16).236 These linear-dendritic 
polymeric micelles were investigated for temperature-induced controlled release of 
therapeutic agents as well as active targeting by subsequent functionalisation of the 
peripheral acid groups with biospecific ligands. The combination of hydrophilic, 
hydrophobic and charged groupings on single polymer chains, coupled with the ability to 
interchange these properties via temperature or pH switching has given rise to materials 
with elaborate solution structures that strongly resemble biological entities. Thermo-
responsive polymers are considered as one of the most widely utilised stimuli-responsive 
polymers, as they are easy to apply both in vitro and in vivo.237,238,239,240,241,242 
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Figure 1.16 Diagrammatic representation of reversible formation and disruption of the linear–dendritic 
polymeric micelles triggered by temperature; i) above LCST; ii) below LCST. 
 
1.4.2 pH-responsive materials 
Synthetic pH-responsive polymers are formed from monomers that are weakly basic or 
acidic. These moieties protonate reversibly as a function of pH, the adjustment of which 
alters the ionic interaction, hydrogen bonding and hydrophobic interaction with water, 
resulting in a reversible micro-phase separation or self-organisation phenomenon.226 As a 
direct result, pH-responsive polymers are fully soluble in aqueous solution at appropriate 
pH, as they are typically hydrated, swollen and hydrophilic in their ionic state (Figure 
1.17A). As the pH varies, the polymers become dehydrated, compact and more 
hydrophobic in their neutral form (Figure 1.17B).243 This transition occurs at a pH that is 
defined as the apparent pKa or pKb and is very susceptible to change when the chemical 
substituents of the polymer backbone244,245 or the polymeric architectures246 are adjusted. 
 
 
Figure 1.17 Diagrammatic representation of a pH-responsive polymer in: A) Swollen, hydrated state 
upon addition of acid (i) and; B) Collapsed, hydrophobic polymer upon addition of base (ii). 
A change in behaviour upon a switch in pH is specifically attractive for biological 
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applications due to the abundant pH gradients existing in normal and pathophysiological 
states. A leading example is the extracellular pH of tumours,247,248 and endosomal and 
lysosomal compartments of cells possessing a slightly more acidic pH (~4.5)249 than blood 
and normal tissues (~7.4).250 The synthesis of pH-responsive polymers has been 
extensively studied, with the influences of pH, co-solvent and electrolytes altering the 
solubility, volume properties and chain conformations.226 In particular, tertiary amine 
methacrylate-based block copolymers possess responsiveness to multiple external stimuli 
(such as pH, temperature and salts – largely relevant to the human body) and have received 
an increased amount of interest.251 
 
The ease of synthesis and the self-assembly of diblock copolymers to form pH-responsive 
micelles has extensively been investigated.252 Double hydrophilic block copolymers,253 
where one hydrophilic block is susceptible to change in solution conditions such as pH, 
avoids the use of co-solvents. Armes and co-workers have explored this concept in detail, 
and confirmed that manipulating the pH of the water led to micelle 
formation/dissociation.254 Additionally, the construction of pH-responsive branched 
copolymer NPs which reversibly form “core-shell” morphologies have been studied.255 
 
The copolymers crafted as the “building blocks” for assembly of higher-order materials 
have endless possibilities.256 This has encouraged the inclusion of biocompatible polymers 
into pH-responsive micelles,257 combinations of different diblock copolymers to form 
complex micelles258 and triblock copolymers to produce multi-responsive triple-shell 
architectures (that are multi-responsive).259 Other approaches have included the covalent 
conjugation of drugs to polymers via acid degradable linkages such as hydrazone, ester 
and carbamate linkers.260,261,262,263 This enables control over the drug release rate, similar 
to smart nano-carrier systems, as opposed to the drug being physically entrapped in the 
hydrophobic core which is the conventional method for micelle encapsulation. 
 
1.5 Concluding remarks 
 
Despite the considerable on-going research into nanomedicine for drug delivery 
applications, there are still many biodistribution and clinical translation concerns that need 
to be addressed.20 Current drug delivery vehicles such as block copolymer micelles offer 
high loading capabilities as well as the ability to tune the chemical composition and 
function of the diblock copolymers.264 Micelles may be constructed to respond to triggers 
from external stimuli, governing self-assembly and dis-assembly and making them a 
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highly attractive option for drug delivery. The ability to cross-link the core and/or shell of 
micelles also offers increased stability in physiological media. Current research efforts are 
investigating functionalisation of the diblock copolymers within micelle systems,265 in 
order to target specific sites of interest. 
 
Continued efforts to develop more effective syntheses, with control over molecular weight 
distributions, specificity of surface functionality and the on-going understanding of in vivo 
interactions of dendrimers,266 has resulted in the commercial application of PAMAM in 
medical use. Despite this, dendrimer syntheses continue to be expensive and time 
consuming. There is little detail of commercial synthesis available but the early patent by 
Tomalia and Dewald267 suggests the production of 51.2 g of Generation 3 polyamine 
dendrimer required 9 g ammonia, 978 g methanol, 1.3 kg ethylenediamine and 455 g 
methyl acrylate (Figure 1.18). Synthetic improvements have been vast, however, each 
generation of growth continues to require an exponentially increasing number of reactions 
in order to increase the molecular weight of the macromolecule. 
 
Figure 1.18 Relative representation of the inefficient mass amount of reactants required: 9 g ammonia 
(purple), 978 g methanol (green), 1.3 kg ethylenediamine (orange) and 455 g methyl acrylate (blue) 
reported by Tomalia and Dewald267 to produce 51.2 g of Generation 3 polyamine dendrimer (red). 
 
The advancement of controlled polymerisation techniques has allowed the rational design 
of high molecular weight materials through inexpensive and relatively straightforward 
procedures. In recent developments, the combined concepts of linear-dendritic hybrids 
and branched vinyl polymers (Figure 1.19) has resulted in the introduction of hyp-
polydendrons, incorporating the highly extensive surface functionality of dendrimers with 
a branched polymer core. Hyp-polydendrons have previously been synthesised from 
relatively small dendrons as initiators for branched vinyl polymerisation (cf. Section 
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1.3.1.1.2). The combination of many dendrons via a non-crosslinked, branched polymer 
core in one synthetic step avoids complex dendrimer synthesis. Current reports in the 
literature have investigated the modification of the structural components, by introducing 
a mixed dendron/PEG initiator system.268 
 
Figure 1.19 Diagrammatic representation of the combined concepts of linear-dendritic hybrids and 
branched copolymers to produce hyp-polydendrons. 
 
1.6 Project Aims 
 
Ultimately, the focus of hyp-polydendron NP formation is their assessment as potential 
nanomedicines using a series of in vitro pharmacological studies that includes modelling 
of oral administration. These novel materials are intended to offer benefits as 
nanomedicines through increased stability, encapsulation properties, enhanced 
bioavailability and decreased drug toxicity, based on the modifications made within the 
hyp-polydendron structure. The steps involved to produce the variety of hyp-polydendrons 
synthesised in order to allow such assessment is to be carried out as so: 
 
1.? Firstly, the research presented here aims to introduce amphiphilicity into hyp-
polydendrons through the use of tertiary amine functional dendritic chain-ends and 
branched hydrophobic polymer segments, whilst allowing comparison with analogous 
linear-dendritic hybrids. The use of 2-hydroxypropyl methacrylate (HPMA) and the 
co-polymerisation of HPMA and EGDMA, will also allow comparison to similar 
material studies. The effects of amphiphilicity on the stability and behaviour of the 
polymeric NPs formed will be studied and discussed in depth. 
 
As well as studying the effects of varying dendron generation and surface chemistry 
compared to the hyp-polydendrons already reported in the literature, the research 
presented here aims to investigate other chemical variations within the hyp-
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polydendron structure. There are multiple variations available for hyp-polydendron 
design and synthesis, offering the opportunity to control both structural and chemical 
behaviour. These include: variation of the chemical composition of the primary 
polymer chains (Figure 1.20a), utilising different monomers within the vinyl co-
polymerisation to produce primary polymer chains with different chemical properties; 
alteration of the chemistry of the dendron chain end (Figure 1.20b), resulting in 
different surface chemistry; and alternatively the linker chemistry within the molecule 
can be tailored to potentially generate functionality within the internal structure of the 
dendron.  
In addition, the architecture of the primary chains is a potential site for variation with 
the production of statistical and block copolymers (Figure 1.20c), as well as variation 
of the degree of polymerisation (Figure 1.20d). The one-pot polymerisation could 
enable initiation by multiple initiators (dendron and non-dendron) to result in mixed 
surface groups on the hyp-polydendron (Figure 1.20e) and, finally, the incorporation 
of an alternative divinyl monomer to EGDMA can be incorporated to introduce 
different brancher chemistry (Figure 1.20f).
 
Figure 1.20 Targeted architectural and chemical variations of hyp-polydendron structure; a) primary 
polymer chain chemistry; b) dendron chemistry; c) primary polymer chain architecture; d) primary 
polymer chain length; e) mixed surface functionality and f) brancher chemistry. 
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2.? Following the synthesis and characterisation of a range of materials with many of the 
structural and chemical variations outlined above, the ability of hyp-polydendrons to 
form stable NPs via nanoprecipitation in aqueous media (Figure 1.21B) will be 
compared with the linear-dendritic analogues (Figure 1.21A). The variation in 
chemical and structural components within the hyp-polydendron will allow 
investigations to be carried out to uncover the effects of chain-end dendron generation 
and chemistry, precipitation medium pH and polymer architecture on the ability of 
each material to generate NPs; the resulting NP diameter and dispersity and subsequent 
response to changes in pH will be studied in detail.  
 
3.? Additionally, the recently reported co-nanoprecipitation method will be applied in this 
work,269 combining linear-dendritic polymer hybrids with hydrophobic, branched 
copolymers prior to the nanoprecipitation process (Figure 1.21C) to produce stabilised 
nanoprecipitates. These studies are expected to provide insights into the synthesis 
variables within hyp-polydendron architectures and the effect of these modifications 
on NP formation and behaviour. 
 
Figure 1.21 Hypothetical aims to produce stable nanoparticle dispersions in aqueous media from A) 
linear-dendritic polymer hybrids; B) Hyp-polydendrons and; C) Co-nanoprecipitation of linear-
dendritic polymers and branched copolymers. 
 
4.? The inclusion of a pH-responsive monomer into the hyp-polydendron core is 
hypothesised to provide, for the first time, stabilised hyp-polydendron 
nanoprecipitates in neutral pH, that dis-assemble into unimolecular species upon the 
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addition of acid. Additionally, the introduction of an acid-cleavable brancher is 
expected to provide potential opportunities for a double NP degradation mechanism: 
first, the dissociation of the nanoprecipitate into solvated branched polymers (Figure 
1.22i), and secondly the degradation of the branched polymers into their individual 
primary chains of relatively mono-disperse and low molecular weight (Figure 1.22ii).
The size and charge of NPs used for nanomedicine applications have been shown to 
affect the efficient clearance of materials from the body and degradation into 
biologically benign components and clearance is required.270  
 
 
 
 
Figure 1.22 Hypothetical diagrammatic representation of the pH-responsive hyp-polydendron 
containing a pH-responsive polymer core and an acid-cleavable brancher, and the proposed modes of 
hydrolysis resulting in initial solvated branched polymers (i), followed by linear-dendritic polymer 
hybrids (ii). 
 
5.? Finally, the production of biodegradable linear-dendritic hybrids and hyp-
polydendrons is a key aim of the research presented. The broadening of the controlled 
vinyl polymerisation techniques to include ring-opening polymerisation (ROP) of 
cyclic and bicyclic esters will be investigated. The resulting polyesters from 
conventional ROP are known to undergo degradation via cleavage of the backbone 
ester bonds (Figure 1.23) making these, and their resulting NPs, a key target to be 
studied. 
 
 
Figure 1.23 Diagrammatic representation of proposed degradation of biodegradable hyp-polydendrons 
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via cleavage of the ester bonds. 
 
1 http://www.avert.org/professionals/hiv-around-world/global-statistics#sthash.V7jLUZow.dpuf 
2 A. Shahiwala and M. M. Amiji, Future HIV Ther., 2007, 1, 49-59. 
3 J. W. Mellors, A. Munoz, J. V. Giorgi, J. B. Margolick, C. J. Tassoni, P. Gupta, L. A. Kingsley, J. A. 
Todd, A. J. Saah, R. Detels and J. P. Phair, Ann. Int. Med, 1997, 126, 946-954. 
4 G. Behrens, C. Knuth, I. Schedel, M. Mendila and R. E. Schmidt, The Lancet, 1998, 351, 1057-1058. 
5 P. Sendi, A. J. Palmer, A. Gafni and M. Battegay, Pharmacoeconomics, 2001, 19, 709-713. 
6 T.-W. Chun, L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. 
Chadwick, J. Margolick, T. C. Quinn and Y. H. Kuo, "Quantification of latent tissue reservoirs and 
total body viral load in HIV-1 infection." 1997, 183-188. 
7 E. Feeney, E. Muldoon and W. G. Powderly, Curr. Opin. HIV AIDS, 2006, 1, 430-436. 
8 T. Shirasaka, Jap. J. Clin. Med., 2010, 68, 480-485. 
9 T. K. Vyas, L. Shah and M. M. Amiji, Exp. Opin. Drug Del., 2006, 3, 613-628. 
10 J. M. Lanao, E. Briones and C. I. Colino, J. Drug Target., 2007, 15, 21-36. 
11 S. Dai, P. Ravi, K. C. Tam and B. W. Mao, Langmuir, 2003, 19, 5175-5177. 
12 R. Duncan and M. J. Vicent, Adv. Drug Deliver. Rev., 2013, 65, 60–70. 
13 F. M. Veronese, O. Schiavon, G. Pasut, R. Mendichi, L. Andersson, A. Tsirk, J. Ford, G. Wu, S. 
Kneller, J. Davies and R. Duncan, Bioconjugate Chem., 2005, 16, 775-784. 
14 R. Duncan, Curr. Opin. Biotechnol., 2011, 22, 492–501. 
15 S. H. Medina and M. E. H. El-Sayed, Chem. Rev., 2009, 109, 3141–3157 3141. 
16 O. C. Farokhzad and R. Langer, Adv. Drug Deliver. Rev., 2006, 58, 1456–1459. 
17 Y. Liu, H. Miyoshi and M. Nakamura, Int. J. Cancer, 2007, 120, 2527–2537. 
18 D. F. Emerich and C. G. Thanos, J. Drug Target., 2007, 15, 163-183. 
19 D. A. Groneberg, M. Giersig, T. Welte and U. Pison, Curr. Drug Targets, 2006, 7, 643-648. 
20 R. Duncan and R. Gaspar, Mol. Pharm., 2011, 8, 2101-2141. 
21 R. Gasper and R. Duncan, Adv. Drug Deliver. Rev., 2009, 61, 1220–1231. 
22 M. Vellard, Curr. Opin. Biotechnol., 2003, 14, 444-450. 
23 X. Fu, Y. Zhang, X. Wang, M. Chen, Y. Wang, J. Nie, Y. Meng and W. Han, Curr. Protein Pept. 
Sci., 2015, 16, 329-336. 
24 B. Manish and T. Marar. Int. J. Curr. Microbiol. App. Sci., 2015, 4, 701-712. 
25 I. Judson, J. A. Radford, M. Harris, J. Y. Blay, Q. van Hoesel, A. le Cesne, A. T. van Oosterom, M. 
J. Clemons, C. Kamby, C. Hermans, J. Whittaker, E. Donato di Paola, J. Verweij and S. Nielsen, Eur. 
J. Cancer, 2001, 37, 870–877. 
26 M. E. O’Brien, N. Wigler, M. C. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, 
P. Tomczak, S. P. Ackland and F. Orlandi, Ann. Oncol., 2004, 15, 440-449. 
27 J. Picus and M. Schultz, Semin. Oncol., 1999, 26, 14-18. 
28 K. P. Johnson, B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. 
Panitch, J. W. Rose, R. B. Schiffer, T. Vollmer, L. P. Weiner and J. S. Wolinsky, Neurology, 1998, 50, 
701-708. 
???????????????????????????????????????? ????????????????????
CHAPTER 1 
40 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
29 E. A. Forssen, R. Male-Brune, J. P. Adler-Moore, M. J. A. Lee, P. G. Schmidt, T. B. Krasieva, S. 
Shimizu and B. J. Tromberg, Cancer Res., 1996, 56, 2066-2075. 
30 J. Tollemar, O. Ringden, S. Andersson, B. Sundberg, P. Ljungman and G. Tyden, Bone Marrow 
Transpl., 1993, 12, 577-582. 
31 M. J. Glantz, K. A. Jaeckle, M. C. Chamberlain, S. Phuphanich, L. Recht, L. J. Swinnen, B. Maria, 
S. LaFollette, G. B. Schumann, B. F. Cole and S. B. Howell, Clin. Cancer Res., 1999, 5, 3394-3402. 
32 R. C. F. Leonard, S. Williams, A. Tulpule, A. M. Levine and S. Oliveros. The Breast, 2009, 18, 218-
224. 
33 R. M. Bukowski, C. Tendler, D. Cutler, E. Rose, M. M. Laughlin and P. Statkevich, Cancer, 2002, 
95, 389-396. 
34 G. M. Chertow, S, K. Burke, J. M. Lazarus, K. H. Stenzel, D. Wombolt, D. Goldberg, J. V. Bonventre 
and E. Slatopolsky, Am. J. Kidney Dis., 1997, 29, 66-71. 
35 V. R. Participants, Retina, 2005, 25, 119-134. 
36 F. J. Zieve, M. F. Kalin, S. L. Schwartz, M. R. Jones and W. L. Bailey, Clin. Ther., 2007, 29, 74-83. 
37 G. Molineux, Curr. Pharm. Design, 2004, 10, 1235-1244. 
38 S. Zeuzem, M. Diago, E. Gane, K. R. Reddy, P. Pockros, D. Prati, M. Shiffman, P. Farci, N. Gitlin, 
C. B. O’Brien, F. Lamour and P. Lardelli, Gastroenterology, 2004, 127, 1724-1732. 
39 K. A. Rodvold, W. F. Bennett, and K. A. Zib, J. Clin. Pharmacol., 1997, 37. 
40 J. A. Simon, Menopause, 2006, 13, 222-231. 
41 D. Gambling, T. Hughes, G. Martin, W. Horton and G. Manvelian, Anesth. Analg., 2005, 100, 1065-
1074. 
42 Macugen Diabetic Retinopathy Study Group. Ophthalmology, 2006, 113, 23-28. 
43 M. R. Green, G. M. Manikhas, S. Orlov, B. Afanasyev, A. M. Makhson, P. Bhar and M. J. Hawkins, 
Ann. Oncol., 2006, 17, 1263-1268. 
44 A. Sánchez-Fructuoso, L. Guirado, J. C. Ruiz, V. Torregrosa, E. González, M. L. Suárez, R. Gallego 
and AnemiaTrans Study Group. Transpl. P., 2010, 42, 2931-2934. 
45 M. Connock, S. Tubeuf, K. Malottki, A. Uthman, J. Round, S. Bayliss, C. Meads and D. Moore, 
Health Technol. Assess., 2010, 14, 1-10. 
46 S. Johal, C. Knight, M. J. Bell and S. Ralston, Value in Health, 2011, 14, A438. 
47 J. Kling, Nat. Biotechnol., 2011, 29, 197-200. 
48 E. Proksch, J-M. Jensen, A. Crichton-Smith, A. Fowler and J. Clitherow, Der Hautarzt, 2007, 58, 
604-610. 
49 M. A. Rodriguez, R. Pytlik, T. Kozak, M. Chhanabhai, R. Gascoyne, B. Lu, S. R. Deitcher and J. N. 
Winter, Cancer, 2009, 115, 3475-3482. 
50 C. E. Mora-Huertas, H. Fessi and A. Elaissari, Int. J. Pharm., 2010, 385, 113-142. 
51 V. Wagner, A. Dullaart, A. K. Bock and A. Zweck, Nat. Biotech. 2006, 24, 1211-1217. 
52 V. K. Pawar, Y. Singh, J. G. Meher, S. Gupta and M. K. Chourasia, J. Control. Release, 2014, 183, 
51−66. 
53 B. E. Rabinow, Nat. Rev. Drug Discov., 2004, 3, 785−796. 
CHAPTER 1 
41 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
54 H. Zhang, D. Wang, R. Butler, N.L. Campbell, J. Long, B. Tan, D. J. Duncalf, A. J. Foster, A. 
Hopkinson, D. Taylor, D. Angus, A. I. Cooper and S. P. Rannard, Nat. Nanotechnol. 2008, 3, 506−511. 
55 T. O. McDonald, M. M. P. Giardiello, M. Siccardi, N. J. Liptrott, D. Smith, P. Roberts, P. Curley, A. 
Schipani, S. H. Khoo, J. Long, A. J. Foster, S. P. Rannard and A. Owen, Adv. Healthcare Mater., 2014, 
3, 400-411. 
56 T. O. McDonald, P. Martin, J. P. Patterson, D. Smith, M. Giardiello, M. Marcello, V. See, R. K. 
O’Reilly, A. Owen and S. P. Rannard, Adv. Funct. Mater. 2012, 22, 2469−2478. 
57 X. Guan, X. Hu, S. Liu, Y. Huang, X. Jing and Z. Xie, RSC Adv. 2014, 4, 55187−55194. 
58 T. Sun, Y. S. Zhang, B. Pang, D. C. Hyun, M. Yang and Y. Xia, Angew. Chem. Int. Ed. Engl., 2014, 
53, 12320-12364. 
59 P. K. Dhal, S. C. Polomoscanik, L. Z. Avila, S. R. Holmes-Farley and R. J. Miller, Adv. Drug Deliver. 
Rev., 2009, 6, 1121-1130. 
60 J. M. Harris and R. B. Chess, Nature Rev. Drug Discov., 2003, 2, 214–221. 
61 G. Pasut, A. Guiotto and F. Veronese, Expert Opin. Therap. Patents, 2004, 14, 859–894. 
62 R. Duncan, Anticancer Drugs, 1992, 3, 175–210. 
63 J. Kopecek, P. Kopeckova, T. Minko and Z. Lu, Eur. J. Pharm. Biopharm., 2000, 50, 61–81. 
64 Y. Matsumura and K. Kataoka, Cancer Sci., 2009, 100, 572-579. 
65 D. Edinger and E. Wagner, Nanomed. Nanobiotechnol., 2011, 3, 33-46. 
66 R. Duncan, Nat. Rev. Drug Discov., 2003, 2, 347-360. 
67 R. Duncan, Nat. Rev. Cancer, 2006, 6, 688-701. 
68 H. Ringsdorf, J. Polym. Sci. Polym. Symp., 1975, 51, 135−153. 
69 T. Tanaka, S. Shiramoto, M. Miyashita, Y. Fujishima and Y. Kaneo, Int. J. Pharm., 2004, 277, 39–
61.  
70 J.–O. Deguchi, M. Aikawa, C.-H. Tung, E. Aikawa, D.-E. Kim, V. Ntziachristos, R. Weissleder and 
P. Libby, Circulation, 2006, 114, 55–62.  
71 W. R. Sanhai, J. H. Sakamoto, R. Canady and M. Ferrari, Nat. Nanotechnol. 2008, 3, 242–244. 
72 F. F. Davis, Adv. Drug Deliver. Rev., 2002, 54, 457–458. 
73 Macugen Diabetic Retinopathy Study Group. Ophthalmology, 2006, 113, 23-28. 
74 S. Foser, A. Schacher, K. A. Weyer, D. Brugger, E. Dietel, S. Marti and T. Schreitmüller, Protein 
Expres. Purif., 2003, 30, 78-87. 
75 R. Duncan, Nat. Rev. Drug Discov., 2003, 2, 347-360. 
76 P. A. Vasey, S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan and A. H. Thomson, Clin. 
Cancer Res., 1999, 5, 83-94. 
77 R. Duncan, ACS Sym. Ser., (ed. Kwon, G. S.) 1–92 (Marcel Dekker, New York, 2005) 
78 L. W. Seymour, D. R. Ferry, D. Anderson, S. Hesslewood, P. J. Julyan, R. Poyner and J. Doran, J. 
Clin. Oncol., 2002, 20, 1668-1676. 
79 M. J. Vicent, F. Greco, R. I. Nicholson and R. Duncan, Angew. Chem. Int. Ed. Engl., 2005, 44, 2–6. 
80 R. Duncan, M. J. Vicent, F. Greco and R. I. Nicholson, Cancer, 2005, 12 (Suppl. 1), S189–S199. 
81 A. Sahu, U. Bora, N. Kasoju and P. Goswami, Acta Biomater., 2008, 4, 1752-1761. 
CHAPTER 1 
42 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
82 D. A. Christian, S. Cai, D. M. Bowen, Y. Kim, J. D. Pajerowski and D. E. Discher, Eur. J. Pharm. 
Biopharm., 2009, 71, 463-474. 
83 U. Borchert, U. Lipprandt, M. Bilang, A. Kimpfler, A. Rank, R. Peschka-Sűss, R. Schubert, P. 
Lindner and S. Főrster, Langmuir, 2006, 22, 5843–5847. 
84 Y. Mai and A. Eisenberg, Chem. Soc. Rev. 2012, 41, 5969-5985. 
85 Z. Li, M. A. Hillmyer and T. P. Lodge, Langmuir, 2006, 22, 9409-9417. 
86 T. P. Lodge, Macromol. Chem. Phys., 2003, 204, 265-273. 
87 A. H. Gröschel, F. H. Schacher, H. Schmalz, O. V. Borisov, E. B. Zhulina, A. Walther and A. H. E. 
Müller, Nat. Commun., 2012, 3, 1-10. 
88 J.-F. Lutz and A. Laschewsky, Macromol. Chem. Phys., 2005, 206, 813-817. 
89 M. Moffitt, K. Khougaz and A. Eisenberg, Acc. Chem. Res., 1996, 29, 95-102. 
90 A. P. Gast, Curr. Opin. Colloid In., 1997, 2, 258-263. 
91 K. Prochazka, T. J. Martin, P. Munk and S. E. Webber, Macromolecules, 1996, 20, 6518-6525. 
92 G. E. Yu, Z. Yang, M. Ameri, D. Attwood, J. H. Collett, C. Price and C. J. Booth, Phys. Chem. B 
1997, 101, 4394-4401. 
93 F. L. Baines, S. P. Armes, N. C. Billingham and Z. Tuzar, Macromolecules, 1996, 29, 8151-8159. 
94 S. Liu, N. C. Billingham and S. P. Armes, Angew. Chem. Int. Ed. Engl., 2001, 40, 2328-2331. 
95 V. Butun, N. C. Billingham and S. P. Armes, J. Am. Chem. Soc., 1998, 120, 11818-11819. 
96 H. Otsuka, Y. Nagasaki and K. Kataoka, Adv. Drug Deliver. Rev., 2003, 55, 403−419. 
97 A. Lavasanifar, J. Samuel and G. S. Kwon, Adv. Drug Deliver. Rev., 2002, 54, 169−190. 
98 S. B. La, T. Okano and K. J. Kataoka, Pharm. Sci., 1996, 85, 85−90. 
99 A. Rösler, G. W. M. Vandermeulen and H-A. Klok, Adv. Drug Deliver. Rev., 2012, 64, 270–279. 
100 X. Liu, R. Ma, J. Shen, Y. Xu, Y. An and L. Shi, Biomacromolecules, 2012, 13, 1307−1314. 
101 K. Kataoka, A. Harada and Y. Nagasaki, Adv. Drug Deliver. Rev., 2012, 64, 246-255. 
102 L. Zhang and S. Granick, Nano. Lett. 2006, 6, 694-698. 
103 V. P. Torchilin, Nat. Rev. Drug Discov., 2005, 4, 145-160. 
104 S. Vemuri and C. T. Rhodes, Pharm. Acta Helv., 1995, 70, 95-111. 
105 S. M. Moghimi and J. Szebeni, Prog. Lipid Res. 2003, 42, 463-478. 
106 D. W. Northfelt, B. J. Dezube, J. A. Thommes, B. J. Miller, M. A. Fischl, A. Friedman-Kien, L. D. 
Kaplan, C. Du Mond, R. D. Mamelok and D. H. Henry, J. Clin. Oncol., 1998, 16, 2445-2451. 
107 R. M. Rifkin, S. A. Gregory, A. Mohrbacher and M. A. Hussein, Cancer 2006, 106, 848-858. 
108 E. Nagore, A. Insa and O. Sanmartin, Am. J. Clin. Dermatol., 2000, 1, 225–234.  
109 D. Lorusso, A. Di Stefano, V. Carone, A. Fagotti, S. Pisconti, and G. Scambia, Ann. Oncol., 2007, 
18, 1159-1164. 
110 C. Strazielle, H. Benoit and O. Vogl, Eur. Polym. J., 1978, 14, 331-334. 
111 E. W. Buhleier, W. Wehner and F. Vögtle, Synthesis, 1978, 2, 155-158. 
112 D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder and P. Smith, 
Polym. J., 1985, 17, 117-132. 
113 D. A. Tomalia and J. M. J. Fréchet, J. Polym. Sci. Polym. Chem., 2002, 40, 2719-2728. 
114 D. A. Tomalia, A. M. Naylor and W. A. Goddard, Angew. Chem. Int. Ed. Engl., 1990, 102, 119–
CHAPTER 1 
43 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
157. 
115 D. A. Tomalia, A. M. Naylor and W. A. Goddard, Angew. Chem. Int. Ed. Engl., 1990, 29, 138–175. 
116 E. Roseita and D. A. Tomalia, Drug Discov. To., 2001, 6, 427-436. 
117 N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J. W. Weener, E. W. Meijer, W. 
Paulus and R. Duncan, J. Control. Release, 2000, 65, 133-148. 
118 R. Jevpraesesphant, J. Penny, R. Jalal, D. Attwood, N. B. Keown and A. D’Emanuele, Int. J. Pharm., 
2003, 252, 263-266. 
119 C. J. Hawker and J.M.J. Fréchet, J. Am. Chem. Soc., 1990, 112, 7638– 7647. 
120 J. M. J. Fréchet, J. Mater. Sci. Pure Appl. Chem., 1996, 33, 1399–1425. 
121 C. Hawker and J. M. J. Fréchet, Chem. Commun., 1990, 1010-1013. 
122 A. W. Bosman, H. M. Janssen, and E. W. Meijer. Chem. Rev., 1999, 99, 1665-1688. 
123 F. Aulenta, W. Hayes and S. Rannard, Eur. Polym. J., 2003, 39, 1741-1771. 
124 U. Boas and P. M. H. Heegaard, Chem. Soc. Rev., 2004, 33, 43-63. 
125 D. Astruc, E. Boisselier and C. Ornelas, Chem. Rev. 2010, 110, 1857–1959. 
126 M. J. Cloninger, Curr. Opin. Chem. Biol., 2002, 6, 742–748. 
127 R. Esfand and D. A. Tomalia, Drug Discov. To., 2001, 6, 427-436.  
128 A. J. Khopade, F. Caruso, P. Tripathi, S. Nagaich and N. K. Jain, Int. J. Pharm., 2002, 232, 157-
162. 
129 S. H. Battah, C.-E. Chee, H. Nakanishi, S. Gerscher, A. J. MacRobert and C. Edwards, Bioconjugate 
Chem., 2001, 12, 980-988. 
130 A. Saovapakhiran, A. D’Emanuele, D. Attwood and J. Penny, Bioconjugate Chem., 2009, 20, 693-
701. 
131 O. L. Padilla De Jesús, H. R. Ihre, L. Gagne, J. M. J. Fréchet, Bioconjugate Chem., 2002, 13, 453-
461. 
132 Y. Matsumura and H. Maeda, Cancer Res., 1986, 12, 6387-6392. 
133 R. Rupp, S. L. Rosenthal and L. R. Stanberry. Int. J. of Nanomed., 2007, 2, 561-566. 
134 D. Tyssen, S. A. Henderson, A. Johnson, J. Sterjovski, K. Moore, J. La, M. Zanin, S. Sonza, P. 
Karellas, M. P. Giannis and G. Krippner, PloS one, 2010, 5, e12309. 
135 Y.-H. Jiang, P. Emau, J. S. Cairns, L. Flanary, W. R. Morton, T. D. McCarthy and C. C. & Tsai, 
AIDS Res. Hum. Retrov., 2005, 21, 207-213. 
136 http://www.starpharma.com/drug_delivery/dep_docetaxel. 
137 M. Nishikawa, Y. Takakura and M. Hashida, Adv. Drug Deliver. Rev., 1996, 21, 135-155. 
138 R. M. Kannan, E. Nance, S. Kannan and D. A. Tomalia, J. Intern. Med., 2014, 276, 579–617. 
139 B. Helms, J. L. Mynar, C. J. Hawker and J. M. J. Fréchet and F. C.Szoka, Jr., J. Am. Chem. Soc., 
2004, 126, 15020-15021. 
140 A. D. Schlüter and J. P. Rabe, Angew. Chem. Int. Ed. Engl., 2000, 39, 864–883.  
141 Y. Chen, X. Xiong, Chem. Commun., 2010, 46, 5049–5060. 
142 D. A. Tomalia and P. Kirchoff, U.S. Patent 4,694,064, 1987. 
143 S. M. Grayson, J. M. J. Fréchet, Macromolecules, 2001, 34, 6542-6544. 
144 C. C. Lee, S. M. Grayson and J. M. J. Fréchet, J. Polym. Sci. Polym. Chem., 2004, 42, 3563-3578. 
CHAPTER 1 
44 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
145 B. Helms, J. L. Mynar, C. J. Hawker and J. M. J. Fréchet, J. Am. Chem. Soc., 2004, 126, 15020-
15021. 
146 C. J. Hawker and J. M. J. Fréchet, Polymer, 1992, 33, 1507-1511. 
147 Z. Bo and A. Dieter Schlüter, Chem.-A Eur. J., 2000, 6, 3235-3241. 
148 C. C. Lee, M. Yoshida, J. M. J. Fréchet, E. E. Dy and F. C. Szoka. Bioconjugate Chem., 2005, 16, 
535-541. 
149 M. V. Walter, P. Lundberg, A. Hult and M. Malkoch, J. Polym. Sci. Polym. Chem., 2011, 49, 2990-
2995. 
150 I. Gitsov, J. Polym. Sci. Polym. Chem, 2008, 46, 5295– 5314.  
151 I. Gitsov and J. M. J. Fréchet, Macromolecules, 1993, 26, 6536–6546. 
152 C. J. Hawker, K. L. Wooley and J. M. J. Fréchet, J. Chem. Soc., Perkin Trans., 1993, 1, 1287–1297. 
153 H. Ihre, A. Hult, J. M. J. Fréchet and I. Gitsov, Macromolecules, 1998, 31, 4061–4068.  
154 M. Malkoch, E. Malmstrom and A. Hult, Macromolecules, 2002, 35, 8307–8314. 
155 P. Lundberg, M. V. Walter, M. I. Montañez, D. Hult, A. Hult, A. Nyström, and M. Malkoch, Polym. 
Chem., 2011, 2, 394-402. 
156 E. R. Gillies and J. M. J. Fréchet, J. Am. Chem. Soc., 2002, 124, 14137-14146. 
157 S. N. J. Pang, J. Am. Coll. Toxicol., 1993, 12, 429-457. 
158 M. J. Joralemon, R. K. O'Reilly, J. B. Matson, A. K. Nugent, C. J. Hawker and K. L. Wooley, 
Macromolecules, 2005, 38, 5436-5443. 
159 P. Wu, A. K. Feldman, A. K. Nugent, C. J. Hawker, A. Scheel, B. Voit, J. Pyun, J. M. J. Frechet, K. 
B. Sharpless and V. V. Fokin, Angew. Chem., Int. Ed. Engl., 2004, 43, 3928-3932. 
160 C. Ornelas, J. R. Aranzaes, E. Cloutet, S. Alves and D. Astruc, Angew. Chem., Int. Ed. Engl., 2007, 
46, 872-877. 
161 S. E. R. Auty, O. C. J. Andrén,  F. Y. Hern,  M. Malkoch and S P. Rannard, Polym. Chem., 2015, 6, 
573–582. 
162 D. Wang, P. Kopecková, T. Minko, V. Nanayakkara and J. Kopecek, Biomacromolecules, 2000, 1, 
313-319. 
163 E. R. Gillies, T. B. Jonsson and J. M. J. Fréchet, J. Am. Chem. Soc., 2004, 126, 11936-11943. 
164 O. L. Padilla de Jesus, H. Ihre, L. Gagne, J. M. J. Frechet, F. C. J. Szoka, Bioconjugate Chem., 2002, 
13, 453–461. 
165 M. Shamis, H. N. Lode and D. Shabat, J. Am. Chem. Soc., 2004, 126, 1726-1731. 
166 F. M. H. de Groot, C. Albrecht, R. Koekkoek, P. H. Beusker and H. W. Scheeren, Angew. Chem. 
Int. Ed. Engl., 2003, 115, 4628-4632. 
167 R. J. Amir, N. Pessah, M. Shamis and D. Shabat, Angew. Chem. Int. Ed. Engl., 2003, 115, 4632-
4637. 
168 Y. H. Kim, J. Polym. Sci. Polym. Chem., 1998, 36, 1685-1698. 
169 B. J. Voit, J. Polym. Sci. Polym. Chem., 2000, 38, 2505-2525. 
170 P. J. Flory, J. Am. Chem. Soc., 1952, 74, 2718-2723. 
171 J. M. J. Fréchet, M. Henmi, I. Gitsov, S. Aoshima, M. R. Leduc and R. B. Grubbs, Science, 1995, 
269, 1080-1083. 
CHAPTER 1 
45 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
172 K. Ishihara, N. Hamada, S. Kato and I. Shinohara, J. Polym. Sci. Polym. Chem. 1984, 22, 881-884. 
173 A. Suzuki and T. Tanaka, Nature, 1990, 346, 345-347. 
174 C. H. Lin, J. S. Xiang and K. Matyjaszewski, Macromolecules, 1993, 26, 2785-2790. 
175 C. R. Yates and W. Hayes, Eur. Polym. J., 2004, 40, 1257-1281. 
176 E. Malmström and A. Hult. J. Macromol. Sci. C Polym. Rev., 1997, 37, 555-579. 
177 B. Romagnoli and W. Hayes, J. Mater. Chem., 2002, 12, 767-799. 
178 E. Žagar and M. Žigon, Prog. Polym. Sci., 2011, 36, 53-88. 
179 X. Zeng, Y. Zhang, Z. Wu, P. Lundberg, M. Malkoch and A. M. Nyström, J. Polym. Sci Pol. Chem., 
2012, 50, 280–288. 
180 R. A. T. M. van Benthem, Prog. Org. Coat., 2000, 40, 203-214. 
181 P. E. Froehling, J. Polym. Sci Pol. Chem., 2004, 42, 3110-3115. 
182 M. Seiler, Fluid Phase Equilibr., 2006, 241, 155–174  
183 A. Yokoyama and T. Yokozawa, Macromolecules, 2007, 40, 4093-4101. 
184 C. J. Hawker, J. Am. Chem. Soc., 1994, 116, 11185-11186. 
185 M. Kato, M. Kamigaito, M. Sawamoto and T. Higashimura, Macromolecules, 1995, 28, 1721-1723. 
186 M. Szwarc, M. Levy and R. Milkovich, J. Am. Chem. Soc., 1956, 78, 2656-2657. 
187 K. Matyjaszewski, Am. Chem. Soc.; Distributed by Oxford University Press, 2003. 
188 M. Kamigaito, T. Ando and Mitsuo Sawamoto, Chem. Rev., 2001, 101, 3689-3746. 
189 N. M. B. Smeets, Eur. Polym. J., 2013, 49 2528–2544. 
190 K. Hong, D. Uhrig and J. W. Mays, Curr. Opin. Solid St. M., 1999, 4, 531-538. 
191 R. Vijayaraghavan and D. R. MacFarlane, Chem. Commun., 2004, 6, 700-701. 
192 K. Matyjaszewski, Am. Chem. Soc., 1998. 
193 J. Chiefari, Y. K. Chong, F. Ercole, J. Krstina, J. Jeffery, T. P. T. Le, R. T. A. Mayadunne, G. F. 
Meijs, C. L. Moad, G. Moad, E. Rizzardo and S. H. Thang, Macromolecules, 1998, 31, 5559-5562. 
194 C. Chevigny, D. Gigmes, D. Bertin, J. Jestin and F. Boue, Soft Matter, 2009, 5, 3741-3753. 
195 S. G. Gaynor, J-S. Wang and K. Matyjaszewski, Macromolecules, 1995, 28, 8051-8056. 
196 K. Matyjaszewski and J. Xia, Chem. Rev., 2001, 101, 2921-2990. 
197 J. S. Wang and K. Matyjaszewski, J. Am. Chem. Soc., 1995, 117, 5614-5615. 
198 J. Wang and K. Matyjaszewski, Macromolecules, 1995, 28, 7901-7910. 
199 S. B. Lee, A. J. Russell and K. Matyjaszewski, Biomacromolecules, 2003, 4, 1386-1393. 
200 K. Matyjaszewski, K. Davis, T. E. Patten and M. Wei, Tetrahedron, 1997, 53, 15321-15329. 
201 M. Teodorescu and K. Matyjaszewski, Macromolecules, 1999, 32, 4826-4831. 
202 W. Tang and K. Matyjaszewski, Macromolecules, 2007, 40, 1858-1863. 
203 W. Tang and K. Matyjaszewski, Macromolecules, 2006, 39, 4953-4959. 
204 F. di Lena and K. Matyjaszewski, Prog. Polym. Sci., 2010, 35, 959-1021. 
205 G. Chambard, B. Klumperman and A. L. German, Macromolecules, 2000, 33, 4417-4421. 
206 P. Flory, Principles of Polymer Chemistry; Cornell University Press: Ithaca, NY, 1953. 
207 A. R. Wang and S. Zhu, Polym. Eng. Sci., 2005, 45, 720-727. 
208 W. H. Stockmayer, J. Chem. Phys., 1944, 12, 125-131. 
209 J. Rosselgong and S. P. Armes, Macromolecules, 2010, 43, 2145-2156. 
CHAPTER 1 
46 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
210 F. Isaure, P. A. G. Cormack and D. C. J. Sherrington, Mater. Chem., 2003, 13, 2701-2710. 
211 F. Isaure, P. A. G. Cormack and D. C. Sherrington, Macromolecules, 2004, 37, 2096-2105. 
212 N. O’Brien, A. McKee, D. C. Sherrington, A. T. Slark and A.Titterton, Polymer, 2000, 41, 6027-
6031. 
213 P. A. Costello, I. K. Martin, A. T. Slark, D. C. Sherrington and A. Titterton, Polymer, 2002, 43, 245-
254. 
214 Y. Li and S. P. Armes, Macromolecules, 2005, 38, 8155-8162. 
215 I. Bannister, N. C. Billingham, S. P. Armes, S. P. Rannard and P. Findlay, Macromolecules, 2006, 
39, 7483-7492. 
216 F. L. Hatton, P. Chambon, T. O. McDonald, A. Owen and S. P. Rannard, Chem. Sci., 2014, 5, 1844-
1853. 
217 R. G. Ezell, C. L. McCormick and J. Appel, Polym. Sci, 2007, 104, 2812-2821. 
218 F. M. Richardson, S. R. Armentrout and C. L. McCormick, J. Appl. Polym. Sci., 1999, 74, 2290-
2300. 
219 T. Nishio, R. Suzuki, Y. Tsukada, H. Kanazawa, T. Okano and T. Miyabe-Nishiwaki, J. 
Chromatogr., A, 2009, 1, 7427-7432. 
220 B. Mattiasson, A. Kumar, A. E. Ivanov and I. Y. Galaev, Nat. Protoc., 2007, 2, 213-220. 
221 M. Malchur, D. Volodkin, B, Heurtault, P. Andre, P. Schaaf, H. Mohwald, J. C. Voegal, A. 
Sokolowski, V. Ball, F. Boulmedais and B. Benoit Frisch, Langmuir, 2008, 24, 10209-10215. 
222 D. Crespy and R. M. Rossi, Polym. Int., 2007, 56, 1461-1468. 
223 C. de las Heras Alarcon, S. Pennadam and A. Cameron, Chem. Soc. Rev., 2005, 34, 276-285. 
224 A. K. Bajpai, S. K. Shukla, S. Bhanu and S. Kankane, Prog. Polym. Sci., 2008, 33, 1088-1118. 
225 L. E. Bromberg and E. S. Rori, Adv. Drug Deliver. Rev., 1998, 31, 197-221. 
226 S. Dai, P. Ravi and K. C. Tam, Soft Matter, 2008, 4, 435-449. 
227 J. P. Magnusson, A. Khan, G. Pasparakis, A. O. Saeed, W. Wang and A. Cameron, J. Am. Chem. 
Soc., 2008, 130, 10852-10853. 
228 X. Jiang, C. A. Lavender, J. W. Woodcock and B. Zhao, Macromolecules, 2008, 41, 2632-2643. 
229 L. E. Bromberg and E. S. Ron, Adv. Drug Deliver. Rev., 1998, 31, 197-221. 
230 C. de las Heras Alarcón, S. Pennadam and C. Alexander, Chem. Soc. Rev., 2005, 34, 276–285. 
231 M. Arotcarena, B. Heise, S. Ishaya and A. Laschewsky, J. Am. Chem. Soc., 2002, 124, 3787–3793.  
232 K. S. Murthy, Q. G. Ma, E. E. Remsen, T. Kowalewski and K. L. Wooley, J. Mater. Chem., 2003, 
13, 2785–2795. 
233 J. V. M. Weaver, Y. Q. Tang, S. Y. Liu, P. D. Iddon, R. Grigg, N. C. Billingham, S. P. Armes, R. 
Hunter and S. P. Rannard, Angew. Chem., Int. Ed. Engl., 2004, 43, 1389–1392.  
234 K. B. Thurmond, E. E. Remsen, T. Kowalewski and K. L. Wooley, Nucleic Acids Res., 1999, 27, 
2966–2971.  
235  K. B. Thurmond, T. Kowalewski and K. L. Wooley, J. Am. Chem. Soc., 1996, 118, 7239–7240.  
236 H.-I. Lee, J. A. Lee, Z. Poon and P. T. Hammond, Chem. Commun., 2008, 32, 3726–3728. 
237 S. Freiberg and X. Zhu, Int. J. Pharm., 2004, 282, 1–18. 
238 R. X. Liu, M. Fraylich and B. R. Saunders, Colloid Polym. Sci., 2009, 287, 627–643. 
CHAPTER 1 
47 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
239 E. Kharlampieva, V. Kozlovskaya, J. Tyutina and S. A. Sukhishvili, Macromolecules, 2005, 38, 
10523–10531. 
240 C. A. Kavanagh, Y. A. Rochev, W. A. Gallagher, K. A. Dawson and A. K. Keenan, Pharmacol. 
Ther., 2004, 102, 1–15. 
241 F. Eeckman, A. J. Moes and K. Amighi, Int. J. Pharm., 2002, 241, 113–125. 
242 M. Hruby, J. Kucka, H. Mackova, O. Lebeda and K. Ulbrich, Chem. Listy, 2008, 102, 21–27. 
243 J. V. M. Weaver, R. T. Williams, B. J. L. Royles, P. H. Findlay, A. I. Cooper and S. 
 P. Rannard, Soft Matter, 2008, 4, 985–992. 
244 C. Worner and R. Mulhaupt, Angew. Chem., Int. Ed. Engl., 1993, 32, 1306-1308. 
245 E. M. M. De Brabander-van den Berg and E. W. Meijer, Angew. Chem., Int. Ed. Engl., 1993, 32, 
1308–1311. 
246 J. Ruiz, G. Lafueute, S. Marceu, C. Ornelas, S. Lazare, E. Cloutet, J.-C. Blais and D. Astruc, J. Am. 
Chem. Soc., 2003, 125, 7250-7257. 
247 K. Engin, D. B. Leeper, J. R. Cater, A. J. Thistlethwaite, L. Tupchong and J. D. McFarlane, J. D. 
Int. J. Hyperthermia, 1995, 11, 211-216. 
248 L. E. Gerweck and K. Seetharaman, Cancer Res. 1996, 56, 1194-1198. 
249 G. Helmlinger, F. Yuan, M. Dellian and R. K. Jain, Nature Medicine, 1997, 3, 177-182. 
250 I. Mellman, R. Fuchs and A. Helenius, Annu. Rev. Biochem. 1986, 55, 663-700. 
251 J. Hu, G. Zhang, Z. Ge and S. Liu, Progress in Polymer Science, 2014, 39, 1096-1143. 
252 B.W. Mao, L.H. Gan, Y.Y. Gan, K.C. Tam and O.K. Tan, Polymer, 2005, 46, 10045–10055. 
253 H. Cölfen, Macromol. Rapid Commun., 2001, 22, 219-252. 
254 M. Vamvakaki, D. Palioura, A. Spyros, S. P. Armes, and S. H. Anastasiadis, Macromolecules, 2006, 
39, 5106-5112. 
255 J. V. M. Weaver and Dave J. Adams, Soft Matter, 2010, 6, 2575–2582. 
256 K. M. Huh, H. C. Kang, Y. J. Lee and Y. H. Bae, Macromol. Res., 2012, 20, 224-233. 
257 X. Liu, R. Ma, J. Shen, Y. Xu, Y. An and Linqi Shi, Biomacromolecules, 2012, 13, 1307−1314. 
258 S. Lee, K. Saito, H.-R. Lee, M. J. Lee, Y. Shibasaki, Y. Oishi and B.-S. Kim, Biomacromolecules, 
2012, 13, 1190−1196. 
259 W. Tian, X. Lv, L. Huang, N. Ali and J. Kong, Macromol. Chem. Phys., 2012, 213, 2450−2463. 
260 X. Q. Yang, J. J. Grailer, I. J. Rowland, A. Javadi, S. A. Hurley, V. Z. Matson, D. A. Steeber and S. 
Q. Gong, ACS Nano., 2010, 4, 6805−6817. 
261 B. S. Kim, H. Lee, Y. H. Min, Z. Poon and P. T. Hammond, Chem. Commun., 2009, 28, 4194−4196. 
262 R. P. Tang, W. H. Ji, D. Panus, R. N. Palumbo and C. Wang, J. Control. Release, 2011, 151, 18−27. 
263 X. Z. Tang and C. Y. J. Pan, Biomed. Mater. Res.: Part A, 2008, 86, 428−438. 
264 K. Kataoka, A. Harada and Y. Nagasaki, Adv. Drug Deliver. Rev., 2001, 47, 113-131. 
??? R. K. O'Reilly, C. J. Hawker and K. L. Wooley, Chem. Soc. Rev., 2006, 35, 1068-1083. 
??? C. C. Lee, J. A. MacKay, J. M. J. Fréchet & F. C. Szoka, Nat. Biotechnol., 2005, 23, 1517–1526. 
267 D. A. Tomalia and J. R. Dewald, 1985. Dense star polymers having core, core branches, terminal 
groups. United States Patent, 4,507,466, 26 March. 
CHAPTER 1 
48 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
268 F. L. Hatton, L. M. Tatham, L. R. Tidbury, P. Chambon, T. He, A. Owen and S. P. Rannard, Chem. 
Sci., 2015, 6, 326-334. 
269 J. Ford, P. Chambon, J. North, F. L. Hatton, M. Giardiello, A. Owen and S. P. Rannard, 
Macromolecules, 2015, 48, 1883-1893. 
270 D. S. Kohane and R. Langer, Chem. Sci., 2010, 1, 441-446. 
CHAPTER 2 
50 
 
 
 
 
 
 
Chapter 2 
 
 
 
 
 
Synthesis and nanoprecipitation studies of 2-hydroxypropyl methacrylate 
linear-dendritic polymer hybrids and hyperbranched-polydendrons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication from this research chapter 
‘Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear–dendritic hybrid 
polymers and hyperbranched-polydendrons containing tertiary amine functional 
dendrons’ 
Hannah E. Rogers, Pierre Chambon, Sam E. R. Auty, Faye Y. Hern, Andrew Owen and 
Steve P. Rannard. 
Soft Matter, 2015, 11, 7005-7015. 
 
  
CHAPTER 2 
51 
2.1 Introduction 
 
The combination of dendron chain ends and linear polymer chains has led to numerous 
studies of the new class of materials, linear-dendritic polymer hybrids.1 Branching within 
the linear segment has recently extended this concept to the formation of hyperbranched-
polydendrons (hyp-polydendrons). These were first reported by Hatton et al.,2 and 
produced by introducing simultaneous branching during the propagation of the vinyl 
segment of a linear-dendritic hybrid (Figure 2.1).  
 
Figure 2.1 Co-polymerisation of 2-hydroxypropyl methacrylate (HPMA) and ethylene glycol 
dimethacrylate (EGDMA) initiated by a Generation 2 1,3-dibenzyloxy-2-propanol dendron atom 
transfer radical polymerisation (ATRP) initiator to produce a hyp-polydendron. 
 
The concepts associated with the free-radical “Strathclyde” polymerisation,3,4,5,6,7 were 
utilised and the presence of a dendron macroinitiator within the controlled radical co-
polymerisation of a mixture of vinyl and divinyl monomers was used to form soluble, 
high molecular weight branched polymers. 
 
Aqueous nanoparticles (NPs) with monomodal size distributions were prepared via 
nanoprecipitation.8 These materials showed high stability and offered options for tailored 
functionality. Further reports have described the modification of the polymeric structural 
components, by introducing a library of hyp-polydendrons containing varied levels of 
dendron/p(ethylene glycol) (PEG) surface groups.9 These amended hyp-polydendrons 
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present varied biological interactions with cells that offer the potential for tuneable NP 
permeation through the gut epithelium. 
 
The synthesis of pH-responsive polymers has been extensively studied, particularly the 
processes in which pH, co-solvent and electrolytes manipulate the solubility, volume 
and chain conformations.10 This has led to the construction of pH-responsive branched 
copolymer NPs, which reversibly form “core-shell” morphologies.11 The transition at 
which a pH-responsive polymer changes morphology occurs at a pH known as the 
apparent pKa or pKb (Chapter 1, Section 1.4.2). This is very susceptible to change when 
the chemical substituents on the polymer backbone12,13,14,15 or the polymeric 
architectures16 are adjusted. 
 
This chapter aims to introduce amine-functionality into the dendron end groups of hyp-
polydendrons to form the first amphiphilic examples of this class of material and 
investigate the effect of architecture, dendron generation and pH on the behaviour of the 
polymeric NPs formed from these complex architectures. 
 
2.2 Strategy for synthesising Generation 0-2 amine-functionalised 
dendron ATRP initiators 
 
In order to confer pH-responsive behaviour to the surface of dendrons, tertiary amines 
were introduced by using a range of dimethylamino-derived functionalities. Such 
functionality was targeted as these groups provide hydrophilicity under acidic conditions 
and allow for new amphiphilic linear-dendritic hybrids and hyp-polydendrons to be 
synthesised. 
 
A series of tertiary amine functional dendron initiators was designed, ranging from the 
zeroth to the second generation (G0-G2), which had significant chemical similarity. The 
synthesis of the G1 and G2 dendrons required the Michael addition of 2-
(dimethylamino)ethyl acrylate (DMEA) to the primary amine-containing molecules, 1-
amino-2-propanol or 1-[N, N-bis(2-aminopropyl)-amino]-2-propanol (APAP) (Scheme 
2.1ii). These also contained secondary hydroxyl functionality, to initially produce, 
AmG1-OH and AmG2-OH. AmG0-OH was commercially available as 1-
dimethylamino-2-propanol. 
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Scheme 2.1 Diagrammatic representation of amine-functionalised dendron ATRP initiators (AmG0-
Br, AmG1-Br & AmG2-Br).  
 
The simple bromoesterification reaction with α-bromoisobutyryl bromide (BiB)17 was 
used to yield the three amine-functionalised dendritic ATRP initiators (AmG0-Br, 
AmG1-Br and AmG2-Br) (Scheme 2.1i). 
 
2.2.1 Synthesis of 1-[N, N-bis(2-aminopropyl)-amino]-2-propanol 
 
In previous reports, an AB2 monomer comprising a mixture of primary amines and 
secondary hydroxyls has been synthesised,18 using diethylene triamine and propylene 
glycol; this strategy was chosen again with slight modification (Scheme 2.2), to produce 
the primary amine molecule required for the AmG2-OH synthesis.  
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Scheme 2.2 Synthesis of 1-[N,N-bis(2-aminopropyl)-amino]-2-propanol. 
 
The synthesis of APAP was achieved in four synthetic steps (Scheme 2.2). [tBOC2-
BAPA-G1] was firstly synthesised by reacting 1,1’-carbonyl diimidazole (CDI) with 
tertiary butanol to produce the imidazole carboxylic ester. Bis(3-aminopropyl)amine 
(BAPA) was then introduced to react selectively with the intermediate to produce 
[tBOC2-BAPA-G1];19 analysis was conducted using 1H (Appendix, Figure A1) and 13C 
nuclear magnetic resonance spectroscopy (NMR; Appendix, Figure A2) and electro-
spray mass-spectrometry (ES-MS; Appendix, Figure A3). 
 
The second step of the synthesis utilised the ring opening of propylene oxide (PO) to 
functionalise the focal point of [tBOC2-BAPA-G1]. This strategy was selected because 
of mild reaction conditions and reports of high yields of similar reactions.4 PO also 
exhibits a low boiling point (34°C), therefore, any excess can be easily removed by 
evaporation under vacuum. Similarly, 1H (Appendix, Figure A4) and 13C NMR 
(Appendix, Figure A5) and ES-MS (Appendix, Figure A6) were used to characterise the 
[tBOC2-BAPA-OH]. 
 
Thirdly, the removal of the N-tertiary butoxycarbonyl (tBOC) protecting groups of 
[tBOC2-BAPA-OH], using concentrated hydrochloric acid in ethyl acetate, resulted in 
the tris-ammonium salt APAP.3HCl. The reaction was left to stir until the generation of 
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CO2 ceased, and was monitored using 1H NMR (D2O) until the singlet at approximately 
1.50 ppm, corresponding to the tertiary butyl groups, had disappeared. 
 
In the final step, the resulting tris-ammonium salt APAP.3HCl was converted to the free 
amine AB2 branching molecule APAP. The synthesis of similar molecules has used ion 
exchange beads to transform the salt to the free amine, and required vacuum distillation 
to obtain a pure product.4 After attempting to use ion exchange beads, which resulted in 
low yields (<20 %), a strong base, 4M sodium hydroxide (NaOH) was used to 
deprotonate the salt. In doing so, this liberated the free-base amine APAP, which 
separated from solution as an oil. Extraction of the oil from the mixture, using 
chloroform (CHCl3), resulted in recovery of APAP as a pale yellow oil in 81% yield. 
 
The 1H NMR spectrum (Figure 2.2) confirms complete decarboxylation due to 
disappearance of the singlet corresponding to the 18 protons correlating to the tBOC 
protecting groups in [tBOC2-BAPA-OH] (Appendix, Figure A4). The 13C NMR 
spectrum shows 6 distinct C environments (Appendix, Figure A7) and the ES-MS has a 
molecular ion peak of [MH]+ = 190.2 Da; calculated (C9H23N3O) = 189.3 Da (Appendix, 
Figure A8). 
 
 
Figure 2.2 1H NMR spectrum (CDCl3, 400 MHz) of 1-[N,N-bis(2-aminopropyl)-amino]-2-propanol. 
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2.2.2 Synthesis of tertiary amine functional dendron ATRP initiators (AmG0-Br, 
AmG1-Br and AmG2-Br) 
 
As mentioned previously, the synthesis strategy aimed to employ the simple Michael 
addition of acrylates (in our case DMEA) to primary amines (Scheme 2.1ii).20 Initially, 
the synthesis of AmG1-OH and AmG2-OH was achieved by Michael addition in simple 
one pot reactions between either 1-amino-2-propanol or APAP with DMEA. Solvent and 
excess acrylate were removed in vacuo in order to isolate the products. ES-MS, 1H and 
13C NMR analysis were used to confirm the structure purity of the product. The 
disappearance of the two singlet signals at ~6 ppm (Figure 2.3 and 2.4), corresponding to 
the protons on the double bond of the DMEA, confirm all unreacted acrylate has been 
removed from the purified products. 
 
 
Figure 2.3 1H NMR spectrum (CDCl3, 400 MHz) of AmG1-OH. 
 
All 22 protons neighbouring nitrogen atoms within AmG1-OH, are collectively seen 
between 2.2–2.6 ppm (Figure 2.3a, b, e and f). The 4 protons neighbouring the oxygen 
atom on the DMEA arms are found downfield at 4.1 ppm (Figure 2.3c), due to the 
electronegativity of the oxygen, as expected. The methyl group (Figure 2.3h) is seen 
upfield and integrates to 3 protons, as expected. The 13C NMR shows a peak at 173.0 
ppm, assigned as the ester carbonyl group within the DMEA arm (Appendix, Figure A9). 
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Molecular ion peaks at [M+H]+ m/z = 362.3 and [M+Na]+ m/z = 385.3 were observed in 
the ES-MS analysis; calculated (C17H35N3O5) = 361.5 Da (Appendix, Figure A10). 
 
Figure 2.4 1H NMR spectrum (CDCl3, 400 MHz) of AmG2-OH. 
 
Similarly, for the AmG2-OH dendron, all the protons neighbouring the nitrogen atoms 
(50 protons) are collectively accounted for between 2.2–2.6 ppm (Figure 2.4a, b, e, f, h 
and i). The protons neighbouring the oxygen atom in the DMEA arms (8 protons) are 
found downfield at 4.1 ppm, due to the deshielding effect of the oxygen (Figure 2.4c). 
The 13C NMR confirms a carbonyl peak at 173.0 ppm (Appendix, Figure A11). The ES-
MS reveals molecular ion peaks at 762.2 m/z [M+H]+ and 784.6 m/z [M+Na]+; 
calculated (C37H75N7O9) = 762.0 Da (Appendix, Figure A12). 
 
The ATRP initiators were synthesised by esterification between BiB and the different 
dendron alcohols (AmG0-OH, AmG1-OH and AmG2-OH; Scheme 2.1i). Isolation and 
purification was achieved by liquid/liquid extraction (dichloromethane (DCM)/saturated 
sodium hydrogen carbonate (NaHCO3) solution) to remove unreacted alcohol, solvents 
and salts, with characterisation by NMR spectroscopy and ES-MS.  
 
In all cases, the appearance of resonances corresponding to the two new methyl groups 
neighbouring the Br atom at ~ 1.9 ppm (integrating to 6 protons) (Figures 2.5d, 2.6h and 
2.7k) and the shift of the lone proton in the ester focal point to ~5.1 ppm (Figures 2.5e, 
2.6g and 2.7j), indicated successful synthesis and purity of the products. 
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The protons neighbouring the nitrogen atom in the AmG0-Br can individually be seen at 
2.29 ppm (Figure 2.5a) and separate integration patterns agree with the expected 
structure; 6 protons for the methyl groups neighbouring the Br atom and 3 protons in 
total for the CH3 (Figure 2.5e). The 13C NMR contained a peak at 170.9 ppm accounting 
for the new carbonyl group (Appendix, Figure A13), and the ES-MS reveals a molecular 
ion peak at 252.0; calculated (C9H18NO2Br) m/z = 252.15 Da (Appendix, Figure A14). 
 
Figure 2.5 1H NMR (CDCl3, 400 MHz) spectrum of AmG0-Br. 
 
Similarly, for the AmG1-Br and AmG2-Br, the methyl protons neighbouring the 
terminal nitrogen atoms integrate to 12 and 24 protons respectively at ~2.2 ppm (Figures 
2.6a and 2.7a) and agree with the integration values of 3 protons for the methyl groups in 
the newly formed ester group (Figure 2.6i and 2.7m). The 13C NMR spectra for these 
molecules contain a new peak at 166.6 ppm (AmG1-Br) (Appendix, Figure A15) and 
171.2 ppm (AmG2-Br) (Appendix, Figure A16) accounting for the new carbonyl group 
within the ester residing in the focal point of the dendron. AmG1-Br exhibited molecular 
ion peaks [M+H]+ at m/z = 510.2 and [M+Na]+ m/z = 534.2; calculated (C21H40N3O6Br) 
m/z = 510.5 (Appendix, Figure A17) and the AmG2-Br at [M+H]+ = 912.5 m/z, 
[M+Na]+ = 934.5 m/z and [M+K]+ = 950.5 m/z; calculated (C21H40N3O6Br) m/z = 911.0 
(Appendix, Figure A18). 
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Figure 2.6 1H NMR spectrum (CDCl3, 400 MHz) of AmG1-Br. 
 
 
Figure 2.7 1H NMR spectrum (CDCl3, 400 MHz) of AmG2-Br. 
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This straightforward approach to low generation dendron initiator synthesis proved 
robust and highly reproducible and has been repeated, producing >5.37 g (99% yield) for 
AmG2-OH and >3.30 g (54% yield) for AmG2-Br. 
 
2.3 Linear polymerisation of HPMA and co-polymerisation of 
HPMA and EGDMA using EBiB and AmG0-Br, AmG1-Br and 
AmG2-Br ATRP initiators 
 
In previous studies, an average degree of polymerisation (DPn) = 50 monomer units for 
the linear polymer segment and primary chain length has been shown to yield linear-
dendritic polymers (Mw ~ 13,000 – 20,000 g mol-1)2 and hyp-polydendrons of HPMA 
(Mw > 1,000,000 g mol-1)2 that undergo successful nanoprecipitation into water. 
Therefore, this chain length was targeted for all polymers within this study to allow 
comparison with previous reports. 
 
The EBiB, AmG0-Br, AmG1-Br and AmG2-Br ATRP initiators were each studied in 
the polymerisation of HPMA. Traditionally, chain entanglement and functionality of 
polymer pendant groups has been shown to govern the solution and bulk properties 
associated with high molecular weight linear polymers. Recent examples of such tailored 
behaviour include dendronised polymers which exhibit worm-like morphologies due to 
steric hindrance between neighbouring dendrons.21 Alternatively, investigations into 
linear-dendritic polymer hybrids have unveiled the effects chain end functionality has on 
NP behaviour in aqueous media.22 Here, we hypothesise that the size and/or amphiphilic 
nature of the amine-functionalised dendron chain ends will enable NP behavioural 
changes in aqueous media, compared to p(HPMA50) NPs previously reported and allow 
new opportunities.23 
 
2.3.1 Linear polymerisation of HPMA using EBiB and AmG0-Br, AmG1-Br and 
AmG2-Br ATRP initiators 
 
Linear-dendritic hybrid polymers of HPMA, targeting chain lengths of DPn = 50 
monomer units per chain, p(HPMA50), were synthesised at 30°C in methanol (MeOH) 
(50 w/v%) and initiated by the different dendron ATRP initiators previously described 
(Scheme 2.1). Copper chloride/2,2’-bipyridyl (Cu(I)Cl/bpy) was employed as the catalyst 
system using the following molar ratio [Initiator]:[M]:[CuCl]:[bpy] = 1:50:1:2. To allow 
for comparison with un-functionalised materials, the commercially available initiator 
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EBiB was also used to initiate the linear polymerisation of HPMA (Figure 2.8). 
 
 
 
Figure 2.8 Diagrammatic representation of the linear polymerisation of HPMA using ethyl and 
AmG0-G2 functional dendron ATRP initiators. 
 
Number average molecular weight (Mn), weight average molecular weight (Mw) and 
dispersity (Ð = Mw/Mn) of the resulting p(HPMA50) polymer and dendritic polymer 
hybrids were determined by triple detection gel permeation chromatography (GPC) 
(Table 2.1).
 
The formation of the linear polymer and linear-dendritic hybrids using EBiB and the 
dendron initiators AmG0-Br, AmG1-Br and AmG2-Br achieved high monomer 
conversion (>94 %) as determined by 1H NMR of the crude reaction medium samples 
(Table 2.1). The polymers were purified by passing through a basic alumina column to 
remove the catalytic system, followed by precipitation into hexane. 
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Table 2.1 GPC analysis of amine-functional linear-dendritic hybrids and hyp-polydendrons and 
materials without amine end group functionality. 
    GPCa   
Polymer Conversionb 
(%) 
Mn 
Theoryc 
(g mol-1) 
Mn  
(g mol-1) 
Mw  
(g mol-1) 
Đ DPn 
EBiB-p(HPMA50) 99 7100 12750 15850 1.24 87 
AmG0-p(HPMA50) 99 7390 11250 16300 1.45 76 
AmG1-p(HPMA50) 96 7430 13150 18050 1.37 88 
AmG2-p(HPMA50) 94 7690 12900 16350 1.26 83 
EBiB-p(HPMA50-
co-EGDMA0.95) 
99 - 39800 1019000 22.63 - 
AmG0-p(HPMA50-
co-EGDMA0.9) 
99 - 33600 728500 21.70 - 
AmG1-p(HPMA50-
co-EGDMA0.9) 
99 - 46800 595200 12.71 - 
AmG2-p(HPMA50-
co-EGDMA0.9) 
99 - 37500 216400 5.77 - 
a Triple detection analysis using THF/2% triethylamine (TEA) as eluent;  
b Determined by NMR;  
c Mn Theory = (Mw monomer*DP targeted)+Mw initiator 
 
The GPC refractive index (RI) and right angle light scattering (RALS) chromatograms 
for the linear polymer and the linear-dendritic polymer hybrids, EBiB-p(HPMA50), 
AmG0-p(HPMA50), AmG1-p(HPMA50) and AmG2-p(HPMA50), synthesised with each 
initiator are shown in Figure 2.9. 
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Figure 2.9 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
EBiB-p(HPMA50). C) RI chromatograms and D) RALS chromatograms for AmG0-p(HPMA50). E) RI 
chromatograms and F) RALS chromatograms for AmG1-p(HPMA50). G) RI chromatograms and H) 
RALS chromatograms for AmG2-p(HPMA50).  
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The GPC chromatograms show that the linear and linear-dendritic polymers have a 
monomodal distribution, expected for a controlled polymerisation, although a slight 
shoulder is seen in the RALS chromatograms as previously reported for HPMA 
polymerisation.24 For all linear polymer samples, a higher number average molecular 
weight than the theoretical targeted value was obtained; either due to the inefficiency of 
the dendron initiators, the coupling of chain ends at high conversions, or the presence of 
a small amount of dimethacrylate impurity within the HPMA monomer.24 Despite this, 
the linear polymer series were self-consistent in their achieved DPn, all exhibiting similar 
Mn values ranging from 11250-13150 g mol-1 (Table 2.1). This allowed an accurate 
assessment of material behaviour with respect to differences in chain end functionality 
and not large differences in molecular weight or dispersity. 
 
The DPn could not be determined directly by 1H NMR due to the overlapping signals of 
the initiator chain end residues and the polymer repeat units; however, the linear 
materials were analysed by 1H NMR spectroscopy and the p(HPMA50) spectra are shown 
in Figure 2.10 and Appendix, Figures A19-21. 
 
 
Figure 2.10 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(HPMA50). 
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2.3.2 Co-polymerisation of HPMA and EGDMA using EBiB and AmG0-Br, 
AmG1-Br and AmG2-Br ATRP initiators 
 
The EBiB, AmG0-Br, AmG1-Br and AmG2-Br dendron ATRP initiators were used in 
the co-polymerisation of HPMA and a divinyl monomer EGDMA, in order to produce a 
highly branched polymer and a series of systematically varying hyp-polydendrons. 
 
The branched co-polymerisation of HPMA and EGDMA was conducted under identical 
conditions to those used for linear polymer and linear-dendritic polymer synthesis, but 
with the addition of a low concentration of EGDMA (Figure 2.11).  
 
 
Figure 2.11 Diagrammatic representation of the co-polymerisation of HPMA and EGDMA using 
EBiB and AmG0-, AmG1- and AmG2-Br ATRP initiators. 
 
When using EBiB as the initiator, an appropriate molar ratio of brancher:initiator of 
0.95:1 was employed in order to avoid crosslinking and gelation (Chapter 1, Section 
1.3.1.1.1); high molecular weight, soluble polymer, EBiB-p(HPMA50-co-EGDMA0.95) 
(Table 2.1) was recovered. When using the AmG0-Br, AmG1-Br and AmG2-Br
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initiators, gel formation was seen within the HPMA/EGDMA co-polymerisations at the 
brancher:initiator ratio of 0.95:1, yet the soluble hyp-polydendrons AmG0-p(HPMA50-
co-EGDMA0.9), AmG1-p(HPMA50-co-EGDMA0.9) and AmG2-p(HPMA50-co-
EGDMA0.9) were achieved at a slightly lower brancher:initiator ratio of 0.90:1. This 
further suggests a reduced initiator efficiency, as poor initiation will lead to fewer 
propagating polymer chains and a higher effective brancher:initiator ratio within each 
reaction. An identical DPn = 50 monomer units was targeted for the primary polymer 
chain length and analysis by GPC and 1H NMR spectroscopy analysis for each polymer 
is collated in Table 2.1. Figure 2.12 shows the GPC RI and RALS chromatogram, for 
each branched polymer.  
 
The branched polymers start to elute at much lower retention volumes than their linear-
polymer analogues due to the fraction of very higher molecular weight material present 
within the molecular weight distribution, highlighting the contrast with the linear 
polymers which have narrow, monomodal distributions. The broad distributions of the 
branched materials, including the hyp-polydendrons, is derived from both the varied 
number of conjoined chains within the polymer samples and a wide range of possible 
architectures due to the statistical incorporation of EGDMA along the primary polymer 
chains. 
 
The branched materials were also analysed by 1H NMR spectroscopy and the 
p(HPMA50-co-EGDMA0.9) spectra are shown in Figure 2.13 and Appendix, Figures A22-
24. The EGDMA proton peaks are masked by the HPMA proton peaks, due to the 
similar chemical environment of the mono-functional monomer residues (Figure 2.13b’ 
and f). 
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Figure 2.12 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
EBiB-p(HPMA50-co-EGDMA0.95). C) RI chromatograms and D) RALS chromatograms for AmG0-
p(HPMA50-co-EGDMA0.9). E) RI chromatograms and F) RALS chromatograms for AmG1-
p(HPMA50-co-EGDMA0.9). G) RI chromatograms and H) RALS chromatograms for AmG2-
p(HPMA50-co-EGDMA0.9).  
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Figure 2.13 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(HPMA50-co-EGDMA0.9). 
 
2.3.3 Kinetic studies of polymerisation of HPMA and co-polymerisation of 
HPMA and EGDMA using EBiB, AmG0-Br, AmG1-Br and AmG2-Br ATRP 
initiators 
 
Kinetic experiments were undertaken for each of the polymerisations to confirm first 
order kinetics with respect to monomer concentration, to follow the evolution of 
molecular weight with respect to monomer conversion and to ensure control of the 
polymerisation via ATRP was maintained during the reactions. 
 
In all cases, the kinetic studies indicated first order kinetics for the linear polymerisations 
with linear evolution of Mn with conversion (Figure 2.14). 
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Figure 2.14 Kinetic plots for linear DP50 polymers. A) and B) EBiB-p(HPMA50), C) and D) AmG0-
p(HPMA50), E) and F) AmG1-p(HPMA50), G) and H) AmG2-p(HPMA50). A, C, E and G) Conversion 
(blue squares), ln([M]0/[M]) (red circles); B, D, F and H) Mn (red circles) and Ð (blue lines). 
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Interestingly, the polymerisations initiated by AmG1-Br and AmG2-Br appeared to 
propagate faster than reactions using the other initiators, achieving approximately 90% 
conversion in 5 hours; the EBiB and AmG0-Br polymerisations showed very similar 
kinetics. Ð values were relatively consistent from 40% monomer conversion, although 
values tended to be 1.45 > Ð > 1.2. 
 
Branched co-polymerisations initiated by either EBiB or AmG0-Br showed almost 
identical polymerisation rates as the respective linear polymerisations conducted in the 
absence of EGDMA (Figure 2.15), however, hyp-polydendron synthesis using the 
AmG1-Br and AmG2-Br initiators propagated noticeably slower than their analogous 
linear-dendritic polymer reactions. Molecular weight analyses were enabled by 
determining average dn/dc values of the time points analysed (Table 2.2). 
 
Table 2.2 Average dn/dc values of p(HPMA50) linear/linear-dendritic polymers and p(HPMA50-co-
EGDMAx) copolymer/hyp-polydendrons. 
 
Target polymer dn/dca 
EBiB-p(HPMA50) 0.0802 
AmG0-p(HPMA50) 0.0853 
AmG1-p(HPMA50) 0.0716 
AmG2-p(HPMA50) 0.0658 
EBiB-p(HPMA50-co-EGDMA0.95) 0.0739 
AmG0-p(HPMA50-co-EGDMA0.9) 0.0825 
AmG1-p(HPMA50-co-EGDMA0.9) 0.0858 
AmG2-p(HPMA50-co-EGDMA0.9) 0.0758 
a THF eluent containing 2% TEA (v/v) 
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Figure 2.15 Kinetic plots for branched DP50 polymers. A) and B) EBiB-p(HPMA50-co-EGDMA0.95), 
C) and D) AmG0-p(HPMA50-co-EGDMA0.9), E) and F) AmG1-p(HPMA50-co-EGDMA0.9), G) and H) 
AmG2-p(HPMA50-co-EGDMA0.9). A, C, E and G) Conversion (blue squares), ln([M]0/[M]) (red 
circles); B, D, F and H) Mn (red circles) and Ð (blue lines), Mw (black diamonds). 
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Linear semi-logarithmic plots were observed within branched polymerisations using each 
of the initiators, confirming first order kinetics (Figure 2.15); the development of Mn and 
Mw within the branched polymerisations showed the well reported25 dramatic increase at 
conversions >80 % which was very noticeable within the relationship of Mw vs. 
conversion, leading to multimodal GPC chromatograms (Figure 2.12).  
 
Mw values of the branched polymers up to 1.02x106 g mol-1 were observed, suggesting 
significant contributions to the physical mass of each sample from complex branched 
structures containing on weight average > 64 primary chains (EBiB-p(HPMA50-co-
EGDMA0.95)), > 45 primary chains (AmG0-p(HPMA50-co-EGDMA0.9)), > 33 primary 
chains (AmG1-p(HPMA50-co-EGDMA0.9)) and > 13 primary chains (AmG2-p(HPMA50-
co-EGDMA0.9)); number average structures appear to contain at least 3 conjoined chains. 
Each primary chain of the hyp-polydendrons contains a dendron initiator end group, 
therefore the weight average branched architectures contain approximately 45 tertiary 
amine (AmG0-p(HPMA50-co-EGDMA0.9)), 66 tertiary amine (AmG1-p(HPMA50-co-
EGDMA0.9)) or 52 tertiary amine (AmG2-p(HPMA50-co-EGDMA0.9)) chain end 
functional groups. It is notable that the size of the dendron initiator appeared to 
determine the extent of the branching and therefore the Mw and Ð values obtained.  
 
2.4 Nanoprecipitation of linear polymers, amine-functionalised 
linear-dendritic hybrids, branched copolymers and amine-
functionalised hyp-polydendrons 
 
Linear and branched hydrophobic polymers derived from HPMA have been previously 
nanoprecipitated to produce well-defined stable NPs as reported by Slater et al,23 with 
clear charge-stabilisation (negative zeta potential (ζ)) as an aqueous NP dispersion. This 
approach has been extended to include the new linear-dendritic hybrids and hyp-
polydendrons studied here to assess if stable NPs can be prepared under similar 
conditions. 
 
Nanoprecipitation is a rapid, controlled assembly of hydrophobic organic molecules and 
has been used to form NPs of small molecule compounds and polymers. Under 
nanoprecipitation conditions, macromolecules are hypothesised to collapse into non-
solvated coils which aggregate to form nuclei that assemble until reaching a colloidal-
stability. As the solution of solvated polymer chains in a good solvent is added to the 
anti-solvent, the expanded polymer coils collapse (Figure 2.16), as the water-miscible 
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solvent and water diffuse together and the quality of the solvent environment, for the 
hydrophobic polymers, diminishes. 
 
 
Figure 2.16 Proposed mechanism in which the linear-dendritic polymer hybrids (A) and hyp-
polydendrons (C) derived from amine-functional dendron initiators collapse and aggregate in order to 
achieve stabilisation; B) Representative nanoprecipitation method formed from an initial 
tetrahydrofuran (THF) concentration of 5 mg mL-1 producing an aqueous concentration of 1 mg mL-1 
at pH = 7.8. 
 
The aggregates must achieve colloidal stability to prevent macro-scale phase separation 
and this is often achieved by steric or charge repulsion. The linear-dendritic polymers 
and hyp-polydendrons discussed here are expected to nanoprecipitate successfully and 
display enhanced stability in the presence of aqueous NaCl when compared with 
previously reported p(HPMA50) and p(HPMA50-co-EGDMAx) polymers, as the presence 
of the amine functionalised dendron chain ends provides a surface functionality capable 
of generating positive charge through protonation.  
 
A range of parameters such as polymer concentration, dilution factor, primary polymer 
chain length, composition, and architecture have all shown to have an effect on the 
control of nanoprecipitation.23 In order to determine the impact of a varying number of 
parameters on NP formation for these new materials, a series of experiments were 
conducted including: 1) fast vs. slow addition of good solvent to a fixed volume of 
water, 2) variation of mass of polymer nanoprecipitated, and 3) varied polymer 
concentration within the good solvent. Precipitation into a fixed volume of water 
allowed trends to be identified. 
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Studies within the Rannard group have employed a rapid addition of polymer solutions 
to volumes of stirred water, whereas other literature examples of nanoprecipitation 
include the preparation of anisotropic polymer NPs via addition in a slow, drop-wise 
manner.26 In order to test the effect of the rate of nanoprecipitation, both addition 
methods were evaluated. Each polymer sample was dissolved in THF at a concentration 
of 5 mg mL-1 and 2 mL of each solution was subjected to a rapid solvent switch through 
i) rapid addition (fast; Table 2.3), and ii) drop-wise addition (slow; Table 2.3) into 10 
mL of deionised water (pH = 7.8) at ambient temperature. Rapid addition involved 
instantaneous addition of the polymeric solution to the deionised water, whereas the 
slow addition was accomplished via drop-wise addition of the polymeric solution over a 
period of 30 seconds. Each experiment led to a final polymer concentration of 1 mg mL-
1 in water after THF removal by evaporation overnight, as monitored by 1H NMR. The 
NPs that appeared stable were analysed by dynamic light scattering (DLS) to assess NP 
hydrodynamic diameters (Dz) and polydispersity (PDI) values. 
 
Table: 2.3 DLS analysis of nanoprecipitated p(HPMA50-co-EGDMAx) branched copolymer and hyp-
polydendrons dissolved in THF (5 mg mL-1) into deionised water (pH=7.8) (fast vs. slow addition) 
resulting in an end NP concentration of 1 mg mL-1. 
 p(HPMA50-co-EGDMAx) 
 EBiB- AmG0- AmG1- AmG0- 
Addition 
Method 
Dz 
(nm) 
PDI Dz 
(nm) 
PDI Dz 
(nm) 
PDI Dz 
(nm) 
PDI 
Fast 99 0.101 882 0.420 79 0.181 187 0.231 
Slow 178 0.082 157 0.269 165 0.097 149 0.099 
 
 
The EBiB-, AmG1- and AmG2-p(HPMA50-co-EGDMAx) branched copolymers all 
formed stable NP dispersions with Dz size values similar to previous NPs formed from 
p(HPMA50-co-EGDMAx), regardless of the addition method. The AmG0-p(HPMA50-co-
EGDMA0.9) copolymer formed much larger NPs, with a broad distribution of NP sizes, 
after fast administration of the polymer solution into water. This suggests a lack of 
controlled aggregation when this particular polymer solution is introduced rapidly into 
the anti-solvent. All copolymers displayed narrower particle size distributions when 
added to the aqueous phase via the slower, drop-wise method, implying a slightly more 
controlled NP formation manner when this technique is used (Figure 2.17). For all 
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further nanoprecipitations conducted throughout this study, the slow drop-wise method 
was therefore utilised. 
 
 
 
Figure 2.17 DLS traces of fast (green) vs. slow (red) addition for A) EBiB-, B) AmG0-, C) AmG1-, 
and D) AmG2-p(HPMA50-co-EGDMAx) into deionised water (pH = 7.8) (1 mg mL-1). 
  
The effect of varying the mass of polymer precipitated into a fixed volume of water was 
studied by using differing amounts of good solvent, resulting in different end NP 
concentrations within the aqueous media (Table 2.4). Good solvent solutions of the 
p(HPMA50-co-EGDMA0.9) branched copolymer and the hyp-polydendrons were 
generated at concentrations of 5 mg mL-1 and 10 mg mL-1 in THF. Varying volumes of 
each solution, ranging from 0.5 mL of the 10 mg mL-1 solution to 5 mL of the 5 mg mL-1 
solution, were nanoprecipitated into deionised water (5 mL) to achieve end 
concentrations of 1, 2 and 5 mg mL-1 after THF evaporation overnight; this ensured 
consistent fixed masses of 5 mg, 10 mg and 25 mg of each copolymer were 
nanoprecipitated into the fixed volume of water for each of the three experiments. 
Maintaining a constant mass of polymer during the different nanoprecipitations was 
important in order to evaluate the effect of varying solvent quality within the mixed 
solvent environments for each end nanoprecipitation condition. 
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Table: 2.4 DLS analysis of p(HPMA50-co-EGDMAx) branched copolymer and hyp-polydendrons 
comparing different start and end NP concentrations in deionised water (pH=7.8). 
Concentration  
(mg mL-1) 
p(HPMA50-co-EGDMAx) 
EBiB- AmG0- AmG1- AmG2- 
Start End 
Dz 
(nm) 
PDI Dz 
(nm) 
PDI Dz 
(nm) 
PDI Dz 
(nm) 
PDI 
5 1 
2 
5 
87 
118 
- 
0.082 
0.124 
- 
108 
147 
- 
0.228 
0.392 
- 
226 
258 
424 
0.086 
0.377 
0.226 
245 
- 
- 
0.033 
- 
- 
10 1 
2 
5 
99 
105 
169 
0.080 
0.085 
0.116 
110 
116 
98 
0.292 
0.337 
0.357 
146 
204 
228 
0.280 
0.280 
0.228 
170 
183 
- 
0.100 
0.097 
- 
 
In several instances, when larger volumes of THF solution (> 2 mL) were added to 
water, stable NP dispersions failed to form (Table 2.4). Only the AmG1-p(HPMA50-co-
EGDMA0.9) formed stable NPs at a concentration of 5 mg mL-1 from the addition of 5 
mL of a 5 mg mL-1 copolymer/THF solution. The instantaneous formation of 
nanoprecipitates has been demonstrated and limits of solvent mixtures have been 
previously considered.27 The addition of large volumes of good solvent to the anti-
solvent phase results in a mixed liquid environment capable of preventing 
nanoprecipitation. The large volume of polymeric solvent reduces the solvent quality 
and delays instant particle formation, and consequently prohibits stable NP formation in 
these studies. This was further confirmed when successful final NP concentrations of 2 
and 5 mg mL-1 were achieved using a starting polymer concentration of 10 mg mL-1 
following the addition of the same polymer mass in a reduced amount of solvent. 
 
Overall, a general increase in the measured Dz values was observed when targeting 
increasing final NP concentrations. A greater difference was observed for particles 
prepared from the 5 mg mL-1 copolymer solutions, which is expected as there is a 
greater increase in solvent utilised during nanoprecipitation (1, 2 and 5 mL for targeted 
end concentrations of 1, 2 and 5 mg mL-1 opposed to 0.5, 1 and 2.5 mL for the 
nanoprecipitation prepared from 10 mg mL-1 copolymer solution). 
 
When targeting final aqueous NP concentrations of 1, 2 and 5 mg mL-1 using AmG0-
p(HPMA50-co-EGDMA0.9) and starting with 10 mg mL-1 copolymer solution in THF, 
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the NP diameters are very similar (Table 2.4); this is also seen when targeting NP 
concentrations of 1 and 2 mg mL-1 using EBiB- and AmG2-p(HPMA50-co-EGDMAx), 
and 2 and 5 mg mL-1 NP dispersions using AmG1-p(HPMA50-co-EGDMA0.9), also 
prepared from the 10 mg mL-1 THF solution (Table 2.4). To understand this further, the 
derived count rate (DCR) was taken into consideration i.e. the amount of detectable NP 
aggregations. The DCR displayed an increase in scattering as the final targeted NP 
concentration increased (87050, 92700 and 291300 kcps for the AmG0-p(HPMA50-co-
EGDMA0.9) 1, 2 and 5 mg mL-1 respectively). This suggests that increasing the polymer 
concentration leads to an increased number of particles of similar size. Multiple 
nanoprecipitations have shown to be possible through direct addition of polymer 
solutions to aqueous NP dispersions after solvent removal, resulting in a higher particle 
concentration of nanoprecipitates of the same size.27 
 
Conversely, nanoprecipitation of AmG1-p(HPMA50-co-EGDMA0.9) produced particles 
with a Dz = 258 and 424 nm at a targeted final NP concentration of 2 and 5 mg mL-1 
respectively when using an initial polymer concentration of 5 mg mL-1. The DCRs are 
similar in both these instances (400400 and 325300 kcps at 2 and 5 mg mL-1 
respectively), suggesting that the increased polymer mass contributes to the formation of 
larger particles. 
 
Stable NP dispersions were produced for all copolymers when targeting a final NP 
concentration of 1 mg mL-1, independent of the starting polymer concentration (Table 
2.4). The starting polymer concentration of 5 mg mL-1 overall produced NPs with 
narrower size distributions; therefore, a starting concentration of 5 mg mL-1 was selected 
for all further nanoprecipitations, with the aim of producing aqueous polymeric NP 
dispersions of 1 mg mL-1. The volume of water for all nanoprecipitations was also 
standardised as 10 mL, allowing production of sufficient NP samples for further analysis 
and studies. The nanoprecipitation process is dependent on many different factors that 
influence the NPs produced and it was, therefore, paramount to fix parameters, such as 
concentration and dilution, in order to attribute differences in NP behaviour to the 
varying surface functionalities, polymer compositions and architectures investigated 
within this project. 
 
Following the successful synthesis of linear polymers, linear-dendritic hybrids, branched 
copolymers and hyp-polydendrons, the EBiB-p(HPMA50) and EBiB-p(HPMA50-co-
EGDMA0.95) polymers were dissolved separately in THF at a concentration of 5 mg mL-
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1. 2 mL of each solution was subjected to a solvent switch through drop-wise addition 
into 10 mL of deionised water (pH 7.8) at ambient temperature, to give a final polymer 
concentration of 1 mg mL-1. Both polymers formed stable NPs in aqueous media and 
analysis was conducted by DLS to assess Dz, ζ and PDI. NPs formed from the linear 
EBiB-p(HPMA50) were significantly larger and more polydisperse than their branched 
analogues as previously reported (Table 2.5).23 The same nanoprecipitation conditions 
were exploited in an attempt to produce stable NP dispersions from the linear-dendritic 
hybrids (AmG0-p(HPMA50), AmG1-p(HPMA50) and AmG2-p(HPMA50)) and the hyp-
polydendrons (AmG0-p(HPMA50-co-EGDMA0.9), AmG1-p(HPMA50-co-EGDMA0.9) and 
AmG2-p(HPMA50-co-EGDMA0.9)) possessing amine functionality. 
 
Table 2.5 DLS analysis of nanoprecipitated linear-dendritic polymer hybrids and hyp-polydendrons 
dissolved in THF (5 mg mL-1) into deionised (pH=7.8) and acidic (pH=4.0) water to produce end NP 
concentrations of 1 mg mL-1. 
 pH = 7.8a  pH = 4.0a 
Polymer Dz 
(nm) 
PDI ζ 
(mV) 
Dz 
(nm) 
PDI ζ (mV) 
EBiB-p(HPMA50) 780 0.230 -34 - - - 
AmG0-p(HPMA50) - - - 581 0.280 +52 
AmG1-p(HPMA50) - - - 246 0.193 +40 
AmG2-p(HPMA50) - - - 491 0.165 +44 
EBiB-p(HPMA50-co-EGDMA0.95) 178 0.082 -20 - - - 
AmG0-p(HPMA50-co-EGDMA0.9) 157 0.269 -12 147 0.304 +55 
AmG1-p(HPMA50-co-EGDMA0.9) 165 0.097 -31 102 0.271 +45 
AmG2-p(HPMA50-co-EGDMA0.9) 149 0.099 -22 196 0.373 +61 
a Initial pH 
 
The linear-dendritic materials failed to form stable NPs and all resulted in macrophase 
separation. However, the hyp-polydendrons formed stable NPs (Figure 2.18) for each 
generation of dendron end group (Table 2.5). 
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Figure 2.18 Representative SEM images of nanoprecipitated AmG2-p(HPMA50-co-EGDMA0.9) 
formed from an initial THF concentration of 5 mg mL-1 producing an aqueous concentration of 1 mg 
mL-1 at pH = 7.8. 
 
The difference in stability between the linear-dendritic hybrids and the equivalent hyp-
polydendrons appears to result from the presence of the branching within the complex 
architecture, and potentially as a direct consequence from the way in which the NPs pack 
during the nanoprecipitation process. Regarding the obvious difference in molecular 
weight between these linear and branched entities, the branched hyp-polydendrons are 
comprised of different numbers of conjoined linear-dendritic hybrid chains and any 
physical mass of equivalent samples will possess the same number of primary chains and 
chain ends; this feature of the polymers is independent of whether the polymer under 
discussion is linear or branched. The GPC analysis has also shown that there is a 
considerable amount of linear material present within the molecular weight distributions 
of the hyp-polydendrons, supporting the proposition of the branched material fraction 
directing the behaviour of the overall distribution. It is feasible to suggest that the 
materials of higher molecular weight form larger nuclei under the changing solvent 
conditions, which would also explain the larger Dz sizes for EBiB-p(HPMA50) compared 
to the EBiB-p(HPMA50-co-EGDMA0.95) where rapid attainment of colloidal stability is 
achieved, leading to the arrest of any further aggregation processes. 
 
The negative ζ values witnessed for the EBiB-initiated polymers are in concordance with 
previous studies of these materials,23 and with reports of the adsorption of hydroxide ions 
at the hydrophobic solid/water interface.28 The presence of amine functionality provided 
by the dendrons does not seem to greatly influence these observations at neutral pH and 
titrations of the individual dendron initiators, AmG0-Br, AmG1-Br and AmG2-Br 
allowed an estimation of the pKa values of the dendrons to be pKa(AmG0) ≈ 6.4, 
pKa(AmG1) ≈ 6.2, pKa(AmG2) ≈ 6.2 (Figure 2.19), confirming a relative lack of 
protonation at the nanoprecipitation pH of 7.8. 
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Figure 2.19 pH studies of AmG0–G2 dendron initiators leading to pKa estimations (AmG0-Br = 
green open diamonds, AmG1-Br = blue open triangles and AmG2-Br = red open squares).
 
2.5 Impact of pH on linear-dendritic hybrids and hyp-polydendrons 
 
Due to the amine functionality present within the linear-dendritic hybrids and hyp-
polydendrons, a comparative behavioural study could be conducted upon 
nanoprecipitation into acidic water (pH = 4). All linear and branched polymers were 
insoluble at pH 4, and all but one (AmG2-p(HPMA50)) were insoluble at pH 2; AmG2-
p(HPMA50) gave an aqueous, transparent solution at a concentration of 1 mg mL-1. The 
density of tertiary amine groups associated with the AmG2 dendron end group can 
possibly account for this solubility, however, it is notable that the equivalent hyp-
polydendron did also not show solubility at this pH. Due to the hydrophobic nature of 
p(HPMA50), the AmG2-p(HPMA50) was not expected to be completely solvated at pH 2. 
DLS analysis revealed identifiable nanoprecipitates (Dz = 82 nm, PDI = 0.079) within the 
aqueous solution after 24 hours (Appendix, Figure A25). These appear to represent an 
aggregated species, (further confirmed by a DCR = 20030 kcps), but the exact nature is 
unclear.  
 
To investigate the impact of pH further, nanoprecipitation was carried out under identical 
conditions as described above, with the exception that the anti-solvent medium was 
aqueous HCl (1M) at pH 4 (Table 2.5). As anticipated, the formation of charge-stabilised 
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NPs was not achieved for either the EBiB-p(HPMA50) or EBiB-p(HPMA50-co-
EGDMA0.95) polymers, when nanoprecipitated into low pH and both underwent 
macroscale precipitation. All linear-dendritic hybrids and hyp-polydendrons produced 
stable NP dispersions, however, and once again, the hyp-polydendrons generated lower 
Dz values than their linear equivalents (Table 2.5). 
 
Highly positive ζ values were measured by DLS, even for materials bearing only a single 
tertiary amine chain end, which are expected for protonated amine functionality and 
suggests there are a large number of dendron chain ends at the surface of the NPs. It may 
be expected that upon assembly and formation of the NPs, dendron chain ends become 
entrapped within the main bulk of the nanoprecipitate, as observed in previous reports of 
materials containing mixtures of hydrophobic dendrons and PEG chain ends.2 These 
internalised dendrons would be predicted to also protonate after nanoprecipitation into 
acidic water and would, therefore, be somewhat hydrated. 
 
In order to study the response of the linear-dendritic hybrids and hyp-polydendron NPs to 
changes in pH, the materials prepared in aqueous HCl were subjected to a titration 
through the slow addition of base (1M NaOH), with continuous monitoring of ζ to 
investigate isoelectric points (IEPs). The NPs formed from the linear-dendritic hybrids 
(AmG0-p(HPMA50), AmG1-p(HPMA50) and AmG2-p(HPMA50)) were remarkably more 
robust to alterations in pH than their corresponding hyp-polydendron nanoprecipitates, 
which underwent substantial precipitation even after the initial addition of base. Data for 
the hyp-polydendrons were therefore not reliable with accurate ζ measurements being 
unobtainable due to phase separation during the experiment. More reliable IEP 
measurements for the linear-dendritic hybrids were attainable, showing a steady decrease 
in ζ values upon the addition of base (Figure 2.20A), and steady PDI values until 
approaching pH values of 5.4-5.8. A corresponding decrease in scattering intensity 
(DCR) was simultaneously observed as the nanoprecipitates lost charge/stabilisation and 
precipitation began to occur (Figure 2.20B). 
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Figure 2.20 Isoelectric point determination via the slow addition of base to linear-dendritic polymer 
NP dispersions. A) Zeta-potential and (B) and derived count rate of nanoprecipitates of AmGx-
p(HPMA50) linear–dendritic hybrids (AmG0-p(HPMA50) = blue open triangles, AmG1-p(HPMA50) = 
red open circles and AmG2-p(HPMA50) = green open squares) formed at pH = 4.0 and undergoing 
base titration. All DLS measurements were at 25°C. 
 
The lack of stability retention during slow changes in pH for all materials studied, led to 
an investigation of the rapid switching of pH (Table 2.6). This involved the addition of 
NaOH (1M; 36 μL) to each NP dispersion prepared in aqueous HCl (pH~4), producing 
an end pH~12 (Table 2.6), measured by a pH probe. Following this, HCl (1M; 36 μL) 
was added to the alkaline NP dispersions, lowering the pH (~3) once more. Neither 
EBiB-p(HPMA50) nor EBiB-p(HPMA50-co-EGDMA0.95) produced stable 
nanoprecipitates in acidic pH so were not included in the study. 
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Table 2.6 DLS analysis of nanoprecipitated linear–dendritic polymer hybrids and hyp-polydendrons 
into acidic water (pH=4) and the effects of NP size and surface charge following the rapid switching 
of pH. 
 
pH = 4.0a 
(Final pH = 3.6-4.1) 
+ 1M NaOH 
(Final pH = 11.5-11.9) 
+ 1M HCl 
(Final pH = 3.1-3.4) 
Polymer 
Dz 
(nm) 
PDI 
ζ 
(mV) 
Dz 
(nm) 
PDI ζ (mV) 
Dz 
(nm) 
PDI 
ζ 
(mV) 
AmG0-p(HPMA50) 581 0.280 +52 - - - - - - 
AmG1-p(HPMA50) 246 0.193 +40 158 0.197 -48 - - - 
AmG2-p(HPMA50) 491 0.165 +44 162 0.279 -51 168 0.173 +32 
AmG0-p(HPMA50-
co-EGDMA0.9) 
147 0.304 +55 - - - - - - 
AmG1-p(HPMA50-
co-EGDMA0.9) 
102 0.271 +45 96 0.143 -47 157 0.117 +31 
AmG2-p(HPMA50-
co-EGDMA0.9) 
196 0.373 +61 136 0.236 -48 163 0.130 +36 
a Initial pH 
 
The linear and branched polymer nanoprecipitates prepared in acidic pH conditions and 
bearing AmG0 dendron chain ends underwent macroscale precipitation upon rapid base 
addition. The linear-dendritic hybrids and hyp-polydendrons containing AmG1 and 
AmG2 dendron functionality were able to maintain stable NPs upon addition of base 
without any indication of phase separation; Dz values decreased for all samples and a 
switch from highly positive ζ values to highly negative ζ values was witnessed. The 
decrease in Dz and switch of surface charge is not unexpected as the NPs become overall 
more hydrophobic and deprotonated. Lack of protonation would result in the dendrons 
on the surface collapsing back onto the hydrophobic NP surface and the dendrons packed 
within the NP interior, carrying protonated amines and bound water, would also be 
expected to become somewhat hydrophobic resulting in the expulsion of water and an 
overall collapse of the entire structure. 
 
Generally, the linear-dendritic hybrids showed a larger decrease in Dz following the pH 
switch (the largest specifically being with the AmG2-p(HPMA50) material) in 
comparison to the branched materials. This implies a more complicated and less ordered 
arrangement of the linear-dendritic hybrids within the NP structures, possibly resulting 
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from a greater degree of freedom within each individual linear polymer chain during 
particle formation than their branched equivalents. 
 
To study the reversibility of the pH switch, HCl was rapidly added to the samples that 
were able to avoid phase separation during base addition. This returned the NP 
dispersions to their original acidic environments. Within the series of linear-dendritic 
hybrids, only the NPs derived from AmG2-p(HPMA50) were able to maintain their 
colloidal stability and displayed highly positive ζ values as well as a slight increase in Dz. 
This small increase in hydrodynamic diameter may be due to the lack of acid penetration 
into the hydrophobic NP core and the protonation of dendrons only taking place at the 
surface, resulting in a limited amount of swelling. Interestingly, the hyp-polydendrons 
comprising both the AmG1- and AmG2- dendrons were able to successfully undergo the 
second pH switch. All final NPs exhibited similar diameters (157-168 nm) in acid 
following the two pH switches (Figure 2.21). 
 
 
Figure 2.21 Diagrammatic representation of amine-functional hyp-polydendron nanoprecipitates 
formed at pH=4 and change in solvation of the core and surface dendrons: (A) deprotonation and 
collapse of amine-functional dendrons on addition of base, with subsequent protonation of surface 
functional groups on addition of acid, (B) representation of protonated and hydrated exterior and 
interior dendrons with collapsed vinyl polymer chains within the hyp-polydendron structure, (C) 
deprotonated and collapsed structure of dendrons and vinyl polymer chains. 
 
An additional experiment was conducted where the AmG2-p(HPMA50) and AmG2-
p(HPMA50-co-EGDMA0.9) materials were nanoprecipitated into aqueous NaOH (pH 12) 
in order to determine the nature of the resulting nanoprecipitates in this medium. 
Interestingly, nanoprecipitates were generated that exhibited very similar sizes and ζ 
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values compared to when the same materials were initially prepared in acidic conditions 
and treated with base (AmG2-p(HPMA50): Dz = 152 nm, PDI = 0.081, ζ = -46.0 mV; 
AmG2-p(HPMA50-co-EGDMA0.9): Dz = 127 nm, PDI = 0.135, ζ = -43.1 mV). Once 
again, smaller particles were formed from hyp-polydendrons when compared to its linear 
analogue. 
 
2.6 Conclusions 
 
The synthesis of amine-functionalised dendron initiators for ATRP was achieved, with 
consequent controlled formation of linear-dendritic polymer hybrids and hyp-
polydendrons. The nanoprecipitates derived from the materials are unique and display 
behaviour that appears to benefit from both the presence and generation of the dendron 
end groups and the branching of the methacrylate polymer chains. The linear-dendritic 
hybrids and hyp-polydendrons exhibit varying behaviour in aqueous media that assumes 
a different arrangement of dendrons and vinyl polymer segments within the 
nanoprecipitates. This is directed predominantly by the branched polymer architecture 
and the chemical dissimilarity of the charged chain-ends and the uncharged and 
collapsed polymer chains. These differences appear to modify the ability of the NP 
surfaces to protonate and deprotonate, presumably leading to rapid hydroxide adsorption 
in the deprotonated state. 
 
2.7 Experimental 
 
[tBOC-BAPA-G1] – CDI (19.55 g, 0.12 mol, 2 eq.) was added to an oven-dried 500 mL 
2-neck round-bottomed flask (RBF) fitted with a reflux condenser, magnetic stirrer and a 
dry N2 inlet. Anhydrous toluene (200 mL) was added and the flask was purged with N2 
for 10 minutes. The solution was stirred at 60°C and tertiary butanol, (17.87 g, 23 mL, 
0.24 mol, 4 eq.) added via a warm syringe. The mixture was left stirring at 60°C for 6 
hours under a positive flow of N2. BAPA (7.91 g, 8.43 mL, 0.06 mol, 1 eq.) was added 
drop wise, and the reaction was left stirring for a further 18 hours at 60°C under a 
positive flow of N2. Following this, the solution was allowed to cool to room 
temperature, and the pale yellow solution was filtered to remove any solid imidazole, and 
concentrated in vacuo. The resulting viscous oil was dissolved in DCM (300 mL) washed 
with distilled water (2 x 200 mL) and once with brine (150 mL). The organic layer was 
dried with anhydrous Na2SO4, filtered, and concentrated in vacuo. Yield: 15.74 g, white 
solid, (79%). 1H NMR (400 MHz, CDCl3): δ = 1.45 (s, 18H), 1.66 (m, 4H), 2.65 (t, 4H), 
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3.20 (m, 4H), 5.28 (s, br, -NH). 13C NMR (100 MHz, CDCl3): δ = 28.7, 30.0, 39.3, 47.8, 
79.5, 156.3. Calcd: [MH]+ (C16H33N3O4) m/z = 332.3 Da. Found: ES-MS: [MH]+ m/z = 
332.3 Da. Anal. Calcd for C16H33N3O4: C 57.98%; H 10.04%; N 12.68%. Found: C 
57.84%; H 10.45%; N 12.91%. 
 
[tBOC-BAPA-OH] – [tBOC-BAPA-G1] (15.74 g, 0.047 mol) was added to a 500 mL 2-
necked RBF fitted with a reflux condenser, magnetic stirrer and a dry N2 inlet. The flask 
was degassed with dry N2 for 10 minutes, and dissolved in dry ethanol (200 mL). Whilst 
stirring, and maintaining the temperature at 30°C, PO (8.27 g, 9.96 mL, 0.142 mol) was 
added drop wise to the solution over a period of 10 minutes. Under a positive flow of dry 
N2, the reaction was left stirring at 30°C for 18 hours. After this time, the solvent and 
excess propylene oxide were removed in vacuo, and the crude product purified by liquid 
chromatography (silica gel, eluting with ethyl acetate (EtOAc):MeOH), 80:20). Yield: 
15.7 g, pale yellow oil at ambient temperature, solidifying to an off white solid upon 
cooling (85%). 1H NMR (400 MHz, CDCl3): δ = 1.12 (d, 3H), 1.45 (s, 18H), 1.64 (m, 
4H), 2.30 (d, 2H), 2.34-2.67 (d of m, 4H), 3.16 (m, 4H), 3.77 (m, 1H), 4.99 (s, br, -NH). 
13C NMR (100 MHz, CDCl3): δ = 27.6, 28.7, 38.8, 51.8, 60.9, 63.0, 79.5, 156.5. Calcd: 
[MH]+ (C19H40N3O5) m/z = 390.3 Da. Found: ES-MS: [MH]+ m/z = 390.3 Da. Anal. 
Calcd for C19H40N3O5: C 58.58%; H 10.09%; N 10.09%. Found: C 58.50%; H 10.19%; 
N 10.82%. 
1-[N, N-bis (2-aminopropyl)-amino]-2-propanol] [APAP] – To a 500 mL RBF, 
[tBOC-BAPA-OH] (15.70 g, 0.04 mol) was dissolved in EtOAc, (160 mL) and 
concentrated HCl (12M, 36%) (16.33 g, 13.8 mL) was added very slowly. CO2 began to 
rapidly evolve. The reaction vessel was heated to 55°C and stirred vigorously for 5 hours 
before leaving overnight at room temperature. After removal of EtOAc in vacuo, 1H 
NMR (D2O) confirmed complete decarboxylation and formation of APAP.3HCl. 
For the formation of APAP, the crude oil was dissolved very slowly in 4M NaOH 
(160 mL), and reduced by approximately half its volume on a rotary evaporator (60°C). 
A yellow oily substance formed on the surface of the NaOH solution. The mixture was 
extracted with CHCl3 (2 x 160 mL), the organic layers combined, dried with anhydrous 
Na2SO4, filtered, and concentrated in vacuo. Yield: 6.2 g, pale yellow oil (81%). 1H 
NMR (400 MHz, CDCl3): δ = 1.11 (d, 3H), 1.60 (m, 4H), 2.10 (s, br, -OH), 2.32 (m, 
2H), 2.39-2.67 (d of m, 4H), 2.75 (t, 4H), 3.79 (m, 1H). 13C NMR (100 MHz, CDCl3): δ 
= 20.1, 30.7, 40.5, 52.1, 62.7, 63.9. Calcd: [MH]+ (C9H23N3O) m/z = 189.3 Da. Found: 
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CI-MS: [M+H]+ m/z = 190.2 Da. Anal. Calcd for C9H23N3O: C 57.10%; H 12.25%; N 
22.20%. Found: C 55.18%; H 12.15%; N 20.53%. 
AmG0-Br – 1-dimethylamino-2-propanol (1.12 g, 10.86 mmol, 1 eq.), TEA (1.54 g, 15.2 
mmol, 1.4 eq.) and DMAP (132.7 mg, 1.086 mmol, 0.1 eq.) were added to a 250 mL 2 
necked RBF containing DCM (160 mL). The flask was deoxygenated under a positive N2 
purge for 10 minutes. BiB (2.62 g, 1.4 mL, 11.4 mmol, 1.05 eq.) was added drop wise 
while the solution was stirring in an ice bath under a positive flow of N2. The reaction 
mixture was allowed to warm to room temperature and left stirring overnight. The 
organic phase was washed with saturated sodium hydrogen carbonate (NaHCO3) solution 
(3 x 160 mL) and the solution was subsequently dried with anhydrous sodium sulfate 
(Na2SO4). Yield: 2.38 g, yellow oil (84%). 1H NMR (400 MHz, CDCl3) δ = 1.27 (d, 3H), 
1.89 (s, 6H), 2.17-2.55 (m, 8H), 5.07 (m, 1H). 13C NMR (100 MHz, CDCl3) δ = 17.8, 
31.1, 46.2, 56.1, 64.0, 70.7, 170.9. Calcd [M+H]+ (C9H18NO2Br) m/z = 252.15 Da. 
Found: ES-MS: [M+H]+ m/z = 252.0 Da. Anal. Calcd for C9H18NO2Br: C 42.86%; H 
7.14%; N 5.55%. Found C 42.87%; H 7.20%; N 5.55%. 
 
AmG1-OH – DMEA (6.0 g, 42 mmol, 6 eq.) was added to a 50 mL 2 necked RBF 
containing IPA (12 mL). The flask was deoxygenated under a positive N2 purge for 10 
minutes. 1-amino-2-propanol, (0.53 g, 7.0 mmol, 1 eq.) dissolved in IPA (12 mL) was 
added drop wise while the solution was stirring in an ice bath under a positive flow of 
N2. The final mixture was stirred for a further 10 minutes at 0°C before being allowed to 
warm to room temperature and left stirring for 48 hours. The solvent was removed and 
the product left to dry in vacuo overnight. Yield: 2.75 g, yellow oil (92%). 1H NMR (400 
MHz, CDCl3) δ = 1.08 (d, 3H), 2.18-2.62 (m, 22H), 2.69 (m, 2H), 2.89 (m, 2H), 3.77 (m, 
1H), 4.16 (m, 4H). 13C NMR (100 MHz, CDCl3): δ = 19.7, 32.6, 45.6, 49.5, 57.8, 62.1, 
62.5, 63.8, 173.0. Calcd [M+H]+ (C17H35N3O5) m/z = 361.5 Da. Found: ES-MS: [M+H]+ 
m/z = 362.3 and [M+Na]+ m/z=385.3. Anal. Calcd for C17H35N3O5: C 56.43%; H 9.68%; 
N 11.62%. Found C 57.45%; H 9.77%; N 11.12%. 
 
AmG1-Br – AmG1-OH (1.12 g, 10.86 mmol, 1 eq.), TEA (1.54 g, 15.2 mmol, 1.4 eq.) 
and 4-dimethyl-aminopyridine (DMAP) (132.7 mg, 1.086 mmol, 0.1 eq.) were added to a 
250 mL 2 necked RBF containing DCM (160 mL). The flask was deoxygenated under a 
positive N2 purge for 10 minutes. BiB (2.62 g, 1.4 mL, 11.4 mmol, 1.05 eq.) was added 
drop wise while the solution was stirring in an ice bath under a positive flow of N2. The 
reaction mixture was allowed to warm to room temperature and left stirring overnight. 
CHAPTER 2 
88 
The organic phase was washed with saturated NaHCO3 solution (3 x 160 mL) and then 
dried with anhydrous Na2SO4 and the product left to dry in vacuo overnight. Yield: 1.06 
g, yellow oil (67%). 1H NMR (400 MHz, CDCl3) δ = 1.22 (d, 3H), 1.89 (s, 6H), 2.24-
2.69 (m, 22H), 2.83 (m, 4H), 4.20 (m, 4H), 5.0 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 
= 18.5, 33.0, 44.2, 50.3, 56.4, 58.7, 59.1, 59,.7, 68.3, 69.2, 166.6, 172.0. Calcd: [M+H]+ 
(C21H40N3O6Br) m/z = 510.5 Da. Found: ES-MS: [M+H]+ m/z = 510.2 and [M+Na]+ m/z 
= 534.2. Anal. Calcd for C21H40N3O6Br: C 49.41%; H 7.84%; N 8.24%. Found: C 
49.41%; H 7.90%; N 8.23%.  
 
AmG2-OH – DMEA (6.00 g, 42 mmol, 6 eq.) was added to a 50 mL round 2 necked 
RBF containing IPA (12 mL). The flask was deoxygenated under a positive N2 purge for 
10 minutes. APAP (1.32 g, 6.984 mmol, 1 eq.) dissolved in IPA (12 mL) was added drop 
wise while the solution was stirring in an ice bath under a positive flow of N2. The final 
mixture was stirred for a further 10 minutes at 0°C, allowed to warm to room 
temperature and left stirring for 48 hours. The solvent was removed and the product left 
to dry in vacuo overnight. Yield: 5.37 g, yellow oil (99%). 1H NMR (400 MHz, CDCl3) δ 
= 1.13 (d, 3H), 1.67 (m, 4H), 2.26-2.65 (m, 50H), 2.77 (m, 8H), 3.87 (m, 1H), 4.17 (m, 
8H). 13C NMR (100 MHz, CDCl3) δ = 20.0, 24.5, 32.2, 45.7, 48.9, 51.6, 52.2, 57.8, 62.1, 
62.3, 63.6, 173.0. Calcd [M+H]+ (C37H75N7O9) m/z = 762.0 Da. Found: ES-MS: [M+H]+ 
m/z = 762.6 and [M+Na]+ m/z = 784.6. Anal. Calcd for C37H75N7O9: C 58.27%; H 
9.84%; N 12.86%. Found C 58.32%; H 9.92%; N 12.87%. 
 
AmG2–Br – AmG2-OH (5.14 g, 6.749 mmol, 1 eq.), TEA (0.96 g, 9.45 mmol, 1.4 eq.) 
and DMAP (82.5 mg, 0.675 mmol, 0.1 eq.) were added to a 250 mL 2 necked RBF 
containing DCM (160 mL). The flask was deoxygenated under a positive N2 purge for 10 
minutes. BiB (1.63 g, 0.88 mL, 7.09 mmol, 1.05 eq.) was added drop wise while the 
solution was stirring in an ice bath under a positive flow of N2. The reaction mixture was 
allowed to warm to room temperature and left stirring overnight. The organic phase was 
washed with saturated NaHCO3 solution (3 x 160 mL). The solution was dried with 
anhydrous Na2SO4 and the product left to dry in vacuo overnight. Yield: 3.30 g, yellow 
oil (54%).1H NMR (400 MHz, CDCl3) δ = 1.26 (d, 3H), 1.56 (m, 4H), 1.91 (s, 6H), 2.22-
2.67 (m, 50H), 2.76 (m, 8H), 4.19 (m, 8H), 5.04 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 
= 17.9, 24.9, 30.7, 32.6, 45.8, 48.9, 51.7, 52.7, 56.2, 57.7, 58.6, 62.0, 71.1, 171.2, 172.7. 
Calcd [MH]+ (C41H80N7O10Br) m/z = 911.0 Da. Found: ES-MS: [M+H]+ m/z = 912.5, 
[M+Na]+ m/z = 934.5 m/z and [M+K]+ m/z = 950.5. Anal. Calcd for C41H80N7O10Br: C 
54.01%; H 8.78%; N 10.76%. Found C 54.05%; H 8.85%; N 10.76%. 
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Typical linear polymerisation of HPMA (EBiB-, AmG0-, AmG1- and AmG2-
p(HPMA50)) – In a typical synthesis, targeting a DPn = 50 monomer units (p(HPMA)50), 
bpy (173.3 mg, 1.1096 mmol, 2 eq.), HPMA (4.0 g, 27.7 mmol, 50 eq.) and MeOH (35% 
v/v based on HPMA) were placed into a 50 mL RBF. The solution was stirred and 
deoxygenated using a N2 purge for 15 minutes. Cu(I)Cl (54.9 mg, 0.5548 mmol, 1 eq.) 
was added to the flask and left to purge for a further 5 minutes. AmG2-Br (0.505 g, 
0.555 mmol, 1 eq.) was added to the flask under a positive flow of N2, and the solution 
was left to polymerise at 30°C. Reactions were terminated when >99 % conversion was 
reached, as judged by 1H NMR, by exposure to oxygen and addition of THF. The 
catalyst residues were removed by passing the mixture over a neutral alumina column. 
THF was removed under vacuum to concentrate the sample before precipitation into 
hexane and drying in the vacuum oven overnight. 
 
Typical synthesis of a hyperbranched polydendron using the co-polymerisation of 
HPMA and EGDMA, (EBiB-, AmG0-, AmG1- and AmG2-p(HPMA50-co-EGDMAx)) 
– In a typical synthesis, targeting a DPn = 50 monomer units within the primary chain, 
bpy (173.3 mg, 1.11 mmol, 2 eq.), HPMA (4 g, 27.7 mmol, 50 eq.), EGDMA (99.0 mg, 
0.4993 mmol, 0.9 eq.) and MeOH (35% v/v based on HPMA) were placed into a 50 mL 
RBF. The solution was stirred and deoxygenated using a N2 purge for 15 minutes. 
Cu(I)Cl (54.9 mg, 0.5548 mmol, 1 eq.) was added to the flask and left to purge for a 
further 5 minutes. AmG2-Br (0.505 g, 0.555 mmol, 1 eq.) was added to the flask under a 
positive flow of N2, and the solution was left to polymerise at 30°C. Reactions were 
terminated when >99 % conversion was reached, as judged by 1H NMR, by exposure to 
oxygen and addition of THF. The catalyst residues were removed by passing the mixture 
over a neutral alumina column. THF was removed under vacuum to concentrate the 
sample before precipitation into hexane. 
 
Typical procedure for aqueous nanoprecipitation of p(HPMA50) and p(HPMA50-co-
EGDMAx)] - The materials were dissolved in THF at a concentration of 5 mg mL-1. 2 
mL of this solution was then subjected to a rapid solvent switch through drop wise 
addition into 10 mL of water, to give a final polymer NP concentration of 1 mg mL-1 in 
water after THF removal by evaporation overnight. 
 
                                                
1 M. V. Walter, P. Lundberg, A. Hult and M. Malkoch, J. Polym. Sci., Part A: Polym. Chem., 2011, 
49, 2990-2995. 
CHAPTER 2 
90 
                                                                                                                                     
2 F. L. Hatton, P. Chambon, T. O. McDonald, A. Owen and S. P. Rannard, Chem. Sci., 2014, 5, 1844-
1853. 
3 N. O’Brien, A. McKee, D. C. Sherrington, A. T. Slark and A.Titterton, Polymer, 2000, 41, 6027-
6031. 
4 P. A. Costello, I. K. Martin, A. T. Slark, D. C. Sherrington and A. Titterton, Polymer, 2002, 43, 245-
254. 
5 F. Isaure, P. A. G. Cormack and D. C. J. Sherrington, Mater. Chem., 2003, 13, 2701-2710. 
6 A. T. Slark, D. C. Sherrington, A. Titterton and I. K. J. Martin, Mater. Chem., 2003, 13, 2711-2720. 
7 F. Isaure, P. A. G. Cormack and D. C. Sherrington, Macromolecules, 2004, 37, 2096-2105. 
8 H. Fessi, F. Puisieux and J. P. Devissaguet, 1988. Procédé de préparation de systèmes colloïdaux 
dispersibles d’une substance sous forme de nanocapsules. European Patent 274961 A1, 20 July. 
9 F. L. Hatton, L. M. Tatham, L. R. Tidbury, P. Chambon, T. He, A. Owen and S. P. Rannard, Chem. 
Sci., 2015, 6, 326-334. 
10 S. Dai, P. Ravi and K. C. Tam, Soft Matter, 2008, 4, 435–449. 
11 J. V. M. Weaver and D. J. Adams, Soft Matter, 2010, 6, 2575–2582. 
12 D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder and P. Smith, 
Polym. J., 1985, 17, 117-132. 
13 C. Worner and R. Mulhaupt, Angew. Chem., Int. Ed. Engl., 1993, 32, 1306-1308. 
14 E. M. M. De Brabander-van den Berg and E. W. Meijer, Angew. Chem., Int. Ed. Engl., 1993, 32, 
1308–1311. 
15 C. Hawker and J. M. J. Fréchet, J. Chem. Soc., Chem. Commun., 1990, 1010-1013. 
16 J. Ruiz, G. Lafueute, S. Marceu, C. Ornelas, S. Lazare, E. Cloutet, J.-C. Blais and D. Astruc, J. Am. 
Chem. Soc., 2003, 125, 7250-7257. 
17 F. Lecolley, C. Waterson, A. J. Carmichael, G. Mantovani, S. Harrisson, H. Chappell, A. Limer, P. 
Williams, K. Ohno and D. M. Haddleton, J. Mater. Chem., 2003, 13, 2689–2695.  
18 A. Stoddart, W. J. Feast and S. P. Rannard, Soft Matter, 2012, 8, 1096-1108. 
19 S. P. Rannard and N. J. Davis, Org. Lett., 2000, 2, 2117-2120. 
20 K. Sarkar and P. P. Kundu, Int. J. Biol. Macromol., 2012, 51 859– 867. 
21 Y. Chen and X. Xiong, Chem. Commun., 2010, 46, 5049–5060. 
22 E. R. Gillies, T. B. Jonsson and J. M. J. Fréchet, J. Am. Chem. Soc., 2004, 126, 11936-11943. 
23 R. A. Slater, T. O. McDonald, D. J. Adams, E. R. Draper, J. V. M. Weaver and S. P. Rannard, Soft 
Matter, 2012, 8, 9816-9827. 
24 A. Blanazs, J. Madsen, G. Battaglia, A. J. Ryan and S. P. Armes, J. Am. Chem. Soc., 2011, 133, 
16581-16587. 
25 I. Bannister, N. C. Billingham, S. P. Armes, S. P. Rannard and P. Findlay, Macromolecules, 2006, 
39, 7483-7492. 
26 S. Hornig, T. Heinze, C. Remzi Becer and U. S. Schubert, J. Mater. Chem., 2009, 19, 3838-3840. 
27 J. Ford, P. Chambon, J. North, F. L. Hatton, M. Giardiello, A. Owen and S. P. Rannard, 
Macromolecules, 2015, 48, 1883-1893. 
28 R. Zangi and J. B. F. N. Engberts, J. Am. Chem. Soc. 2005, 127, 2272-2276. 
CHAPTER 3 
92?
?
?
?
?
?
?
Chapter 3 
?
?
?
?
Linear polymer, linear-dendritic polymer hybrid, branched copolymer 
and hyp-polydendron synthesis?
? ?
CHAPTER 3 
93?
3.1 Introduction 
 
Chapter 2 demonstrated the production of amine-functionalised linear-dendritic polymer 
hybrids comprised of 2-hydroxypropyl methacrylate (HPMA) and corresponding hyp-
polydendrons generated by the co-polymerisation of HPMA and ethylene glycol 
dimethacrylate (EGDMA). Recently reported hyp-polydendrons are composed of benzyl 
dendritic surface functionality, also containing a branched HPMA polymer core.1 As 
well as studying the effects of varying dendron surface functionality, the research 
presented here aims to investigate other variables within the hyp-polydendron structure 
(Figure 3.1). 
 
 
Figure 3.1 Targeted architectural and chemical variation of hyp-polydendrons; i) dendron generation; 
ii) primary polymer chain chemistry; iii) dendron chemistry; iv) primary polymer chain architecture; 
v) primary polymer chain length; vi) brancher chemistry; vii) mixed surface functionality. 
 
The number of options available for hyp-polydendron manipulation is considerable, 
offering the opportunity to control both structural and chemical behaviour. These 
include: variation of the chemical composition of the primary polymer chain (Figure 
3.1ii), utilising different monomers within the polymerisation to produce polymers with 
different chemical properties; variation of dendron generation has already highlighted 
the ability to produce linear-dendritic polymer hybrids and hyp-polydendrons with G0-
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G2 dendron chain ends (Figure 3.1i; Chapter 2) and variation in physical behaviour; the 
chemistry of the dendron can be varied (Figure 3.1iii), resulting in different surface 
chemistry; and alternatively the linker chemistry within the molecule can be tailored to 
potentially generate functionality within the internal structure of the dendron. In 
addition, the architecture of the primary chains can be adjusted to produce statistical and 
block copolymers, composed of different monomers (Figure 3.1iv), and the degree of 
polymerisation and monomer composition can be varied. Variation in homopolymer 
primary chain length leads to control over the dendron:linear chain ratio, potentially 
analogous to hydrophilic-lipophilic balance within polymeric surfactants (Figure 3.1v) 
and the one-pot polymerisation allows for initiation by multiple initiators (dendron and 
non-dendron) to result in mixed surface groups on the hyp-polydendron (Figure 3.1vii).  
 
This chapter aims to outline the synthesis and characterisation of a range of materials 
with many of the structural and chemical variations outlined above. The properties of 
materials will be discussed in later chapters in a series of comparative studies. 
?
3.2 Variation of primary chain chemistry within linear polymers, 
linear-dendritic polymer hybrids, branched copolymers and hyp-
polydendrons 
 
Previously reported hyp-polydendrons have focussed on HPMA homopolymer primary 
chains (Figure 3.2i); however, atom transfer radical polymerisation (ATRP) has been 
utilised to polymerise a very broad range of other methacrylate monomers.2 New 
monomers that have been taken into consideration within this work include the highly 
hydrophobic monomer, tertiary butyl methacrylate (tBuMA) (Figure 3.2ii) and the pH-
responsive monomer, 2-(diethylamino) ethyl methacrylate (DEA) (Figure 3.2iii).  
Figure 3.2 Monomers considered for utilisation in ATRP to produce hyp-polydendrons; i) HPMA; ii) 
tertiary butyl methacrylate (tBuMA); iii) 2-(diethylamino) ethyl methacrylate (DEA). 
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The ATRP conditions for tBuMA have been thoroughly investigated,3,4 and this 
monomer provides a more hydrophobic polymer to allow comparisons with HPMA. 
DEA was selected for this study as the presence of tertiary amines allows for the 
production of pH-responsive hyp-polydendrons. The use of pH-responsive materials has 
been widely reported in the literature for triggered release drug delivery applications in a 
range of different physiological conditions.5 
 
All ATRP polymerisations and co-polymerisations conducted in this study target a 
number average degree of polymerisation (DPn) = 50 monomer units per primary 
polymer chain unless otherwise stated. The solvent and temperature conditions of each 
polymerisation have been tailored to each particular monomer following various 
literature procedures.6 The catalyst system for all polymerisations was copper 
chloride/2,2’-bipyridyl (Cu(I)Cl/bpy) using the following molar ratio 
[initiator]:[M]:[CuCl]:[bpy] = 1:50:1:2. In all homopolymerisation instances, the 
commercially available initiator, ethyl α-bromoisobutyrate (EBiB), has been used as a 
polymerisation initiator in order to compare initiation efficiency. Additionally, 
comparative studies between dendritic/non-dendritic surface functionality on future 
nanoparticle (NP) behaviour is to be investigated (Chapter 4). 
 
During the ATRP reactions, the monomer conversions were monitored to ensure high 
levels were reached in all cases; this is important to enable targeting of DPn and for the 
attainment of high molecular weight branched polymers.7 Monomer conversions were 
determined by 1H nuclear magnetic resonance spectroscopy (NMR) of the crude reaction 
media. The only expected chemical difference between linear and branched polymer 
NMR spectra was the presence of EGDMA, but these peaks overlap with the main peaks 
associated with the polymer and were not observable. For most polymers, the DPn values 
could not be determined by 1H NMR due to the overlapping signals of the initiators’ 
chain ends with the polymer repeat units.  
 
Kinetic studies were conducted for each homopolymerisation to confirm first order 
kinetics with respect to monomer concentration. When new ATRP initiators were 
utilised, it was important to follow the evolution of molecular weight with respect to 
monomer conversion and to ensure no interference in the ATRP mechanism. Linear 
semi-logarithmic plots were used to confirm first order kinetics and the monitoring of a 
linear development of number average molecular weight (Mn) with respect to monomer 
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conversion was generally observed, leading to monomodal molecular weight 
distributions for all linear and linear-dendritic polymers conducted in the study. ?
?
Weight average molecular weight (Mw) was also closely monitored within the branched 
polymerisations and showed the well reported8 dramatic increase at high conversions, 
leading to multimodal gel permeation chromatography (GPC) chromatograms as 
expected. Molecular weight analyses were enabled by determining average dn/dc values 
for each linear/linear-dendritic/branched copolymer/hyp-polydendron.? Estimations to 
establish the weight average number of conjoined primary linear-dendritic polymer 
chains within each hyp-polydendron assumed that the linear-dendritic polymer 
synthesised under identical conditions fully represented the primary chains within the 
branched polymerisation. The simple division of Mw (hyp-polydendron) by Mw (linear-
dendritic polymer equivalent), therefore gives the weight average number of conjoined 
primary chains. Following this, the weight average number of surface functional groups 
can be estimated from the number of chain ends and the number of functional groups per 
dendron.?
 
All polymer molecular weights and dispersities (Ð = Mw/Mn) were determined by triple 
detection GPC; for all linear polymers, Mn values were greater than the theoretical values 
either due to initiator inefficiency and/or disproportionation leading to a small 
concentration of macromonomer.9 Despite the higher than targeted Mn values obtained, 
the linear polymers and linear-dendritic polymer hybrids appeared to deviate from 
theoretical values in a generally consistent manner, allowing an accurate assessment of 
structure/chemical impact on material behaviour without specific consideration of highly 
variable molecular weights. All polymers are referred to using their target DPn 
throughout the discussion, irrespective of the actual DPn achieved. 
 
Branched copolymers and hyp-polydendrons were successfully synthesised following 
incorporation of a low concentration of EGDMA into the polymerisation reaction, as 
reported in Chapter 2. When using EBiB as the initiator, a molar ratio of brancher: 
initiator of 0.95:1 was employed, unless otherwise stated. When using any dendron 
ATRP initiator (AmG0-Br, AmG1-Br, AmG2-Br, AmG1U-Br or BnG2-Br), gel 
formation was seen within the co-polymerisations at this ratio but soluble hyp-
polydendrons were achieved at lower brancher: initiator ratios (0.9:1). This further 
suggests a lower initiator efficiency, as poor initiation will lead to fewer propagating 
polymer chains and a higher effective brancher:chain ratio within each reaction. The 
CHAPTER 3 
97?
0.9:1 brancher: initiator ratio was selected for all hyp-polydendrons unless otherwise 
stated. 
?
3.2.1 Linear polymerisation of DEA and co-polymerisation of DEA and 
EGDMA using EBiB and amine-functional dendron ATRP initiators 
 
The controlled polymerisation conditions associated with tertiary amine methacrylates 
have been extensively studied and reported.10,11,12 The interesting behaviour of linear-
dendritic HPMA polymer hybrids and hyp-polydendrons in alternating pH (Chapter 2) 
was investigated due to the amphiphilic behaviour of primary chains due to protonation 
of the amine-functionalised dendron chain ends at low pH. This, consequently, enabled 
the production of pH-responsive linear-dendritic and hyp-polydendron polymers. 
 
As a weak polybase with a pKa of ~7.3, p(DEA) is a cationic polyelectrolyte in aqueous 
solution.13 It has been shown to effectively bind with negatively charged 
deoxyribonucleic acid (DNA), which has been recognised as an ideal characteristic in the 
design of gene delivery vehicles.14 Polymerisation techniques for DEA include anionic 
polymerisation, first reported by Nagasaki et al.,15 group-transfer polymerisation by 
Armes and co-workers,16,17 and the first homopolymerisation via ATRP by Tam and co-
workers.4 
 
3.2.1.1 Linear polymerisation of DEA using EBiB and amine-functional dendron 
ATRP initiators 
 
Initially, linear polymers of DEA were synthesised at 40°C (56 wt% v/v) in isopropanol 
(IPA), initiated by EBiB (Scheme 3.1). Tertiary amine methacrylates have been reported 
as undergoing transesterification in methanol, rendering it an unsuitable solvent.18  
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Scheme 3.1 Schematic representation of the linear polymerisation of DEA (2) using EBiB (1) 
producing the linear polymer EBiB-p(DEA50). 
 
The three dendron initiators, AmG0-Br, AmG1-Br and AmG2-Br synthesised in Chapter 
2, were also used to polymerise DEA in identical conditions (Figure 3.3). 
 
 
Figure 3.3 Diagrammatic representation of the polymerisation of DEA using AmG0-Br, AmG1-Br 
and AmG2-Br. 
 
All linear and linear-dendritic polymers were purified by passing through a basic alumina 
column to remove the catalytic system, followed by precipitation into cold petroleum 
ether (40-60) before analysis by GPC. Analysis of the EBiB-p(DEA50) shows higher Mn 
values (almost double) than targeted (Table 3.1), as previously discussed.  
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Table 3.1 GPC analysis of EBiB and amine-functionalised DEA linear and linear-dendritic polymers 
and DEA-EGDMA branched copolymer and hyp-polydendrons. 
    GPCa   
Polymer Conversion 
(%)b 
Mn Theory  
(g mol-1) c 
Mn  
(g mol-1) 
Mw  
(g mol-1) 
Đ DPn 
EBiB-p(DEA50) 98 9380 18050 20900 1.16 97 
AmG0-p(DEA50) 99 9440 16350 19650 1.20 88 
AmG1-p(DEA50) 97 9690 17450 20900 1.20 94 
AmG2-p(DEA50) 97 10090 23650 34400 1.46 128 
EBiB-p(DEA50-
co-EGDMA0.95) 
98 - 689200 1403000 2.04 - 
AmG0-p(DEA50-
co-EGDMA0.9) 
92 - 39500 173500 4.40 - 
AmG1-p(DEA50-
co-EGDMA0.9) 
99 - 21700 288000 13.28 - 
AmG2-p(DEA50-
co-EGDMA0.9) 
99 - 125700 341800 2.72 - 
a Triple detection analysis using THF/2%TEA as eluent; b Determined by NMR; c Mn 
Theory = (Mw monomer*DP targeted)+Mw initiator 
 
Despite this, the polymerisation was controlled, as confirmed by the low Ð value and 
reached high monomer conversion (98%). All linear-dendritic DEA materials had similar 
Mn values, with the AmG0-p(DEA50) having the lowest Mn (16350 g mol-1) and the 
AmG2-p(DEA50) having the highest (23650 g mol-1). The AmG2-p(DEA50) appears to 
show a reduction in initiator efficiency and less control over the molecular weight 
distribution (Table 3.1). The linear-dendritic hybrids, AmG0-p(DEA50), AmG1-p(DEA50) 
and AmG2-p(DEA50) also achieved high monomer conversion (>97 %) and an example 
of a typical linear-dendritic DEA polymer hybrid NMR spectrum assignment is shown in 
Figure 3.4, and the others displayed in Appendix, Figures A26-28. The GPC refractive 
index (RI) and right angle light scattering (RALS) chromatograms for the linear and 
linear-dendritic polymers, EBiB-p(DEA50), AmG0-p(DEA50), AmG1-p(DEA50) and 
AmG2-p(DEA50), displayed mono-modal molecular weight distributions (Figure 3.5). 
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Figure 3.4 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA50). 
 
Figure 3.5 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
EBiB-p(DEA50) (black), AmG0-p(DEA50) (green), AmG1-p(DEA50) (blue) and AmG2-p(DEA50)
(red); C) RI chromatograms and D) RALS chromatograms for EBiB-p(DEA50-co-EGDMA0.95) 
(black), AmG0-p(DEA50-co-EGDMA0.9) (green), AmG1-p(DEA50-co-EGDMA0.9) (blue) and AmG2-
p(DEA50-co-EGDMA0.9) (red). 
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Separate kinetic studies revealed that the polymerisations initiated by AmG0-Br, AmG1-
Br and AmG2-Br appeared to propagate at relatively similar rates (Figure 3.6A), with 
the fastest (the AmG0-Br) achieving approximately 80% conversion in 3 hours. 
Molecular weight analyses were enabled by determining average dn/dc values from the 
number of time points taken (Appendix, Table A1). The Ð values, for each 
polymerisation, decreased as the reaction progressed, although end values were as high 
as Ð = 1.46 (AmG2-p(DEA50)). 
 
 
?
Figure 3.6 Kinetic plots for A and B) Linear-dendritic AmG0-p(DEA50), AmG1-p(DEA50) and 
AmG2-p(DEA50) and C) and D) AmG0-p(DEA50-co-EGDMA0.9). A) Conversion AmG0-p(DEA50) 
(green squares), ln([M]0/[M]) (green circles); AmG1-p(DEA50) (blue squares), ln([M]0/[M]) (blue 
circles) and AmG2-p(DEA50) (red squares), ln([M]0/[M]) (red circles). B) Mn AmG0-p(DEA50) (green 
circles); AmG1-p(DEA50) (blue circles) and AmG2-p(DEA50) (red circles); Ð AmG0-p(DEA50) (green 
lines); AmG1-p(DEA50) (blue lines) and AmG2-p(DEA50) (red lines). C) Conversion (blue squares), 
ln([M]0/[M]) (red circles); D) Mn (red circles), Mw (black diamonds) and Ð (blue lines). 
 
3.2.1.2 Co-polymerisation of DEA and EGDMA using EBiB and amine-
functionalised dendron ATRP initiators 
 
Following the successful preparation of a linear DEA polymer and linear-dendritic DEA 
polymer hybrids containing amine functional dendron chain ends, EGDMA was 
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introduced into the polymerisation initiated by EBiB, to produce the branched copolymer 
EBiB-p(DEA50-co-EGDMA0.95) (Scheme 3.2). 
 
Scheme 3.2 Schematic representation of the branched co-polymerisation of DEA (2) and EGDMA (3) 
using EBiB (1) producing the branched copolymer EBiB-p(DEA50-co-EGDMA0.95). 
 
The branched co-polymerisation of DEA with EGDMA was conducted under identical 
conditions to those used for linear polymer synthesis, albeit at a lower monomer 
concentration (38.9 wt% v/v as opposed to 56.0 wt% v/v for the linear equivalent) to 
avoid gelation.19,20 This resulted in a soluble, high-molecular weight polymer (Mn = 
689,200 g mol-1) being recovered (Table 3.1) at high monomer conversion (98%). 
 
Following the successful preparation of a high-molecular weight DEA branched 
copolymer, the amine-functionalised dendron ATRP initiators were used to co-
polymerise DEA and EGDMA, to produce hyp-polydendrons (Figure 3.7).  
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Figure 3.7 Diagrammatic representation of the co-polymerisation of DEA and EGDMA using AmG0-
Br, AmG1-Br and AmG2-Br. 
 
The GPC RI and RALS chromatograms for the branched polymer and hyp-polydendrons 
(Figure 3.5C and D) confirm high levels of branching, due to broad, bimodal 
distributions in comparison to the narrow, mono-modal traces observed for the linear 
equivalent polymerisations. 
 
The branched co-polymerisation initiated by EBiB required a longer polymerisation time 
(Appendix, Figure A29A and B) in contrast to the respective linear polymer reaction 
conducted in the absence of EGDMA (Appendix, Figure A30). The amine-functional 
dendron ATRP initiators required longer co-polymerisation times (Appendix, Figure 
A29C, D, E and F) in comparison to their respective linear-dendritic polymer reactions 
conducted in the absence of EGDMA (Figure 3.6); the AmG0-p(DEA50-co-EGDMA0.9) 
took > 42 hours (compared to 6 hours) to reach 80% monomer conversion (Figure 3.6C 
and D).  
 
The EBiB-p(DEA50-co-EGDMA0.95) reached an Mw of 1.4x106 g mol-1 suggesting a 
significant contribution to the physical mass of the sample from complex branched 
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structures containing on weight average > 67 primary polymer chains. The Mw values for 
the amine-functional hyp-polydendrons steadily increase as the dendron generation 
increases (Table 3.1), although the AmG1-p(DEA50-co-EGDMA0.9) suggests having 
more (on average) linear chains joined together (> 14 primary polymer chains) than the 
AmG0- or AmG2-p(DEA50-co-EGDMA0.9) (> 9 and 10 primary polymer chains 
respectively) (Table 3.1). All hyp-polydendrons show similar levels of primary chain 
contribution per branched polymer. Therefore, as each primary chain of the hyp-
polydendrons contains a dendron initiator end group, the weight average branched 
architectures contain approximately 14 tertiary amine (AmG0-p(DEA50-co-EGDMA0.9)), 
28 tertiary amine (AmG1-p(DEA50-co-EGDMA0.9)) and 40 tertiary amine (AmG2-
p(DEA50-co-EGDMA0.9)) functional chain end groups. An example of a typical 
p(DEA50-co-EGDMAx) 1H NMR spectrum is shown (Figure 3.8) with major peaks 
assigned, with the others displayed in Appendix, Figures A31-33. 
 
 
Figure 3.8 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA50-co-EGDMA0.9) 
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3.2.2 Linear polymerisation of tBuMA and co-polymerisation of tBuMA and 
EGDMA using EBiB and AmG2-Br ATRP initiators 
 
Both ATRP initiators, EBiB (Scheme 3.3 1) and AmG2-Br (Scheme 3.3 3) were used to 
polymerise tBuMA (Scheme 3.3 2) and copolymerise tBuMA and EGDMA (Scheme 3.4 
3) in IPA/H2O at 20°C. Rannard and co-workers first reported the ambient temperature 
waterborne ATRP of a hydrophobic monomer (nBuMA) in homogenous alcoholic 
media in 2001.21 A ratio of 92.5:7.5% IPA:H2O proved to be ideal solvent conditions, 
allowing short reaction times without compromising the control of the polymerisation. 
All materials were purified by passing through a basic alumina column to remove the 
catalytic system, followed by precipitation into cold hexane before analysis by GPC 
(Table 3.2). 
 
 
Scheme 3.3 Schematic representation of the linear polymerisation of tBuMA (2) using EBiB (1) and 
AmG2-Br (3) as ATRP initiators producing the linear polymer EBiB-p(tBuMA50) and linear-dendritic 
polymer hybrid AmG2-p(tBuMA50). 
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Scheme 3.4 Schematic representation of the branched co-polymerisation of tBuMA (2) and EGDMA 
(3) using EBiB (1) and AmG2-Br (4) as ATRP initiators producing the branched copolymer EBiB-
p(tBuMA50-co-EGDMA0.95) and hyp-polydendron AmG2-p(tBuMA50-co-EGDMA0.9). 
 
The linear polymer, EBiB-p(tBuMA50), and linear-dendritic polymer hybrid, AmG2-
p(tBuMA50) both reached high monomer conversion (>94 %); however, the AmG2-
p(tBuMA50) exhibited a more controlled polymerisation, resulting in a lower dispersity 
value (Đ = 1.11). The linear-dendritic polymer hybrid was also recovered with an Mn = 
6900 g mol-1 and DPn close to the targeted theoretical value of 7940 g mol-1. The 
branched copolymer (EBiB-p(tBuMA50-co-EGDMA0.95)) and hyp-polydendron (AmG2-
p(tBuMA50-co-EGDMA0.9)) were recovered at high monomer conversion (>96 %) and 
analysis was conducted by GPC as previously stated (Table 3.2). The hyp-polydendron 
was recovered with a higher Mn and Mw value (273300 g mol-1) than the EBiB-initiated 
branched copolymer (Mw = 150400 g mol-1), which could be due to the former reaching
99% conversion. The AmG2-p(tBuMA50-co-EGDMA0.9) contained on average > 36 
primary chains in comparison to > 5 primary chains for the EBiB-p(tBuMA50-co-
EGDMA0.95) due to the hyp-polydendron consisting of a higher molecular weight. Each 
primary chain of the hyp-polydendron contains an AmG2 dendron chain end, therefore 
the weight average branched architecture contains approximately 144 tertiary amine 
chain end functional groups. The 1H NMR spectra of AmG2-p(tBuMA50) and AmG2-
p(tBuMA50-co-EGDMA0.9) with major peaks assigned is presented in Figures 3.9 and 
3.10 respectively, with the EBiB-p(tBuMA50) and EBiB-p(tBuMA50-co-EGDMA0.95) 
shown in Appendix, Figures A34 and A35. 
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Table 3.2 GPC analysis of EBiB and amine-functionalised tBuMA linear polymer, linear-dendritic 
polymer hybrid, copolymer and hyp-polydendron. 
    GPCa   
Polymer 
Conversion 
(%)b 
Mn Theory 
(g mol-1)c 
Mn  
(g mol-1) 
Mw  
(g mol-1) 
Đ DPn 
EBiB-p(tBuMA50) 95 7230 19750 27450 1.38 138 
AmG2-p(tBuMA50) 94 7940 6900 7650 1.11 48 
EBiB-p(tBuMA50-co-
EGDMA0.95) 
96 - 63800 150400 2.36 - 
AmG2-p(tBuMA50-co-
EGDMA0.95) 
99 - 88200 273300 3.10 - 
a Triple detection analysis using THF/2%TEA as eluent; b Determined by NMR; c Mn Theory = 
(Mw monomer*DP targeted)+Mw initiator
 
 
Figure 3.9 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(tBuMA50). 
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Figure 3.10 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(tBuMA50-co-EGDMA0.9). 
 
The linear polymers EBiB-p(tBuMA50) and AmG2-p(tBuMA50) exhibited mono-modal 
molecular weight distributions upon inspection of the GPC RI and RALS 
chromatograms (Figure 3.11). Figure 3.11 also shows the GPC RI and RALS 
chromatograms for the branched copolymer and hyp-polydendron, showing broader size 
distributions in comparison to their linear analogues. 
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Figure 3.11 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
EBiB-p(tBuMA50) (black) and AmG2-p(tBuMA50) (red); C) RI chromatograms and D) RALS 
chromatograms for EBiB-p(tBuMA50-co-EGDMA0.95) (black) and AmG2-p(tBuMA50-co-EGDMA0.9). 
 
The linear polymerisation initiated by EBiB appeared to propagate faster (Appendix, 
Figure A36A and B) than the reaction using AmG2-Br, achieving approximately 60% 
conversion in 5 hours; in comparison, the AmG2-Br polymerisation required ~16 hours 
to reach a similar conversion (Figure 3.12A). Dispersity values decreased gradually as 
the polymerisations proceeded and the polymers reached high conversion. Molecular 
weight analyses were enabled by determining average dn/dc values from the number of 
time points taken (Appendix, Table A2). 
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Figure 3.12 Kinetic plots for linear AmG2-p(tBuMA50) and branched AmG2-p(tBuMA50-co-
EGDMA0.9). A and C) Conversion (blue squares), ln([M]0/[M]) (red circles); B and D) Mn (red 
circles), Ð (blue lines) and Mw (black diamonds). 
 
Kinetic studies suggest that the EBiB-initiated branched co-polymerisation has an almost 
identical polymerisation rate to the respective linear polymerisation conducted in the 
absence of EGDMA (Appendix, Figure A36C and D), reaching 95% conversion in 8 
hours. The hyp-polydendron synthesis using AmG2-Br initiator propagated noticeably 
slower than the analogous linear-dendritic polymer reaction, taking 24 hours to reach 
94% conversion (Figure 3.12C). 
 
3.3 Variation of primary chain architecture to produce statistical 
and block linear-dendritic polymer hybrids and hyp-polydendrons 
 
DEA has been co-polymerised with a wide variety of monomers via facile controlled 
polymerisation techniques in order to synthesise materials that easily produce pH-
responsive NPs,22 with huge potential in the drug delivery field.23 The incorporation of 
DEA into highly branched polymers allows for subsequent quaternisation of the tertiary 
amine groups leading to water-soluble cationic polyelectrolytes.24 Monomers included in 
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the co-polymerisation with DEA include tBuMA and methacrylic acid (MAA) to 
investigate the micellar behaviour under varying pH and the effects of NaCl addition.25 
Triple-shell architectures, consisting of DEA, vinylcaprolactam and 2-
(dimethylamino)ethyl methacrylate (DMA) triblock terpolymers have even been 
obtained by sequential reversible addition–fragmentation chain transfer polymerisations 
to produce a double responsive system.26 The application of ATRP to design and 
synthesise a variety of novel polymeric architectures, has also included reports of shell-
cross linked particles comprising DEA and p(ethylene glycol) (PEG) that swell upon a 
change in pH.27 
 
These ideologies encourage modification of the primary chain architecture to produce 
statistical and block linear-dendritic copolymers and hyp-polydendrons, composed of 
different monomers. The amounts of each monomer composition and block length can, 
also, be modified. 
 
3.3.1 Statistical co-polymerisations using AmG2-Br ATRP initiator to produce 
linear-dendritic copolymer hybrids and hyp-polydendrons 
 
Following the successful homopolymerisations of HPMA (Chapter 2), DEA and tBuMA 
to produce a variety of linear-dendritic polymer hybrids and hyp-polydendrons, the 
incorporation of different monomer units to produce statistical linear-dendritic polymer 
hybrids and hyp-polydendrons was investigated (Figure 3.13). 
 
Figure 3.13 Diagrammatic representation of the statistical linear-dendritic polymer hybrids and hyp-
polydendrons synthesised incorporating HPMA (blue), DEA (green) and tBuMA (red). 
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DEA was incorporated into both the HPMA and tBuMA polymerisations in order to 
introduce a pH-response into both hyp-polydendron systems. Previous 
homopolymerisations with HPMA (Chapter 2) and DEA have utilised varying 
generations of dendrons as ATRP initiators, producing a variety of dendron generation as 
a chain end/surface group for the linear-dendritic hybrids/hyp-polydendrons. In this 
study, only the AmG2-Br ATRP initiator was selected for polymerisation initiation, in 
order to focus investigations on varying compositions and architectural differences of the 
polymers produced. The statistical and block linear-dendritic polymer hybrids and hyp-
polydendrons all targeted a DPn = 50 monomer units for the primary chain, in ratios of 
33:66, 50:50 and 66:33 mol%, DEA: HPMA/tBuMA unless otherwise stated. 
 
3.3.1.1 Statistical co-polymerisation of DEA and HPMA using AmG2-Br ATRP 
initiator 
?
AmG2-Br (Scheme 3.5 1) was used to co-polymerise DEA (Scheme 3.5 2) and HPMA 
(Scheme 3.5 3) at 40°C in IPA in a one-pot statistical polymerisation to produce three 
linear-dendritic polymers, AmG2-p(DEA17-co-HPMA33), AmG2-p(DEA25-co-HPMA25) 
and AmG2-p(DEA33-co-HPMA17).  
?
Scheme 3.5 Schematic representation of the statistical linear co-polymerisations of DEA (2) and 
HPMA (3) using AmG2-Br (1) as the ATRP initiator producing statistical linear-dendritic polymer 
hybrids AmG2-p(DEA17-co-HPMA33), AmG2-p(DEA25-co-HPMA25) and AmG2-p(DEA33-co-
HPMA17). 
?
The linear-dendritic hybrids were collected at high monomer conversion (>99 %) with 
the p(DEAx-co-HPMAy) 1H NMR spectra shown in Figure 3.14 and Appendix, Figures 
A37 and 38, with major peaks assigned. In all cases, the polymers were purified by 
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passing through a basic alumina column to remove the catalytic system and precipitating 
into cold petroleum ether (40-60). The linear-dendritic polymer hybrids all possessed 
similar Mn values that were closer to targeted theoretical values than any of the 
previously synthesised linear-dendritic DEA and HPMA homopolymer hybrids. Mw 
values were also similar and Đ values were low (Table 3.3), confirmed further by the 
monomodal, narrow RI and RALS chromatograms (Figure 3.15). 
 
Table 3.3 GPC analysis of AmG2-initiated amine-functional DEA-HPMA and DEA-tBuMA 
statistical linear-dendritic hybrids and hyp-polydendrons. 
    GPCa  
Polymer Conversionb 
(%) 
Mn Theory  
(g mol-1) 
Mn  
(g mol-1) 
Mw  
(g mol-1) 
Đ 
AmG2-p(DEA33-co-HPMA17) 99 9400c 11750 14600 1.24 
AmG2-p(DEA25-co-HPMA25) 99 9070c 12600 16550 1.31 
AmG2-p(DEA17-co-HPMA33) 99 8740c 12200 16000 1.31 
AmG2-p(DEA33-co-HPMA17-
co-EGDMA0.9) 
99 - 247500 398300 1.61 
AmG2-p(DEA25-co-HPMA25-
co-EGDMA0.9) 
99 - 268900 1971000 7.33 
AmG2-p(DEA17-co-HPMA33-
co-EGDMA0.9) 
99 - 682000 4510000 66.15 
AmG2-p(DEA33-co-tBuMA17) 99 9360d 9000 10350 1.15 
AmG2-p(DEA25-co-tBuMA25) 99 9020d 9800 11350 1.16 
AmG2-p(DEA17-co-tBuMA33) 99 8670d 9850 11050 1.12 
AmG2-p(DEA33-co-tBuMA17-
co-EGDMA0.9) 
99 - 209200 392400 1.88 
AmG2-p(DEA25-co-tBuMA25-
co-EGDMA0.9) 
99 - 67200 140900 2.10 
AmG2-p(DEA17-co-tBuMA33-
co-EGDMA0.9) 
99 - 149200 531100 3.56 
a Triple detection analysis using THF/2% TEA eluent; b Determined by 1H NMR; c Mn 
Theory = (Mw HPMA monomer*DP HPMA targeted)/+ (Mw DEA monomer*DP DEA 
targeted)+Mw AmG2; d Mn Theory = (Mw tBuMA monomer*DP tBuMA targeted)/+ (Mw 
DEA monomer*DP DEA targeted)+Mw AmG2 
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Figure 3.14 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA33-co-HPMA17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
115?
 
 
Figure 3.15 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
AmG2-p(DEA33-co-HPMA17) (green), AmG2-p(DEA25-co-HPMA25) (purple) and AmG2-p(DEA17-co-
HPMA33) (blue); C) RI chromatograms and D) RALS chromatograms for AmG2-p(DEA33-co-
HPMA17-co-EGDMA0.9) (green), AmG2-p(DEA25-co-HPMA25-co-EGDMA0.9) (purple) and AmG2-
p(DEA17-co-HPMA33-co-EGDMA0.9) (blue). 
 
3.3.1.2 Statistical co-polymerisation of DEA, HPMA and EGDMA using AmG2-
Br ATRP initiator 
 
Following the successful preparation of linear-dendritic DEA-HPMA polymer hybrids 
containing amine dendron chain end functionality, EGDMA (Scheme 3.6 4) was 
introduced into the polymerisation initiated by AmG2-Br, to produce the hyp-
polydendrons AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9), AmG2-p(DEA25-co-
HPMA25-co-EGDMA0.9) and AmG2-p(DEA17-co-HPMA33-co-EGDMA0.9). The 
p(DEAx-co-HPMAy-co-EGDMA0.9) 1H NMR spectra is shown in Figure 3.16 and 
Appendix, Figures A39 and 40 with major peaks assigned. 
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Scheme 3.6 Schematic representation of the statistical branched co-polymerisations of DEA (2), 
HPMA (3) and EGDMA (4) using AmG2-Br (1) as the ATRP initiator producing the hyp-
polydendrons AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9), AmG2-p(DEA25-co-HPMA25-co-
EGDMA0.9) and AmG2-p(DEA17-co-HPMA33-co-EGDMA0.9).
 
 
Figure 3.16 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA25-co-HPMA25-co-EGDMA0.9). 
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The statistical hyp-polydendrons formed materials of noticeably high molecular weights 
in comparison to previously synthesised DEA and HPMA hyp-polydendrons, following 
high monomer conversions for all, with Mw values up to 4.51x106 g mol-1 (Table 3.3). 
There is a noticeable increase in Mn and Mw (and Đ) as the HPMA content within the 
polymer is increased, with the AmG2-p(DEA17-co-HPMA33-co-EGDMA0.9) containing
the most linear chains joined together, on weight average > 282 primary chains (1,128 
tertiary amine surface groups) (> 27 primary chains (108 tertiary amine surface groups) 
(AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9)) and > 119 primary chains (476 tertiary 
amine surface groups) (AmG2-p(DEA25-co-HPMA25-co-EGDMA0.9)). The hyp-
polydendrons show a significant level of primary chain contribution per branched 
polymer, also displayed by the broad RI and RALS molecular weight distributions 
(Figure 3.15). 
 
3.3.1.3 Statistical co-polymerisation of DEA and tBuMA using AmG2-Br ATRP 
initiator 
 
AmG2-Br (Scheme 3.7 1) was additionally used to co-polymerise DEA (Scheme 3.7 2) 
and tBuMA (Scheme 3.7 3) at 40°C in IPA/H2O28 in a one-pot statistical polymerisation 
to produce three linear-dendritic polymers, AmG2-p(DEA17-co-tBuMA33), AmG2-
p(DEA25-co-tBuMA25) and AmG2-p(DEA33-co-tBuMA17). 
 
Scheme 3.7 Schematic representation of the statistical linear co-polymerisations of DEA (2) and 
tBuMA (3) using AmG2-Br (1) as the ATRP initiator producing the linear-dendritic polymer hybrids 
AmG2-p(DEA33-co-tBuMA17), AmG2-p(DEA25-co-tBuMA25) and AmG2-p(DEA17-co-tBuMA33).
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The statistical linear-dendritic hybrids were collected at high monomer conversion 
(>99 %), as determined by 1H NMR of the crude polymerisation media. Polymers were 
purified by passing through a basic alumina column and precipitating into cold petroleum 
ether (40-60). The 1H NMR spectra for the AmG2-p(DEAx-co-tBuMAy) statistical linear-
dendritic hybrids are shown in Figure 3.17 and Appendix, Figures A41 and 42.
 
 
Figure 3.17 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA17-co-tBuMA33). 
 
The linear-dendritic polymer hybrid series were consistent in their achieved DPn, as well 
as exhibiting high levels of control confirmed by the low dispersity values (Đ=1.12-1.16) 
(Table 3.3) and narrow monomodal weight distributions (Figure 3.18). Interestingly, the 
linear-dendritic polymer containing the highest content of tBuMA, AmG2-p(DEA17-co-
tBuMA33) demonstrated the highest level of control. The AmG2-p(tBuMA50) previously 
displayed greater levels of polymerisation control (Đ=1.11) in comparison to the AmG2-
p(DEA50) (Đ=1.46). 
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Figure 3.18 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
AmG2-p(DEA33-co-tBuMA17) (green), AmG2-p(DEA25-co-tBuMA25) (orange) and AmG2-p(DEA17-
co-tBuMA33) (red); C) RI chromatograms and D) RALS chromatograms for AmG2-p(DEA33-co-
tBuMA17-co-EGDMA0.9) (green), AmG2-p(DEA25-co-tBuMA25-co-EGDMA0.9) (orange) and AmG2-
p(DEA17-co-tBuMA33-co-EGDMA0.9) (red). 
 
3.3.1.4 Statistical co-polymerisation of DEA, tBuMA and EGDMA using AmG2-
Br ATRP initiator 
 
EGDMA (Scheme 3.8 4) was subsequently introduced to the co-polymerisations in order 
to produce the tBuMA-containing statistical hyp-polydendrons, AmG2-p(DEA33-co-
tBuMA17-co-EGDMA0.9), AmG2-p(DEA25-co-tBuMA25-co-EGDMA0.9) and AmG2-
p(DEA17-co-tBuMA33-co-EGDMA0.9) (Scheme 3.8).
 
CHAPTER 3 
120?
 
Scheme 3.8 Schematic representation of the statistical branched co-polymerisations of DEA (2), 
tBuMA (3) and EGDMA (4) using AmG2-Br (1) as the ATRP initiator producing the hyp-
polydendrons AmG2-p(DEA33-co-tBuMA17-co-EGDMA0.9), AmG2-p(DEA25-co-tBuMA25-co-
EGDMA0.9) and AmG2-p(DEA17-co-tBuMA33-co-EGDMA0.9). 
 
Highly branched materials with broad molecular weight distributions (Figure 3.18) were 
recovered with molecular weights ranging from 140900 g mol-1 (AmG2-p(DEA33-co-
tBuMA17-co-EGDMA0.9)) to 531100 g mol-1 (AmG2-p(DEA33-co-tBuMA17-co-
EGDMA0.9)) (Table 3.3). The branched structures contained on weight average > 38 
primary chains (AmG2-p(DEA33-co-tBuMA17-co-EGDMA0.9)), > 12 primary chains 
(AmG2-p(DEA25-co-tBuMA25-co-EGDMA0.9)) and > 48 primary chains (AmG2-
p(DEA17-co-tBuMA33-co-EGDMA0.9)). Each primary chain of the hyp-polydendrons 
contains an AmG2 dendron initiator end group, therefore the weight average branched 
architectures contain approximately 152 tertiary amine (AmG2-p(DEA33-co-tBuMA17-
co-EGDMA0.9)), 48 tertiary amine (AmG2-p(DEA25-co-tBuMA25-co-EGDMA0.9)) or 192 
tertiary amine (AmG2-p(DEA17-co-tBuMA33-co-EGDMA0.9)) chain end functional 
groups. The 1H NMR spectra of p(DEAx-co-tBuMAy-co-EGDMA0.9) statistical hyp-
polydendrons are shown in Figure 3.19 and Appendix, Figures A43 and 44. 
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Figure 3.19 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA33-co-tBuMA17-co-EGDMA0.9). 
As well as a range of statistical linear-dendritic polymer hybrids and hyp-polydendrons, 
dendritic block copolymer hybrids and block hyp-polydendrons of varying branched 
tBuMA core were also synthesised. 
 
3.3.2 Block co-polymerisations using AmG2-Br ATRP initiator to produce 
linear-dendritic copolymer hybrids and hyp-polydendrons 
 
Rannard and co-workers have previously documented the synthesis of complex polymer 
nanostructures using a one-pot ATRP approach, avoiding separate self-assembly and 
chemical-fixation steps.29 Well-defined branched block terpolymer NPs were 
synthesised by the initial production of simple linear hydrophilic p(oligo(ethylene 
glycol) methacrylatex) (OEGx), followed by subsequent addition of the hydrophobic 
nBuMA and EGDMA to the growing OEG chain. This allowed branching to occur and 
chemical bond formation between other growing p(nBuMAx) blocks, hence building a 
structure composed of covalently linked copolymer chains (Scheme 3.9). This chemical 
synthesis strategy allowed design and manipulation of NP size by variation of the block 
lengths, whereby a systematic increase in particle size was observed. This simplistic 
one-pot method allows for the facile production of block terpolymers, where the block 
length can easily be altered. 
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Scheme 3.9 Schematic representation of block branched copolymer synthesis via initial 
polymerisation of OEG (2) initiated by EBiB (1), followed by introduction of second monomer feed 
containing nBuMA (3) and EGDMA (4). 
 
This work utilised the same concepts as just described, albeit with the initial fabrication 
of linear-dendritic polymer hybrids from which to grow the branched hydrophobic 
polymer core from. Initially, diblock copolymers with dendron chain ends were 
produced in order to confer control. Succeeding this, EGDMA was introduced in the 
second feed of monomer.  
 
Much attention has been invested into block copolymers containing MAA segments,30 
where the properties of such weak polyelectrolytes govern the self-assembled structures 
by changes in pH and salt concentrations. The route to such MAA functionality is 
introduced by the incorporation of protected monomers with masked acid groups into 
the polymer chains. Essential prerequisites for the protected monomer are good 
‘livingness’ under each polymerisation condition and selective deprotection under mild 
conditions. 
 
The controlled polymerisation of the block copolymer p(DEAx-b-tBuMAy) has 
previously been reported, using both DEA-Cl and tBuMA-Cl as the macroinitiators.4 
Armes and co-workers have already considered the opportunities in combining a 
protected monomer (methacrylic acid) with a pH-responsive monomer (DMA)31,32 and 
uncovered difficulties upon hydrolysis. The research described claimed that conditions 
required to remove the tertiary butyl groups were likely to cause intermolecular cross-
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linking between the DMA blocks. Fortunately, in this study, the tBuMA polymer is 
merely integrated into the dendritic materials to provide a hydrophobic domain for drug 
encapsulation. 
 
The design of these branched block hyp-polydendrons also provides a robust 
hydrophobic core for drug encapsulation, surrounded by dendritic pH-responsive chain 
ends to provide stability in aqueous media. The growth of linear DEA arms surrounding 
a branched hydrophobic core (Figure 3.20), presents a wholly different architecture 
platform in which nanoprecipitates collapse and self-assemble from. 
 
 
Figure 3.20 Diagrammatic representation of: i) Block linear-dendritic DEA-tBuMA polymer hybrid 
(AmG2-p(DEAx-b-tBuMAy)) and ii) Block DEA-tBuMA-EGDMA hyp-polydendron (AmG2-
p(DEAx-b-(tBuMAy-co-EGDMA0.9))). 
 
AmG2-Br (Scheme 3.10 1) was used to polymerise DEA (Scheme 3.10 2) at 40°C in 
IPA using the following molar ratio [Initiator]:[M]:[CuCl]:[bpy]=1:33/25/17:1:2. Upon 
reaching 73-92% monomer conversion, the second feed of tBuMA monomer (Scheme 
3.10 3) of varying compositions (33, 50, 66 mol%) (DPn=17, 25, 33 respectively) was 
introduced, with Cu(I)Cl/bpy ([M]:[CuCl]:[bpy]=17/25/33:1:2) in IPA/H2O (92.75:7.5%) 
to produce the three linear-dendritic block polymer hybrids, AmG2-(DEA33-b-tBuMA17), 
AmG2-(DEA25-b-tBuMA25) and AmG2-(DEA17-b-tBuMA33). The addition of EGDMA 
(Scheme 3.10 4) into the second feed to tBuMA monomer feed to encourage branching 
to occur between the growing tBuMA polymer chains, resulted in the production of 3 
block hyp-polydendrons, AmG2-(DEA33-b-(tBuMA17-co-EGDMA0.9)), AmG2-(DEA25-
b-(tBuMA25-co-EGDMA0.9)) and AmG2-(DEA17-b-(tBuMA33-co-EGDMA0.9)). 
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Scheme 3.10 Schematic representation of the initial polymerisation of DEA (2) initiated by AmG2-Br 
(1), followed by a second monomer feed of tBuMA (3) or tBuMA and EGDMA (4) to produce block 
linear-dendritic polymer hybrids (AmG2-(DEA33-b-tBuMA17), AmG2-(DEA25-b-tBuMA25) and 
AmG2-(DEA17-b-tBuMA33)) and hyp-polydendrons (AmG2-(DEA33-b-(tBuMA17-co-EGDMA0.9)), 
AmG2-(DEA25-b-(tBuMA25-co-EGDMA0.9)) and AmG2-(DEA17-b-(tBuMA33-co-EGDMA0.9))). 
 
Conversions of both the linear DEA chain and the final linear-dendritic polymer and hyp-
polydendron were monitored via 1H NMR spectroscopy of the crude polymerisation 
media. Purification to remove the catalytic system was carried out by passage through a 
basic alumina column, followed by precipitation into cold petroleum ether (40-60). The 
1H NMR spectra for the linear-dendritic block DEA-tBuMA polymers and block DEA-
tBuMA-EGDMA hyp-polydendron are shown in Figure 3.21, and Appendix A45-48. 
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Figure 3.21 1H NMR spectra (MeOD, 400 MHz) of A) AmG2-p(DEA25-b-tBuMA25) and B) AmG2-
p(DEA25-b-(tBuMA25-co-EGDMA0.9)). 
 
The linear-dendritic block polymer hybrids displayed considerably higher Mn values 
compared to the theoretical values predicted (Table 3.4). However, a high level of 
control was still present due to equally high Mw values, resulting in significantly low Đ 
values (1.16-1.21). The RI and RALS chromatograms also displayed monomodal 
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distributions (Figure 3.22). Block hyp-polydendrons were collected at high monomer 
conversions and GPC confirms the presence of highly branched materials (Table 3.4 and 
Figure 3.22). The AmG2-p(DEA25-b-(tBuMA25-co-EGDMA0.9)) possessed the highest 
molecular weight (528900 g mol-1), which was > twice the molecular weight of the other 
block hyp-polydendrons. 
 
Table 3.4 GPC analysis of AmG2-initiated amine-functional block DEA-tBuMA linear-dendritic 
polymer hybrids and block DEA-tBuMA-EGDMA hyp-polydendrons. 
     GPCa 
DEA 
(DPn) 
Conversion 
(%)b 
tBuMA 
(DPn) 
Conversion 
(%)b 
Mn Theory 
(g mol-1) c 
Mn  
(g mol-1) 
Mw 
(g mol-1) 
Đ 
33 80 17 99 9360 35400 40850 1.16 
25 92 25 99 9020 33000 46450 1.21 
17 73 33 99 8670 40350 45100 1.12 
33 99 17 99 - 86900 192100 2.21 
25 94 25 99 - 265400 528900 1.99 
17 95 33 99 - 92300 251800 2.73 
50 93 65 98 - 40400 145100 3.60 
a Triple detection analysis using THF/2% TEA as eluent, b Determined by NMR, c Mn 
Theory = (Mw tBuMA monomer*DP tBuMA targeted) + (Mw DEA monomer*DP DEA 
targeted) + Mw AmG2 dendron chain end 
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Figure 3.22 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
AmG2-p(DEA33-b-tBuMA17) (green), AmG2-p(DEA25-b-tBuMA25) (orange) and AmG2-p(DEA17-b-
tBuMA33) (red); C) RI chromatograms and D) RALS chromatograms for AmG2-p(DEA33-b-
(tBuMA17-co-EGDMA0.9)) (green), AmG2-p(DEA25-co-(tBuMA25-co-EGDMA0.9)) (orange) and 
AmG2-p(DEA17-co-(tBuMA33-co-EGDMA0.9)) (red). 
 
The complex branched structures contained on weight average > 5 primary chains (20 
tertiary amine surface groups) (AmG2-p(DEA33-b-(tBuMA17-co-EGDMA0.9))), 
> 11 primary chains (44 tertiary amine surface groups) (AmG2-p(DEA25-b-(tBuMA25-co-
EGDMA0.9))), > 6 primary chains (24 tertiary amine surface groups) (AmG2-p(DEA17-b-
(tBuMA33-co-EGDMA0.9))).  
 
3.4 Variation of primary polymer chain length 
 
Slater et al. have previously investigated architecture-driven aqueous stability of 
hydrophobic linear and branched polymers.33 Linear vs. branched dendritic polymeric 
HPMA NPs have similarly showed behavioural differences in aqueous media (Chapter 
2). The report continues to study differences of varying polymer chain lengths within 
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branched polymers, ultimately presenting a clear trend of decreasing solubility with 
increasing chain length. The hydrophobic branched polymers form NPs between 60-800 
nm with the lowest DPn primary chains forming the largest NPs, driven by the polymer 
chain length. Such subtle variations in the branched structure led to eventual macroscale 
precipitation in some cases, confirming that the origins of long term stability are 
architecture-dependent. In lieu of these reported observations, the primary polymer chain 
length within the block DEA-tBuMA hyp-polydendron was increased. 
 
Following the successful synthesis of the hyp-polydendrons targeting a DPn=50 
monomer units per primary polymer chain, a branched block hyp-polydendron with 
increased lengths of DEA and tBuMA was designed AmG2-p(DEA50-b-(tBuMA65-co-
EGDMA0.9)) (Figure 3.23). The preparation of AmG2-p(DEA50-b-(tBuMA65-co-
EGDMA0.9)) would allow for behavioural comparisons to be made to the DPn=50 
analogues, containing similar polymer compositions but with different block lengths. 
 
 
Figure 3.23 Chemical structure of AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)). 
 
AmG2-Br was used to initiate DEA (DPn=50) using the following molar ratio 
[Initiator]:[M]:[CuCl]:[bpy] = 1:50:1:2. Following this, a second feed of tBuMA 
(DPn=65) and EGDMA monomer was introduced with the molar ratio Cu(I)Cl/bpy 
([M]:[CuCl]:[bpy] = 65:1:2. Identical temperature, solvents and purification techniques 
for the DPn=50 hyp-polydendrons were applied. Analysis by 1NMR (Appendix, Figure 
A49) and GPC confirmed the production of the hyp-polydendron, AmG2-p(DEA50-b-
(tBuMA65-co-EGDMA0.9)) (Table 3.4 and Figure 3.24). Despite the longer polymer 
blocks, the AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) was recovered with a lower 
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Mw and Mn values compared to the block DEA-tBuMA-EGDMA hyp-polydendrons 
containing a DPn=50 monomer units. 
 
 
Figure 3.24 GPC chromatograms of AmG2-p(DEA50-co-(tBuMA65-co-EGDMA0.9)); A) RI 
chromatogram and B) RALS chromatogram. 
 
3.5 Variation of dendron chemistry via introduction of benzyl 
surface functionality and urethane linker chemistry 
 
Chapter 2 introduced the new synthesis of tertiary amine-functionalised Generation 0-2 
dendron ATRP initiators, AmG0-Br, AmG1-Br and AmG2-Br (Figure 3.25). 
 
 
Figure 3.25 Amine-functionalised dendron ATRP initiators of varying generation synthesised in 
Chapter 2; i) AmG2-Br; ii) AmG1-Br and iii) AmG0-Br represented by red, blue and green wedges 
(iv) respectively. 
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These were utilised in the polymerisation of HPMA to produce linear-dendritic hybrids 
and hyp-polydendrons. Further to this, the amine-functionalised dendrons have been 
utilised as ATRP initiators to successfully polymerise DEA and tBuMA, demonstrating 
examples of variable polymer cores on offer for incorporation within the hyp-
polydendron. Following the chemistry variation of the polymer primary chains, the 
chemistry within the dendron chain end was considered. 
 
The alternatives for dendron surface chemistry are very broad and tertiary amines offer 
one option, due to their pH responsive nature. Comparisons between hyp-polydendrons, 
comprising different dendritic surface groups, present options for unique behaviour and 
applications. Amine vs. benzyl-functionality is an interesting comparison due to the 
former bearing pH-responsive groups, and the latter being hydrophobic (Figure 3.26i). 
Further to this, the surface chemistry is not the only structural variable within the 
dendron, the linker chemistry also has the potential to be modified. A tertiary amine-
functionalised Generation 1 dendron ATRP initiator was synthesised via 1,1’-
carbonyldiimidazole (CDI) coupling chemistry, introducing a urethane group into the 
dendron molecule (Figure 3.26ii). 
 
 
Figure 3.26 Chemical structures of new dendron ATRP initiators: i) Benzyl ester functionalised 
Generation 2 dendron ATRP initiator (BnG2-Br); ii) Amine-functionalised urethane Generation 1 
dendron ATRP initiator (AmG1U-Br).
 
3.5.1 Synthesis of tertiary amine functional G1 dendron ATRP initiator 
containing urethane linker chemistry (AmG1U-Br) 
 
The amine-functionalised dendrons previously utilised as ATRP initiators within this 
work were initially synthesised via Michael addition to produce dendrons bearing a 
secondary alcohol as the focal point. A similar approach was taken, through initial 
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dendron precursor production (AmG1U-OH), albeit via CDI chemistry. The second step 
utilised the same bromoesterification reaction witnessed in Chapter 2, to produce the 
ATRP initiator (AmG1U-Br) from the alcohol bearing dendron (Scheme 3.11). 
 
 
Scheme 3.11 Synthesis of AmG1U-Br by initial production of AmG1U-OH via CDI chemistry 
followed by bromoesterification. 
 
The synthesis of AmG1U-OH was achieved by a simple one pot reaction beginning with 
the reaction of 1-dimethylamino-2-propanol (Scheme 3.11 1) with CDI (Scheme 3.11 2) 
to give the imidazole carboxylic ester (Scheme 3.11 3). The imidazole carboxylic ester 
underwent selective coupling to the primary amines of 1-[N, N-bis(2-aminopropyl)-
amino-2-propanol (APAP) (Scheme 3.11 4), previously synthesised in Chapter 2. 
AmG1U-OH was analysed by 1H and 13C NMR and electro-spray mass spectrometry 
(ES-MS) (Figure 3.27 and Appendix, Figures A50 and 51). All protons neighbouring 
tertiary or secondary amine groups collectively integrated to 22 (Figure 3.27a, b, g, h). 
The methine proton situated within the initial APAP molecule, integrates to 1 proton 
(Figure 3.27i) and is located in a different environment to the 2 methine protons (Figure 
3.27c) donated by the imidazole carboxylic ester intermediate (Figure 3.27c). The 13C 
NMR shows a peak at 156.7 ppm, attributing to the carbonyl residing in the urethane 
group. Molecular ion peaks are seen at 448.3 m/z ([M+H]+) and 470.3 m/z ([M+Na]+) 
in the ES-MS, (theoretical [M+H]+ (C21H45N5O5) m/z = 447.6). 
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Figure 3.27 1H NMR spectrum (CDCl3, 400 MHz) of AmG1U-OH. 
 
The synthesis of the ATRP initiator, AmG1U-Br, was achieved by esterification of 
AmG1U-OH using α-bromoisobutyryl bromide (BiB) (Scheme 3.11 5) in a one pot 
reaction. The product was isolated by a dichloromethane/saturated sodium hydrogen 
carbonate solution (DCM/aq. NaHCO3) wash to remove any unreacted alcohol and 
characterised by 1H and 13C NMR and ES-MS (Figure 3.28 and Appendix, Figures A52 
and 53). 
 
A singlet peak appears at 1.92 ppm (Figure 3.28k), corresponding to the 2 methyl groups 
neighbouring the Br atom, integrating to 6 protons. The downfield shift of the methine 
proton, neighbouring the new ester bond, from 3.78 ppm to 5.06 ppm (Figure 3.28i), 
suggests the successful production of AmG1U-Br. The 13C NMR spectrum witnesses a 
peak at 171.5 and 30.9 ppm, accounting for the new carbonyl group in the ester, and the 
new methyl groups respectively. Molecular ion peaks are obtained at 598.3 m/z 
[M+H]+, 620.3 m/z [M+Na]+ and 636.3 m/z [M+K]+ (calculated [M+H]+ 
(C25H50N5O6Br) m/z = 596.6). 
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Figure 3.28 1H NMR spectrum (CDCl3, 400 MHz) of AmG1U-Br. 
 
3.5.2 Synthesis of benzyl ester functional G2 dendron ATRP initiator (BnG2-Br) 
?
The AmG2-Br was previously synthesised via the Michael addition34 of 2-
(dimethylamino) ethyl acrylate to APAP. The same strategy was employed to produce 
the new Generation 2 hydrophobic benzyl ester dendron ATRP initiator, BnG2-Br, by 
initially reacting benzyl acrylate (Scheme 3.12 1) with APAP (Scheme 3.12 2) to 
produce BnG2-OH.  
?
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Scheme 3.12 Synthesis of BnG2-Br by initial production of BnG2-OH via Michael addition followed 
by bromoesterification. 
 
BnG2-OH was isolated following concentration in vacuo to remove solvent and any 
excess acrylate. ES-MS, 1H and 13C NMR analysis were used to confirm the structure of 
the product (Figure 3.29 and Appendix, Figures A54 and 55). The absence of the 2 
singlet signals at ~6 ppm, corresponding to the benzyl acrylate protons, confirm all 
acrylate has been removed. All 20 aromatic protons are collectively seen between 7.27-
7.41 ppm (Figure 3.29a, b, c). The 8 methylene protons neighbouring the oxygen atom 
on the benzyl acrylate arm are found downfield at 5.09 ppm (Figure 3.29d), due to the 
electronegativity of the oxygen. The methyl protons, situated on the focal point of the 
dendron, are seen upfield and integrate to three protons (Figure 3.29l). The aromatic 
protons are clearly seen in the 13C NMR at 128.6 ppm and the carbonyls in the ester 
groups are seen at 172.7 ppm. The molecular ion peak is situated at 838.5 m/z 
(theoretical [M+H]+ (C49H63N3O9) m/z = 838.0). 
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Figure 3.29 1H NMR spectrum (CDCl3, 400 MHz) of BnG2-OH. 
 
BiB (Scheme 3.12 3)?was then used in an esterification reaction overnight35 with the 
dendron alcohol, BnG2-OH, to prepare the ATRP initiator, BnG2-Br (Scheme 3.12). The 
product was isolated by liquid/liquid extraction using DCM/aq. NaHCO3, in order to 
remove any unreacted alcohol and characterised by 1H and 13C NMR spectroscopy 
(Figure 3.30 and Appendix, Figure A56) and ES-MS (Appendix, Figure A57).?
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Figure 3.30 1H NMR spectrum (CDCl3, 400 MHz) of BnG2-Br. 
 
The appearance of the signal at 1.90 ppm (Figure 3.30m) correspond to the 2 methyl 
groups neighbouring the Br. The shift of the methine proton neighbouring the ester bond 
from 3.71 ppm (Figure 3.29k) to 5.00 ppm (Figure 3.30k), confirms the esterification 
reaction has taken place. The aromatic protons integrate to 20 protons (Figure 3.30a, b, 
c), likewise the protons for the methyl group neighbouring the new ester group (Figure 
3.30l) resumes to integrate to 3. The 13C NMR shows the appearance of a peak at 170.8 
ppm accounting for the introduction of a second carbonyl group into the molecule. An 
m/z = 988.4 was obtained which was in concordance with the predicted m/z = 987.0 for 
C53H68N3O10Br. Once again, this straightforward approach to low generation dendron 
initiator synthesis proved robust, and their ability to initiate polymerisations was 
subsequently investigated. 
?
3.5.3 Linear polymerisation of DEA and co-polymerisation of DEA and 
EGDMA using AmG1U-Br and BnG2-Br dendron ATRP initiators 
 
AmG1U-Br and BnG2-Br dendron ATRP initiators were used to polymerise DEA in 
identical conditions previously utilised to produce the amine-functionalised linear-
dendritic DEA polymer hybrids (Figure 3.31). The AmG1U-Br ATRP initiator was, also, 
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utilised in the co-polymerisation of DEA and EGDMA to produce the hyp-polydendron 
AmG1U-p(DEA50-co-EGDMA0.9). 
 
 
Figure 3.31 Diagrammatic representation of the polymerisation of DEA using AmG1U-Br and BnG2-
Br, and co-polymerisation of DEA and EGDMA using AmG1U-Br. 
 
Both the AmG1U- and BnG2-p(DEA50) linear-dendritic polymer hybrids were collected 
at high monomer conversion (>95 %). As previously witnessed, the Mn values were > 
twice as high as the targeted Mn (Table 3.5), with DPn values > twice the targeted 
theoretical value estimated by GPC. 1H NMR analysis of Bn-p(DEA50) also allowed 
assessment of the DPn, by comparison of the aromatic signal attributing to the benzyl 
chain end group (Figure 3.32), with resonances assigned to p(DEA50) proton peaks 
residing in the polymer backbone, following subtraction of the integration accounting 
for the methyl protons neighbouring the Br atom (Figure 3.32q). The AmG1U-p(DEA50) 
1H NMR spectrum is displayed in Appendix, Figure A58. 
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Table 3.5 GPC analysis of amine-functionalised and benzyl-functionalised DEA linear-dendritic 
polymer hybrids and hyp-polydendron. 
   GPCa 
Polymer Conversion 
(%)b 
Mn Theory 
(g mol-1) c 
Mn 
(g mol-1) 
Mw 
(g mol-1) 
Đ DPnd DPne 
AmG1U-p(DEA50) 99 9780 20300 22850 1.13 109 - 
BnG2-p(DEA50) 95 10220 20750 25850 1.25 107 97 
AmG1U-p(DEA50-
co-EGDMA0.9) 
99 - 125000 327000 2.62 - - 
a Triple detection analysis using THF/2%TEA as eluent; b Determined by NMR; c Mn Theory = 
(Mw monomer*DP targeted)+Mw initiator; d Determined by GPC; e Determined by 1H NMR. 
 
 
 
Figure 3.32 1H NMR spectrum (MeOD, 400 MHz) of BnG2-p(DEA50). 
 
Both linear-dendritic hybrids demonstrated high levels of control, observed by the 
narrow dispersity values and the monomodal, narrow molecular weight distributions 
displayed in the GPC chromatograms (Figure 3.33) (particularly the AmG1U-p(DEA50) 
(Đ = 1.13)). 
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Figure 3.33 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
AmG1U-p(DEA50) (green) and BnG2-p(DEA50) (purple); C) RI chromatogram and D) RALS 
chromatogram for AmG1U-p(DEA50-co-EGDMA0.9). 
 
A soluble, high molecular weight hyp-polydendron was collected succeeding high 
monomer conversion (99%) (Table 3.5). The AmG1U-p(DEA50-co-EGDMA0.9) was 
analysed by 1H NMR (Appendix, Figure A59) and GPC, possessing an Mw (327000 g 
mol-1) that was less than the AmG2-p(DEA50-co-EGDMA0.9) (341800 g mol-1) but 
greater than the AmG1-p(DEA50-co-EGDMA0.9) (288000 g mol-1), suggesting an 
increase in dendron generation encourages the production of more highly branched 
polymers, when producing DEA-EGDMA hyp-polydendrons. The broad GPC RI and 
RALS chromatograms are shown in Figure 3.33. 
Kinetic experiments were undertaken for the AmG1U-initiated linear polymerisation, 
confirming first order kinetics with respect to monomer concentration. The molecular 
weight, with respect to monomer conversion, appeared to evolve slower (Figure 3.34A) 
than the reactions initiated by AmG0-Br and AmG1-Br. The reaction required 24 hours 
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to reach high conversion, similarly to the AmG2-Br polymerisation. The kinetics of the 
branched polymerisation were first order in respect to Mn and Mw development, showing 
a dramatic increase at high conversions (Figure 3.34D), which was very noticeable 
within the relationship of Mw and conversion. Similarly, to the AmG2-p(DEA50-co-
EGDMA0.9), a high Mn was recovered, suggesting a large number of linear-dendritic 
polymer chains have joined together; > 14 primary chains, suggesting 28 tertiary amine 
chain end functional groups contribute to the hyp-polydendron surface functionality on 
average. 
 
 
 
Figure 3.34 Kinetic plots for linear AmG1U-p(DEA50) (A and B) and branched AmG1U-p(DEA50-co-
EGDMA0.9) (C and D). A and C) Conversion (blue squares), ln([M]0/[M]) (red circles); B and D) Mn 
(red circles), Ð (blue lines) and Mw (black diamonds). 
 
3.6 Variation of initiators in a one-pot tBuMA and EGDMA co-
polymerisation
 
The introduction of multi-functional initiators has led to the formation of dumbbell and 
clover-leaf NPs.36 Rannard and co-workers have subsequently utilised mixed initiator 
systems, involving a Generation 2 dendron initiator and a PEG macroinitiator.37 This 
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new synthetic strategy enabled the formation of complex spherical NPs with mixed 
surface functionality. The synthesis of hyp-polydendrons offers a unique opportunity for 
systematic incorporation of mixed functionalities through the mixing of ATRP initiators. 
 
A tBuMA hyp-polydendron was designed to contain a minimal amount of amine-
functional dendritic surface functionality (Figure 3.35). Hyp-polydendrons comprising of 
mixed surface functionality have uncovered behavioural differences when existing as 
nanoprecipitates.37 A molar ratio EBiB:AmG2-Br 0.9:0.1 was used to initiate tBuMA in 
the presence of EGDMA. Analysis was conducted via 1H NMR (Appendix, Figure A60) 
and GPC, confirming a high molecular weight hyp-polydendron, EBiB0.9-(AmG2)0.1-
p(tBuMA50-co-EGDMA0.95) (Mw = 137100 g mol-1, Mn = 78800 g mol-1 and Đ=1.74; 
Figure 3.36). 
Figure 3.35 Diagrammatic representation of p(tBuMA50-co-EGDMA0.95) containing 90 mol% EBiB 
chain ends and 10% AmG2 chain ends. 
 
?
Figure 3.36 GPC chromatograms of A) RI chromatogram and B) RALS chromatogram for EBiB0.9-
(AmG2)0.1-p(tBuMA50-co-EGDMA0.95). 
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3.7 Variation of brancher within the hyp-polydendron structure 
 
Previous reports have described the synthesis of a bifunctional methacrylate monomer, 
ethylene glycol di(1-methacryloyloxy)ethyl ether via an addition reaction between 
ethylene glycol divinyl ether and MAA.38 This bifunctional methacrylate monomer was 
used as a cross-linker in the preparation of several star-shaped polymers, where the 
cross-linked points could easily be cleaved by hydrolysis following acid addition. Here, 
the synthesis of a new pH-responsive brancher, 1,4-butanediol di(methacryoyloxy)-ethyl 
ether (BDME), (Figure 3.37ii) is reported. The use of such a cross-linker at low 
concentrations relative to initiators would be able to make pH-cleavable hyp-
polydendrons. 
 
Figure 3.37 Branchers utilised in hyp-polydendron synthesis. i) ethylene glycol dimethacrylate 
(EGDMA), ii) 1,4-butanediol di(methacryoyloxy)-ethyl ether (BDME). 
 
3.7.1 Synthesis of new acid-cleavable brancher 
The pH-responsive branching unit BDME was successfully prepared through an addition 
reaction between MAA (Scheme 3.13 1) and 1,4-butanediol divinyl ether (BDVE) 
(Scheme 3.13 2), utilising a trace amount of 4-tert-butylcatechol acting as a radical 
inhibitor. The product was confirmed by 1H NMR (Figure 3.38), 13C NMR and ES-MS 
(Appendix, Figures A61 and 62). 
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Scheme 3.13 Schematic representation and mechanism of addition reaction between 1,4-butanediol 
divinyl ether (BDVE) (2) and methacrylic acid (1) to produce 1,4-butanediol di(methacryoyloxy)-
ethyl ether (BDME). 
 
 
Figure 3.38 1H NMR spectrum (CDCl3, 400 MHz) of BDME with important integrations assigned. 
 
The methine proton signals at 5.97 ppm integrating to 2 protons (Figure 3.38c) and the 2 
methyl groups neighbouring the methine proton integrate to 6 protons at 1.95 ppm 
(Figure 3.38d) suggests the successful bond formation between the divinyl ether and the 
carboxylic acid on the MAA. The methyl groups neighbouring the carbon double bond 
integrate to 6 protons (Figure 3.38a) and the methylene protons in the backbone of the 
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molecule integrate collectively to 4 protons in each environment (Figure 3.38e and f). 
The 13C NMR shows peaks at 166.9 and 136.5 ppm, which can be assigned to the 
carbonyl groups and the vinyl carbons respectively. Molecular ion peaks of 337.2 and 
353.1 m/z were observed, accounting for the [M+Na]+ and [M+K]+ respectively 
(Calculated m/z = 314.4). 
 
3.7.2 Utilisation of BDME brancher in ATRP to produce a series of hyp-
polydendrons  
 
Following successful production of a range of branched copolymers and hyp-
polydendrons using EGDMA, the newly synthesised BDME was incorporated into three 
hyp-polydendron procedures, all initiated by AmG2-Br (Scheme 3.14 1). Initially, 
BDME (Scheme 3.14 3) was copolymerised with DEA (Scheme 3.14 2) to produce 
AmG2-p(DEA50-co-BDME2.0). To ensure incorporation of the divinyl monomer into the 
polymer backbone, the molar concentration of BDME was increased (2 molar eq.). This 
molar ratio was used for all BDME-containing hyp-polydendrons, and the polymerisation 
conditions were identical to each EGDMA equivalent procedure. 
 
 
Scheme 3.14 Schematic representation of the polymerisation of DEA (2) and BDME (3) initiated by 
AmG2-Br (1) to produce AmG2-p(DEA50-co-BDME2.0). 
 
The incorporation of BDME into the polymerisation of DEA resulted in a highly 
branched polymer (Table 3.6). The Mn and Mw calculated by GPC were similar values to 
the AmG2-Br initiated DEA and EGDMA co-polymerisation, insinuating consistency 
with initiation efficiency. The RI and RALS traces display broad, bimodal molecular 
weight distributions (Figure 3.39). The AmG2-p(DEA50-co-BDME2.0) contains on 
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average 9 primary polymer chains, and consequently 37 tertiary amine chain ends per 
hyp-polydendron. The 1H NMR spectrum is shown in Figure 3.40. 
 
Table 3.6 GPC analysis of BDME-containing and their EGDMA-equivalent hyp-polydendrons. 
   GPCa  
Polymer Conversion 
(%)b 
Mn  
(g mol-1) 
Mw  
(g mol-1) 
Đ 
AmG2-p(DEA50-co-EGDMA0.9) 99 125700 341800 2.72 
AmG2-p(DEA50-co-BDME2.0) 99 157300 321100 2.04 
AmG2-p(DEA33-co-HPMA17-co-
EGDMA0.9) 
99 247500 398300 1.61 
AmG2-p(DEA33-co-HPMA17-co-
BDME2.0) 
99 305300 733400 2.40 
AmG2-p(DEA17-b-(tBuMA33-co-
EGDMA0.9)) 
99 92300 251800 2.73 
AmG2-p(DEA17-b-(tBuMA33-co-
BDME2.0)) 
99 444100 594800 1.34 
a Triple detection analysis using THF/2% TEA eluent; b Determined by NMR 
 
 
Figure 3.39 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
AmG2-p(DEA50-co-BDME2.0) (green), AmG2-p(DEA33-co-HPMA17-co-BDME2.0) (purple) and 
AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)) (orange). 
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Figure 3.40 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA50-co-BDME2.0). 
Following the successful synthesis of a branched polymer via inclusion of BDME, the 
brancher was incorporated into the statistical co-polymerisation of DEA and HPMA and 
the block co-polymerisation of DEA and tBuMA to produce AmG2-p(DEA33-co-
HPMA17-co-BDME2.0) (Figure 3.41i) and AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)) 
(Figure 3.41ii) respectively. 
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Figure 3.41 Diagrammatic representation of the statistical co-polymerisation of DEA, HPMA and 
BDME to produce i) AmG2-p(DEA33-co-HPMA17-co-BDME2.0); and the block polymerisation of 
DEA, tBuMA and BDME to produce ii) AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)). 
 
Both BDME-containing hyp-polydendrons contained higher Mn and Mw values (~ twice 
as large) as their EGDMA equivalents (Table 3.6). This may be due to the longer BDME 
molecule allowing easier access for the linear polymer chains to branch within the 
reaction media. AmG2-p(DEA33-co-HPMA17-co-BDME2.0) and AmG2-p(DEA17-b-
(tBuMA33-co-BDME2.0)) 1H NMR spectra are shown in Appendix, Figures A63 and 64 
respectively. Highly branched materials were also confirmed from the multimodal 
weight distributions observed during GPC analysis (Figure 3.39). The AmG2-p(DEA17-
co-HPMA33-co-BDME2.0) contained > 50 primary chains suggesting ~ twice as many 
primary polymer chains in comparison to the AmG2-p(DEA33-co-HPMA17-co-
EGDMA0.9), with 200 tertiary amine chain end functional groups. The Mn value obtained 
for AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)) was noticeably large, with the hyp-
polydendron comprised of > 13 primary chains, with 52 tertiary amine chain end 
functional groups. 
 
3.8 Conclusions 
 
The homopolymerisations of DEA using dendron ATRP initiators produced linear-
dendritic hybrids with Mn values > twice the targeted theoretical value. The hyp-
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polydendrons proceeded to high monomer conversions and produced materials with 
molecular weights > 300,000 g mol-1. The linear-dendritic hybrid AmG2-p(tBuMA50) 
displayed more polymerisation control compared to the EBiB-p(tBuMA50); and the hyp-
polydendron AmG2-p(tBuMA50-co-EGDMA0.9) contained a higher molecular weight 
than the EBiB-containing branched copolymer. Generally, the polymerisations and co-
polymerisations monitored proceeded via 1st order kinetics, as expected, and produced 
monomodal distributions of polymer chains when a linear polymer was targeted and a 
much broader disperse polymer species when the divinyl monomer was incorporated and 
a branched polymer was targeted. 
 
The statistical linear-dendritic DEA-HPMA hybrids conveyed high levels of control, and 
the statistical DEA-HPMA hyp-polydendrons had considerably high molecular weights 
compared to the DEA and HPMA hyp-polydendrons (Chapter 2). tBuMA was 
successfully incorporated into the linear-dendritic polymer chain and hyp-polydendron 
core, and subsequently utilised to produce block DEA-tBuMA hybrids and a branched 
tBuMA core produced from growing linear DEA chains in one-pot block co-
polymerisations. 
 
A tBuMA-EGDMA hyp-polydendron containing both dendron and non-dendron surface 
groups was successfully synthesised via incorporation of both EBiB and AmG2-Br 
ATRP initiators within the reaction. New dendron ATRP initiators were successfully 
synthesised containing different surface and linker chemistry. The linear polymerisations 
of DEA proceeded in a similar manner to the amine-functionalised DEA hybrids. Finally, 
DEA, statistical DEA-HPMA and block DEA-tBuMA hyp-polydendrons were 
successfully produced containing a new acid-cleavable brancher. 
 
Overall, the research presents synthetic explorations within a new polymeric material 
class. The versatility observed in hyp-polydendron synthesis has been successfully 
demonstrated. The hyp-polydendron structure has been altered by variation of multiple 
components, including the monomer chemistry, the hyp-polydendron architecture, the 
surface functionality, the use of multiple initiators and the incorporation of a newly 
synthesised brancher.  
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3.9 Experimental 
 
Typical linear polymerisation of DEA (EBiB-, AmG0-, AmG1-, AmG2-, AmG1U- and 
BnG2-p(DEA50)) – In a typical synthesis, targeting a DPn = 50 monomer units 
(p(DEA50)), bpy (134.9 mg, 0.8637 mmol, 2 eq.), DEA (4 g, 21.59 mmol, 50 eq.) and 
IPA (56% v/v based on DEA) were placed into a 25 mL round-bottomed flask (RBF). 
The solution was stirred and deoxygenated using a N2 purge for 15 minutes. Cu(I)Cl 
(42.8 mg, 0.4318 mmol, 1 eq.) was added to the flask and left to purge for a further 5 
minutes. AmG2-Br (0.3934 g, 0.4318 mmol, 1 eq.) was added to the flask under a 
positive flow of N2 and the solution was left to polymerise at 40°C. Reactions were 
terminated when >99 % conversion was reached, as judged by 1H NMR, by exposure to 
oxygen and addition of acetone. The catalyst residues were removed by passing the 
mixture over a basic alumina column. Acetone was removed under vacuum to 
concentrate the sample before precipitation into cold petroleum ether (40-60).  
 
Typical synthesis of branched copolymer and hyperbranched polydendrons using 
the co-polymerisation of DEA and EGDMA, (EBiB-, AmG0-, AmG1-, AmG2- and 
AmG1U-p(DEA50-co-EGDMAx))???In a typical synthesis, targeting a DPn = 50 monomer 
units (p(DEA50-co-EGDMAx)), bpy (134.9 mg, 0.8637 mmol, 2 eq.), DEA (4 g, 21.59 
mmol, 50 eq.), EGDMA (77.0 mg, 0.3886 mmol, 0.9 eq.) and IPA (38.9% v/v based on 
DEA) were placed into a 25 mL RBF. The solution was stirred and deoxygenated using 
a N2 purge for 15 minutes. Cu(I)Cl (42.8 mg, 0.4318 mmol, 1 eq.) was added to the flask 
and left to purge for a further 5 minutes. AmG2-Br?(0.3934 g, 0.4318 mmol, 1 eq.) was 
added to the flask under a positive flow of N2, and the solution was left to polymerise at 
40°C. Reactions were terminated when >99 % conversion was reached, as judged by 1H 
NMR, by exposure to oxygen and addition of acetone. The catalyst residues were 
removed by passing the mixture over a basic alumina column. Acetone was removed 
under vacuum to concentrate the sample before precipitation into cold petroleum ether 
(40-60). 
 
Typical linear polymerisation of tBuMA (EBiB- and AmG2-p(tBuMA50)) – In a 
typical synthesis, targeting a DPn = 50 monomer units (p(tBuMA50)), bpy (134.9 mg, 
0.8637 mmol, 2 eq.), tBuMA (3.07 g, 21.59 mmol, 50 eq.) and IPA/H2O (92.5:7.5 %) 
(24.2% v/v based on tBuMA) were placed into a 25 mL RBF. The solution was stirred 
and deoxygenated using a N2 purge for 15 minutes. Cu(I)Cl (42.8 mg, 0.4318 mmol, 1 
eq.) was added to the flask and left to purge for a further 5 minutes. AmG2-Br (0.3934 
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g, 0.4318 mmol, 1 eq.) was added to the flask under a positive flow of N2 and the 
solution was left to polymerise at 20°C. Reactions were terminated when >99 % 
conversion was reached, as judged by 1H NMR, by exposure to oxygen and addition of 
THF. The catalyst residues were removed by passing the mixture over a basic alumina 
column. THF was removed under vacuum to concentrate the sample before precipitation 
into cold hexane.  
 
Typical synthesis of branched copolymer and hyperbranched polydendrons using 
the co-polymerisation of tBuMA and EGDMA, (EBiB- and AmG2-p(tBuMA50-co-
EGDMAx)) – In a typical synthesis, targeting a DPn = 50 monomer units (p(tBuMA50)), 
bpy (134.9 mg, 0.8637 mmol, 2 eq.), tBuMA (3.07 g, 21.59 mmol, 50 eq.), EGDMA (77 
mg, 0.3886 mmol, 0.9 eq.) and IPA/H2O (92.5:7.5 %) (32.4% v/v based on tBuMA) 
were placed into a 25 mL RBF. The solution was stirred and deoxygenated using a N2 
purge for 15 minutes. Cu(I)Cl (42.8 mg, 0.4318 mmol, 1 eq.) was added to the flask and 
left to purge for a further 5 minutes. AmG2-Br (0.3934 g, 0.4318 mmol, 1 eq.) was 
added to the flask under a positive flow of N2 and the solution was left to polymerise at 
20°C. Reactions were terminated when >99 % conversion was reached, as judged by 1H 
NMR, by exposure to oxygen and addition of THF. The catalyst residues were removed 
by passing the mixture over a basic alumina column. THF was removed under vacuum 
to concentrate the sample before precipitation into cold hexane.  
 
Typical linear statistical polymerisation of DEA and HPMA (AmG2-p(DEAx-co-
HPMAy)) – In a typical synthesis, targeting a DPn = 50 monomer units (p(DEA25-co-
HPMA25)), bpy (134.9 mg, 0.8637 mmol, 2 eq.), DEA (2 g, 10.80 mmol, 25 eq.), HPMA 
(1.5567 g, 10.80 mmol, 25 eq.) and IPA (25.9% v/v based on monomer) were placed 
into a 25 mL RBF. The solution was stirred and deoxygenated using a N2 purge for 15 
minutes. Cu(I)Cl (42.8 mg, 0.4318 mmol, 1 eq.) was added to the flask and left to purge 
for a further 5 minutes. AmG2-Br (0.3934 g, 0.4318 mmol, 1 eq.) was added to the flask 
under a positive flow of N2, and the solution was left to polymerise at 40°C. Reactions 
were terminated when >99 % conversion was reached, as judged by 1H NMR, by 
exposure to oxygen and addition of acetone. The catalyst residues were removed by 
passing the mixture over a basic alumina column. Acetone was removed under vacuum 
to concentrate the sample before precipitation into cold petroleum ether (40–60).  
 
Typical synthesis of statistical hyperbranched polydendrons using the co-
polymerisation of DEA, HPMA and EGDMA, (AmG2-p(DEAx-co-HPMAy-co-
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EGDMA0.9)) – In a typical synthesis, targeting a DPn = 50 monomer units (p(DEA25-co-
HPMA25-co-EGDMA0.9)), bpy (134.9 mg, 0.8637 mmol, 2 eq.), DEA (2 g, 10.80 mmol, 
25 eq.), HPMA (1.5567 g, 10.80 mmol, 25 eq.), EGDMA (77.0 mg, 0.3886 mmol, 0.9 
eq.) and IPA (25.9% v/v based on monomer) were placed into a 25 mL RBF. The 
solution was stirred and deoxygenated using a N2 purge for 15 minutes. Cu(I)Cl (42.8 
mg, 0.4318 mmol, 1 eq.) was added to the flask and left to purge for a further 5 minutes. 
AmG2-Br (0.3934 g, 0.4318 mmol, 1 eq.) was added to the flask under a positive flow 
of N2, and the solution was left to polymerise at 40°C. Reactions were terminated when 
>99 % conversion was reached, as judged by 1H NMR, by exposure to oxygen and 
addition of acetone. The catalyst residues were removed by passing the mixture over a 
basic alumina column. Acetone was removed under vacuum to concentrate the sample 
before precipitation into cold petroleum ether (40–60). 
 
Typical statistical linear polymerisation of DEA and tBuMA (AmG2-p(DEAx-co-
tBuMAy)) – In a typical synthesis, targeting a DPn = 50 monomer units (p(DEA25-co-
tBuMA25)), bpy (134.9 mg, 0.8637 mmol, 2 eq.), DEA (2 g, 10.80 mmol, 25 eq.), 
tBuMA (1.5352 g, 10.80 mmol, 25 eq.) and IPA/H2O (92.5:7.5%) (30.6% v/v based on 
monomer) were placed into a 25 mL RBF. The solution was stirred and deoxygenated 
using a N2 purge for 15 minutes. Cu(I)Cl (42.8 mg, 0.4318 mmol, 1 eq.) was added to 
the flask and left to purge for a further 5 minutes. AmG2-Br (0.3934 g, 0.4318 mmol, 1 
eq.) was added to the flask under a positive flow of N2, and the solution was left to 
polymerise at 40°C. Reactions were terminated when >99 % conversion was reached, as 
judged by 1H NMR, by exposure to oxygen and addition of acetone. The catalyst 
residues were removed by passing the mixture over a basic alumina column. Acetone 
was removed under vacuum to concentrate the sample before precipitation into cold 
petroleum ether (40–60).  
 
Typical synthesis of statistical hyperbranched polydendrons using the co-
polymerisation of DEA, tBuMA and EGDMA, (AmG2-p(DEAx-co-tBuMAy-co-
EGDMA0.9)) – In a typical synthesis, targeting a DPn = 50 monomer units (p(DEA25-co-
tBuMA25-co-EGDMA0.9)), bpy (134.9 mg, 0.8637 mmol, 2 eq.), DEA (2 g, 10.80 mmol, 
25 eq.), tBuMA (1.5352 g, 10.80 mmol, 25 eq.), EGDMA (77.0 mg, 0.3886 mmol, 0.9 
eq.) and IPA/H2O (92.5:7.5%) (30.6% v/v based on monomer) were placed into a 25 mL 
RBF. The solution was stirred and deoxygenated using a N2 purge for 15 minutes. 
Cu(I)Cl (42.8 mg, 0.4318 mmol, 1 eq.) was added to the flask and left to purge for a 
further 5 minutes. AmG2-Br (0.3934 g, 0.4318 mmol, 1 eq.) was added to the flask 
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under a positive flow of N2, and the solution was left to polymerise at 40°C. Reactions 
were terminated when >99 % conversion was reached, as judged by 1H NMR, by 
exposure to oxygen and addition of acetone. The catalyst residues were removed by 
passing the mixture over a basic alumina column. Acetone was removed under vacuum 
to concentrate the sample before precipitation into cold petroleum ether (40–60). 
 
Typical block linear polymerisation of DEA and tBuMA (AmG2-p(DEAx-b-
tBuMAy)) – In a typical synthesis, targeting an overall DPn = 50 monomer units 
(p(DEA25-b-tBuMA25)), bpy (134.9 mg, 0.8637 mmol, 2 eq.), DEA (2.00 g, 10.80 mmol, 
25 eq.) and IPA (29.6-45.6% v/v based on monomer) were placed into a 25 mL RBF. 
The solution was stirred and deoxygenated using a N2 purge for 15 minutes. Cu(I)Cl 
(42.8 mg, 0.4318 mmol, 1 eq.) was added to the flask and left to purge for a further 5 
minutes. Cu(I)Cl/bpy was added to the reaction flask in the molar ratio 
([M]:[CuCl]:[bpy]=25:1:2). AmG2-Br (0.3934 g, 0.4318 mmol, 1 eq.) was added to the 
flask under a positive flow of N2, and the solution was left to polymerise at 40°C. Upon 
73-92% monomer conversion, the second feed of tBuMA (1.54 g, 10.80 mmol, 25 eq.) 
was introduced, with Cu(I)Cl/bpy ([M]:[CuCl]:[bpy]=25:1:2) in IPA/H2O (92.75:7.5%) 
(31.6-32.9 w/v%). Reactions were terminated when >99 % conversion was reached, as 
judged by 1H NMR, by exposure to oxygen and addition of acetone. The catalyst 
residues were removed by passing the mixture over a basic alumina column. Acetone 
was removed under vacuum to concentrate the sample before precipitation into cold 
petroleum ether (40–60). 
 
Typical synthesis of a block hyperbranched polydendron using the co-
polymerisation of DEA, tBuMA and EGDMA, (AmG2-p(DEAx-b-(tBuMAy-co-
EGDMA0.9))) – In a typical synthesis, targeting an overall DPn = 50 monomer units 
(p(DEA25-b-(tBuMA25-co-EGDMA0.9)), bpy (134.9 mg, 0.8637 mmol, 2 eq.), DEA 
(2.00 g, 10.80 mmol, 25 eq.) and IPA (29.6-45.6% v/v based on monomer) were placed 
into a 25 mL RBF. The solution was stirred and deoxygenated using a N2 purge for 15 
minutes. Cu(I)Cl (42.8 mg, 0.4318 mmol, 1 eq.) was added to the flask and left to purge 
for a further 5 minutes. Cu(I)Cl/bpy was added to the reaction flask in the molar ratio 
([M]:[CuCl]:[bpy]=25:1:2). AmG2-Br (0.3934 g, 0.4318 mmol, 1 eq.) was added to the 
flask under a positive flow of N2, and the solution was left to polymerise at 40°C. Upon 
73-92% monomer conversion, the second feed of tBuMA (1.54 g, 10.80 mmol, 25 eq.) 
and EGDMA (77 mg, 0.389 mol, 0.9 eq.) was introduced, with Cu(I)Cl/bpy 
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([M]:[CuCl]:[bpy]=25:1:2) in IPA/H2O (92.75:7.5%) (31.6-32.9 w/v%). Reactions were 
terminated when >99 % conversion was reached, as judged by 1H NMR, by exposure to 
oxygen and addition of acetone. The catalyst residues were removed by passing the 
mixture over a basic alumina column. Acetone was removed under vacuum to 
concentrate the sample before precipitation into cold petroleum ether (40–60). 
 
AmG1U-OH – CDI (1.9460 g, 12 mmol, 2 eq.) was added to an oven-dried 100 mL 2-
neck RBF fitted with a reflux condenser, magnetic stirrer and a dry N2 inlet. Anhydrous 
toluene (20 mL) was added and the flask purged with N2 for 10 minutes. The solution 
was stirred at 60°C and dimethylamino propan-2-ol (2.4758 g, 24 mmol, 4 eq.) added 
via a syringe. The mixture was left stirring at 60°C for 6 hours under a positive flow of 
N2. APAP (1.1338 g, 6 mmol, 1 eq.) was added drop wise, and the reaction was left 
stirring for a further 18 hours at 60°C under a positive flow of N2. Following this, the 
solution was allowed to cool to room temperature, and the pale yellow solution was 
filtered to remove any solid imidazole, and concentrated in vacuo. The resulting viscous 
oil was dissolved in DCM (20 mL) washed with 1M NaHCO3 aq. (3 x 30 mL). The 
organic layer was dried with anhydrous sodium sulfate (Na2SO4), filtered, and 
concentrated in vacuo. Yield: 1.5424 g, yellow oil, (58%). 1H NMR (400 MHz, CDCl3) 
δ 1.11 (m, 3H), 1.22 (m, 3H), 1.29 (d, 3H), 1.65 (m, 4H), 2.04 – 2.68 (m, 22H), 3.22 (m, 
4H), 3.80 (m, 1H), 4.89 (m, 2H), 5.59 (s, br, -NH), 5.73 (s, br, -NH), 5.98 (s, br, -OH). 
13C NMR (100 MHz, CDCl3) δ 18.9, 20.8, 27.2, 39.7, 46.0, 52.6, 62.6, 64.4, 68.4, 72.5, 
156.7. Calcd [M+H]+ (C21H45N5O5) m/z = 447.6 . Found: ESI-MS: [M+H]+ m/z = 447.2 
and [M+Na]+ m/z = 470.3. Anal. Calcd for C21H45N5O5: C, 56.38; H, 10.07; N, 15.66. 
Found C, 56.06; H, 10.33; N, 14.78. 
AmG1U-Br – AmG1U-OH (1.5424 g, 3.4 mmol, 1 eq.), triethylamine (TEA) (0.4886 g, 
4.8 mmol, 1.4 eq.) and 4-dimethyl-aminopyridine (DMAP; 42.1 mg, 0.34 mmol, 0.1 eq.) 
were added to a 250 mL 2 necked RBF containing DCM (110 mL). The flask was 
deoxygenated under a positive N2 purge for 10 minutes. BiB (0.8326 g, 0.45 mL, 3.62 
mmol, 1.05 eq.) was added drop wise while the solution was stirring in an ice bath under 
a positive flow of N2. The reaction mixture was allowed to warm to room temperature 
and left stirring overnight. The organic phase was washed with saturated NaHCO3 
solution (3 x 110 mL). The solution was dried with anhydrous Na2SO4 and the product 
left to dry in vacuo overnight. Yield: 0.6937 g, yellow oil, (37%). 1H NMR (400 MHz, 
CDCl3) δ 1.22 (d, 3H), 1.25 (d, 3H), 1.29 (d, 3H) 1.64 (m, 4H), 1.92 (s, 6H), 2.15-2.87 
(m, 24H), 3.19 (m, 4H), 4.92 (m, 2H), 5.06 (m, 1H), 5.22 (s, br, -NH), 5.50 (s, br, -NH), 
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5.64 (s, br, -OH). 13C NMR (100 MHz, CDCl3) δ 18.3, 19.2, 27.4, 30.9, 39.5, 46.0, 52.3, 
56.3, 59.4, 64.4, 68.4, 72.4, 156.4, 171.5. Calcd [M+H]+ (C25H50N5O6Br) m/z = 596.6. 
Found: ESI-MS: [M+H]+ m/z = 598.3, [M+Na]+ m/z = 620.3 and [M+K]+ m/z = 636.3 
Anal. Calcd for C25H50N5O6Br: C, 50.28; H, 8.38; N, 11.73. Found C, 50.39; H, 8.58; N, 
11.51. 
BnG2-OH – BA (3.00 g, 18 mmol, 6 eq.) was added to a 50 mL round 2 necked RBF 
containing IPA (12 mL). The flask was deoxygenated under a positive N2 purge for 10 
minutes. APAP (1.32 g, 6.984 mmol, 1 eq.) dissolved in IPA (12 mL) was added drop 
wise while the solution was stirring in an ice bath under a positive flow of N2. The final 
mixture was stirred for a further 10 minutes at 0°C, allowed to warm to room 
temperature and left stirring for 48 hours. The solvent was removed and the product left 
to dry in vacuo overnight. Yield: 1.6262 g, yellow oil, (63%). 1H NMR (400 MHz, 
CDCl3) δ 1.07 (d, 3H), 1.53 (m, 4H), 2.19-2.56 (m, 18H), 2.77 (m, 8H), 3.69 (m, 1H), 
5.08 (m, 8H), 7.33 (m, 20H). 13C NMR (100 MHz, CDCl3) δ = 20.0, 24.5, 32.2, 45.7, 
48.9, 51.6, 52.2, 57.8, 62.1, 62.3, 63.6, 173.0. Calcd [M+H]+ (C49H63N3O9) m/z = 838.0. 
Found: ESI-MS: [M+H]+ m/z = 838.5. Anal. Calcd for C49H63N3O9: C, 70.17; H, 7.52; 
N, 5.01%. Found C, 69.56; H, 7.41; N, 4.57%. 
 
BnG2–Br – BnG2-OH (1.6262 g, 1.9 mmol, 1 eq.), TEA (0.2739 g, 2.6 mmol, 1.4 eq.) 
and DMAP (23.7 mg, 0.19 mmol, 0.1 eq.) were added to a 250 mL 2 necked RBF 
containing DCM (60 mL). The flask was deoxygenated under a positive N2 purge for 10 
minutes. BiB (0.5577 g, 0.30 mL, 2.3 mmol, 1.25 eq.) was added drop wise while the 
solution was stirring in an ice bath under a positive flow of N2. The reaction mixture was 
allowed to warm to room temperature and left stirring overnight. The organic phase was 
washed with saturated NaHCO3 solution (3 x 60 mL). The solution was dried with 
anhydrous Na2SO4 and the product left to dry in vacuo overnight. Yield: 1.19 g, yellow 
oil (62%). 1H NMR (400 MHz, CDCl3) δ 1.22 (d, 3H), 1.54 (m, 4H), 1.90 (s, 6H), 2.24-
2.65 (m, 18H), 2.77 (m, 8H), 5.00 (m, 1H), 5.09 (s, 8H), 7.33 (m, 20H).  13C NMR (100 
MHz, CDCl3) δ = 17.0, 23.9, 29.7, 31.6, 48.3, 50.8, 51.6, 55.2, 57.7, 65.2, 70.0, 127.15, 
127.2, 127.5, 135.0, 171.4. Calcd [M+H]+ (C53H68N3O10Br) m/z = 987.0. Found: ESI-
MS: [M+H]+ m/z = 988.4. Anal. Calcd for C53H68N3O10Br: C, 64.44; H, 6.89; N, 4.26%. 
Found C, 63.40; H, 6.96; N, 4.18%.  
 
BDME – BDVE (5.03 g, 5.6 mL, 35.36 mmol, 1 eq.) was added to a two-necked 250 
mL RBF equipped with a condenser, a magnetic stirrer and a positive flow of N2. A 
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small amount of radical inhibitor 4-tert-butylcatechol (end of a spatula) was added and 
the mixture deoxygenated using a N2 purge for 15 minutes. Once dissolved, the 
temperature was raised to 70ºC. MAA (15.22 g, 15.1 mL, 0.1769 mol, 5 eq.) was added 
drop wise over 10 minutes through a septa. The reaction was allowed to proceed at 70ºC 
for a further 6 hours with stirring. After this time, the reaction was stopped by cooling 
and exposing to the air. The crude product was dissolved in chloroform (100 mL) and 
washed with basic H2O (~pH 12, 3 x 100 mL). The combined washings were collected 
and dried over NaSO4 and the solvent removed by rotary evaporation. Yield: 8.73 g, 
yellow oil, (79%). 1H NMR (400 MHz, CDCl3) δ 1.43 (d, 6H), 1.65 (m, 4H), 1.95 (s, 
6H), 3.51 (m, 2H), 3.68 (m, 2H), 5.60 (s, 2H), 5.97 (m, 2H), 6.15 (s, 2H). 13C NMR (100 
MHz, CDCl3) δ 18.4, 20.6, 26.0, 30.9, 68.9, 97.0, 126.0, 136.5, 166.9. Calcd [M+H]+ 
(C16H26O6) m/z = 314.4. Found: ESI-MS: [M+Na]+ m/z = 337.2 and [M+K]+ m/z = 
353.1. Anal. Calcd for C16H26O6: C, 61.07; H, 8.27%. Found C, 61.33; H, 8.45%. 
?
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4.1 Introduction 
 
Polymeric nanoparticles (NPs) have been extensively studied as drug carriers in the 
pharmaceutical field1,2,3,4,5 and reviews of the mechanism of NP formation,6,7 the 
classification of NP systems and preparation techniques8,9 have been published by a 
number of research collaborations. The interest in nanoprecipitation is on a continuous 
rise due to its versatility and compatibility with a range of polymeric materials, as well 
as the rapid formation of well-defined NPs in water.10,11,12 
 
The nanoprecipitation method, also known as solvent displacement or interfacial 
deposition, was first reported in 1989 by Fessi et al.13 Accordingly, the preparation of 
NPs  was described to require both solvent and anti-solvent phases in order to produce a 
rapid and controlled assembly of stable hydrophobic organic macromolecules. The 
aggregation of macromolecules has been shown to continue until a colloidally stable 
dispersion is formed, with stability derived from steric or electrostatic repulsion. 
Nanoprecipitation is believed to form NPs in three distinct stages: nucleation, growth 
and aggregation.14 The rate of each step governs the particle size and the driving force of 
these phenomena is super-saturation, which is the ratio of polymer concentration and 
polymer solubility in the solvent mixture. 
 
During a typical aqueous nanoprecipitation experiment a solution of hydrophobic 
polymer in a good, water-miscible organic solvent, is added to water which acts as the 
solvent-miscible anti-solvent (Figure 4.1A). This leads to NP formation via the 
suggested nucleation/growth mechanism.14 During diffusion of the solvent and anti-
solvent phases, the solvated and expanded polymer chains collapse and consequently 
associate to form colloidally-stable NPs. 
  
Successful literature examples of nanoprecipitation include the large-scale generation of 
polymeric NPs under clinically relevant conditions, highlighted in recent reports of 
positive phase II human clinical trial results from nanoprecipitates derived from linear 
A-B block copolymers of p(ethylene glycol) (PEG) and either p(lactic acid)15,16,17  or 
p(alkylcyanoacrylate)s.18 Nanoprecipitation provides a facile, less complex and widely 
applicable technique compared to dialysis.19 It also allows for polymer and guest 
molecules to be co-dissolved in a common solvent to generate early indications of 
potential encapsulation before undertaking further, more complicated studies. 
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Figure 4.1 General nanoprecipitation method. A) Drop-wise addition of polymer dissolved in water 
miscible good solvent to water, leading to mixing and formation of a solvent/anti-solvent environment 
(i); B) Evaporation of water miscible solvent from water causing aggregation of NPs (ii); forming (C) 
a stable aqueous NP dispersion. 
 
4.2 Nanoprecipitation of linear polymers, linear-dendritic hybrids, 
branched copolymers, terpolymers and hyp-polydendrons 
 
All linear polymers, linear-dendritic polymer hybrids, branched copolymers, terpolymers 
and hyp-polydendrons described in Chapter 3 were evaluated for their ability to 
nanoprecipitate. Figure 4.2 shows the suggested collapse and aggregation behaviour of 
linear-dendritic polymer hybrids and hyp-polydendrons following nanoprecipitation. 
 
 
 
Figure 4.2 Diagrammatic representation of the nanoprecipitation of A) linear-dendritic hybrids, and 
B) hyperbranched-polydendrons derived from dendron initiators. A proposed stable NP dispersion is 
achieved following: i) initial collapse of hydrophobic polymers and; ii) association and aggregation to 
produce stabilised nanoprecipitates. 
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A variety of nanoprecipitation parameters were previously investigated in order to 
optimise the conditions for NP formation and identify common parameters for use with 
the materials synthesised in Chapter 2; this included comparisons of slow addition 
(Figure 4.3A) and fast addition (Figure 4.3B) of the polymer solution to the aqueous anti-
solvent media. The majority of these p(2-hydroxypropyl methacrylate-co-ethylene glycol 
dimethacrylate) (p(HPMA50-co-EGDMAx)) materials displayed similar NP sizes with 
narrower particle size distributions when added to the aqueous phase via the slower, 
drop-wise method. This implied a slightly more controlled NP formation manner when 
this technique was used. 
?
 
Figure 4.3 Diagrammatic representation of the nanoprecipitation parameters investigated in Chapter 2 
including fast (A) vs. slow (B) addition of polymer solution to aqueous media; and targeting varying 
polymer end concentrations in aqueous media, where (C) represents a lower polymer concentration 
and (D) represents a higher polymer concentration following evaporation of good solvent overnight. 
 
Additionally, the initial polymer concentration in solvent and the targeted final NP 
concentration in water was varied (Figure 4.3C and D). Stable NP dispersions were 
generally produced for all copolymers in Chapter 2, when targeting a final NP 
concentration of 1 mg mL-1. This was independent of the starting polymer concentration, 
and a starting polymer concentration of 5 mg mL-1 overall produced NPs with narrower 
size distributions. 
 
Following the studies outlined in Chapter 2, and to allow direct comparisons for the 
range of polymer variants synthesised in Chapter 3, all polymers reported here were 
dissolved at a standardised initial concentration of 5 mg mL-1 to produce a targeted 
1 mg mL-1 aqueous NP dispersion, after drop-wise addition and subsequent solvent 
removal by evaporation overnight at ambient temperature. The tertiary butyl 
CHAPTER 4 
161
methacrylate polymers (p(tBuMA50) and p(tBuMA50-co-EGDMAx)) were dissolved in 
tetrahydrofuran (THF) as the good solvent phase, whilst all other linear, linear-dendritic 
and branched polymers containing 2-(diethylamino) ethyl methacrylate (DEA) were 
dissolved in acetone, following the failure of THF to act as a good solvent in these cases. 
 
Analysis of the stable NP dispersions was conducted by dynamic light scattering (DLS) 
to assess NP hydrodynamic diameters (Dz), zeta-potentials (ζ) and polydispersities 
(PDI). For all materials containing DEA, nanoprecipitation studies utilising acidic water 
as the anti-solvent were conducted and final pH values after nanoprecipitation were 
measured. Due to protonation of these materials at low pH (or upon the addition of acid 
following pH studies), number average diameters (Dn) and derived count rates (DCR) 
were interpreted with caution as unreliable data may be readily generated. The reasoning 
for this behaviour is described below. 
 
According to Rayleigh Theory,20 the light scattering intensity produced by particles is 
proportional to r6 where r is the particle radius. Light scattered by a particle of diameter, 
2r, and refractive index, n, from a beam of unpolarised light of wavelength λ and 
intensity I0 is given in Equation 4.1, where R is the distance to the particle and θ is the 
scattering angle. 
 
Equation 4.1 Rayleigh Theory. 
 
This infers that a theoretical particle diameter of 50 nm scatters light up to 1,000,000 
times more than a particle diameter of 5 nm (i.e. factor of the 10 in radius), meaning the 
presence of any large particles, even a very small number, in a NP dispersion will 
misrepresent the size distribution to generate an inaccurate weighting of the particle 
sizes present when studied under scattering intensity considerations only. It is, therefore, 
vital to take into consideration the number distribution of the dispersion; number 
distributions are calculated from scattering data using Mie Theory,21 which calculates 
the particle size distribution assuming a volume equivalent sphere model. This model is 
an exact description of how spherical particles of all sizes and optical properties scatter 
light. The DLS instrument directly measures light scattering and utilises Mie theory to 
extrapolate to a number distribution, therefore a number of assumptions, such as the 
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perfect spherical nature of the particles, are utilised which may not accurately represent 
the sample under investigation and lead to additional errors within the calculated number 
distribution. 
 
Figure 4.4 shows a hypothetical example of a population comprising two distinct near-
mono-disperse particle populations with diameters of 5 and 50 nm in a 1:1 number ratio. 
The number distribution (Figure 4.4A) shows two peaks centred at 5 and 50 nm, with a 
1:1 number ratio. The volume distribution (Figure 4.4B), shows the two peaks in a 
1:1,000 ratio, as the volume of a sphere is equal to 4/3πr3. The intensity distribution 
shows a 1:1,000,000 ratio between the two distributions, as the intensity of scattering is 
proportional to r6 from Rayleigh's approximation. The DCR was also monitored to 
confirm either nanoprecipitate aggregation, or the existence of solubilised polymers in 
low pH. 
 
 
Figure 4.4 Diagrammatic representation of DLS analysis through A) number; B) volume and C) 
intensity. 
 
4.2.1 Nanoprecipitation studies of linear, linear-dendritic DEA polymers and 
DEA-EGDMA branched copolymers and hyp-polydendrons 
 
Polymers derived from DEA are well known for solubilising in acidic media and 
existing as a cationic polyelectrolye due to protonation of the tertiary amines.22 Reports 
of p(DEA) also describe quarternisation of the tertiary amine groups using reagents such 
as methyl iodide,23 in some cases forming highly branched water-soluble 
polyelectrolytes after polymerisation using atom transfer radical polymerisation 
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(ATRP)-based self-condensing vinyl polymerisation techniques.24 DEA-based NPs have 
also been widely exploited due to the advantageous applications that polycations have to 
offer.25 Cross-linked polymer NPs containing a pH-responsive core and hydrophilic 
charged shell have been designed to disrupt endosomes and mediate drug/cell binding.26 
These developments were designed in consideration of the polymer’s ability to absorb 
protons in response to acidification within endosomes, theoretically disrupting vesicles. 
Double hydrophilic graft copolymers containing p(DEA) have also been prepared to 
introduce colloidal stability to gold NPs with controllable size in aqueous media without 
any external reducing agent.27 Weaver et al. have polymerised DEA and EGDMA from 
a PEG macroinitiator under conventional free radical polymerisation conditions to 
produce pH-responsive branched NPs.28 Further investigations have led to cross-linking 
the hydrophilic shell domains, rendering the micellar aggregates as single 
nanoparticulates that do not display critical micelle concentrations and are stable to very 
high dilution.29 
 
Over recent decades, the self-assembly behaviour of tertiary amine methacrylate-based 
copolymers in alternating pH environments has been extensively explored.30 The design 
and synthesis of such copolymers has provided a means to control the pKa values of 
varying copolymers via changes in the chemical structure and/or the composition of the 
pH-responsive polymer to meet the requirements of particular target applications. By 
amending the solubility/insolubility balance, pKa values have existed between plasma 
physiological pH (~7.4) and abnormal pathologic tissue31 (~7.2-6.5) or intracellular 
micro-environmental pH.32,33 
 
Solution properties and micellisation behaviour of double hydrophilic diblock 
copolymers, p(hexaethylene glycol methacrylatex-co-DEAy) comprising an ionisable 
p(DEA) domain,  in aqueous media have been investigated through DLS and 1H nuclear 
magnetic resonance (NMR) spectroscopy over a range of different pH values.34 These 
findings revealed a copolymer in its unimer state at low pH due to the hydrophilicity of 
the protonated tertiary amine units, while an increase of the solution pH resulted in the 
deprotonation of the amine residues, which subsequently become hydrophobic and lead 
to the formation of micelles consisting of a DEA core and a p(hexaethylene glycol 
methacrylate) corona. These investigations have demonstrated the potential for drug 
delivery vehicle platforms to be generated. 
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Within this study, nanoprecipitation studies were conducted initially for the range of 
p(DEA)-containing materials described in Chapter 3; namely linear EBiB-p(DEA50), 
linear-dendritic AmG0-p(DEA50), AmG1-p(DEA50), AmG2-p(DEA50), AmG1U-
p(DEA50), branched EBiB-p(DEA50-co-EGDMA0.95) and the hyp-polydendrons AmG0-
p(DEA50-co-EGDMA0.9), AmG1-p(DEA50-co-EGDMA0.9), AmG2-p(DEA50-co-
EGDMA0.9) and AmG1U-p(DEA50-co-EGDMA0.9), Table 4.1. 
 
NPs formed from EBiB-p(DEA50) were significantly more polydisperse than dispersions 
generated from the branched analogue, suggesting a much more controlled aggregation 
of highly branched polymers and the rapid attainment of stability during the 
nanoprecipitation of these materials. This architectural effect is also seen across all of the 
linear-dendritic and hyp-polydendron materials in Table 4.1, strongly suggesting the 
influence of branching being a critical parameter within the behaviour of these materials. 
EBiB-p(DEA50) formed smaller NPs than EBiB-p(HPMA50) under neutral aqueous 
conditions, however, the size distribution was bimodal when using tertiary-amine 
methacrylates. Despite the somewhat broad and multi-modal distributions within the 
linear-dendritic polymer series, both these materials and their hyp-polydendron 
equivalents, across all generations of dendron end group, appeared to form stable NPs 
(Table 4.1 and Figure 4.5) following the same trend as seen with EBiB-initiated 
materials; linear dendritic polymer hybrids much more polydisperse than their branched 
equivalents. The linear polymer and linear-dendritic polymer hybrids produced bimodal 
size distributions in neutral water upon inspection by DLS (Figure 4.5A), resulting in 
their large PDI values, and existed as two populations showing lack of control in NP 
formation. 
 
 
Figure 4.5 DLS size distribution analysis of A) AmG2-p(DEA50) and B) AmG0-p(DEA50-co-
EGDMA0.9) (green), AmG1-p(DEA50-co-EGDMA0.9) (blue) and AmG2-p(DEA50-co-EGDMA0.9) (red) 
NP dispersions in pH=7.8. 
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All HPMA-containing linear-dendritic polymer hybrids failed to form stabilised 
nanoprecipitates in neutral pH aqueous conditions (Chapter 2). The marked difference in 
NP formation between the linear-dendritic hybrids and the hyp-polydendrons appears to 
result from branching, which may influence how the initial nuclei form, aggregate and 
assemble during the nanoprecipitation process. The formation of nuclei from hyp-
polydendrons will benefit from the fraction of the overall molecular weight distribution 
comprising large numbers of conjoined chains as, in principle, the collapse of a single 
branched molecule containing, for example, > 50 primary chains will form a nucleus that 
would otherwise require 50 linear-dendritic hybrid chains to coalesce into a single 
structure (Figure 4.6). Formation of such nuclei allow the linear fraction of the hyp-
polydendron molecular weight distribution to assemble quickly, rather than form small 
structures containing low numbers of chains that slowly build into nuclei themselves. 
 
 
Figure 4.6 Proposed aggregation in aqueous media of A) Linear-dendritic polymer hybrids; and B) 
hyp-polydendrons. 
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Table 4.1 DLS analysis of nanoprecipitated particles from linear, linear-dendritic and branched 
polymers and hyp-polydendrons prepared in neutral water (pH 7.8) at a concentration of 1 mg mL-1. 
Polymer Dz (nm) PDI Dn (nm) ζ (mV) 
EBiB-p(HPMA50) 780 0.230  -34 
AmG0-p(HPMA50) - - - - 
AmG1-p(HPMA50) - - - - 
AmG2-p(HPMA50) - - - - 
EBiB-p(HPMA50-co-EGDMA0.95) 178 0.082 145 -20 
AmG0-p(HPMA50-co-EGDMA0.9) 157 0.269 75 -12 
AmG1-p(HPMA50-co-EGDMA0.9) 165 0.097 124 -31 
AmG2-p(HPMA50-co-EGDMA0.9) 149 0.099 108 -22 
EBiB-p(DEA50) 47 0.249 24 +23 
AmG0-p(DEA50) 51 0.413 21 +21 
AmG1-p(DEA50) 148 0.249 13 +16 
AmG2-p(DEA50) 65 0.381 12 +19 
AmG1U-p(DEA50) 82 0.408 33 +45 
EBiB-p(DEA50-co-EGDMA0.95) 139 0.088 102 +34 
AmG0-p(DEA50-co-EGDMA0.9) 168 0.086 123 +47 
AmG1-p(DEA50-co-EGDMA0.9) 74 0.086 54 +31 
AmG2-p(DEA50-co-EGDMA0.9) 58 0.065 43 +22 
AmG1U-p(DEA50-co-EGDMA0.9) 68 0.172 39 +26 
AmG2-p(DEA33-co-HPMA17) - - - - 
AmG2-p(DEA33-co-HPMA17) - - - - 
AmG2-p(DEA33-co-HPMA17) - - - - 
AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9) 144 0.113 106 +16 
AmG2-p(DEA25-co-HPMA25-co-EGDMA0.9) 183 0.166 140 +16 
AmG2-p(DEA17-co-HPMA33-co-EGDMA0.9) 113 0.099 82 +13 
AmG2-p(DEA33-co-tBuMA17) - - - - 
AmG2-p(DEA33-co-tBuMA17) - - - - 
AmG2-p(DEA33-co-tBuMA17) - - - - 
AmG2-p(DEA33-co-tBuMA17-co-EGDMA0.9) - - - - 
AmG2-p(DEA25-co-tBuMA25-co-EGDMA0.9) - - - - 
AmG2-p(DEA17-co-tBuMA33-co-EGDMA0.9) - - - - 
1 Italics indicate a bimodal size distribution measured by DLS. 
 2 – indicates failure to form stabilised NPs without observable macroscale precipitation. 
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The hyp-polydendrons experience a decrease in PDI as the amount of tertiary amine 
increases on the dendron (Figure 4.5B), suggesting the NPs arrange and pack themselves 
in a slightly more controlled manner and achieve colloidal stability earlier in the 
growth/aggregation stage of nanoprecipitation. This is also observed in the decrease in 
Dz and Dn values as the tertiary amine density at the polymer chain ends increases (see 
Chapter 2) from AmG0- through to AmG2-. This does also imply that a decreasing 
amount of polymeric material is required to achieve colloidally stable NPs; these clear 
trends are not seen in the linear equivalent materials. The HPMA-containing series of 
hyp-polydendrons (Chapter 2), also show a decrease in PDI with increasing dendron 
generation, albeit to a single value, with broader size distributions (PDI = 0.269) 
generated when using the AmG0- end group; comparison to nanoprecipitations of DEA-
branched materials containing the AmG0- end group (PDI = 0.086) suggesting the 
importance of primary chain chemistry. 
 
The EBiB-, AmG0, AmG1-, AmG2- and AmG1U- hyp-polydendrons exhibited positive 
ζ values, with the presence of extra amine functionality provided by the dendrons not 
significantly influencing these observations; although a higher zeta potential is seen for 
all branched EBiB-, AmG0, AmG1- and AmG2- materials in comparison to their linear 
equivalents and the branched materials do show a weak trend towards higher potentials 
with decreasing dendron generation. The highly positive zeta potentials observed for the 
EBiB-p(DEA50) and EBiB-p(DEA50-co-EGDMA0.95) indicate the values are highly 
governed by the primary polymer chains.? It is probable that, upon assembly and 
formation of these NPs, dendron chain ends would also become entrapped within the 
main bulk of the nanoprecipitates, as well as arranging themselves on the surface, hence 
further suggesting the zeta potential appears to be dominated by the amine functionality 
of the primary p(DEA50) chains.  
 
Both hyp-polydendrons bearing AmG1 dendron chain ends with differing dendron 
chemistry (AmG1-p(DEA50-co-EGDMA0.9) and AmG1U-p(DEA50-co-EGDMA0.9)) have 
almost identical Dz values of 74 and 68 nm respectively (Table 4.1). This is a strong 
indication that the chemistry of the dendron end group is not as important as the number 
of terminal groups; however, the PDI does vary with the AmG1U end group generating a 
much higher PDI. 
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4.2.2 Nanoprecipitation studies of linear, linear-dendritic, branched copolymers 
and hyp-polydendrons comprising tBuMA 
 
Chapter 2 has interestingly shown stable NPs are produced by amine-functionalised 
linear-dendritic polymer hybrids in pH 4, however EBiB initiated materials, equivalent 
to those initiated by amine-functional dendrons, were not stable. This was determined to 
be due to the increased charge stabilisation available by the tertiary amine groups at the 
periphery of the dendron chain ends. The instability of EBiB-p(HPMA50-co-
EGDMA0.95) has already been reported in aqueous NaCl, and salt stability is essential for 
many biological applications.1 
 
Chapter 2 also explored the production of NPs by precipitation into aqueous HCl from 
amine-functionalised linear-dendritic p(HPMA50) and amine-functionalised p(HPMA50-
co-EGDMA0.9), following the failure of the former to form stable nanoprecipitates in 
water at near-neutral pH. This clearly indicated that the dendron chain ends contribute to 
the stabilisation of the nanoprecipitates, as the EBiB-initiated linear and branched 
analogues underwent macro-scale precipitation in acidic pH. 
 
The nanoprecipitation of a range of materials containing p(tBuMA50) and p(tBuMA50-
co-EGDMAx) was therefore investigated within this study, as these highly-hydrophobic 
primary chains may behave very differently to the similar structures containing 
p(HPMA50) and p(HPMA50-co-EGDMAx), discussed in Chapter 2. 
 
Upon nanoprecipitation of the EBiB-p(tBuMA50), AmG2-p(tBuMA50), 
EBiB-p(tBuMA50-co-EGDMA0.95) and AmG2-p(tBuMA50-co-EGDMA0.9) polymers into 
neutral water (pH = 7.8), precipitation was observed with large polymer masses forming 
rapidly. Upon investigation by scanning electron microscopy (SEM), the macroscale 
precipitates were seen to be comprised of nanoparticles, strongly suggesting a successful 
nanoprecipitation process but a high level of instability of the NPs leading to 
uncontrolled aggregation (Figure 4.7). The instability of these polymers in pH 7.8, 
compared to the linear and branched HPMA materials, demonstrates the difference that 
polymer composition has on stable NP aggregation. The AmG2-p(tBuMA50), similarly 
resulted in macroscale precipitation compared to the AmG2-p(HPMA50), however, the 
latter was able to produce stable NPs in acidic water. This concept is applied to the 
AmG2-p(tBuMA50) later on in this study, in an attempt to produce stable NPs (cf. 
Section 4.2.4.3). 
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Figure 4.7 SEM image of macroscale precipitation of AmG2-p(tBuMA50-co-EGDMA0.9) NP 
aggregates following nanoprecipitation into neutral water (pH = 7.8) at 1 mg mL-1.
 
4.2.3 Nanoprecipitation studies of statistical linear-dendritic DEA-HPMA 
polymers and DEA-HPMA-EGDMA hyp-polydendrons  
 
As previously observed, the AmG2 dendron chain end has provided excellent 
nanoprecipitation behaviour to a range of materials, possibly through playing a key role 
in determining the packing and arrangement of the nanoprecipitates produced from 
linear-dendritic polymer hybrids and hyp-polydendrons derived from HPMA. The range 
of statistical copolymers synthesised in Chapter 3, vary systematically in the degree of 
amphiphilicity in the primary polymer chains comprising the branched structure of the 
hyp-polydendrons, and this is expected to also modify the behaviour and stability of the 
NPs formed. 
 
The linear-dendritic hybrid AmG2-p(HPMA50) failed to produce stable NPs upon 
nanoprecipitation into neutral (pH 7.8) water; however, AmG2-p(HPMA50-co-
EGDMA0.9) was conversely able to form NPs exhibiting control during nanoprecipitation 
into neutral water with polydispersity values < 0.1. This may be due to, as already 
mentioned, the instantaneous collapse of a large number of conjoined primary polymer 
chains within the hyp-polydendron on addition to water, compared to the collapse of 
single linear-dendritic hybrid polymer chains and subsequent assembly. The AmG2-
p(DEA50) equally failed to demonstrate any level of control in neutral pH, confirmed by 
the bimodal distribution measured by DLS. The AmG2-p(DEA50-co-EGDMA0.9) 
succeeded in producing stable NPs with a narrow size distribution (PDI = 0.065). 
CHAPTER 4 
170
 
The DEA-HPMA statistical copolymer linear-dendritic hybrids, AmG2-p(DEA33-co-
HPMA17), AmG2-p(DEA25-co-HPMA25), AmG2-p(DEA17-co-HPMA33) and statistical 
hyp-polydendrons (AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9), AmG2-p(DEA25-co-
HPMA25-co-EGDMA0.9) and AmG2-p(DEA17-co-HPMA33-co-EGDMA0.9) were also 
evaluated under nanoprecipitation conditions into neutral water. All linear-dendritic 
polymers, once again, failed to form stable NPs and resulted in large aggregates 
precipitating out of solution. The hyp-polydendrons, however, successfully produced 
stable NP dispersions, supported by monomodal size distributions measured by DLS 
(Table 4.1 and Figure 4.8). 
 
 
Figure 4.8 DLS size distribution analysis of AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9) (green), 
AmG2-p(DEA25-co-HPMA25-co-EGDMA0.9) (purple) and AmG2-p(DEA17-co-HPMA33-co-
EGDMA0.9) (blue) NP dispersions in pH=7.8. 
 
The inability of the linear-dendritic hybrids to form particles and the contrasting ready 
formation of nanoprecipitates by hyp-polydendrons, again, appears to confirm the clear 
benefit from having the complex architecture. As previously described, this is 
hypothesised to be due to the rate and mechanism of nucleation (cf. Figure 4.6), the 
efficiency of aggregation and attainment of charge stabilisation. 
 
The positive ζ values measured for these statistical terpolymer hyp-polydendron 
nanoprecipitates were slightly lower (+13 to +16 mV) than the values of the NPs 
produced from AmG2-p(DEA50-co-EGDMA0.9) (+22 mV); this may result directly from 
the minor decrease in DEA content within the primary chains. The nanoprecipitates 
formed from the AmG2-p(DEA17-co-HPMA33-co-EGDMA0.9) contained the narrowest 
size distribution and lowest ζ value, suggesting an increased level of control when using 
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a higher content of HPMA co-monomer in the NP formation, compared to the other 
statistical terpolymer hyp-polydendrons, and also the impact of the lower DEA content 
on the eventual ζ values. 
 
4.2.4 Nanoprecipitation studies of linear-dendritic hybrid polymers and hyp-
polydendrons containing DEA and tBuMA, and the effect of primary chain 
architecture 
 
4.2.4.1 Nanoprecipitation studies of statistical linear-dendritic copolymers and 
hyp-polydendrons comprising DEA and tBuMA 
 
Upon the nanoprecipitation of the statistical linear-dendritic hybrids and hyp-
polydendrons containing tBuMA and DEA: namely AmG2-p(DEA33-co-tBuMA17), 
AmG2-p(DEA25-co-tBuMA25), AmG2-p(DEA17-co-tBuMA33), AmG2-p(DEA33-co-
tBuMA17-co-EGDMA0.9), AmG2-p(DEA25-co-tBuMA25-co-EGDMA0.9) and AmG2-
p(DEA17-co-tBuMA33-co-EGDMA0.9); macroscale precipitation was observed in all 
cases following evaporation of acetone. This is in marked contrast to the hyp-
polydendrons comprising statistical primary chains of DEA and HPMA, and the 
incorporation of the highly hydrophobic monomer, tBuMA, appears to completely 
dominate the solution behaviour. 
 
4.2.4.2 Nanoprecipitation studies of block linear-dendritic DEA-tBuMA 
polymers and DEA-tBuMA-EGDMA hyp-polydendrons  
 
The polymer architecture of the primary chain copolymers could also be modified to 
form a block copolymer (or gradient copolymer), where the hydrophobic tBuMA 
monomers that dominated the statistical copolymer behaviour were predominantly 
isolated into one block segment. It was hypothesised that this architectural difference 
would potentially allow the formation of stable NPs comprised of DEA and tBuMA. The 
synthesis of linear-dendritic block polymer hybrids (Figure 4.9i) and block hyp-
polydendrons (Figure 4.9ii) was therefore undertaken, using the same molar ratios of 
tBuMA: DEA utilised within the analogous statistical copolymer equivalents (66: 33, 50: 
50 and 33: 66). This also allows a direct behavioural comparison based on the polymer 
architecture of the primary chains within the hyp-polydendron and the linear-dendritic 
hybrids. 
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Figure 4.9 Architectural variation of linear-dendritic hybrids and hyp-polydendrons comprising  DEA 
and tBuMA to establish stable NPs in neutral water. i) Statistical and linear-dendritic block 
copolymers and; ii) statistical and block copolymer hyp-polydendrons. 
 
Amphiphilic block copolymers conventionally contain connected hydrophilic and 
hydrophobic segments, providing an array of morphologies in the solid state and 
selective solvents.35,36 The nature of each polymer fragment has been extensively 
manipulated using many controlled polymerisation techniques,37 allowing for control 
over the chemical and physical properties desired for the block copolymer, and resulting 
in highly ordered structures during the self-assembly process. 
 
Linear-dendritic block copolymer hybrids in low pH, allow for a bespoke opportunity 
for new micelle species through self-assembly. Previous studies bear witness to changes 
in self-assembly behaviour upon incorporation of stimuli-responsive polymers within the 
linear polymer chain.38 Examples include PEG-based biocompatible linear-dendritic 
copolymers that form thermo-responsive micelles that completely disrupt into unimers 
upon cooling below their lower critical solution temperature and then reform again upon 
heating,39 and assembled pH-responsive linear-dendritic micelles with tuneable drug 
release rates.40 The curious amphiphilic characteristic associated with the linear-
dendritic hybrid architectures pinpoint evolving application potential,41 particularly the 
construction of nano-sized particles in environmentally friendly media. 
 
The nanoprecipitation of all of the block linear-dendritic hybrids and block hyp-
polydendrons into neutral water (pH=7.8), namely:  AmG2-p(DEA33-b-tBuMA17), 
AmG2-p(DEA25-b-tBuMA25), AmG2-p(DEA17-b-tBuMA33), AmG2-p(DEA33-b-
(tBuMA17-co-EGDMA0.9)), AmG2-p(DEA25-b-(tBuMA25-co-EGDMA0.9)) and AmG2-
p(DEA17-b-(tBuMA33-co-EGDMA0.9)); equally led to macroscale precipitation. This 
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suggests the architecture of the primary chain copolymers is not critical to successful 
nanoprecipitation under these conditions. 
 
4.2.4.3 The production of stable nanoprecipitates from DEA-tBuMA linear-
dendritic polymer hybrids and and DEA-tBuMA-EGDMA hyp-polydendrons 
 
Following the failed production of NPs from statistical and block DEA-tBuMA 
materials, two additional strategies to overcome this inability to controllably self-
assemble were considered. Initially, the overall primary polymer chain length was 
increased within the block hyp-polydendron to produce chains with a similar DEA to 
tBuMA ratio to the shorter chain-containing block polymers but with an overall larger 
DEA component relative to dendron chain end. This may lead to a higher contribution to 
charge stabilisation from the p(DEA) block segment (Figure 4.10B); AmG2-p(DEA50-b-
(tBuMA65-co-EGDMA0.9)) was subsequently synthesised to evaluate this hypothesis. 
This subtle variation in the branched polymer structure was observed to generate 
successful NP formation and prevent macroscale precipitation in neutral water; offering 
additional flexibility to the hyp-polydendron approach. 
 
Figure 4.10 Proposed solutions for producing stable p(DEAx-tBuMAy)-derived NPs: A) 
Nanoprecipitation into aqueous HCl for increased charge stabilisation; B) increased primary polymer 
length within the block hyp-polydendron. 
 
Secondly, the anti-solvent was replaced with acidic water (Figure 4.10A) due to the 
successful nanoprecipitation of AmG2-p(HPMA50-co-EGDMA0.9) NPs under these 
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conditions, presumably due to the increased protonation of the dendron chain ends 
(Chapter 2). In the current case, charge-stabilisation was expected via dendron 
protonation with an additional contribution from primary polymer chain protonation. 
 
The use of the acidic anti-solvent medium (aqueous HCl; pH = 4) was studied for all the 
statistical and block linear-dendritic polymer hybrids and hyp-polydendron materials 
comprising DEA and tBuMA (Table 4.2), to evaluate the ability of increased protonation 
to enable successful nanoprecipitation; nanoprecipitates were successfully formed for all 
materials without observable macrophase separation. In addition, the AmG2-p(DEA50) 
and AmG2-p(DEA50-co-EGDMA0.9) were nanoprecipitated under these conditions for 
comparison. 
 
All statistical and block copolymer linear-dendritic hybrids and hyp-polydendrons 
containing all ratios of DEA and tBuMA formed stable NPs when nanoprecipitating into 
acidic water (Table 4.2). For these particular materials, the hyp-polydendrons were more 
polydisperse than the relevant linear equivalents, and often multi-modal within their size 
distributions. 
 
The Dn values for the statistical linear-dendritic polymers containing DEA and tBuMA 
were >17 nm (Table 4.2), confirming the lack of dissolution at the final solution pH, 
which was much higher than the initial pH = 4, similarly witnessed for the linear-
dendritic DEA polymer and DEA-EGDMA hyp-polydendron. The narrow size 
distributions (Figure 4.11A) may have resulted from arrangement of the highly dense 
tertiary amine dendron to the NP surface in order to protect the hydrophobic tBuMA 
polymer components, within the nanoprecipitate, from the aqueous media. Upon DLS 
analysis of the corresponding hyp-polydendron samples, broader size distributions were 
clearly evident, suggesting that the complex architectures may be restricted in their 
mobility and unable to rearrange under these conditions to form clearly defined 
structures (Figure 4.11B). 
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Table 4.2 DLS analysis of nanoprecipitated particles (1 mg mL-1) prepared from linear, linear-
dendritic, branched polymer and hyp-polydendron solutions (5 mg mL-1) derived from DEA and 
tBuMA into neutral (pH=7.8) and acidic (pH=4) water. 
 
pH=7.8a 
pH=4.0a 
(Final pH=5.9-7.4) 
Polymer Dz 
(nm) 
PDI Dn 
(nm) 
ζ 
(mV) 
Dz 
(nm) 
PDI Dn 
(nm) 
ζ 
(mV) 
AmG2-p(DEA50) 65 0.381 12 +19 42 0.231 23 +36 
AmG2-p(DEA50-co-EGDMA0.9) 58 0.065 43 +22 49 0.120 32 +29 
AmG2-p(DEA33-co-tBuMA17) - - - - 44 0.167 19 +32 
AmG2-p(DEA25-co-tBuMA25) - - - - 37 0.181 17 +34 
AmG2-p(DEA17-co-tBuMA33) - - - - 65 0.172 30 +39 
AmG2-p(DEA33-co-tBuMA17-co-
EGDMA0.9) 
- - - - 51 0.222 18 +35 
AmG2-p(DEA25-co-tBuMA25-co-
EGDMA0.9) 
- - - - 134 0.284 33 +52 
AmG2-p(DEA17-co-tBuMA33-co-
EGDMA0.9) 
- - - - 129 0.222 62 +40 
AmG2-p(DEA33-b-tBuMA17) - - - - 38 0.192 19 +37 
AmG2-p(DEA25-b-tBuMA25) - - - - 40 0.136 24 +38 
AmG2-p(DEA17-b-tBuMA33) - - - - 40 0.112 25 +37 
AmG2-p(DEA33-b-(tBuMA17-co-
EGDMA0.9)) 
- - - - 23 0.322 12 +30 
AmG2-p(DEA25-b-(tBuMA25-co-
EGDMA0.9)) 
- - - - 84 0.197 44 +35 
AmG2-p(DEA17-b-(tBuMA33-co-
EGDMA0.9)) 
- - - - 28 0.366 13 +31 
AmG2-p(DEA50-b-(tBuMA65-co-
EGDMA0.9)) 
163 0.082 123 +35 58 0.167 34 +28 
AmG2-p(tBuMA50) - - - - 104 0.250 43 +43 
AmG2-p(tBuMA50-co-
EGDMA0.9) 
- - - - 233 0.295 79 +31 
a Initial pH of water. 
1 Italics indicates a bimodal size distribution measured by DLS. 
 2 – indicates failure to form stabilised NPs with observable macroscale precipitation. 
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Figure 4.11 DLS size distribution analysis for A) AmG2-p(DEA33-co-tBuMA17) (green), AmG2-
p(DEA25-co-tBuMA25) (orange) and AmG2-p(DEA17-co-tBuMA33) (red); B) AmG2-p(DEA33-co-
tBuMA17-co-EGDMA0.9) (green), AmG2-p(DEA25-co-tBuMA25-co-EGDMA0.9) (orange) and AmG2-
p(DEA17-co-tBuMA33-co-EGDMA0.9) (red) NP dispersions in pH=4. 
 
The observed Dn values within the statistical hyp-polydendron nanoprecipitates appear 
to increase as the DEA content decreases and the hyp-polydendrons become less soluble 
in low pH (Table 4.2); this is a general trend witnessed within each series of these 
materials studied. 
 
Small NP diameters were observed for all linear-dendritic block copolymer hybrids (Dn 
= 19-25 nm), all with monomodal size distributions (Figure 4.12A) and behaving very 
similarly to the equivalent statistical copolymer hybrid analogues. None of the materials 
were soluble in acidic water, and the Dn confirms nanoprecipitate formation. A slight 
increase in Dn values was witnessed as the level of hydrophobic tBuMA primary 
polymer chain was increased. The dispersity of the linear-dendritic block copolymer 
hybrid nanoprecipitate samples improved as the hydrophobic content increased, 
suggesting an increase in the driving forces for self-assembly and aggregation. In spite 
of the variation in DEA segment lengths, within the self-assembled linear-dendritic 
block copolymer nanoparticles, the ζ values obtained were virtually identical (+37, +38 
and +37 mV) suggesting there is an equal tertiary amine density surrounding the 
nanoprecipitates, created by a combination of the DEA polymer and AmG2 dendrons 
that are protonated in acidic pH. 
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Figure 4.12 DLS size by intensity analysis for A) AmG2-p(DEA33-b-tBuMA17) (green), AmG2-
p(DEA25-b-tBuMA25) (orange) and AmG2-p(DEA17-b-tBuMA33) (red); B) AmG2-p(DEA33-b-
(tBuMA17-co-EGDMA0.9)) (green), AmG2-p(DEA25-b-(tBuMA25-co-EGDMA0.9)) (orange) and 
AmG2-p(DEA17-b-(tBuMA33-co-EGDMA0.9)) (red) NP dispersions in pH=4. 
 
Evidently, the low pH plays a vital role in the generation of stabilised NPs, again, 
suggesting a predominantly charge stabilised mechanism for such nanoprecipitates. In 
comparison to the statistical linear-dendritic equivalents, no significant difference in 
particle size (Dz or Dn) was witnessed. The only note-worthy observation could be the 
high DCR obtained for AmG2-p(DEA17-co-tBuMA33), the polymer containing the 
highest level of hydrophobicity across the range of these co-polymeric dendritic hybrids. 
 
Upon nanoprecipitation of the block copolymer hyp-polydendrons, AmG2-p(DEA33-b-
(tBuMA17-co-EGDMA0.9)), AmG2-p(DEA25-b-(tBuMA25-co-EGDMA0.9)) and AmG2-
p(DEA17-b-(tBuMA33-co-EGDMA0.9)) all formed stable nanoprecipitates at low pH 
(Figure 4.12B). AmG2-p(DEA25-b-(tBuMA25-co-EGDMA0.9)) produced the only 
monomodal size distribution (Figure 4.12B) and NPs with the largest Dz and Dn size 
values. The AmG2-p(DEA33-b-(tBuMA17-co-EGDMA0.9)) and AmG2-p(DEA17-b-
(tBuMA33-co-EGDMA0.9)) produced bimodal size distributions accounting for the 
existence of a variety of nanoprecipitate species. For these two materials, almost 
identical values for particle sizes, count rates and surface charge were measured by DLS 
(Table 4.2). 
 
As mentioned above, all block copolymer hyp-polydendrons exhibited broader size 
distributions in comparison to the linear-dendritic block copolymer hybrid equivalents. 
This trend was also observed when DEA-tBuMA statistical hyp-polydendrons were 
nanoprecipitated, suggesting the linear-dendritic polymer hybrids have a higher degree 
of freedom to form nanoprecipitates. This, however, was not witnessed within the DEA 
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series of linear-dendritic hybrids and hyp-polydendrons, where branching seemed to 
encourage more stabilised aggregations, having lower polydispersity values. 
 
In all cases of statistical and block dendritic polymer materials comprising DEA and 
tBuMA, stable NPs were not generated via nanoprecipitation into neutral water. The 
block copolymer hyp-polydendron with increased primary chain length, AmG2-
p(DEA50-b-(tBuMA65-co-EGDMA0.9)), (Chapter 3, Section 3.4) was, however, able to 
successfully undergo nanoprecipitation into both neutral and acidic water (Figure 4.13), 
unlike any of the previous statistical and block hyp-polydendrons consisting of primary 
polymer chain lengths containing average degrees of polymerisation (DPn) = 50 
monomer units (Table 4.2). The nanoprecipitates formed from the AmG2-p(DEA50-b-
(tBuMA65-co-EGDMA0.9)) hyp-polydendron exhibited a Dz = 163 nm with a very low 
PDI = 0.082 in neutral water; a size within the previously reported range as successful 
for various nanocarrier candidates within the literature.42 
 
 
Figure 4.13 DLS size analysis by intensity (A) for AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) in 
neutral (green) and acidic (red) water; and by number (B) in neutral (green) and acidic (red) water at a 
concentration of 1 mg mL-1.
 
The stable nanoprecipitates of AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) prepared in 
low pH = 4 water showed noticeably smaller Dz values than those formed in neutral 
water, suggesting a decreased amount of packing within the growth stages of the 
nanoprecipitation. This observation again suggests that the protonated p(DEA) block 
segments contribute strongly to the stabilisation, but may also indicate that the longer 
chains may be providing steric stabilisation as solvated chains at the surface of the NP. It 
is also possible that the increased hydrophobicity from the longer p(tBuMA) block 
segment may also play a role in the successful nanoprecipitation. 
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Comparatively, the nanoprecipitation of AmG2-p(DEA50) and AmG2-p(DEA50-co-
EGDMA0.9) into aqueous HCl produced stable NPs, supported by the monomodal size 
distributions (Table 4.2 and Figure 4.14). 
 
Figure 4.14 DLS size distribution analysis of AmG2-p(DEA50) (red) and AmG2-p(DEA50-co-
EGDMA0.9) (green) prepared in acidic water (pH=4) at a concentration of 1 mg mL-1. 
 
The AmG2-p(DEA50) produced NPs with more narrow PDI values within aqueous HCl 
than at neutral pH, most likely due to the more rapid and controlled establishment of 
charge stabilisation via efficient protonation. The Dz values obtained for AmG2-
p(DEA50) was very similar to the DEA/tBuMA-containing linear-dendritic block 
polymer hybrid NPs prepared in aqueous HCl than, for example, the large sizes 
measured for the linear amphiphilic hybrids in Chapter 2. The AmG2-p(DEA50-co-
EGDMA0.9) produced stable, slightly smaller NPs in acidic media compared to those 
prepared in neutral water (Dz = 49 and 58 nm respectively) and the Dn value of 32 nm 
confirms a lack of complete solubilisation at lower pH.  
 
In a similar study, a comparison of the nanoprecipitation of EBiB-p(tBuMA50), AmG2-
p(tBuMA50), EBiB-p(tBuMA50-co-EGDMA0.95) and AmG2-p(tBuMA50-co-EGDMA0.9) 
using an acidic water anti-solvent was conducted. Chapter 2 witnessed stable NP 
formation due to the amine functionality present in the linear-dendritic polymer hybrids 
and hyp-polydendrons of materials comprising p(HPMA) chains and the benefits of the 
amine functional dendron were also expected to be seen with p(tBuMA)-containing 
materials. As anticipated, the NPs were not successfully achieved for either the EBiB-
p(tBuMA50) polymer or EBiB-p(tBuMA50-co-EGDMA0.95) copolymer under these 
conditions and macroscale precipitation was observed. In contrast, the linear-dendritic 
hybrid, AmG2-p(tBuMA50) and hyp-polydendron, AmG2-p(tBuMA50-co-EGDMA0.9) 
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samples produced stable NP dispersions during addition to water at a low pH (Table 4.2) 
following no previous success at neutral pH (cf. Section 4.2.2). NPs formed from both 
the linear-dendritic polymer hybrid and hyp-polydendron exhibited highly positive ζ 
values as expected. Both NP distributions are relatively broad compared to the 
p(HPMA)-derived NPs; particularly the linear-dendritic polymer hybrid in comparison 
to AmG2-p(HPMA50) (PDI = 0.165), suggesting a less controlled aggregation; this may 
be due to the increased hydrophobicity of the tBuMA primary chains. Unlike the 
p(HPMA)-derived materials, the branched AmG2-p(tBuMA50-co-EGDMA0.9) produced 
nanoprecipitates with a Dz value greater than the linear equivalent. This may be due to 
the high molecular weight hyp-polydendron containing an increased amount of 
hydrophobic polymer compared to the linear-dendritic equivalent, and undergoing 
increased aggregation to achieve stabilisation. It is also important to note that the glass 
transition temperature of p(tBuMA) homopolymer is well known to be 118°C and as 
such, the rapid nanoprecipitation may lead to the “locking in” of polymer conformations 
and a reduced ability to relax after addition to the anti-solvent. 
 
4.3 pH-responsive studies of linear polymers, linear-dendritic 
hybrids, branched copolymers and hyp-polydendrons  
 
The materials that produced monomodal, stable NP dispersions in neutral water were 
subjected to the rapid addition of acid (1M HCl) to establish any pH-responsive 
behaviour or ability to withstand environmental changes. Following acid addition, the 
changes in nanoprecipitate structure and assembly were investigated by DLS analysis 
and compared. The materials which were stable when generated using aqueous anti-
solvent at pH = 4, and those that produced bimodal distributions, were not included in 
the study. If the materials were to be considered as nanomedicine drug delivery vehicles, 
a large number of drug molecules are acidic or basic and the requirements of anti-solvent 
pH may be highly restrictive. For example, encapsulation of a basic drug in acidic 
aqueous conditions would be impractical, therefore, NPs prepared in neutral water are 
more widely applicable and less likely to cause difficulties in drug encapsulation. 
 
Chapter 2 demonstrated interesting behaviour upon the rapid-switching of pH, for 
nanoprecipitates formed from linear-dendritic polymer hybrids and hyp-polydendrons 
comprised of HPMA. Successful NP formation has been observed for the majority of 
linear polymers, linear-dendritic hybrids, copolymers, terpolymer and hyp-polydendrons 
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synthesised in Chapter 3, following nanoprecipitation into neutral water. The majority of 
these materials contain pH-responsive compositions with varying DEA content and 
primary polymer architecture, therefore the behaviour of the different materials upon a 
switch in pH is of interest. 
 
pH-responsive polymers have gathered much attention due to their emerging in vitro 
studies, in vivo biomedical applications and the relevance of modulating pH in living 
organisms.43 This attractiveness has extended to the exploration of terpolymers, the 
majority of which exhibit pH-responsiveness via pH-cleavable chemical linkages.44 
Tertiary amine methacrylate-based polymers, such as p(DEA50-co-EGDMAx), have the 
advantage of possessing pH-responsive properties without the production of any 
byproducts upon hydrolysis or acidolysis. 
 
Also included in this study, was the preparation of NPs from hyp-polydendrons 
containing the acid-cleavable brancher, 1,4-butanediol di(methacryoyloxy)-ethyl ether 
(BDME; Chapter 3, Section 3.7), such as AmG2-p(DEA50-co-BDME2.0), AmG2-
p(DEA33-co-HPMA17-co-BDME2.0) and AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)), 
which all successfully produced stable NPs in neutral water. 
 
In general, the size and charge of the majority of NPs used for nanomedicine applications 
can have an effect on efficient clearance from the body as intact NPs and degradation 
into biologically benign components and clearance is required.45 This process still creates 
concerns for many clinical applications as, without efficient clearance or degradation, 
toxicity may arise from the nanocarrier material which is a potential long term health 
issue. For globular proteins, a Dz of approximately 5–6 nm appears to allow rapid 
clearance from the body via renal filtration and urinary excretion.46  
 
The BDME-containing hyp-polydendrons synthesised here provide potential 
opportunities for two modes of NP degradation: first, the dissociation of the 
nanoprecipitate into solvated branched polymers, and secondly the degradation of the 
branched polymers into their individual primary chains of relatively mono-disperse and 
low molecular weight (Figure 4.15). 
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Figure 4.15 Proposed route of acid-triggered disassembly of AmG2-p(DEA50-co-BDME2.0) 
nanoprecipitates to initial individual, hyp-polydendrons, and eventual hydrolysis to primary polymer 
chains. 
 
4.3.1 pH-responsive studies of linear, linear-dendritic DEA polymers and DEA-
EGDMA branched copolymers and hyp-polydendrons 
 
Synthetic pH-responsive polymers are formed from monomers that are weakly basic or 
acidic. These moieties protonate/deprotonate reversibly as a function of pH, the 
adjustment of which alters the ionic interaction, hydrogen bonding and hydrophobic 
interaction and results in a reversible microphase separation or self-organisation 
phenomenon.47 Consequently, acid-responsive polymers are fully soluble in aqueous 
solution at low pH, being largely hydrated, swollen and hydrophilic in their ionic state. 
At high pH, the polymers become dehydrated, compact and more hydrophobic in their 
neutral form.28 This transition occurs at a pH that is defined as the apparent pKa or pKb 
and is very susceptible to change when the chemical substituents on the polymer 
backbone48,49 or the polymeric architectures50 are adjusted. A change in behaviour upon 
a switch in pH is specifically attractive for biological applications due to the abundant 
pH gradients existing in normal and pathophysiological states.51 
 
All NPs generated from DEA-containing polymers were subjected to the rapid switching 
of pH to observe and understand their pH-responsive behaviour (Table 4.3). Only the 
AmG2-p(DEA50-co-EGDMA0.9) from the branched DEA hyp-polydendron series was 
included for comparative NP behaviour. 
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Table 4.3 DLS analysis following the addition of acid on nanoprecipitated particles prepared from 
branched DEA, DEA-HPMA and DEA-tBuMA hyp-polydendron NP dispersions prepared in neutral 
water pH=7.8. 
 pH of water 
 pH = 7.8a 
(Final pH = 6.9-7.9) 
+ 1M HCl 
(Final pH = 2.2-3.2) 
Polymer Dz 
(nm) 
PDI Dn 
(nm) 
DCR 
(kcps) 
Dz 
(nm) 
PDI Dn 
(nm) 
DCR 
(kcps) 
AmG2-p(DEA50-co-
EGDMA0.9) 
58 0.065 43 97000 47 0.364 6 850 
AmG2-p(DEA33-co-
HPMA17-co-EGDMA0.9) 
144 0.113 106 391100 37 0.515 6 300 
AmG2-p(DEA25-co-
HPMA25-co-EGDMA0.9) 
183 0.166 140 533400 63 0.462 7 700 
AmG2-p(DEA17-co-
HPMA33-co-EGDMA0.9) 
113 0.099 82 95100 164 0.363 16 1500 
AmG2-p(DEA50-b-
(tBuMA65-co-
EGDMA0.9)) 
163 0.082 123 451800 192 0.079 156 232960 
AmG2-p(DEA50-co-
BDME2.0) 
61 0.241 32 38700 457 0.535 5 266 
AmG2-p(DEA33-co-
HPMA17-co-BDME2.0) 
410 0.204 310 46400 131 0.418 5 925 
AmG2-p(DEA17-b-
(tBuMA33-co-BDME2.0)) 
107 0.086 76 286300 134 0.073 103 284200 
a Initial pH 
1 Italics indicates a bimodal size distribution measured by DLS. 
 
Upon rapid acid addition, AmG2-p(DEA50-co-EGDMA0.9) NPs resulted in a colourless 
solution (final pH = 2.2-3.2) (Figure 4.16B), confirming complete solubilisation of the 
materials at this low pH. The DCR value also dropped significantly, clearly indicating 
that this hyp-polydendron nanoprecipitate existed as dissolved unimolecular species 
under these conditions (Figure 4.16A). This confirms that the Dz and broad PDI values 
measured following acid addition were not true indications of the main population of 
particles existing in this acidic environment. A review of the Dn value following the pH 
change showed a diameter of 6 nm, typical of a fully solvated high molecular weight 
branched polymer (Figure 4.17A), as opposed to the measured Dz value of 43 nm 
measured under neutral conditions. 
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Figure 4.16 A) Proposed behaviour of stabilised AmG2-p(DEA50-co-EGDMA0.9) nanoprecipitates 
and their existence as individual entities upon the addition of acid (H+), B) Cloudy, AmG2-p(DEA50-
co-EGDMA0.9) NP dispersion (1 mg mL-1) resulting in colourless, solution upon the addition of acid. 
 
 
 
Figure 4.17 DLS analysis of size distribution (A) and number distribution (B) of AmG2-p(DEA50-co-
EGDMA0.9) before (green) and after acid addition (red-dotted). 
 
4.3.2 pH-responsive studies of statistical linear-dendritic DEA-HPMA polymers 
and DEA-HPMA-EGDMA hyp-polydendrons 
 
Following the observation of the fully soluble AmG2-p(DEA50-co-EGDMA0.9) hyp-
polydendron in aqueous solution at low pH, the response of the range of statistical 
AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9), AmG2-p(DEA25-co-HPMA25-co-
EGDMA0.9) and AmG2-p(DEA17-co-HPMA33-co-EGDMA0.9) hyp-polydendron NPs was 
investigated. As previously observed, the measured Dz values suggested the presence of 
large, stable nanoprecipitates still remaining within the dispersion (Figure 4.18A). 
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However, as suggested by the large PDI values implying a broad distribution of species, 
upon evaluation of the Dn values (Figure 4.18B) and the DCR, it is quite clear that the 
dispersion contains merely dissolved material.  
 
 
Figure 4.18 DLS analysis of AmG2-p(DEA25-co-HPMA25-co-EGDMA0.9). A) Size distribution 
analysis and; B) Number distribution analysis before (purple) and after addition (ret-dotted). 
 
The Dn values increase slightly with increasing HPMA within the hyp-polydendron 
copolymers, with the largest diameter of 16 nm observed for the AmG2-p(DEA17-co-
HPMA33-co-EGDMA0.9) hyp-polydendron. The fraction of protonatable monomer 
residues within the polymers at low pH decreases across the series of materials studied 
which may result in a low level of residual polymer-polymer interaction at higher HPMA 
content. The sizes may also be an effect of the molecular weight values of the statistical 
hyp-polydendrons, with the AmG2-p(DEA17-co-HPMA33-co-EGDMA0.9) possessing a 
noticeably larger molecular weight (4,510,000 g mol-1) in comparison to the AmG2-
p(DEA33-co-HPMA17-co-EGDMA0.9) and AmG2-p(DEA25-co-HPMA25-co-EGDMA0.9) 
(398,300 and 1,971,000 g mol-1 respectively). 
 
4.3.3 pH-responsive studies of AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) 
 
Upon the addition of acid to AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) NPs, a 
surprising phenomenon was observed. The NP dispersion did not solubilise, despite the 
addition of a large excess of acid (360 mg to 10 mL water). The polymeric NPs, instead,
swelled slightly upon protonation (Figure 4.19), suggesting the potential extension of 
surface AmG2-p(DEA50) block segments extending into the surrounding aqueous 
environment and acting to provide steric stabilisation. It is also possible that the 
increased hydrophobicity within the core of the NP was able to hold together the 
assembled structure whilst some of the internal p(DEA) became protonated at such low 
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pH. This would lead to NP core swelling as well as the formation of extended surface 
polymer chains as the internal chains became hydrated. 
 
 
Figure 4.19 DLS size distribution analysis of AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) before 
(red) and after (ret-dotted) acid addition. 
 
4.3.4 pH-responsive studies of BDME-containing hyp-polydendrons 
 
The AmG2-p(DEA50-co-BDME2.0) nanoprecipitates (Dz = 61 nm; Dn = 32 nm) prepared 
in neutral water (pH=7.8) displayed a broader polydispersity than the corresponding 
AmG2-p(DEA50-co-EGDMA0.9) (Figure 4.20), despite both hyp-polydendrons 
possessing similar molecular weights (Chapter 3). 
 
Figure 4.20 DLS size distribution analysis of AmG2-p(DEA50-co-BDME2.0) (green) and AmG2-
p(DEA50-co-EGDMA0.9) (red). 
 
Upon rapid acid addition, the stabilised AmG2-p(DEA50-co-BDME2.0) NPs became 
soluble as expected, also confirmed by the observed colourless solution replacing a 
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slightly turbid NP dispersion. As previously observed, the Dz values suggest an increase 
in size but the considerable decrease in count rate and Dn values (Table 4.3 and Figure 
4.21) confirmed the existence of individual species.?
 
 
Figure 4.21 DLS number distribution analysis of AmG2-p(DEA50-co-BDME2.0) before (green) and 
after acid addition (red-dotted). 
 
The nanoprecipitation and pH-responsive nature of AmG2-p(DEA33-co-HPMA17-co-
BDME2.0) was studied as a direct comparison. The statistical incorporation of 
hydrophobic monomers within the hyp-polydendron produces control over the chemistry 
of the primary polymer chains and offers modification of the internal NP environment. 
 
The AmG2-p(DEA33-co-HPMA17-co-BDME0.9) produced nanoprecipitates in neutral 
water that were more than double the size of the EGDMA equivalent AmG2-p(DEA33-
co-HPMA17-co-EGDMA0.9) hyp-polydendron NPs (Figure 4.22). The NP dispersion 
displayed a broader size distribution, suggesting a less controlled aggregation process. 
Upon the addition of acid, the nanoprecipitates became soluble as expected, with a 
dramatic decrease in the Dn value from 310 to 5 nm.  
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Figure 4.22 DLS size by intensity (A) and number (B) analysis of AmG2-p(DEA33-co-HPMA17-co-
BDME2.0) (pink) and AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9) (green) prepared in neutral water 
(pH 7.8) at a concentration of 1 mg mL-1. DLS size by intensity (C) and number (D) analysis of 
AmG2-p(DEA33-co-HPMA17-co-BDME2.0) (pink) and AmG2-p(DEA33-co-HPMA17-co-EGDMA0.9) 
(green) following the addition of acid. 
 
Nanoprecipitation of AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)) produced stabilised 
aggregated nanoprecipitates in neutral water, exhibiting high levels of control during the 
aggregation process confirmed by the narrow PDI values. The AmG2-p(DEA17-b-
(tBuMA33-co-BDME2.0)) possesses a very high weight average molecular weight of 
594800 g mol-1 which is greater than twice the equivalent EGDMA-analogue with an Mw 
= 251800 g mol-1. This would imply instantaneous formation of much larger nuclei on 
addition to water; however, these speculations are yet to be investigated. Upon the 
addition of acid to the NPs, the nanoprecipitates failed to become soluble and continued 
to exist as nanoprecipitates (Figure 4.23), as previously observed for the AmG2-
p(DEA50-b-(tBuMA65-co-EGDMA0.9)). An increase in Dz and Dn values of ~ 30 nm in 
both cases was again seen (Table 4.3), suggesting polymer swelling during protonation 
of dendron and primary polymer chains.  
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Figure 4.23 DLS trace of AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)) before (green) and after (red) 
acid addition. 
 
The DLS measurements performed on the BDME-containing nanoprecipitates following 
the addition of acid, despite confirming soluble materials, are not sufficient to verify the 
cleavage of the pH-responsive brancher, nor the existence of primary linear-dendritic 
polymer chains. Hydrolysis of the hyp-polydendrons (AmG2-p(DEA50-co-BDME2.0), 
AmG2-p(DEA33-co-HPMA17-co-BDME2.0), and AmG2-p(DEA17-b-(tBuMA33-co-
BDME2.0))) was carried out in acetone at room temperature in the presence of a small 
amount of aqueous HCl. The hyp-polydendrons became water-soluble upon protonation 
following acid addition. The existence of a solid precipitate, accounting for the cloudy 
solution, cleared immediately upon the addition of deionised water as the precipitate 
dissolved. Cleavage of the brancher upon addition of acid was readily observed from the 
monomodal distributions in the post-hydrolysis gel permeation chromatography (GPC) 
refractive index (RI; Figure 4.24) chromatograms of the BDME-containing branched 
copolymers. 
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Figure 4.24 GPC RI chromatograms of A) AmG2-p(DEA50) (red) and AmG2-p(DEA50-co-BDME2.0) before (green) and after (red-dotted) hydrolysis; B) AmG2-p(DEA33-co-HPMA17) (blue
and AmG2-p(DEA33-co-HPMA17-co-BDME2.0) before (green) and after (red-dotted) hydrolysis; C) AmG2-p(DEA17-b-tBuMA33) (red) and AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)) befor
(green) and after hydrolysis (red-dotted). 
CHAPTER 4 
191
The hydrolysis of the BDME-containing hyp-polydendrons result in polymers with 
lower molecular weights and narrower molecular weight distributions than the precursor 
branched hyp-polydendron. These narrow, monomodal molecular weight distributions 
are indicative of the primary linear-dendritic hybrid polymer chains and the change in 
distribution is readily seen when compared to the highly branched polymer. These 
hydrolysed products are most likely statistical copolymers consisting of p(DEA) and 
p(methacrylic acid). The hydrolysed molecular weight distributions of each hydrolysed 
hyp-polydendron is highly comparable to the GPC analysis of each previously 
synthesised linear-dendritic equivalent polymer. Overlays of the molecular weight 
distributions of AmG2-p(DEA50) (Figure 4.24A), AmG2-p(DEA33-co-HPMA17) (Figure 
4.24B) and AmG2-p(DEA17-b-tBuMA33) (Figure 4.24C) were highly indicative of 
degradation to a distribution of primary chains. 
 
4.4 Encapsulation and release studies 
 
The association of drug molecules to NPs, either covalently attached or encapsulated, 
has been reported for many different polymer classes.52  Drugs can also be encapsulated 
within stable micelles with release mediated by the rate of drug diffusion from the core 
of the micelle.53 Liposomes have also been reported to encapsulate hydrophobic and 
hydrophilic therapeutic agents;54 they can shield the encapsulated agent from the 
external environment and required properties can be tailored through composition, size 
and surface charge to improve circulation half-life.55 
 
The hydrophobic dye molecule, fluoresceinamine (FA), was chosen as a model drug and 
dissolved in acetone at a concentration of 1 mg mL-1. FA was selected due to it being 
partly soluble in water, which was an essential characteristic for the release studies. 1 mL 
(1 mg) of the FA solution was combined with 2 mL of a 5 mg mL-1 solution (10 mg) of 
each AmG2-p(DEA50-co-EGDMA0.9), AmG1U-p(DEA50-co-EGDMA0.9) and AmG2-
p(DEA50-co-BDME2.0) polymer solution (3 mL total; 9 wt% FA). The solutions were 
then subjected to a rapid solvent switch through drop-wise addition into 10 mL of 
deionised water (pH 7.8) at ambient temperature, to give a final polymer concentration of 
1 mg mL-1 in water after acetone removal by evaporation overnight. All combinations 
formed stable uniform NPs in aqueous media and were analysed by DLS (Figure 4.25 
and Table 4.4). 
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Figure 4.25 DLS size distribution analysis of encapsulated FA (9 wt%) AmG1U-p(DEA50-co-
EGDMA0.9) (orange), AmG2-p(DEA50-co-EGDMA0.9) (red) and AmG2-p(DEA50-co-BDME2.0) 
(green) NP dispersions. 
 
Table 4.4 DLS analysis of DEA hyp-polydendrons (blank) and containing encapsulated FA (9 wt%) 
prepared in neutral water. 
 pH=7.8a 
+ encapsulated FA 
(9 wt%)b 
Polymer Dz (nm) PDI Dn (nm) Dz (nm) PDI Dn (nm) 
AmG2-p(DEA50-co-EGDMA0.9) 58 0.065 43 45 0.197 28 
AmG1U-p(DEA50-co-EGDMA0.9) 68 0.172 39 59 0.243 28 
AmG2-p(DEA50-co-BDME2.0) 61 0.241 32 38 0.190 20
a Blank DEA hyp-polydendrons; b DEA hyp-polydendrons nanoprecipitated with FA. 
?
Due to the pH-responsive nature of the DEA, a visual release study of the encapsulated 
dye was conducted. The 9 wt % dye-loaded NP dispersions (0.1 mg FA encapsulated in 
1 mg hyp-polydendron) were transferred independently into a dialysis membrane 
(molecular weight cut-off: 2000 g mol-1) and submerged into a body of deionised water 
at pH 7.8, (Figure 4.26i).
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Figure 4.26 Visual representation of FA release from encapsulated DEA hyp-polydendron NP 
dispersion before (i) and after (ii) acid addition. 
 
The dialysis membrane within the water was left stirring for 48 hours to allow for any 
free or weakly-adsorbed FA to pass through the membrane. After 48 hours, the water 
had a slight yellow colour that was collected and analysed for the calculation of un-
encapsulated FA (Figure 4.27), and subsequently the amount of encapsulated FA. In 
order to calculate the amount of FA released, a calibration curve was produced 
(Appendix, Figure A65), measuring the absorbance of varying concentrations of FA in 
acidic water using ultraviolet-visible (UV-Vis) spectroscopy. This allowed samples to be 
analysed via UV-Vis, measuring the absorbance at different time points, to determine 
the amount released. 
 
 
Figure 4.27 Amount of FA released before and after acid addition. 
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The water was replaced with fresh, deionised water and left for a further 24 hours to 
ensure only encapsulated FA remained within the dialysis membrane. After this 24 hour 
period, the water remained clear. Acid (HCl, 140 mg) was added to the water until the 
pH reached ~2, and samples of water were taken over a period of time. The majority of 
FA was released within 8 hours for all samples (Figure 4.28). After 24 hours the water 
was replaced with fresh, aqueous HCl (pH ~2) due to equilibration of FA, after which 
the remaining fraction of FA was released. 
 
 
Figure 4.28 Cumulative release of FA over 55 hours (break indicated change in outside water as 
equilibrium was reached). 
A difference in the release of FA within the different hyp-polydendron NP dispersions 
was observed. The AmG2-p(DEA50-co-BDME2.0) appeared to release the encapsulated 
FA faster, potentially due to additional hydrolysis of the brancher, resulting in a more 
rapid dissolution of the branched polymer core. Following the release study, the 
remaining AmG2-p(DEA50-co-BDME2.0) NP dispersion within the dialysis membrane, 
was collected and analysed by GPC. A lower molecular weight and a narrow molecular 
weight distribution (Table 4.5) can be seen from the RI (Figure 4.29) GPC 
chromatogram, confirming hydrolysis of the BDME-containing hyp-polydendron once 
again. 
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Figure 4.29 GPC RI chromatogram overlays of AmG2-p(DEA50) (red); AmG2-p(DEA50-co-
BDME2.0) (green) and AmG2-p(DEA50-co-BDME2.0) after release study (orange). 
 
Table 4.5 GPC analysis of AmG2-p(DEA50) and AmG2-p(DEA50-co-EGDMA0.9) and AmG2-
p(DEA50-co-BDME2.0) before and after the release study. 
GPCa 
Polymer Mn  
(g mol-1) 
Mw  
(g mol-1) 
Đ 
AmG2-p(DEA50) 23650 34400 1.46 
AmG2-p(DEA50-co-BDME2.0) 
-? After hydrolysis 
-? After release study 
157300 
39950 
68800 
321100 
51150 
99500 
2.04 
1.28 
1.45 
AmG2-p(DEA50-co-EGDMA0.9) 
-? After release study 
200645 395261 1.97 
1513000 3938000 2.60 
a Triple detection analysis using THF/2% TEA eluent 
 
Additionally, the remaining AmG2-p(DEA50-co-EGDMA0.9) NP dispersion in the 
dialysis bag following the release study, was collected and analysed by GPC. Figure 4.30 
shows a highly branched polymer remaining in the dialysis bag, compared to the 
narrower, monomodal peak witnessed for the AmG2-p(DEA50-co-BDME2.0), due to the 
EGDMA brancher not undergoing hydrolysis. Distinguishable peaks in the RI overlay 
exactly with distinct peaks observed for the AmG2-p(DEA50-co-EGDMA0.9) before the 
release study. 
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Figure 4.30 GPC RI chromatogram overlays of AmG2-p(DEA50) (red), AmG2-p(DEA50-co-
EGDMA0.9) (green) and AmG2-p(DEA50-co-EGDMA0.9) after release study (orange). 
 
4.5 Conclusions 
 
Overall, the results demonstrate the effects that linear-dendritic polymer and hyp-
polydendron chemistry and architecture, play on the ability to form stable NPs in 
aqueous media. Generally, the hyp-polydendrons produced stable nanoprecipitates with 
narrow size distributions, compared to the linear-dendritic hybrids that typically resulted 
in broad and bimodal size distributions. The proposed explanation stems from how the 
initial nuclei form, with a higher molecular weight hyp-polydendron collapsing to form 
particles already containing a number of conjoined chains, as opposed to the linear 
materials slowly producing nuclei from small structures. Statistical linear-dendritic 
polymer hybrids and hyp-polydendrons containing tBuMA failed to produce stable NPs 
in neutral water (pH=7.8). The change in architecture to produce block hyp-
polydendrons, also failed to produce stable NP dispersions, however, nanoprecipitation 
into acidic water, and increasing the primary polymer chain length, yielded stable 
nanoprecipitates. Again, the ability to tailor the hyp-polydendron architecture to form 
stable NPs is demonstrated.  
 
All DEA-containing NPs underwent a pH-responsive study, with most existing as 
soluble, hydrated polymers at low pH, from protonation of the tertiary amines residing 
in the pendant polymer groups. These propositions were confirmed by observable clear 
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solutions, and noticeable decreases in particle sizes (Dn) and derived count rates 
measured by DLS. All BDME-containing hyp-polydendrons succeeded in producing 
stable NP dispersions. Hydrolysis to linear-dendritic polymer chains was confirmed by 
GPC, displaying monomodal molecular weight distributions. Interestingly, the AmG2-
p(DEA17-b-(tBuMA33-co-BDME2.0)) failed to solubilise upon the addition of acid, 
proposing a NP packing arrangement that prevents acid entry. The successful 
encapsulation of a model dye guest molecule was achieved, with release studies 
revealing changes in the release rate based on minor modifications within the hyp-
polydendron, i.e. the acid-cleavable brancher. 
 
Overall, the ability to form stable nanoprecipitates and the procedure to release a model 
drug has been demonstrated to depend on a variety of different chemical and 
architectural properties within the hyp-polydendron, allowing modifications within the 
structure for tuning properties that have not been previously demonstrated. 
 
4.6 Experimental 
 
Typical procedure for aqueous nanoprecipitation – The materials were dissolved in 
acetone/THF at a concentration of 5 mg mL-1. 2 mL of this solution was then subjected to 
a rapid solvent switch through drop wise addition into 10 mL of water, to give a final 
polymer nanoparticle concentration of 1 mg mL-1 in water after acetone/THF removal by 
evaporation overnight. 
 
Typical procedure for fluoresceinamine encapsulation – FA was dissolved in acetone 
at a concentration of 1 mg mL-1. 1 mL of this solution, along with 2 mL of the p(DEA50-
co-EGDMAx) solution (5 mg mL-1), was then subjected to a rapid solvent switch through 
drop wise addition into 10 mL of water, to give a final polymer nanoparticle 
concentration of 1 mg mL-1 in water after acetone removal by evaporation overnight. 
?
Typical procedure for hydrolysis of BDME-containing hyp-polydendrons –?AmG2-
p(DEA50-co-BDME2.0) was dissolved in acetone at a concentration of 40 mg mL-1 (9 
mL). HCl (5M, 400 μL) was added drop wise to the solution and stirred vigorously at 
room temperature for 20 minutes, resulting in a cloudy solution with solid precipitate. 
Deionised water (9 mL) was added to the acidic polymer solution and left to stir 
overnight in a sealed vial. The hydrolysed polymer solution was frozen in liquid 
nitrogen and lyophilized for 72 hours.?
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Co-nanoprecipitation studies of linear-dendritic polymer hybrids and 
branched, hydrophobic copolymers 
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5.1 Introduction 
 
In 2015, Ford et al. described the formation of stable polymeric nanoparticles (NPs) 
using mixed polymer feeds and through a process known as co-nanoprecipitation.1 Co-
nanoprecipitation differs from the established nanoprecipitation method as two polymers 
are dissolved in the same organic good solvent prior to precipitation into water, which 
acts as an anti-solvent. This published report described the stabilisation of a branched, 
hydrophobic, vinyl copolymer, p(2-hydroxypropyl methacrylate-co-ethylene glycol 
dimethacrylate) initiated by ethyl α-bromoisobutyrate (EBiB-p(HPMA50-co-
EGDMA0.9)) (Scheme 5.1i), with an amphiphilic A-B block copolymer p(ethylene 
glycol-co-HPMA) (PEG45-co-HPMA120) (Scheme 5.1ii) to generate NP dispersions with 
narrow particle size distributions. 
 
Scheme 5.1 Synthesis of branched, hydrophobic, vinyl copolymer, EBiB-p(HPMA50-co-EGDMA0.9) 
(i), and amphiphilic A-B block copolymer, (PEG45-co-HPMA120) (ii) via atom transfer radical 
polymerisation (ATRP). 
 
By varying the ratios of the two polymers within the good solvent solution, differences 
in NP behaviour were observed, ultimately resulting in materials with optimised salt 
stability. The formation of sterically stabilised NPs via the co-nanoprecipitation 
approach is presented schematically in Figure 5.1. Thorough investigations were carried 
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out to show the range of parameters that effect and control the NP stabilisation process: 
dilution factor, primary polymer composition and architecture. The mechanism of NP 
formation was investigated and it was apparent that NPs are formed immediately after 
addition of the polymer solution (good solvent) to the anti-solvent, the addition of large 
volumes of good solvent can prevent nanoprecipitation and repeated nanoprecipitations 
into the same anti-solvent sample led to increased numbers of particles, supporting the 
nucleation and growth mechanism.2 
 
Figure 5.1 Co-nanoprecipitation of branched HPMA copolymer, EBiB-p(HPMA50-co-EGDMA0.9), 
and linear A-B block copolymer (PEG45-co-HPMA120), to produce stabilised NPs. 
 
Overall, the co-nanoprecipitation concept proved a relatively facile technique to 
introduce steric stability to branched polymer nanoprecipitates, particularly in aqueous 
salt conditions, which is essential for in vitro pharmacological studies. Previous research 
reports have described dendrons and conjugated PEG chains covalently-bound to the 
hyp-polydendron surface, where PEG was also confirmed to be present inside the NPs. 
This may present issues, that co-nanoprecipitation may overcome.  
 
The co-nanoprecipitation method allows for investigations of NPs formed from the self-
assembly from different materials. In this current study, linear polymers, copolymers 
and linear-dendritic polymer hybrids will be evaluated in co-nanoprecipitation with 
hydrophobic, branched copolymers (Figure 5.2). A clear advantage of this approach is 
the ability to relatively quickly change the chemical composition of different NP 
structural components, and the ease of tailoring the surface chemistry of the resulting 
NPs. 
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5.2 Co-nanoprecipitation studies of linear polymers and linear-
dendritic hybrids with branched hydrophobic copolymers 
 
Co-nanoprecipitation studies of a series of selected linear polymers, linear-dendritic 
polymer hybrids and branched copolymers synthesised in Chapter 3, were conducted to 
evaluate their suitability for this NP fabrication approach.  
 
For all co-nanoprecipitation experiments, polymers were dissolved in the water-miscible 
good solvent at a concentration of 5 mg mL-1. Solutions of linear polymers and linear-
dendritic polymer hybrids were combined with branched copolymer solutions at a ratio 
of 10:90 wt% (linear:branched) (cf. Section 5.2.2). An aqueous NP dispersion with an 
end concentration of 1 mg mL-1 was targeted, following solvent removal by evaporation 
overnight at ambient temperature. All polymers were dissolved in acetone, apart from the 
t-butyl methacrylate containing polymers, p(tBuMA50) and EBiB-p(tBuMA50-co-
EGDMA0.95) samples, which were solubilised in tetrahydrofuran (THF). 
 
 
Figure 5.2 Diagrammatic representation of the proposed co-nanoprecipitation method utilising linear-
dendritic and branched polymers; A) addition of combined polymer solutions; B) collapse and 
aggregation of polymers to produce; C) stabilised nanoprecipitates. 
 
Analysis of the stable NP dispersions was conducted by scanning electron microscopy 
(SEM) and dynamic light scattering (DLS) to assess number average diameters (Dn), 
hydrodynamic diameters (Dz), zeta-potentials (ζ) and polydispersities (PDI).
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5.2.1 Co-nanoprecipitation studies of linear polymers and linear-dendritic 
hybrids with EBiB-p(DEA50-co-EGDMA0.95) branched copolymer 
 
Initially, the co-nanoprecipitation strategy was studied in combination with the 
pH-responsive branched copolymer EBiB-p(DEA50-co-EGDMA0.95) using the linear 
polymer EBiB-p(DEA50) and linear-dendritic polymer hybrid, AmG2-p(DEA50) 
(Figure 5.3). Each linear polymer component was co-nanoprecipitated with the EBiB-
p(DEA50-co-EGDMA0.95) into 10 mL of deionised water at pH = 7.8.  Both 
combinations formed stable uniform NPs in aqueous media and were analysed by DLS 
(Table 5.1). Upon inspection by DLS, both co-nanoprecipitations formed monomodal, 
stable NP dispersions (Figure 5.4).
 
Figure 5.3 Diagrammatic representation of the co-nanoprecipitation of AmG2-p(DEA50) (i) and 
EBiB-p(DEA50-co-EGDMA0.95) (ii) at 10:90 wt% to produce stable NPs in neutral water at a 
concentration of 1 mg mL-1. 
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Table 5.1 DLS analysis for co-nanoprecipitated particles formed from linear and linear-dendritic 
polymers and branched copolymers at 90:10 wt% (linear:branched) in aqueous media pH=7.8. 
Branched Polymer Linear Polymer Dz (nm) PDI Dn (nm) ζ (mV) 
- EBiB-p(DEA50) 47 0.249 24 +23 
- AmG2-p(DEA50) 65 0.381 12 +19 
- BnG2-p(DEA50) 48 0.348 14 +45 
- EBiB-p(HPMA50) 780 0.230 654 -34 
- AmG2-p(HPMA50) - - - -
EBiB-p(DEA50-co-
EGDMA0.95) 
- 139 0.087 102 +34 
EBiB-p(HPMA-co-
EGDMA0.95) 
- 178 0.082 145 -20 
EBiB-p(tBuMA50-co-
EGDMA0.95) 
- - - - - 
EBiB-p(DEA50-co-
EGDMA0.95) 
EBiB-p(DEA50) 38 0.227 20 +38 
AmG2-p(DEA50) 43 0.171 24 +28 
EBiB-p(HPMA-co-
EGDMA0.95) 
EBiB-p(HPMA50) 161 0.086 124 -34 
AmG2-p(HPMA50) 210 0.072 187 -21 
EBiB-p(DEA50) 136 0.094 99 +48 
AmG2-p(DEA50) 144 0.102 106 +52 
EBiB-p(tBuMA50-co-
EGDMA0.95) 
EBiB-p(DEA50) 192 0.109 151 +40 
AmG2-p(DEA50) 234 0.051 216 +40
BnG2-p(DEA50) 168 0.131 116 +38 
1 Italics indicates a bimodal size distribution measured by DLS.  
2 – indicates failure to form stabilised NPs with observable macroscale precipitation. 
 
 
Figure 5.4 DLS size distribution analysis of co-nanoprecipitated particles comprised of EBiB-p(DEA-
co-EGDMA0.95) with EBiB-p(DEA50) (green) and AmG2-p(DEA50) (red) in neutral water at a 
concentration of 1 mg mL-1. 
CHAPTER 5 
206
The formation of monomodal size distributions suggests that the co-nanoprecipitation 
occurs via a controlled self-assembly. Comparatively, neither the EBiB-p(DEA50) nor 
AmG2-p(DEA50) produced stable NP dispersions independently, confirmed by bimodal 
and broad size distributions (Table 5.1), suggesting a clear and active contribution to the 
co-nanoprecipitation approach by the branched polymer component. In contrast, the 
nanoprecipitation of both EBiB-p(DEA50-co-EGDMA0.95) and AmG2-p(DEA50-co-
EGDMA0.9) produced larger, well-defined nanoprecipitates with narrow size 
distributions which indicates that the linear and linear-dendritic polymers are also key to 
the process. In this instance, the preliminary studies suggest a covalently-bound dendron 
chain end produces NPs via a more controlled aggregation than the co-nanoprecipitation 
approach. The presence of independent linear and branched DEA-containing polymers 
may allow for a variety of outcomes and consequently broad polydispersities. 
 
5.2.2 Co-nanoprecipitation studies of linear polymers and linear-dendritic 
hybrids with EBiB-p(HPMA50-co-EGDMA0.95) hydrophobic copolymer 
 
Following the different behaviour and NP size outcomes from nanoprecipitations of 
covalently dendron-bound AmG2-p(DEA50-co-EGDMA0.9) and co-nanoprecipitation of 
AmG2-p(DEA50) with EBiB-p(DEA50-co-EGDMA0.95), co-nanoprecipitation of linear-
dendritic hybrid polymers and branched copolymers containing HPMA was investigated. 
This allowed comparison of the behaviour of other polymer compositions when the chain 
end was covalently-bound or co-nanoprecipitated with the branched copolymer. Initially, 
co-nanoprecipitation was carried out through combination of the branched, hydrophobic 
copolymer EBiB-p(HPMA50-co-EGDMA0.95) with EBiB-p(HPMA50) and AmG2-
p(HPMA50), previously reported in Chapter 2, at two different linear:branched polymer 
ratios; 50:50 and 10:90 wt% (Figure 5.5). The 50:50 wt% combination failed to produce 
stable NPs, with considerable macroscale precipitation witnessed. The combination 
carried out at 10:90 wt% formed stable uniform NPs in aqueous media (Table 5.1 and 
Figure 5.6). 
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Figure 5.5 Diagrammatic representation of the co-nanoprecipitation of AmG2-p(HPMA50) (i) and 
EBiB-p(HPMA50-co-EGDMA0.95) (ii) at 10:90 wt% to produce stable NPs in neutral water at a 
concentration of 1 mg mL-1. 
 
 
Figure 5.6 DLS size distribution analysis of co-nanoprecipitated EBiB-p(HPMA-co-EGDMA0.95) 
with EBiB-p(HPMA50) (blue) and AmG2-p(HPMA50) (red) in neutral water at a concentration of 1 mg 
mL-1. 
 
The notably narrow PDI values measured by DLS suggest that the EBiB-initiated linear 
material has solely formed uniform mixed NPs with the branched, hydrophobic 
copolymer, as this material generates very large and unstable NPs when nanoprecipitated 
alone (Chapter 2). The monomodal size distributions also confirms the presence of one 
main size distribution, again supporting the co-nanoprecipitation mechanism as the 
EBiB-p(HPMA50) will independently form nanoprecipitates with Dz = 780 nm and PDI = 
0.230; no evidence of very large nanoprecipitates of this size was seen (Figure 5.6). The 
AmG2-p(HPMA50) failed to form NPs in pH=7.8 when nanoprecipitated alone; however, 
when combined with the EBiB-p(HPMA50-co-EGDMA0.95) no macroscale precipitation 
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was observed. The NPs containing AmG2-p(HPMA50) produced larger NPs than those 
co-nanoprecipitated particles containing EBiB-p(HPMA50); compared to the opposing 
trend observed with the individual nanoprecipitation of the branched EBiB-p(HPMA50-
co-EGDMA0.95) and hyp-polydendron AmG2-p(HPMA50-co-EGDMA0.9) material (NP 
Dz=178 and 149 respectively). 
 
To investigate the observed effects and rule out the potential for the varying polymer 
masses directing the nanoprecipitation results, control experiments were conducted using 
two individual THF solutions of EBiB-p(HPMA50-co-EGDMA0.95) and AmG2-
p(HPMA50) resembling the ratios of branched and linear-dendritic hybrid polymer 
mixtures used in the co-nanoprecipitation experiments. Volumes of branched copolymer 
and linear-dendritic hybrid polymer solutions (5 mg mL-1) of 1.8 mL and 0.2 mL were 
used to mimic the 90:10 wt % ratios of the co-nanoprecipitation experiments; these were 
added dropwise to deionised water in separate vials. Stable NPs (0.9 mg mL-1) were 
formed from EBiB-p(HPMA50-co-EGDMA0.95) as expected, with Dz and PDI values 
similar to NPs formed at a concentration of 1 mg mL-1 (Dz = 165 nm, PDI = 0.086). The 
AmG2-p(HPMA50) linear-dendritic hybrid, however, failed to form stable NPs at 0.1 mg 
mL-1 and resulted in macroscale precipitation. As already discussed, the linear-dendritic 
hybrids tend to form smaller nuclei in the changing solvent system and, therefore, 
aggregate to larger sizes. AmG2-p(HPMA50) also previously failed to produce stable NPs 
in neutral water in previous studies (Chapter 2), suggesting that the combination of 
AmG2-p(HPMA50) with the branched copolymer allows formation of stabilised NPs and 
a direct interaction between the two materials is seen. 
 
Negative ζ values were once again obtained for all NPs formed, in concordance with 
previous reports of the adsorption of hydroxide ions at the hydrophobic/water interface3 
and lack of protonation of the amine functionalities at pH = 7.8. 
 
In addition, the combination of two branched polymers within a co-nanoprecipitation 
process was studied. EBiB-p(HPMA50-co-EGDMA0.95) and AmG2-p(HPMA50-co-
EGDMA0.9) were co-nanoprecipitated into deionised water at pH = 7.8 at a branched 
copolymer:hyp-polydendron ratio of 90:10 wt% to match the previous experiments. 
Stable NPs (Dz=595 nm, PDI=0.213 and ζ=-17 mV) were formed. This is not unexpected 
as both branched polymers previously formed stable NPs independently (Chapter 2); 
however, the larger size suggested an indication that the mixing of the polymer structures 
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during nanoprecipitation was more hindered than the relatively simple incorporation of 
the linear-dendritic hybrids. 
 
Following the preparation of stable NPs across the range of statistical hyp-polydendrons 
comprising varying DEA and HPMA molar ratios (Chapter 4), co-nanoprecipitation was 
carried out between combinations of EBiB-p(HPMA50-co-EGDMA0.95) and either EBiB-
p(DEA50) or AmG2-p(DEA50) (Figure 5.7).  
 
Figure 5.7 Diagrammatic representation of the co-nanoprecipitation of AmG2-p(DEA50) (i) and 
EBiB-p(HPMA50-co-EGDMA0.95) (ii) at 10:90 wt% to produce stable NPs in neutral water at a 
concentration of 1 mg mL-1. 
 
This allowed for the formation of NPs containing similar chemical compositions to the 
statistical DEA/HPMA-containing hyp-polydendrons, where comparisons could be 
drawn between covalently-bound and combination materials and their self-assembled 
particles. Additionally, it was hypothesised that a pH-response could be introduced into 
the co-nanoprecipitated particles. EBiB-p(DEA50) and AmG2-p(DEA50) were 
independently co-nanoprecipitated with EBiB-p(HPMA50-co-EGDMA0.95) into deionised 
water (pH = 7.8) and stable NPs indeed formed for both combinations (Figure 5.8 and 
Table 5.1).  
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Figure 5.8 DLS size distribution analysis for co-nanoprecipitated EBiB-p(HPMA-co-EGDMA0.95) 
with EBiB-p(DEA50) (green) and AmG2-p(DEA50) in pH=7.8 (red) in neutral water at a concentration 
of 1 mg mL-1. 
 
The NPs formed from the co-nanoprecipitation of either EBiB-p(DEA50) or AmG2-
p(DEA50) with EBiB-p(HPMA50-co-EGDMA0.95) formed stable NPs with narrow 
polydispersities and highly positive ζ values; both Dz and Dn size values were essentially 
identical (Dz=136 and 144 nm respectively). The positive ζ values and the near identical 
size distributions indicates the influence of the p(DEA) chains, as seen in other 
nanoprecipitations of DEA-containing materials, and not observed when the amine-
functional dendron alone is present; these values were greater than those observed for the 
nanoprecipitates of statistical hyp-polydendrons, suggesting a high density of the linear 
DEA polymer chains at the surface of the particles. 
 
5.2.3 Co-nanoprecipitation studies of linear and linear-dendritic polymers with 
EBiB-p(tBuMA50-co-EGDMA0.95) 
 
The successful co-nanoprecipitation of various combinations of linear and linear-
dendritic polymers with branched copolymers suggested the potential to produce stable 
NPs of tBuMA-containing polymers in neutral water; these had failed to do so previously 
as reported in Chapter 4. Initially, either the linear polymer EBiB-p(tBuMA50) or the 
linear-dendritic polymer AmG2-p(tBuMA50) was co-nanoprecipitated with EBiB-
p(tBuMA50-co-EGDMA0.95) in aqueous media pH=7.8 (Figure 5.9). 
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Figure 5.9 Diagrammatic representation of the co-nanoprecipitation of AmG2-p(tBuMA50) (i) and 
EBiB-p(tBuMA50-co-EGDMA0.95) (ii) at 10:90 wt% in an attempt to produce stable NPs in neutral 
water at a concentration of 1 mg mL-1. 
 
A stable NP dispersion failed to form for either, resulting in macrophase separation. This 
was, perhaps, not surprising as all polymers failed to produce stable NPs during previous 
nanoprecipitation studies (Chapter 4). 
 
The positive impact of p(DEA) chains in previous studies of co-nanoprecipitation 
suggested that the production of stable NPs in aqueous media from hydrophobic EBiB-
p(tBuMA50-co-EGDMA0.95) may be improved by inclusion of EBiB-p(DEA50) or the 
linear-dendritic polymer hybrid AmG2-p(DEA50). It was hypothesised that a fraction of 
the p(DEA) chains may ultimately reside close to the surface of the NP and provide 
charge stabilisation as seen in studies of p(HPMA)-containing materials (Figure 5.10). 
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Figure 5.10 Diagrammatic representation of the co-nanoprecipitation of AmG2-p(DEA50) (i) and 
EBiB-p(tBuMA50-co-EGDMA0.95) (ii) at 10:90 wt% to produce stable NPs in neutral water at a 
concentration of 1 mg mL-1. 
 
Both experiments were successful, generating NPs with similar Dz values of 192 nm and 
234 nm from co-nanoprecipitates containing EBiB-p(DEA50) or AmG2-p(DEA50) 
respectively. The combination containing the linear-dendritic polymer hybrid was 
slightly larger than the non-dendritic material, possibly due to arrangement of dendrons 
on the NP surface or packing within the NP; however, the NP comprising AmG2-
p(DEA50) displayed a narrower size distribution (Figure 5.11A). Both NPs exhibited 
highly positive ζ values, as seen in previous experiments, but interestingly the linear 
DEA materials and EBiB-p(tBuMA50-co-EGDMA0.95) have all previously failed to 
generate uniform nanoprecipitates. 
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Figure 5.11 A) DLS size distribution analysis of EBiB-p(tBuMA50-co-EGDMA0.95) with EBiB-
p(DEA50) (green) and AmG2-p(DEA50) (red); and B) SEM image of co-nanoprecipitated AmG2-
p(DEA50) with EBiB-p(tBuMA50-co-EGDMA0.95) in neutral water at a concentration of 1 mg mL-1. 
 
Comparatively, the statistical and block DEA and tBuMA hyp-polydendrons with an 
average degree of polymerisation = 50 primary polymer chains for all varying 
DEA:tBuMA compositions failed to create stable NP dispersions in pH=7.8 and the 
requirement of additional charge by nanoprecipitating into aqueous HCl was essential to 
eventually produce stable NPs (Figure 5.12i). To combat this, a hyp-polydendron with 
an increased primary polymer chain length, AmG2-p(DEA50-b-(tBuMA65-co-
EGDMA0.9)), was synthesised and the resulting NPs were stable in neutral water (Figure 
5.12ii). The co-nanoprecipitation of AmG2-p(DEA50) with EBiB-p(tBuMA50-co-
EGDMA0.95) produced nanoprecipitates, that are possibly not too dissimilar to the 
AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) as the combination of the two polymers 
of significant block length successfully produced NPs, albeit, of larger sizes (Figure 
5.12iii). 
 
CHAPTER 5 
214
 
 
Figure 5.12 Diagrammatic representation of NP aggregations of A) AmG2-p(DEA25-b-(tBuMA25-co-
EGDMA0.9)) in pH=4; B) AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) in pH=7.8 and; C) Co-
nanoprecipitated AmG2-p(DEA50) with EBiB-p(tBuMA50-co-EGDMA0.95) in pH=7.8. 
 
The impact of the presence of the dendron chemistry within the linear-dendritic hybrid 
on co-nanoprecipitation was studied by utilising a combination of BnG2-p(DEA50) 
(Chapter 3) with EBiB-p(tBuMA50-co-EGDMA0.95). Experiments were conducted using 
deionised water (pH=7.8) and aqueous HCl (pH=4) and stable NPs were produced in 
both aqueous environments. The BnG2-p(DEA50) exhibited a bimodal size distribution 
when nanoprecipitated independently (Table 5.1).  
 
In a comparative study, the EBiB-p(tBuMA50-co-EGDMA0.95) failed to form stable co-
nanoprecipitates with either EBiB-p(DEA50) or AmG2-p(DEA50) in acidic water, due to 
the solubilisation of the linear DEA polymer and linear-dendritic DEA hybrid at low pH. 
This indicates the importance of the collapse of the linear polymer chains and co-
nanoprecipitation, and not just the simple surface adsorption of polymer chains to the 
growing NPs during the nanoprecipitation process. In comparison, the large hydrophobic 
benzyl-functional dendritic chain end on the BnG2-p(DEA50) prevents solubilisation of 
the polymer in aqueous HCl, therefore, offering the potential to yield stable 
nanoprecipitates within different pH environments. Indeed, the co-nanoprecipitation of 
BnG2-p(DEA50) with EBiB-p(tBuMA50-co-EGDMA0.95) led to self-assembled NPs in 
water at both pH = 4 (Dz=165 nm, PDI=0.140, Dn=120 nm, ζ=+68 mV) and 7.8 (Table 
5.1). The co-nanoprecipitates were nearly identical in size with similar size distributions 
(Dz=168 nm at pH = 7.8; 165 nm at pH = 4). Both NP dispersions had highly positive ζ 
values suggesting the presence of protonated linear DEA chains at the nanoprecipitate 
surface, and potentially entrapped hydrophobic chain ends within the nanoprecipitate 
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bulk. The NPs in acidic water exhibited a more positive ζ value due to the increased 
abundance of H+ ions in this media, offering increased levels of protonation of the linear 
DEA polymer chains.  
 
5.3 Co-nanoprecipitation studies of linear and linear-dendritic 
polymers containing tBuMA with EBiB-p(tBuMA50-co-EGDMA0.95) 
in acidic water 
 
Following the unsuccessful production of NPs via co-nanoprecipitation of EBiB-
p(tBuMA50-co-EGDMA0.95) using deionised water (Section 5.2.3), the branched 
copolymer was co-nanoprecipitated with EBiB-p(tBuMA50) and AmG2-p(tBuMA50) into 
acidic water. Only the co-nanoprecipitation containing AmG2-p(tBuMA50) successfully 
produced NPs (Table 5.2 and Figure 5.13), due to the ability of the dendron chain end to 
protonate at low pH. 
 
Table 5.2 DLS analysis for co-nanoprecipitated particles formed from linear/linear-dendritic DEA 
polymers and EBiB-p(tBuMA-co-EGDMA0.95) in acidic water. 
Branched Polymer Polymer Dz (nm) PDI Dn (nm) ζ (mV) 
 EBiB-p(tBuMA50) - - - - 
 AmG2-p(tBuMA50) 104 0.250 43 +46 
 EBiB-p(tBuMA50-co-
EGDMA0.95) 
- - - - 
EBiB-p(tBuMA50-co-
EGDMA0.95) 
EBiB-p(tBuMA50) - - - - 
AmG2-p(tBuMA50) 161 0.114 114 +46 
1 – indicates failure to form stabilised NPs with observable macroscale precipitation. 
 
The failure to form stabilised NPs from the co-nanoprecipitation of EBiB-p(tBuMA50-
co-EGDMA0.95) and AmG2-p(tBuMA50) in neutral water confirms the necessity of 
charge stabilisation, which is delivered by the protonated dendron when utilising an 
acidic anti-solvent environment and has also been observed for the AmG2-p(tBuMA50-
co-EGDMA0.9) hyp-polydendron (Dz=233 nm, PDI=0.295) and AmG2-p(tBuMA50) 
linear-dendritic polymer forming stable NPs in acidic water (Dz=104 nm, PDI=0.250). A 
narrow size distribution was obtained by DLS, compared to the broad size distributions 
measured for the amine-functionalised materials nanoprecipitated independently. 
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Figure 5.13 DLS size distribution analysis (A) and SEM image (B) of co-nanoprecipitated AmG2-
p(tBuMA50) and EBiB-p(tBuMA50-co-EGDMA0.95) in aqueous HCl (1 mg mL-1). 
 
In previous reports of hyp-polydendron synthesis, mixed initiators have been used to 
tailor the chain-end functionality and provide systematically varying behaviour from 
nanoprecipitated materials.4 The stabilisation of EBiB-p(tBuMA50-co-EGDMA0.95) 
nanoprecipitates at low pH using co-nanoprecipitation with a linear-dendritic polymer 
hybrid, suggested that a branched tBuMA-containing copolymer, synthesised using a 
mixed EBiB and AmG2-Br initiation (Chapter 3) may also be able to form stable NPs 
using a conventional single component nanoprecipitation into acidic media. The 
resultant polymer, EBiB0.9-(AmG2)0.1-p(tBuMA50-co-EGDMA0.95) underwent 
nanoprecipitation into deionised water and aqueous HCl and stable NPs failed to form in 
either pH environment.  
 
Nanoprecipitation was then conducted in highly acidic water (pH = 2), and stable NPs 
(Dz = 204 nm; PDI=0.202) were produced. The lower pH requirement may indicate that 
very few dendron chain ends were available at the nanoprecipitate surface. A large 
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amount of chain-ends are situated within the main bulk of the nanoprecipitate after the 
assembly of nuclei and unimers and a significant number if dendrons would be lost and 
incapable of contributing to the charge stabilisation. This would also suggest a more 
efficient dendron chain end arrangement on the nanoprecipitate surface from the linear-
dendritic hybrid upon co-nanoprecipitation. The NPs exhibited a ζ=+58 mV, further 
suggesting nanoprecipitate stabilisation from surface charge but the increased acidity 
may be required to fully protonate the available dendrons. 
 
5.4 pH-responsive studies of co-nanoprecipitated NPs prepared in 
neutral water 
 
Following the successful incorporation of a pH-responsive linear or linear-dendritic 
polymer into a variety of co-nanoprecipitated particles, the effect of acid addition to the 
resultant NPs was investigated. Initially, EBiB-p(DEA50) or AmG2-p(DEA50) co-
nanoprecipitated with EBiB-p(DEA50-co-EGDMA0.95) was studied and comparisons 
were made to similarly composed polymeric NPs formed in Chapter 4, where all 
components were covalently-bound.  
 
The rapid addition of acid (1M HCl) to the NPs prepared from either EBiB-p(DEA50) or 
AmG2-p(DEA50) co-nanoprecipitated with EBiB-p(DEA50-co-EGDMA0.95) (Table 5.3) 
led to complete solubilisation of both the linear and branched DEA component, 
confirmed by the decrease in Dn and derived count rate (DCR) values (Table 5.3). This 
behaviour was equally observed for the nanoprecipitates comprised solely of EBiB-
p(DEA50-co-EGDMA0.95) and AmG2-p(DEA50-co-EGDMA0.9). 
 
Table 5.3 DLS analysis following rapid addition of acid to particles prepared from EBiB- and AmG2-
p(DEA50) co-nanoprecipitated with EBiB-p(DEA50-co-EGDMA0.95). 
  pH = 7.8a  + acidb  
Branched 
Polymer 
p(DEA50) 
Dz 
(nm) 
PDI 
Dn 
(nm) 
DCR 
(kcps) 
Dz 
(nm) 
PDI 
Dn 
(nm) 
DCR 
(kcps) 
EBiB-
p(DEA50-co-
EGDMA0.95) 
EBiB- 38 0.227 20 4500 138 0.357 12 750 
AmG2- 43 0.171 24 9100 79 0.295 5 570 
a Initial pH 
b Addition of 35 μL HCl (aq.) (1M) 
1 Italics indicate a bimodal size distribution measured by DLS. 
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The pH-response of the EBiB-p(DEA50) and AmG2-p(DEA50) co-nanoprecipitated with 
EBiB-p(HPMA50-co-EGDMA0.95) was also investigated via rapid addition of acid (1M 
HCl). The statistical p(DEAx-co-HPMAy-co-EGDMA0.9) hyp-polydendron NPs were 
fully soluble in aqueous solution at low pH confirmed by increased PDI values and 
decreased Dn size values (Chapter 4). Upon the addition of acid to the co-
nanoprecipitated NP dispersions (Figure 5.14A) large aggregates were formed resulting 
in macroscale precipitation (Figure 5.14B). 
 
Figure 5.14 Photographs of co-nanoprecipitated AmG2-p(DEA50) with EBiB-p(HPMA50-co-
EGDMA0.95) NP dispersion in neutral water at a concentration of 1 mg mL-1. A) Stable, cloudy NP 
dispersion before acid addition. B) Large, polymeric aggregates precipitating out of solution upon acid 
addition. 
 
Upon acid addition, the linear-dendritic polymer of the co-nanoprecipitated system was 
solubilised and, therefore, unable to stabilise the EBiB-p(HPMA50-co-EGDMA0.95), 
which as previously demonstrated in Chapter 2, is not stable in acidic conditions. The 
EBiB-p(HPMA50-co-EGDMA0.95), therefore, aggregates to such a large size that it 
precipitates out of solution, which is due to a lack of stability. The co-nanoprecipitation 
of EBiB-p(HPMA50-co-EGDMA0.95) with linear DEA, provides a facile route to produce 
pH-triggered NPs with a hydrophobic branched core, however, the large polymeric 
aggregates produced upon acid addition are potentially problematic in the area of drug 
delivery, with concerns of effective clearance from the body. The potential to form 
wholly soluble molecules upon changes in pH is more attractive when considering 
excretion routes.5 NPs are filtered out through either the glomerular capillary or remain 
within the vasculature, depending on their properties.6 During extraction, they pass 
through several layers of cells which can filter materials up to sizes of 43 nm, however, 
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the functional or physiologic pore size is only around 5 nm.7 
 
Following this, the pH-response of the co-nanoprecipitated NPs consisting of EBiB-
p(tBuMA50-co-EGDMA0.95) stabilised by EBiB-, AmG2- and BnG2-p(DEA50) prepared 
in neutral water were subjected to the rapid addition of acid (1M HCl) (Table 5.4). Upon 
the addition of acid to nanoprecipitates formed from AmG2-p(DEA50-b-(tBuMA65-co-
EGDMA0.9)), the NPs remained stable. As previously observed, the DEA/HPMA-
containing co-nanoprecipitates underwent observable precipitation following dissolution 
of the linear-dendritic DEA polymer hybrid, compared to the covalently-bound statistical 
AmG2-p(DEAx-co-HPMAy-co-EGDMA0.9) NPs becoming soluble in low pH.  
 
Initially, the addition of acid (36 μL 1M HCl aq.) was administered to the EBiB-
p(tBuMA50-co-EGDMA0.95) co-nanoprecipitated with the EBiB-p(DEA50) and AmG2-
p(DEA50). Both NP dispersions continued to exist as self-assembled nanoprecipitates. 
The Dz size values obtained for AmG2-p(DEA50):EBiB-p(tBuMA50-co-EGDMA0.95) 
NPs remained completely unchanged (Table 5.4), and the EBiB-p(DEA50):EBiB-
p(tBuMA50-co-EGDMA0.95) NPs swelled slightly from DEA protonation on the 
nanoprecipitate surface, as previously witnessed in Chapter 2. 
 
Table 5.4 DLS analysis for co-nanoprecipitated particles formed from linear DEA polymer and 
linear-dendritic DEA hybrids with EBiB-p(tBuMA-co-EGDMA0.95) following the addition of acid. 
 
 pH = 7.8a 
+1M HClb  
(Final pH 3.0-3.2) 
+1M HClc  
(Final pH 3.0-3.2) 
pH = 1.7-1.9 
(24 hours) 
Branched 
polymer p(DEA50) 
Dz 
(nm) 
PDI Dz (nm) PDI Dz (nm) PDI 
Dz 
(nm) 
PDI 
EBiB-
p(tBuMA-co-
EGDMA0.95) 
EBiB- 192 0.109 214 0.110 1010 0.667 - - 
AmG2- 234 0.051 233 0.090 269 0.115 908 0.710 
BnG2- 168 0.131 - - 203 0.210 197 0.115 
a Initial pH, b 35 μL, c 350 μL 
1 Italics indicates a bimodal size distribution measured by DLS. 
2 – indicates no measurement. 
 
In order to encourage hydrolysis of these NPs, more acid was administered (350 μL, 1M 
HCl (aq.)). This was enough to fully solubilise the EBiB-p(DEA50), causing macroscale 
precipitation of the EBiB-p(tBuMA50-co-EGDMA0.95) (Figure 5.15A) due to EBiB-
p(tBuMA50-co-EGDMA0.95) previously demonstrating poor stability in any form of 
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aqueous media (Chapter 4). The AmG2-p(DEA50):EBiB-p(tBuMA50-co-EGDMA0.95) 
nanoprecipitates, however, retained stability and experienced an increase in particle size 
due to swelling of the NPs (Table 5.4 and Figure 5.15B). 
 
 
 
Figure 5.15 DLS size distribution analysis for co-nanoprecipitated particles formed from EBiB-
p(tBuMA50-co-EGDMA0.95) with linear and linear-dendritic DEA polymers. A) EBiB-p(DEA50) and 
EBiB-p(tBuMA50-co-EGDMA0.95) before (green) and after addition of 35 μL (red) and 350 μL (red-
dotted) 1M HCl (aq.); B) AmG2-p(DEA50) and EBiB-p(tBuMA50-co-EGDMA0.95) before (green) and 
after addition of 350 μL HCl (1M, aq.) (red) and after 24 hours (red-dotted); C) BnG2-p(DEA50) and 
EBiB-p(tBuMA50-co-EGDMA0.95) before (purple) and after 24 hours following the addition of acid 
350 μL 1M HCl (aq.) (red). 
 
The highly acidic NP dispersion was left over 24 hours and particle size was analysed, 
confirming the eventual solubilisation of the linear-dendritic polymer hybrid and the 
existence of large EBiB-p(tBuMA50-co-EGDMA0.95) precipitates (Figure 5.15B). These 
observations suggest higher levels of protonation are required to solubilise the increased 
amount of tertiary amine groups within the AmG2-p(DEA50). The prolonged exposure to 
acid also suggests inaccessible dendron chain ends within the main bulk of the 
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nanoprecipitate and suggest that it is the protonation of the amine functional groups 
which finally achieves solubilisation. 
 
Upon the addition of acid to co-nanoprecipitated BnG2-p(DEA50):EBiB-p(tBuMA50-co-
EGDMA0.95), the NPs experienced swelling due to protonation of the DEA chain on the 
nanoprecipitate surface (Table 5.4 and Figure 5.15C). After 24 hours, the NPs remained 
intact, suggesting continued stabilisation of the nanoprecipitates from the BnG2-
p(DEA50) from a lack of protonation and a stabilised combination of polymers. 
 
5.5 Conclusions 
 
The co-nanoprecipitation concept provides a relatively facile technique to produce 
stabilised polymer nanoprecipitates. Overall, the co-nanoprecipitated particles prepared 
with linear-dendritic polymers produced nanoprecipitates that were noticeably different 
compared to the nanoprecipitates prepared from similarly composed hyp-polydendrons. 
Independently, the linear-dendritic polymers generally failed to produce stable NP 
dispersions in neutral water when nanoprecipitated alone. The facile construction of NPs 
via co-nanoprecipitation produces a hydrophobic domain, with the opportunity to 
introduce specific characteristics and easily tailored surface functionality, to provide 
eventual enhanced stability. The stabilisation of EBiB-p(tBuMA50-co-EGDMA0.95), 
achieved by co-nanoprecipitation with p(DEA50), provides the first example within this 
project of stabilised p(tBuMA50-co-EGDMA0.95) NPs in neutral water. Additionally, a 
pH-response was introduced into the NP system, where a slower solubilisation of the pH-
responsive AmG2-p(DEA50) was observed compared to the particles containing EBiB-
p(DEA50). The lack of solubilisation upon the addition of acid to particles co-
nanoprecipitated from EBiB-p(tBuMA50-co-EGDMA0.95) with BnG2-p(DEA50), provides 
an insight into the close packed arrangement of NPs, and suggests presence of the 
dendron chain end within the main bulk of the nanoprecipitate. 
 
The endurance of these co-nanoprecipitated NPs within different environments is 
essential should drug delivery application be considered. These studies provide an initial 
insight into how NPs behave differently depending on whether surface functionality is 
covalently bound or not. 
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5.6 Experimental 
 
Typical procedure for aqueous nanoprecipitation – The materials were dissolved in 
acetone/THF at a concentration of 5 mg mL-1. 2 mL of this solution was then subjected to 
a rapid solvent switch through drop wise addition into 10 mL of water, to give a final 
polymer NP concentration of 1 mg mL-1 in water after acetone/THF removal by 
evaporation overnight. 
 
Typical procedure for aqueous co-nanoprecipitation – The linear/linear-dendritic 
polymer solution (5 mg mL-1, 0.2 mL) and branched copolymer/hyp-polydendron 
solution (5 mg mL-1, 1.8 mL) were combined (2 mL) prior to a rapid solvent switch 
through drop wise addition into 10 mL of water, to give a final polymer NP 
concentration of 1 mg mL-1 in water after acetone/THF removal by evaporation 
overnight. 
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6.1 Introduction 
 
The human immunodeficiency virus (HIV) is transmitted via contact with infected 
blood1 or through unprotected sex with an infected person.2,3 It initially infects dendritic 
cells, that consequently transport the virus into the lymphatic system to infect CD4+ T 
cells (a cytotoxic T lymphocyte that directly kill virally infected cells and produce and 
release antiviral cytokines) (Chapter 1, Section 1.1.1).4 The virus can reside in 
reservoirs, such as monocytes and macrophages,5 or in cells and tissues (known as 
sanctuary sites) that are inaccessible to drugs within the systemic circulation;6 current 
anti-retroviral therapies (ART) aim to reduce the viral levels in the blood. Ideally, a 
more effective treatment method would allow penetration of the sanctuary sites. 
 
ART7 is a combination of drugs that penetrate cells through diffusion or active influx.8 
Many of the drugs are poorly water-soluble,9 resulting in a lack of bioavailability. This 
equates to the need for large doses of administered drug in order to achieve therapeutic 
concentrations in the bloodstream. These drugs lead to a variety of dose-dependent side 
effects10,11 and, additionally, the large pill burden generates a high risk of treatment 
failure, due to poor patient adherence with the subsequent development of viral 
resistance.12 Numerous research efforts into the development of simplified and improved 
dosing regimens have been reported using nanocarrier strategies, particularly to 
overcome drug permeability issues13 and/or target specific cells or tissues.14 
 
The important factors that are considered during the design of drug delivery vehicles 
include: the capacity of the carrier to host an adequate drug payload; optimal release 
kinetics for each drug depending on mechanism and location of release within the body; 
mode of excretion and reactivity of all carrier metabolites.15 Specifically, the association 
of drug to a nanoparticle (NP) may be achieved either covalently or via encapsulation 
and several examples have been produced using many different polymer classes; 
encapsulation is featured in this work.16 
 
NPs possess high surface area to mass ratios, and drug NPs may result in more rapid and 
complete dissolution in the gut lumen and offer an enhanced delivery of an effective 
therapeutic dosage into the systemic system.17,18 In many cases, the modification of drug 
distribution and tissue penetration requires the circulating drug to be present as a NP 
rather than a dissolved drug molecule, and the benefits of nanocarriers are derived from 
the presentation of the drug in a NP format. In general, nanocarriers are injected directly 
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into the bloodstream but orally-dosed NPs that can enter the bloodstream through the 
gut, are a key nanomedicine target globally. This will allow simple oral dosing and 
remove the need for daily injection within a clinical setting.  
 
There are five main routes a NP can utilise to cross the gut epithelium and enter into the 
bloodstream (Figure 6.1). In the case of solid drug NPs, surface adhesion followed by 
subsequent dissolution results in high local concentrations that saturate drug transporters 
(Figure 6.1.1). Solid drug NPs may also become trapped in the mucous resulting in rapid 
dissolution close to the intestinal barrier; again, high local concentrations saturate efflux 
systems (Figure 6.1.2). NPs of various types may avoid transport systems by 
paracellular movement across the intestinal barrier (i.e. between cells); tight junctions 
only allow permeation of small (<100 Da.) sized materials,19 so nanomaterials can be 
functionalised to reversible opening tight junctions (Figure 6.1.3). The particulate nature 
of the NPs may result in endocytosis/phagocytosis by immune cells or enterocytes; this 
leaves potential for entry into the systemic circulation via Peyer’s patches20 (Figure 
6.1.4). Finally NPs may enter the lymphatic system prior to entering the systemic 
circulation21 (Figure 6.1.5), either releasing drug within during this process or after 
prolonged circulation and accumulation. 
?
?
?
Figure 6.1 The five main routes in which a NP can enter the systematic circulation: 1) Surface 
interaction and subsequent dissolution; 2) Saturation of efflux systems: 3) Paracellular movement 
across the intestinal barrier; 4) Peyer’s patches and; 5) Lymphatic system. 
 
Stable NPs have been produced for the majority of the materials synthesised within this 
project (Chapters 4 and 5), with particle sizes, surface charge and varying behaviour in 
aqueous media investigated. A selection of these NP dispersions were taken forward for 
pharmacological testing. A range of pharmacological evaluations were conducted 
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including, modelling the NPs crossing the gut epithelium, predicting the behaviour after 
oral administration, studying cellular uptake and cytotoxicity. These were carried out in 
order to evaluate whether these materials possessed any potential drug delivery benefits. 
The pharmacological experiments were carried out by Dr. Lee Tatham and Prof. Andrew 
Owen in the Department of Molecular and Clinical Pharmacology at the University of 
Liverpool. 
 
Initially, the materials’ stability in the presence of a buffering vehicle media (Transport 
Buffer Solution; TBS) was assessed (Figure 6.2A). The stability in such is essential, as 
pharmacological tests were carried out in this media. TBS contains Hanks Buffer Saline 
Solution (25 mM), Bovine Serum Albumin (0.1% w/v) and is adjusted to pH = 7.4. 
Following this, materials were selected to investigate their loading capabilities with a 
hydrophobic traceable marker, fluoresceinamine (FA), as a surrogate for anti-retroviral 
drugs (Figure 6.2B). The successfully loaded materials were then progressed to in vitro 
pharmacological testing as previously mentioned (Figure 6.2C). The loading capabilities 
of the lead candidate exhibiting the most encouraging behaviour as an orally 
administered NP, was also loaded with an ART drug, Efavirenz (EFV) for future 
evaluations (Figure 6.2D) (cf. Section 6.3.5). 
 
 
Figure 6.2 The progression of selection and assessment for NP dispersions to undergo 
pharmacological testing. A) Addition of transport buffer solution to NP dispersion; B) Investigation 
of loading capabilities of the hydrophobic traceable marker, fluoresceinamine; C) In vitro 
pharmacological testing modelling the gut epithelium and; D) Investigation of loading capability of 
the anti-retroviral drug, Efavirenz. 
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6.2 Stability and encapsulation studies of linear and linear-dendritic 
polymers, branched copolymers and hyp-polydendrons 
 
6.2.1 Stability studies in buffering vehicle media 
 
A majority of the materials that produced monomodal, stable NP dispersions in neutral 
water (Chapters 2, 4 and 5) were subjected to the addition of buffering vehicle media (1 
mL to 10 mL NP dispersion), in order to establish the ability of the nanoprecipitates to 
retain stability in a physiologically-relevant media. This included: all p(HPMA50-co-
EGDMAx), p(DEA50-co-EGDMAx), p(DEAx-co-HPMAy-co-EGDMA0.9), AmG2-
p(DEA50-co-(tBuMA65-co-EGDMA0.9)); and the co-nanoprecipitated EBiB-p(HPMA50-
co-EGDMA0.95):p(HPMA50). Dispersions were adjusted to the physiological pH of 
blood, with TBS acting as a buffering vehicle. The buffering vehicle has no detectable 
impact on the various cells studied, allowing for accurate assessment of the nanocarrier 
effects in vitro. Following TBS addition, the changes in nanoprecipitate structure and 
assembly were investigated by dynamic light scattering (DLS) analysis and compared. In 
cases in which the NPs were unable to retain stability, observable macroscale 
precipitation was witnessed, without the need for DLS measurement, and only those that 
retained stability are shown in Table 6.1. 
 
Table 6.1 DLS analysis of nanoprecipitated and co-nanoprecipitated NP dispersions (10 mL, 1 mg 
mL-1) that remained stable following the addition of transport buffer solution (1 mL). 
 pH=7.8a + TBS (aq.)b 
Polymer 
Dz 
(nm) 
PDI 
Dn 
(nm) 
Dz 
(nm) 
PDI 
Dn 
(nm) 
AmG2-p(HPMA50):EBiB-p(HPMA50-
co-EGDMA0.95) 
210 0.072 187 356 0.126 290 
AmG2-p(DEA50-co-EGDMA0.9) 295 0.159 244 346 0.190 308 
AmG1U-p(DEA50-co-EGDMA0.9) 134 0.148 82 39 0.228 18 
AmG2-p(DEA50-b-(tBuMA65-co-
EGDMA0.9)) 
163 0.082 123 163 0.100 123 
a Initial pH, b TBS (aq.) (1 mL) added to 10 mL (1 mg mL-1) NP dispersion  
 
The only NP dispersion containing HPMA monomer residues that was stable in TBS 
was the co-nanoprecipitated AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95). This 
suggests the presence of the dendron chain end on the nanoprecipitate surface 
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contributes a stabilising effect due to the amine functionality, potentially through the 
positive surface charge and possible small steric repulsion. This demonstrates that the 
dendritic functionality is advantageous, allowing stable NPs to exist in physiologically 
relevant media. The AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95) NPs 
experienced an increase in particle size (210 nm to 356 nm) and size distribution (0.072 
to 0.126), suggesting a slight aggregation under these conditions, possibly as a result of 
charge screening (Figure 6.3A). 
 
 
 
Figure 6.3 DLS size distribution analysis before and after TBS addition. A) AmG2-p(HPMA50): 
EBiB-p(HPMA50-co-EGDMA0.95) before (blue) and after (red-dotted) TBS addition; B) AmG2-
p(DEA50-co-EGDMA0.9) before (green) and after (red-dotted) TBS addition; C) AmG1U-p(DEA50-co-
EGDMA0.9) before (orange) and after (red-dotted) TBS addition; and D) AmG2-p(DEA50-b-
(tBuMA65-co-EGDMA0.9)) before (red) and after (red-dotted) TBS addition. 
 
The NP dispersions containing DEA monomer residues required either AmG1U- or 
AmG2- dendritic surface functionality to retain stabilisation on addition of TBS. The 
AmG2-p(DEA50-co-EGDMA0.9) NPs increased in size (Dz = 346 nm) and broadened in 
size distribution (PDI=0.190) (Figure 6.3B) whilst the AmG1U-p(DEA50-co-EGDMA0.9) 
underwent a decrease in Dz to 45 nm (Figure 6.3C). None of the p(DEAx-co-HPMAy-co-
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EGDMA0.9) NPs retained stability upon the addition of TBS and resulted in large 
polymeric aggregates from uncontrollable precipitation. All these materials contain a 
less positive surface charge (Chapter 4) compared to the p(DEA50-co-EGDMAx) NPs, 
suggesting a reduced level of charge stabilisation unable to withstand variation of 
electrolytes in aqueous media. The AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) 
proved stable suggesting that the increased primary polymer chain length, and 
architecture of linear-dendritic DEA polymer block arms contribute in some manner to 
the NP stabilisation process (Figure 6.3D). Following these simple stability studies, 
these materials underwent pharmacological testing. 
 
6.2.2 Encapsulation studies of a hydrophobic fluorescent marker 
 
Many polymeric drug carriers are designed to target two main administration routes: 
intravenous22 (IV) and oral.23 For the treatment of infectious diseases such as HIV, oral 
administration is preferable due to long-term daily dosing, despite the advantageous 
immediate introduction to the systemic circulation with IV administration. The ability of 
the polymeric particles to be loaded with a hydrophobic fluorescent marker acting as a 
drug model, was assessed. FA was selected for encapsulation due to its hydrophobic 
nature, thereby modelling poorly soluble drugs such as many anti-retroviral drugs. 
 
The NPs were prepared as described in Chapter 4 with dissolution of FA (10 mg) in the 
good solvent (10 mL, producing a 1 mg mL-1 FA solution) before combination with the 
polymeric solutions, and subsequent nanoprecipitation into water; the NP sizes 
containing encapsulated FA are shown in Table 6.2 and the monomodal size 
distributions measured by DLS in Figure 6.4.  
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Table 6.2 DLS analysis of nanoparticles containing encapsulated FA. 
 
 pH=7.8a + FA (9 wt%) 
Polymer 
Dz 
(nm) 
PDI 
Dn 
(nm) 
Dz 
(nm) 
PDI 
Dn 
(nm) 
AmG2-p(HPMA50):EBiB-p(HPMA50-co-
EGDMA0.95) 
210 0.072 187 441b 0.265 247 
AmG2-p(DEA50-co-EGDMA0.9) 295 0.159 244 45c 0.197 28 
AmG1U-p(DEA50-co-EGDMA0.9) 134 0.148 82 59c 0.243 28 
AmG2-p(DEA50-b-(tBuMA65 
-co-EGDMA0.9)) 
163 0.082 26 41c 0.256 26 
a Initial pH, b 0.9 wt% FA loading, c 9 wt% FA loading 
    
 
 
 
Figure 6.4 DLS size by intensity distributions of nanoprecipitated and co-nanoprecipitated particles 
with and without encapsulated FA: A) Blank AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95) 
(blue), and encapsulated FA (0.9 wt%; orange-dotted); B) Blank AmG2-p(DEA50-co-EGDMA0.9) 
(green), and encapsulated FA (9 wt%; orange-dotted); C) Blank AmG1U-p(DEA50-co-EGDMA0.9) 
(orange), and encapsulated FA (9 wt%; orange-dotted); and D) Blank AmG2-p(DEA50-b-(tBuMA65-
co-EGDMA0.9)) (red), and encapsulated FA (9 wt%; orange-dotted). 
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The FA encapsulated NPs for pharmacological studies were prepared at 9 wt% (final 
polymer concentration 1 mg mL-1 and theoretical FA amount 0.1 mg mL-1), apart from 
the co-nanoprecipitated AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95), which 
only managed to encapsulate 0.9 wt% FA following several attempts at higher loading. 
This may suggest a high proportion of dendron is residing within the main bulk of the 
nanoprecipitate aggregations. The polymeric NPs for this study included: a co-
nanoprecipitated NP dispersion comprising of HPMA, two pH-responsive DEA hyp-
polydendrons with varying generation of dendritic amine-functionality and dendron 
linker chemistry, and a block DEA-tBuMA-EGDMA hyp-polydendron. 
 
These collectively produce a combined variation of branched polymer core, polymer 
properties, hyp-polydendron NPs and NPs arranged from a separate linear-dendritic and 
branched polymer, different dendron surface and linker chemistry and different polymer 
architecture, to be assessed in vitro using various pharmacological assays. 
 
6.3 Pharmacological studies of hyp-polydendron and co-
nanoprecipitated NPs containing encapsulated FA 
 
6.3.1 Caco-2 Transcellular Permeation Assays  
 
The oral delivery of polymeric nanocarriers via permeation through the gut epithelium 
into the systemic circulation was investigated, initially to determine whether the 
nanocarrier could permeate the monolayer. Following this, cellular accumulation studies 
were undertaken, and experiments carried out to define what mechanisms were 
responsible for the permeation. 
 
The pharmacological assays performed were selected depending on the potential route 
of administration of the drug delivery vehicle. In the case of orally administered 
therapeutics, the Caco-2 (human epithelial colorectal adenocarcinoma) transcellular 
permeability assay is typically used to predict the permeability of materials across a 
model intestinal monolayer.24 This assay was adopted for this project in order to 
evaluate the potential permeation of the selected nanoprecipitated and co-
nanoprecipitated NPs. 
 
The Caco-2 cell line can be cultured to differentiate and become polarised to model the 
intestinal epithelial cells.25 It is important to consider, however, that Caco-2 cells do not 
form as tight monolayers as those found in vivo, with paracellular (between cells) 
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permeation reported for several NP systems.26  Additionally, the expression levels of the 
cell enzymes are highly unlikely to identically mimic those in the human body.27 Despite 
this, the movement of drug across the monolayer is predominantly restricted to 
permeation or active transport through the cells,28 and subsequent supporting cellular 
accumulation studies are carried out to help determine the mechanisms responsible.
 
A graphical representation of the transwell experiment is shown in Figure 6.5, with the 
apical (A) and basolateral (B) chambers shown either side of the epithelial monolayer 
and supporting membrane. The (A) chamber represents the gut side of the epithelium, 
whilst the (B) chamber represents the blood side of the epithelium. The experiment was 
conducted through incubation of the monolayer with the sample added to the (A) 
compartment, measuring the amount of movement across the monolayer over a 4 hour 
period from the A to B compartment (A>B); subsequent measurements were made by 
adding sample to the B compartment and monitoring the movement of sample from the 
B to A compartment (B>A).  
 
 
Figure 6.5 Transwell experiment setup showing apical and basolateral chambers separated by Caco-2 
cell monolayer. 
The movement of sample across the membrane is typically reported as apparent 
permeability (pApp), which describes the flux at which the material traverses per unit 
area of the cell barrier.29 pApp is estimated using equation 6.1: where pApp is apparent 
permeability (cm s-1); dQ/dt is the rate of transport (nM min-1); v is the volume of the 
receiver compartment; A is the surface area of the membrane (cm2); and C0 is the initial 
donor concentration. 
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Equation 6.1 Calculation of apparent permeability where pApp is apparent permeability (cm s-1); 
dQ/dt is the rate of transport (nM min-1); v is the volume of the receiver compartment; A is the surface 
area of the membrane (cm2); and C0 is the initial donor concentration. 
 
Several assumptions are made for an accurate measure of permeability.30 These include 
assumptions that the drug accumulated in the receiver compartment is proportional to 
time; “sink conditions” are compliant; and that cellular accumulation, metabolism and 
nonspecific binding to plastic-ware are absent. “Sink conditions” implies that once the 
material has traversed the monolayer it will not pass back across, however, this is not 
always the case with highly permeable materials. 
 
The behaviour of the materials was investigated with respect to the impact of variation 
within their structural components. First, permeation across the Caco-2 in vitro model of 
human gut epithelium. This would allow a proof-of-concept to be developed for the 
synthesis and potential application of these novel systems. 
 
6.3.1.1 Monolayer Integrity Assessment 
 
The first experiment conducted was to assess the potential of the FA loaded NPs to 
compromise the cell monolayer as damage to the epithelium model will lead to a false 
assessment of permeation. To allow for comparisons, an “aqueous solution” of FA was 
prepared to mimic the permeation of un-encapsulated FA as a control; due to the 
insolubility of FA in water, FA was dissolved in dimethyl sulfoxide (DMSO) and 
subsequently used to spike TBS, so that < 0.5 vol% DMSO was present within the total 
aqueous volume. 10 μM of FA loaded co-nanoprecipitated, nanoprecipitated materials or 
10 μM aqueous FA were added to the A or B chamber of the wells to quantify transport 
in both the A>B and B>A directions, and the plates were sampled 4 hours after 
incubation.  
 
To assess the monolayer integrity following incubation, 100 μL of TBS containing 
2?μL/mL 14C mannitol (0.2 µCi/100 µL) was added to the A compartment and incubated 
for 1 hour. Scintillation fluid (4 mL) was added to 100 μL of both A and B sampled 
contents and quantified on the scintillation counter (Packard Tri-Carb 3100 Liquid 
Scintillation Analyser). The monolayer was considered compromised if the 14C-mannitol 
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pApp was > 0.953 x 10-6 cm s-1.31 The apparent permeability results for the encapsulated 
FA samples are presented in Figure 6.6. 
 
 
Figure 6.6 pApp of 14C mannitol following 1 hour incubation, after monolayer was exposed to each 
FA sample (red-dotted line represents threshold value). 
 
The co-nanoprecipitated AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95) appeared 
to compromise the monolayer over the 4 hour incubation period (pApp=1.23 x 10-6 cm s-
1) and was removed from further study. AmG1U-p(DEA50-co-EGDMA0.9), AmG2-
p(DEA50-co-EGDMA0.9) and AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) were taken 
forward for further testing. 
 
6.3.1.2 Transcellular permeation studies 
 
The transcellular permeation of FA across the Caco-2 cell monolayer following 4 hours 
incubation was measured through fluorescence monitoring (via high performance liquid 
chromatography; HPLC) to determine hyp-polydendron passage from the A 
compartment (A>B). Additionally, the movement of NPs from the B to A compartment 
(B>A) was measured to estimate the permeation from blood>gut, resulting from the 
presence of active transport proteins that have been known to limit oral bioavailability.32 
Comparisons were made with aqueous A>B and B>A permeation. 
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The pApp results for the encapsulated FA materials are shown in Figure 6.7. The A>B 
movements are shown in blue and the B>A are shown in red. 
 
 
Figure 6.7 pApp of aqueous FA and NPs containing encapsulated FA (9 wt%) across the Caco-2 cell 
monolayer (A>B) (blue) and (B>A) (red) following a 4 hour incubation period.?Data shown as +/- 
standard deviation. 
 
AmG1U-p(DEA50-co-EGDMA0.9) showed the greatest increase in the A>B movement of 
FA in the series (5 x 10-6 cm s-1), although not statistically significant (P > 0.5) 
compared to the aqueous (1.44 x 10-6 cm s-1). All encapsulated FA NPs showed an 
increased (or equal) B>A movement, although also not statistically significant (P > 0.5). 
The A>B movement provides a more informative measurement compared to B>A 
movement, and is overall an underestimation of drug permeation. The drug would not 
accumulate in the B compartment in vivo, but would move with the systematic 
circulation, therefore quenching any possible equilibrium of drug concentration. 
Equally, the B>A is an overestimation compared to in vivo, as the flow of the systematic 
circulation would prevent the nano-carriers being in contact with the cells for such a 
prolonged period of time. Despite this, AmG1U-p(DEA50-co-EGDMA0.9) showed 
improved transcellular permeability properties compared to the equivalent aqueous 
preparation. 
 
In order to provide a relative indication of apparent oral administration, the pApp ratio 
(A>B)/(B>A) was calculated (Figure 6.8). The Caco-2 cell monolayer was ensured to be 
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intact throughout. The pApp ratio (A>B/B>A) (Figure 6.8A) and efflux ratio 
(B>A/A>B) (Figure 6.8B), display the relative amount of encapsulated FA NPs that is 
transported in and out of the cell respectively, compared to aqueous FA. 
 
 
Figure 6.8 A) pApp ratio A>B/B>A and B) efflux ratio B>A/A>B for FA encapsulated materials 
compared to the aqueous preparation of FA. Data shown as +/- standard deviation. 
 
The pApp ratio of encapsulated FA AmG1U-p(DEA50-co-EGDMA0.9) NPs (>0.34) 
indicates considerable A>B movement, relative to B>A movement (more movement 
from gut to blood); and the efflux ratio of encapsulated FA AmG1U-p(DEA50-co-
EGDMA0.9) NPs, indicates lessened B>A movement (>2.94) relative to A>B movement, 
suggesting less movement from blood to gut.
 
6.3.2 Cytotoxicity assays  
 
Cytotoxicity assays were deemed appropriate to ensure the nanomaterials were not toxic 
to cells. Typical cytotoxicity assays include the 3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide (MTT) assay33 and adenosine triphosphate (ATP) assay.34 
Both of these assays measure the mitochondrial function of the cells, which may result 
in an underestimated level of cytotoxicity, as cytotoxic effects experienced by the entire 
cell may go unnoticed. 
 
The MTT assay is based on the conversion of MTT to formazan crystals by 
mitochondria present in cells to determine mitochondrial activity.35 The mitochondrial 
activity is related to the number of viable living cells, therefore this assay can be used to 
assess a drug or material’s cytotoxic effects.36 The ATP assay method starts with the 
extraction of cells from the surface of cell culture flasks, in order to suspend in culture 
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media. The assay uses polypropylene plates to prevent the growth of non-neoplastic 
cells over a 5-day incubation period followed by detergent based extraction of cellular 
ATP. The cell production of ATP is a measure of the cell viability as viable cells 
produce ATP whereas dead cells do not.37 All NPs considered to not compromise the 
integrity of the monolayer were utilised in both cytotoxicity assays (Figures 6.9 and 
6.10).  
 
Figure 6.9?Caco-2 cell ATP assay, 5 day incubation: A) Aqueous FA B) DMSO C) AmG2-p(DEA50-
b-(tBuMA65-co-EGDMA0.9)) D) AmG2-p(DEA50-co-EGDMA0.9) E) AmG1U-p(DEA50-co-
EGDMA0.9).?Data shown as +/- standard deviation. 
 
Cytotoxicity of the 4 aqueous nanoprecipitates was evaluated against the Caco-2 cell 
line and no appreciable cytotoxicity was observed at achievable concentrations in assays 
assessing either ATP (Figure 6.9) or MTT turnover (Figure 6.10) as such the 
determination of an IC50 value for each polymer was not possible, indicating very low 
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cytotoxicity towards Caco-2 cells over the concentration range investigated. 
 
 
 
Figure 6.10 Caco-2 cell MTT assay, 5 day incubation: A) Aqueous FA B) DMSO C) AmG2-
p(DEA50-b-(tBuMA65-co-EGDMA0.9)) D) AmG2-p(DEA50-co-EGDMA0.9) E) AmG1U-p(DEA50-co-
EGDMA0.9).?Data shown as +/- standard deviation. 
 
Additional cytotoxicity testing was carried out on the lead nanoprecipitated 
nanomaterial, AmG1U-p(DEA50-co-EGDMA0.9) using Activated Tamm Horsfall Protein 
(ATHP-1) cells. ATHP-1 cells are monocyte-derived macrophage cells so it was 
important to ascertain the cytotoxicity of the materials with these cells, and ensure the 
NPs do not have any overt cytotoxicity to the host cell. The FA loaded sample showed 
increased cytotoxicity to ATHP-1 cells (35% (ATP) and 32% (MTT) cell viability) 
when compared with the aqueous sample of FA (76% (ATP) and 97% (MTT) cell 
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viability) during both assays over the 5 day incubation period (Figure 6.11 and 6.12). 
This may have been due to enhanced accumulation of FA in the ATHP-1 cells compared 
to the aqueous FA (cf. Caco-2 and macrophage cell accumulation studies), however, a 
cytotoxic effect or assay interference from the NPs cannot be ruled out.38 
 
Figure 6.11 ATHP-1 cell ATP assay, 5 day incubation: A) Aqueous FA B) AmG1U-p(DEA50-co-
EGDMA0.9). Data shown as +/- standard deviation. 
 
 
Figure 6.12 ATHP-1 cell MTT assay, 5 day incubation: A) Aqueous FA B) AmG1U-p(DEA50-co-
EGDMA0.9). Data shown as +/- standard deviation. 
 
6.3.3 Caco-2 and ATHP-1 cell accumulation studies 
 
AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA was utilised in 
experiments to measure the cellular accumulation ratio (CAR) in Caco-2 and ATHP-1 
cells (Figure 6.13). It is important to note, that the CAR results may also include NPs 
associated with the cell membrane, without definite confirmation of cell entry. ATHP-1 
can model accumulation of molecules in macrophages.39
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Figure 6.13 Cellular accumulation ratio for aqueous FA and AmG1U-p(DEA50-co-EGDMA0.9) 
containing encapsulated FA (9 wt%) in A) Caco-2 cells; and B) ATHP-1 cells. Data shown as +/- 
standard deviation; **, P < 0.01; and ***, P < 0.001 (ANOVA) (n=3). 
 
Figure 6.13A shows that AmG1U-p(DEA50-co-EGDMA0.9) provides an increased 
accumulation of FA in Caco-2 cells (>0.018) compared to the aqueous (>0.007). Figure 
6.13B also shows AmG1U-p(DEA50-co-EGDMA0.9) has an increased accumulation of 
FA in ATHP-1 cells (>0.024) compared to the aqueous (>0.005). The increased 
accumulation in Caco-2 cells suggests that the earlier observed permeation occurs via a 
transcellular, as opposed to paracellular, pathway. If this is the case, studies can be 
performed to understand whether it is an active or passive process through the cell. 
 
6.3.4 Endocytosis inhibition
 
Polymeric complexes can enter mammalian cells through different endocytic 
pathways.40 For efficient optimisation of the nanocarrier it is important to profile its 
cellular uptake, because this largely determines its intracellular processing and 
subsequent permeation efficiency. Most of the current information on uptake of gene-
delivery vehicles is based on data following the use of chemical inhibitors of endocytic 
pathways.41 Here, a detailed characterisation was performed using 5 commonly used 
endocytosis inhibitors: Chlorpromazine hydrochloride (Chl), Dansylcadaverine (Dan), 
Indomethacin (Ind), Genistein (Gen) and Dynasore hydrate (Dyn) on transcellular 
permeation and CAR in Caco-2 cells. 
 
Initially, the % luminescence was measured with different levels of ATP depletion in 
Caco-2 cells, relative to an untreated control, using 2-Deoxyglucose and Rotenone. This 
was the control experiment to confirm that treating Caco-2 cells with 2-deoxyglucose 
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and rotenone depletes ATP, and was used to decide what concentrations to proceed with 
(Figure 6.14). In this instance, the measurement of ATP was performed using a 
luciferin-luciferase assay in a luminometer, which measures the production of ATP.42 
Following this, cells were incubated with 2-Deoxyglucose/Rotenone for 20 min at 37oC, 
and encapsulated FA AmG1U-p(DEA50-co-EGDMA0.9) NPs were added to the well in 
order to gain an understanding of whether transport was potentially active (ATP-
dependant) or passive (non ATP-dependant). Figure 6.15 shows the Caco-2 CAR % of 
AmG1U-p(DEA50-co-EGDMA0.9) encapsulated with FA (9 wt%), indicating a reduced, 
but not significant, CAR (48%) upon ATP depletion. 
 
 
Figure 6.14 % Luminescence relative to untreated control following treatment of varying 
concentrations of 2-deoxyglucose/Rotenone. Data shown as +/- standard deviation. 
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Figure 6.15 Caco-2 CAR % of AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA (9 
wt%) with and without ATP depletion. Data shown as +/- standard deviation. 
 
Following this, the effect on transcellular permeation (pApp) in the presence of each 
inhibitor was considered (Figure 6.16). Transport across the endocytosis pathway is an 
active process43 and when these processes were inhibited, there was no significant drop 
in pApp (P > 0.5) for AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA. 
This suggests that the movement is not dependant on ATP. 
 
 
Figure 6.16 pApp of aqueous FA (blue) and AmG1U-p(DEA50-co-EGDMA0.9) (9 wt% FA) (red) with 
various endocytosis inhibitors across the Caco-2 cell monolayer following a 4 hour incubation period. 
Data shown as +/- standard deviation. 
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Following this, the 14C-mannitol control experiment was repeated to investigate the 
integrity of the monolayer in the presence of the inhibitors (i.e. that the passage of FA is 
transcellular and not due to a compromised monolayer). Both experiments, aqueous FA 
(Figure 6.17A) and AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA 
(Figure 6.17B), suggest the monolayer remains intact throughout the incubation with 
aqueous FA and AmG1U-p(DEA50-co-EGDMA0.9) with the selected inhibitors.  
 
 
 
Figure 6.17? pApp of 14C mannitol following 1 hour incubation, after monolayer was exposed to 
aqueous FA (A) and AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA (9 wt%; B) with 
various endocytosis inhibitors (red-dotted line represents threshold value). Data shown as +/- standard 
deviation. 
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6.3.5 Encapsulation of an anti-retroviral therapy drug 
 
AmG1U-p(DEA50-co-EGDMA0.9) was loaded with EFV using identical 
nanoprecipitation conditions for FA encapsulation. EFV is a non-nucleoside reverse 
transcriptase inhibitor which prevents the conversion of viral ribonucleic acid strands to 
deoxyribonucleic acid by the reverse transcriptase enzyme. EFV is considered a first-
line global therapy for new cases of HIV infection and is well-tolerated by patients. 
Side-effects of EFV administration include neuropsychiatric disturbances (which may be 
persistent), low incidence of hepatotoxicity and metabolic alterations.44,45,46,47,48 EFV 
was successfully encapsulated within the AmG1U-p(DEA50-co-EGDMA0.9) hyp-
polydendron NP dispersion at 9 wt%. This was confirmed by no observable macroscale 
precipitation of nanomaterial or drug, and a stable NP dispersion producing a 
monomodal size distribution (Figure 6.18). 
 
 
Figure 6.18 DLS size by intensity trace of blank AmG1U-p(DEA50-co-EGDMA0.9) (green), 
encapsulated FA (9 wt%; orange) and encapsulated EFV (9 wt%; blue). 
 
Table 6.3 DLS analysis of AmG1U-p(DEA50-co-EGDMA0.9) (blank) and containing encapsulated FA 
(9 wt%) or encapsulated EFV (9 wt%). 
 
pH=7.8 + FA (9 wt%) + EFV (9 wt%) 
Dz
(nm) 
PDI 
Dn
(nm) 
Dz
(nm) 
PDI 
Dn
(nm) 
Dz
(nm) 
PDI 
Dn
(nm) 
134 0.148 82 59 0.243 28 69 0.194 38 
 
The size of the encapsulated EFV NPs (Dz and Dn) was very similar to the encapsulated 
FA AmG1U-p(DEA50-co-EGDMA0.9) NPs, which were both noticeably smaller than the 
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un-encapsulated NPs (Table 6.3). This may suggest the dye or drug acts as a nucleation 
point and directs the aggregation process. Future studies for AmG1U-p(DEA50-co-
EGDMA0.9) containing encapsulated EFV should include assessing pApp, cytotoxicity 
assessment, accumulation, and the efficacy of the nanocarrier against HIV, compared to 
aqueous EFV efficacy. Furthermore, in order to reduce the likelihood of HIV becoming 
resistant to a class of anti-retroviral drugs, healthcare providers recommend that people 
infected with HIV take a combination of anti-retroviral drugs in previously mentioned 
ART. Future studies may include the encapsulation of other drugs such as the protease 
inhibitors, Lopinavir and Ritonovir.49,50 
 
6.4 Conclusions 
 
Overall, the research presented represents the study of previously synthesised materials 
within a pharmacological relevant manner. It is important to note, and issues have been 
addressed throughout, that there are limitations associated with these in vitro studies and 
how further investigations are essential to understand the behaviour of hyp-polydendron 
NPs. These results primarily suggest that the AmG1U-p(DEA50-co-EGDMA0.9) in 
particular, showed negligible cytotoxicity with a marked increase in transcellular pApp 
(A>B) without damage to the monolayer (membrane). The increased accumulation of 
encapsulated FA compared to the aqueous FA in Caco-2 and ATHP-1 cells could 
suggest uptake of the nano-carrier into primary lymphocytes and consequently, 
macrophages. This presents great advances for future developments that may allow oral 
dosing leading to circulating polymeric NPs. This may prove clinically desirable to 
many nonterminal or chronic diseases that utilise nanomedicines, but wish to avoid 
regular or repeated intravenous administration. 
?
6.5 Experimental 
 
Transcellular permeation studies: Cells were seeded at a density of 3.5 x 104 per well 
into 24 well Costar→ HTS transwell plates, with 0.33 cm2 surface area, and 3 µM pore 
size, and propagated to a monolayer over a 21 day period. Only wells with 
transepithelial electrical resistance (TEER) values >800Ω were used. 10 µM of FA hyp-
polydendron or 10 µM aqueous FA (transport buffer spiked with DMSO dissolved FA, 
DMSO final volume <0.5% of total volume), was added to the apical or basolateral 
compartment of the wells to quantify transport in both A>B and B>A directions. Plates 
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were sampled following 4 hours incubation, A and B contents were stored at -30oC prior 
to analysis. 
 
Monolayer integrity studies: To assess monolayer integrity following incubation, 100 
µL of transport buffer containing 2 µL mL-1 14C mannitol was added to the apical 
compartment and incubated for 1 hour. 4 mL of scintillation fluid was added to 100 µL 
of the sampled contents and quantified on the scintillation counter.  
 
HPLC quantification of FA: 150 µL of sample and prepared calibration for each hyp-
polydendron material, were extracted using 9 volumes of acetone, sonicated for 6 min 
and centrifuged for 3 min prior to drying at 30oC on a vacuum centrifuge. Each sample 
was reconstituted using 150 µL of 25% DMSO. Samples were run on a Dionex HPLC 
using a Fortis C18 column (100 mm x 4.6 mm i.d., 3 µm). The mobile phase consisted 
of: (A) 95% H2O; 5% ACN; 5 mM NH4FA (B) 95% ACN; 5% H2O; 5 mM NH4FA. 
Elution peaks were monitored with a fluorescence detector at; 490 (ex), 530 (em) 
(Thermo Spectrasystem FL3000) and subsequently analysed using Chromeleon v.6.8. 
software. 
 
Caco-2 and macrophage cell accumulation studies: Caco-2 cells were seeded into 6 
well plates (NunclonTM) at a density of 4 x 106 per well and incubated at 37oC 5% CO2 
for 24 hours. THP-1 cells were seeded at a density of 4 x 106 cells per well in a 6 well 
plate and allowed to differentiate to ATHP-1 cells for 7 days in 10 nM PMA 
supplemented RPMI-1640 10% FBS prior to use. Following incubation, the media was 
aspirated and cells washed twice with HBSS (37oC) and subsequently replaced with pre-
warmed (37oC) Transport Buffer containing either 10 µM (final concentration) aqueous 
FA or 10 µM (final concentration) hyp-polydendron formulated FA. Following 24 hours 
incubation at 37oC 5% CO2, 150 µL of the extracellular media was sampled. The 
remaining media was aspirated and cells were washed twice with ice cold HBSS. The 
ice cold HBSS was aspirated and replaced with 500 µL of a 50% acetone 50% water 
solution and incubated for 24 hours at -20oC, 150 µL of the lysate was subsequently 
sampled. Finally, 9 volumes of acetone was added to each intracellular and extracellular 
sample to extract FA for quantification on the HPLC as previously described. Average 
cell volumes were previously determined using a Scepter 2.0 Automated Cell Counter 
(Millipore) and used to calculate Cellular Accumulation Ratios (CAR); (Intracellular 
concentration/Volume)/(Extracellular concentration/Volume). 
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Cytotoxicity assays: Caco-2 cells were seeded into 96 well plates (NunclonTM) at a 
density of 1 x 104 per well and incubated at 37oC 5% CO2 for 24 hours. THP-1 cells 
were seeded at a density of 1 x 104 cells per well in 96 well plates and allowed to 
differentiate to ATHP-1 cells for 7 days in 10 nM PMA supplemented RPMI-1640 10% 
FBS at 37oC 5% CO2 prior to use. Following incubation, the media was aspirated and 
replaced with media containing either varying concentrations (0.1 – 15 µM) of aqueous 
or hyp-polydendron formulated FA as determined by the molarity and mass of FA 
contained in each formulation. The treated cells were then incubated for either 24 or 120 
hours at 37oC 5% CO2. All cytotoxicity analyses were determined using both ATP and 
MTT cell viability assays. 
 
ATP assays: ATP assays were conducted using CellTiter-Glo→ Reagent (Promega) in 
accordance with manufacturer’s instructions. Briefly, the plates and contents were 
initially equilibrated to room temperature. Subsequently, all but 20 µL of media was 
removed from each well and 20 µL CellTiter-Glo→ reagent was added to produce a 1:1 
ratio. The contents were then mixed for 10 minutes on an orbital shaker to induce lysis 
and allow for stabilisation of luminescence signal prior to reading on a TECAN GENios 
plate reader. MTP assay: For MTT assays, 20 µL of a 5 mg mL-1 MTT reagent was 
added to each well and incubated for 2 hours. Subsequently, 100 µL MTT lysis buffer 
(50% N-N-Dimethylformamide in water containing 20% SDS, 2.5% glacial acetic acid 
and 2.5% hydrochloric acid, pH 4.7) was added to each well and lysed overnight at 37°C 
5% CO2. Following incubation, the absorbance of each well was read using a TECAN 
GENios plate reader (560 nm). 
 
ATP depletion of Caco-2 cells using varying concentrations of 2-Deoxyglucose and 
rotenone: Caco-2 cells were incubated with varying concentrations of 2-
Deoxyglucose/rotenone (0/0, 1/50, 2/100 and 3/150 nM) as outlined for 20 min at 37oC 
5% CO2. Following incubation, ATP assays were carried out using CellTiter-GLO® kit 
as previously described to determine relative depletion of ATP compared to an untreated 
control. 
 
Apparent permeability (Papp) of fluoresceinamine encapsulated in polymeric 
nanocarrier materials: Caco-2 cell monolayers were pre-incubated for 30 min in 
transport buffer containing either: 30 µM chlorpromazine (Chl); 200 µM 
dansylcadaverine (Dan); 10 µM genistein (Gen); 150 µM dynasore (Dyn); or 150 µM 
Indomethacin (Ind) prior to washing three times with pre-warmed (37oC) HBSS. 
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Following washing, the Caco-2 monolayers were co-incubated with the various 
endocytosis inhibitors as outlined, and either aqueous (DMSO spiked; <0.1% v/v) or 
nanocarrier formulated fluoresceinamine for 4 h at 37oC 5% CO2. 
 
Statistical analysis: Data was statistically analysed using Prism 5 (GraphPad) and 
StatsDirect statistical software (version 2.7.9). 
?
??????????????????????????????????????????????????????
1 P. M. Kopko, L. P. Fernando, E. N. Bonney, J. L. Freeman and P. V. Holland, Am. J. Clin. Path., 
2001, 116, 562-566. 
2 Z. Matebeni, V. Reddy, T. Sandfort and I. Southey-Swartz, Cult. Health Sex., 2013, 15, 34-47. 
3 T. C. Quinn, M. J. Wawer, N. Sewankambo, D. Serwadda, C. Li, F. Wabwire-Mangen, M. O. 
Meehan, T. Lutalo and R. H. Gray, New Eng. J. Med., 2000, 342, 921-929. 
4 A. Smed-Sörensen and K. Lore, Curr. Opin. HIV AIDS, 2011, 6, 405-410. 
5 J. Embretson, M. Zupancic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Racz and A. T. Haase, 
Nature, 1993, 362, 359-362. 
6 S. M. Schnittman, M. C. Psallidopoulos, H. C. Lane, L. Thompson, M. Baseler, F. Massari, C. H. 
Fox, N. P. Salzman and A. S. Fauci, Science, 1989, 245, 305-308. 
7 B. Autran, G. Carcelaint, T. S. Li, G. Gorochov, C. Blanc, M. Renaud, M. Durali, D. Mathez, V. 
Calvez, J. Leibowitch and C. Katlama, Immun. Lett., 1999, 66, 207-211. 
8 K. Jones, P. G. Hoggard, S. D. Sales, S. Khoo, R. Davey and D. J. Back, AIDS, 2001, 15, 675-681. 
9 N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A. S. Hussain, H. E. 
Junginger, S. A. Stavchansky, K. K. Midha, V. P. Shah and G. L. Amidon, Mol. Pharm., 2004, 1, 85-
96. 
10 E. Feeney, E. Muldoon and W. G. Powderly, Curr. Opin. HIV AIDS, 2006, 1, 430-436. 
11 T. Shirasaka, Jap. J. Clin. Med., 2010, 68, 480-485. 
12 A. Ammassari, M. P. Trotta, N. Shalev, P. Marconi and A. Antinori, Antiviral Ther., 2012, 17, 785-
792. 
13 S. Dai, P. Ravi, K. C. Tam and B. W. Mao, Langmuir, 2003, 19, 5175-5177. 
14 Y.-S. Rhee and H. M. Mansour, Int. J. Nanotechnol., 2010, 8, 84-114. 
15 R. Duncan and M. J. Vicent, Adv. Drug Deliver. Rev., 2013, 65, 60–70. 
16 L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer and O. C. Farokhzad, Clin. Pharmacol. 
Ther., 2008, 83, 761-769. 
17 J. Panyam and V. Labhasetwar, Adv. Drug Deliver. Rev., 2003, 55, 329-347. 
18 K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni and W. E. Rudzinski, J. Control Release, 
2001, 70, 1-20. 
19 S. Yee, Pharm. Res., 1997, 14, 763-766. 
20 J. H. Eldridge, C. J. Hammond, J. A. Meulbroek, J. K. Staas, R. M. Gilley, and T. R. Tice, J. 
Control Release, 1990, 11, 205-214. 
21 C. J. Porter and W. N. Charman, Adv. Drug Deliver. Rev., 2001, 50, 61-80. 
CHAPTER 6 
 
249?
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
22 T. Okuda, S. Kawakami, T. Maeie, T. Niidome, F. Yamashita and M. Hashida, J. Control Release, 
2006, 114, 69-77. 
23 C. Damgé, C. Michel, M. Aprahamian and P. Couvreur, Diabetes, 1988, 37, 246-251. 
24 A. Avdeef, P. Artursson, S. Neuhoff, L. Lazorova, J. Gråsjö and S. Tavelin, Eur. J. Pharm. Sci., 
2005, 24, 333-349. 
25 H. Sun, E. C. Y. Chow, S. Liu, Y. Du and K. S. Pang, Expert Opin. Drug Met., 2008, 4, 395-411. 
26 Y.-H. Lin, C.-K. Chung, C.-T. Chen, H.-F. Liang, S.-C. Chen and H.-W. Sung, 
Biomacromolecules, 2005, 6, 1104-1112. 
27 M. Tsujii, S. Kawano and R. N. DuBois, P. Natl. Acad. Sci., 1997, 94, 3336-3340. 
28 I. J. Hidalgo, T. J. Raub and R. T. Borchardt, Gastroenterology, 1989, 96, 736-749. 
29 R. Elsby, D. D. Surry, V. N. Smith and A. J. Gray, Xenobiotica, 2008, 38, 1140-1164. 
30 K. A. Youdim, A. Avdeef and N. J. Abbott, Drug Discov. Today, 2003, 8, 997-1003. 
31 R. Elsby, D. D. Surry, V. N. Smith and A. J. Gray, Xenobiotica, 2008, 38, 1140-1164. 
32 A. Sparreboom, J. V. Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. F. Meijer, P. Borst, W. 
J. Nooijen, J. H. Beijnen and O. V. Tellingen, P. Natl. Acad. Sci., 1997, 94, 2031-2035. 
33 Z. Yongtang and B. Kunlong, Immunol. J. 1992, 4, 016. 
34 S. P. Crouch, R. Kozlowski, K. J. Slater and J. Fletcher, J. Immunol. Methods, 1993, 160, 81-88. 
35 J. van Meerloo, G. J. Kaspers and J. Cloos, Cancer Cell Culture, Humana Press, 2011, 237-245. 
36 J. Meerloo, G. L. Kaspers, J. Cloos and I. A. Cree, Cancer Cell Culture, Humana Press, 2011, 1, 
pp. 237-245. 
37 R. D. Petty, L. A. Sutherland, E. M. Hunter and I. A. Cree, J. Biolum. Chemilum, 1995, 10, 29-34. 
38 A. Kroll, M. H. Pillukat, D. Hahn and J. Schnekenburger, Arch. of Tox., 2012, 86, 1123-1136. 
39 S. A. Theus, M. D. Cave and K. D. Eisenach, Infect. Immun., 2004, 72, 1169-1173. 
40 H. Hillaireau and Patrick Couvreur, Cell. and Mol. Life Sci., 2009, 66, 2873-2896. 
41 D. Vercauteren, R. E. Vandenbroucke, A. T. Jones, J. Rejman, J. Demeester, S. C. De Smedt, N. 
N. Sanders and K. Braeckmans, Mol. Ther., 2010, 18, 561–569. 
42 S. Glaysher and I. Cree, in Cancer Cell Culture, ed. I. A. Cree, Humana Press, 2011, pp. 247-257. 
43 R. Matteoni and T. E. Kreis, The J. of Cell Biol., 1987, 105, 1253-1265. 
44 F. Gutierrez, A. Navarro, S. Padilla, R. Anton, M. Masia, J. Borras and A. Martin-Hidalgo, Clin. 
Infect. Dis., 2005, 41, 1648-1653. 
45 R. Manfredi, L. Calza and F. Chiodo, J. Acq. Immun. Def. Synd., 2005, 38, 236-238. 
46 K. T. Tashima, L. Bausserman, E. N. Alt, E. Aznar and T. P. Flanigan, HIV Clin. Trials, 2003, 4, 
29-36. 
47 F. Maggiolo, J. Antimicrob. Chemoth., 2009, 64, 910-928. 
48 N. Apostolova, L. J. Gomez-Sucerquia, A. Gortat, A. Blas-Garcia and J. V.Esplugues, Hepatology, 
2011, 54, 1009-1019. 
49 M. A. Alex, A. J. Chacko, S. Jose and E. B. Souto, Eur. J. Pharm. Sci., 2011, 42, 11-18. 
50 A. S. Narang, D. Delmarre and D. Gao, Int. J. Pharm., 2007, 345, 9-25. 
CHAPTER 6 
 
223?
?
?
?
?
?
 
Chapter 6 
 
 
 
 
 
Pharmacological analysis of hyperbranched-polydendrons and co-
nanoprecipitated systems?
? ?
CHAPTER 6 
 
224?
6.1 Introduction 
 
The human immunodeficiency virus (HIV) is transmitted via contact with infected 
blood1 or through unprotected sex with an infected person.2,3 It initially infects dendritic 
cells, that consequently transport the virus into the lymphatic system to infect CD4+ T 
cells (a cytotoxic T lymphocyte that directly kill virally infected cells and produce and 
release antiviral cytokines) (Chapter 1, Section 1.1.1).4 The virus can reside in 
reservoirs, such as monocytes and macrophages,5 or in cells and tissues (known as 
sanctuary sites) that are inaccessible to drugs within the systemic circulation;6 current 
anti-retroviral therapies (ART) aim to reduce the viral levels in the blood. Ideally, a 
more effective treatment method would allow penetration of the sanctuary sites. 
 
ART7 is a combination of drugs that penetrate cells through diffusion or active influx.8 
Many of the drugs are poorly water-soluble,9 resulting in a lack of bioavailability. This 
equates to the need for large doses of administered drug in order to achieve therapeutic 
concentrations in the bloodstream. These drugs lead to a variety of dose-dependent side 
effects10,11 and, additionally, the large pill burden generates a high risk of treatment 
failure, due to poor patient adherence with the subsequent development of viral 
resistance.12 Numerous research efforts into the development of simplified and improved 
dosing regimens have been reported using nanocarrier strategies, particularly to 
overcome drug permeability issues13 and/or target specific cells or tissues.14 
 
The important factors that are considered during the design of drug delivery vehicles 
include: the capacity of the carrier to host an adequate drug payload; optimal release 
kinetics for each drug depending on mechanism and location of release within the body; 
mode of excretion and reactivity of all carrier metabolites.15 Specifically, the association 
of drug to a nanoparticle (NP) may be achieved either covalently or via encapsulation 
and several examples have been produced using many different polymer classes; 
encapsulation is featured in this work.16 
 
NPs possess high surface area to mass ratios, and drug NPs may result in more rapid and 
complete dissolution in the gut lumen and offer an enhanced delivery of an effective 
therapeutic dosage into the systemic system.17,18 In many cases, the modification of drug 
distribution and tissue penetration requires the circulating drug to be present as a NP 
rather than a dissolved drug molecule, and the benefits of nanocarriers are derived from 
the presentation of the drug in a NP format. In general, nanocarriers are injected directly 
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into the bloodstream but orally-dosed NPs that can enter the bloodstream through the 
gut, are a key nanomedicine target globally. This will allow simple oral dosing and 
remove the need for daily injection within a clinical setting.  
 
There are five main routes a NP can utilise to cross the gut epithelium and enter into the 
bloodstream (Figure 6.1). In the case of solid drug NPs, surface adhesion followed by 
subsequent dissolution results in high local concentrations that saturate drug transporters 
(Figure 6.1.1). Solid drug NPs may also become trapped in the mucous resulting in rapid 
dissolution close to the intestinal barrier; again, high local concentrations saturate efflux 
systems (Figure 6.1.2). NPs of various types may avoid transport systems by 
paracellular movement across the intestinal barrier (i.e. between cells); tight junctions 
only allow permeation of small (<100 Da.) sized materials,19 so nanomaterials can be 
functionalised to reversible opening tight junctions (Figure 6.1.3). The particulate nature 
of the NPs may result in endocytosis/phagocytosis by immune cells or enterocytes; this 
leaves potential for entry into the systemic circulation via Peyer’s patches20 (Figure 
6.1.4). Finally NPs may enter the lymphatic system prior to entering the systemic 
circulation21 (Figure 6.1.5), either releasing drug within during this process or after 
prolonged circulation and accumulation. 
?
?
?
Figure 6.1 The five main routes in which a NP can enter the systematic circulation: 1) Surface 
interaction and subsequent dissolution; 2) Saturation of efflux systems: 3) Paracellular movement 
across the intestinal barrier; 4) Peyer’s patches and; 5) Lymphatic system. 
 
Stable NPs have been produced for the majority of the materials synthesised within this 
project (Chapters 4 and 5), with particle sizes, surface charge and varying behaviour in 
aqueous media investigated. A selection of these NP dispersions were taken forward for 
pharmacological testing. A range of pharmacological evaluations were conducted 
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including, modelling the NPs crossing the gut epithelium, predicting the behaviour after 
oral administration, studying cellular uptake and cytotoxicity. These were carried out in 
order to evaluate whether these materials possessed any potential drug delivery benefits. 
The pharmacological experiments were carried out by Dr. Lee Tatham and Prof. Andrew 
Owen in the Department of Molecular and Clinical Pharmacology at the University of 
Liverpool. 
 
Initially, the materials’ stability in the presence of a buffering vehicle media (Transport 
Buffer Solution; TBS) was assessed (Figure 6.2A). The stability in such is essential, as 
pharmacological tests were carried out in this media. TBS contains Hanks Buffer Saline 
Solution (25 mM), Bovine Serum Albumin (0.1% w/v) and is adjusted to pH = 7.4. 
Following this, materials were selected to investigate their loading capabilities with a 
hydrophobic traceable marker, fluoresceinamine (FA), as a surrogate for anti-retroviral 
drugs (Figure 6.2B). The successfully loaded materials were then progressed to in vitro 
pharmacological testing as previously mentioned (Figure 6.2C). The loading capabilities 
of the lead candidate exhibiting the most encouraging behaviour as an orally 
administered NP, was also loaded with an ART drug, Efavirenz (EFV) for future 
evaluations (Figure 6.2D) (cf. Section 6.3.5). 
 
 
Figure 6.2 The progression of selection and assessment for NP dispersions to undergo 
pharmacological testing. A) Addition of transport buffer solution to NP dispersion; B) Investigation 
of loading capabilities of the hydrophobic traceable marker, fluoresceinamine; C) In vitro 
pharmacological testing modelling the gut epithelium and; D) Investigation of loading capability of 
the anti-retroviral drug, Efavirenz. 
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6.2 Stability and encapsulation studies of linear and linear-dendritic 
polymers, branched copolymers and hyp-polydendrons 
 
6.2.1 Stability studies in buffering vehicle media 
 
A majority of the materials that produced monomodal, stable NP dispersions in neutral 
water (Chapters 2, 4 and 5) were subjected to the addition of buffering vehicle media (1 
mL to 10 mL NP dispersion), in order to establish the ability of the nanoprecipitates to 
retain stability in a physiologically-relevant media. This included: all p(HPMA50-co-
EGDMAx), p(DEA50-co-EGDMAx), p(DEAx-co-HPMAy-co-EGDMA0.9), AmG2-
p(DEA50-co-(tBuMA65-co-EGDMA0.9)); and the co-nanoprecipitated EBiB-p(HPMA50-
co-EGDMA0.95):p(HPMA50). Dispersions were adjusted to the physiological pH of 
blood, with TBS acting as a buffering vehicle. The buffering vehicle has no detectable 
impact on the various cells studied, allowing for accurate assessment of the nanocarrier 
effects in vitro. Following TBS addition, the changes in nanoprecipitate structure and 
assembly were investigated by dynamic light scattering (DLS) analysis and compared. In 
cases in which the NPs were unable to retain stability, observable macroscale 
precipitation was witnessed, without the need for DLS measurement, and only those that 
retained stability are shown in Table 6.1. 
 
Table 6.1 DLS analysis of nanoprecipitated and co-nanoprecipitated NP dispersions (10 mL, 1 mg 
mL-1) that remained stable following the addition of transport buffer solution (1 mL). 
 pH=7.8a + TBS (aq.)b 
Polymer 
Dz 
(nm) 
PDI 
Dn 
(nm) 
Dz 
(nm) 
PDI 
Dn 
(nm) 
AmG2-p(HPMA50):EBiB-p(HPMA50-
co-EGDMA0.95) 
210 0.072 187 356 0.126 290 
AmG2-p(DEA50-co-EGDMA0.9) 295 0.159 244 346 0.190 308 
AmG1U-p(DEA50-co-EGDMA0.9) 134 0.148 82 39 0.228 18 
AmG2-p(DEA50-b-(tBuMA65-co-
EGDMA0.9)) 
163 0.082 123 163 0.100 123 
a Initial pH, b TBS (aq.) (1 mL) added to 10 mL (1 mg mL-1) NP dispersion  
 
The only NP dispersion containing HPMA monomer residues that was stable in TBS 
was the co-nanoprecipitated AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95). This 
suggests the presence of the dendron chain end on the nanoprecipitate surface 
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contributes a stabilising effect due to the amine functionality, potentially through the 
positive surface charge and possible small steric repulsion. This demonstrates that the 
dendritic functionality is advantageous, allowing stable NPs to exist in physiologically 
relevant media. The AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95) NPs 
experienced an increase in particle size (210 nm to 356 nm) and size distribution (0.072 
to 0.126), suggesting a slight aggregation under these conditions, possibly as a result of 
charge screening (Figure 6.3A). 
 
 
 
Figure 6.3 DLS size distribution analysis before and after TBS addition. A) AmG2-p(HPMA50): 
EBiB-p(HPMA50-co-EGDMA0.95) before (blue) and after (red-dotted) TBS addition; B) AmG2-
p(DEA50-co-EGDMA0.9) before (green) and after (red-dotted) TBS addition; C) AmG1U-p(DEA50-co-
EGDMA0.9) before (orange) and after (red-dotted) TBS addition; and D) AmG2-p(DEA50-b-
(tBuMA65-co-EGDMA0.9)) before (red) and after (red-dotted) TBS addition. 
 
The NP dispersions containing DEA monomer residues required either AmG1U- or 
AmG2- dendritic surface functionality to retain stabilisation on addition of TBS. The 
AmG2-p(DEA50-co-EGDMA0.9) NPs increased in size (Dz = 346 nm) and broadened in 
size distribution (PDI=0.190) (Figure 6.3B) whilst the AmG1U-p(DEA50-co-EGDMA0.9) 
underwent a decrease in Dz to 45 nm (Figure 6.3C). None of the p(DEAx-co-HPMAy-co-
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EGDMA0.9) NPs retained stability upon the addition of TBS and resulted in large 
polymeric aggregates from uncontrollable precipitation. All these materials contain a 
less positive surface charge (Chapter 4) compared to the p(DEA50-co-EGDMAx) NPs, 
suggesting a reduced level of charge stabilisation unable to withstand variation of 
electrolytes in aqueous media. The AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) 
proved stable suggesting that the increased primary polymer chain length, and 
architecture of linear-dendritic DEA polymer block arms contribute in some manner to 
the NP stabilisation process (Figure 6.3D). Following these simple stability studies, 
these materials underwent pharmacological testing. 
 
6.2.2 Encapsulation studies of a hydrophobic fluorescent marker 
 
Many polymeric drug carriers are designed to target two main administration routes: 
intravenous22 (IV) and oral.23 For the treatment of infectious diseases such as HIV, oral 
administration is preferable due to long-term daily dosing, despite the advantageous 
immediate introduction to the systemic circulation with IV administration. The ability of 
the polymeric particles to be loaded with a hydrophobic fluorescent marker acting as a 
drug model, was assessed. FA was selected for encapsulation due to its hydrophobic 
nature, thereby modelling poorly soluble drugs such as many anti-retroviral drugs. 
 
The NPs were prepared as described in Chapter 4 with dissolution of FA (10 mg) in the 
good solvent (10 mL, producing a 1 mg mL-1 FA solution) before combination with the 
polymeric solutions, and subsequent nanoprecipitation into water; the NP sizes 
containing encapsulated FA are shown in Table 6.2 and the monomodal size 
distributions measured by DLS in Figure 6.4.  
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Table 6.2 DLS analysis of nanoparticles containing encapsulated FA. 
 
 pH=7.8a + FA (9 wt%) 
Polymer 
Dz 
(nm) 
PDI 
Dn 
(nm) 
Dz 
(nm) 
PDI 
Dn 
(nm) 
AmG2-p(HPMA50):EBiB-p(HPMA50-co-
EGDMA0.95) 
210 0.072 187 441b 0.265 247 
AmG2-p(DEA50-co-EGDMA0.9) 295 0.159 244 45c 0.197 28 
AmG1U-p(DEA50-co-EGDMA0.9) 134 0.148 82 59c 0.243 28 
AmG2-p(DEA50-b-(tBuMA65 
-co-EGDMA0.9)) 
163 0.082 26 41c 0.256 26 
a Initial pH, b 0.9 wt% FA loading, c 9 wt% FA loading 
    
 
 
 
Figure 6.4 DLS size by intensity distributions of nanoprecipitated and co-nanoprecipitated particles 
with and without encapsulated FA: A) Blank AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95) 
(blue), and encapsulated FA (0.9 wt%; orange-dotted); B) Blank AmG2-p(DEA50-co-EGDMA0.9) 
(green), and encapsulated FA (9 wt%; orange-dotted); C) Blank AmG1U-p(DEA50-co-EGDMA0.9) 
(orange), and encapsulated FA (9 wt%; orange-dotted); and D) Blank AmG2-p(DEA50-b-(tBuMA65-
co-EGDMA0.9)) (red), and encapsulated FA (9 wt%; orange-dotted). 
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The FA encapsulated NPs for pharmacological studies were prepared at 9 wt% (final 
polymer concentration 1 mg mL-1 and theoretical FA amount 0.1 mg mL-1), apart from 
the co-nanoprecipitated AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95), which 
only managed to encapsulate 0.9 wt% FA following several attempts at higher loading. 
This may suggest a high proportion of dendron is residing within the main bulk of the 
nanoprecipitate aggregations. The polymeric NPs for this study included: a co-
nanoprecipitated NP dispersion comprising of HPMA, two pH-responsive DEA hyp-
polydendrons with varying generation of dendritic amine-functionality and dendron 
linker chemistry, and a block DEA-tBuMA-EGDMA hyp-polydendron. 
 
These collectively produce a combined variation of branched polymer core, polymer 
properties, hyp-polydendron NPs and NPs arranged from a separate linear-dendritic and 
branched polymer, different dendron surface and linker chemistry and different polymer 
architecture, to be assessed in vitro using various pharmacological assays. 
 
6.3 Pharmacological studies of hyp-polydendron and co-
nanoprecipitated NPs containing encapsulated FA 
 
6.3.1 Caco-2 Transcellular Permeation Assays  
 
The oral delivery of polymeric nanocarriers via permeation through the gut epithelium 
into the systemic circulation was investigated, initially to determine whether the 
nanocarrier could permeate the monolayer. Following this, cellular accumulation studies 
were undertaken, and experiments carried out to define what mechanisms were 
responsible for the permeation. 
 
The pharmacological assays performed were selected depending on the potential route 
of administration of the drug delivery vehicle. In the case of orally administered 
therapeutics, the Caco-2 (human epithelial colorectal adenocarcinoma) transcellular 
permeability assay is typically used to predict the permeability of materials across a 
model intestinal monolayer.24 This assay was adopted for this project in order to 
evaluate the potential permeation of the selected nanoprecipitated and co-
nanoprecipitated NPs. 
 
The Caco-2 cell line can be cultured to differentiate and become polarised to model the 
intestinal epithelial cells.25 It is important to consider, however, that Caco-2 cells do not 
form as tight monolayers as those found in vivo, with paracellular (between cells) 
CHAPTER 6 
 
232?
permeation reported for several NP systems.26  Additionally, the expression levels of the 
cell enzymes are highly unlikely to identically mimic those in the human body.27 Despite 
this, the movement of drug across the monolayer is predominantly restricted to 
permeation or active transport through the cells,28 and subsequent supporting cellular 
accumulation studies are carried out to help determine the mechanisms responsible.
 
A graphical representation of the transwell experiment is shown in Figure 6.5, with the 
apical (A) and basolateral (B) chambers shown either side of the epithelial monolayer 
and supporting membrane. The (A) chamber represents the gut side of the epithelium, 
whilst the (B) chamber represents the blood side of the epithelium. The experiment was 
conducted through incubation of the monolayer with the sample added to the (A) 
compartment, measuring the amount of movement across the monolayer over a 4 hour 
period from the A to B compartment (A>B); subsequent measurements were made by 
adding sample to the B compartment and monitoring the movement of sample from the 
B to A compartment (B>A).  
 
 
Figure 6.5 Transwell experiment setup showing apical and basolateral chambers separated by Caco-2 
cell monolayer. 
The movement of sample across the membrane is typically reported as apparent 
permeability (pApp), which describes the flux at which the material traverses per unit 
area of the cell barrier.29 pApp is estimated using equation 6.1: where pApp is apparent 
permeability (cm s-1); dQ/dt is the rate of transport (nM min-1); v is the volume of the 
receiver compartment; A is the surface area of the membrane (cm2); and C0 is the initial 
donor concentration. 
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Equation 6.1 Calculation of apparent permeability where pApp is apparent permeability (cm s-1); 
dQ/dt is the rate of transport (nM min-1); v is the volume of the receiver compartment; A is the surface 
area of the membrane (cm2); and C0 is the initial donor concentration. 
 
Several assumptions are made for an accurate measure of permeability.30 These include 
assumptions that the drug accumulated in the receiver compartment is proportional to 
time; “sink conditions” are compliant; and that cellular accumulation, metabolism and 
nonspecific binding to plastic-ware are absent. “Sink conditions” implies that once the 
material has traversed the monolayer it will not pass back across, however, this is not 
always the case with highly permeable materials. 
 
The behaviour of the materials was investigated with respect to the impact of variation 
within their structural components. First, permeation across the Caco-2 in vitro model of 
human gut epithelium. This would allow a proof-of-concept to be developed for the 
synthesis and potential application of these novel systems. 
 
6.3.1.1 Monolayer Integrity Assessment 
 
The first experiment conducted was to assess the potential of the FA loaded NPs to 
compromise the cell monolayer as damage to the epithelium model will lead to a false 
assessment of permeation. To allow for comparisons, an “aqueous solution” of FA was 
prepared to mimic the permeation of un-encapsulated FA as a control; due to the 
insolubility of FA in water, FA was dissolved in dimethyl sulfoxide (DMSO) and 
subsequently used to spike TBS, so that < 0.5 vol% DMSO was present within the total 
aqueous volume. 10 μM of FA loaded co-nanoprecipitated, nanoprecipitated materials or 
10 μM aqueous FA were added to the A or B chamber of the wells to quantify transport 
in both the A>B and B>A directions, and the plates were sampled 4 hours after 
incubation.  
 
To assess the monolayer integrity following incubation, 100 μL of TBS containing 
2?μL/mL 14C mannitol (0.2 µCi/100 µL) was added to the A compartment and incubated 
for 1 hour. Scintillation fluid (4 mL) was added to 100 μL of both A and B sampled 
contents and quantified on the scintillation counter (Packard Tri-Carb 3100 Liquid 
Scintillation Analyser). The monolayer was considered compromised if the 14C-mannitol 
CHAPTER 6 
 
234?
pApp was > 0.953 x 10-6 cm s-1.31 The apparent permeability results for the encapsulated 
FA samples are presented in Figure 6.6. 
 
 
Figure 6.6 pApp of 14C mannitol following 1 hour incubation, after monolayer was exposed to each 
FA sample (red-dotted line represents threshold value). 
 
The co-nanoprecipitated AmG2-p(HPMA50):EBiB-p(HPMA50-co-EGDMA0.95) appeared 
to compromise the monolayer over the 4 hour incubation period (pApp=1.23 x 10-6 cm s-
1) and was removed from further study. AmG1U-p(DEA50-co-EGDMA0.9), AmG2-
p(DEA50-co-EGDMA0.9) and AmG2-p(DEA50-b-(tBuMA65-co-EGDMA0.9)) were taken 
forward for further testing. 
 
6.3.1.2 Transcellular permeation studies 
 
The transcellular permeation of FA across the Caco-2 cell monolayer following 4 hours 
incubation was measured through fluorescence monitoring (via high performance liquid 
chromatography; HPLC) to determine hyp-polydendron passage from the A 
compartment (A>B). Additionally, the movement of NPs from the B to A compartment 
(B>A) was measured to estimate the permeation from blood>gut, resulting from the 
presence of active transport proteins that have been known to limit oral bioavailability.32 
Comparisons were made with aqueous A>B and B>A permeation. 
 
CHAPTER 6 
 
235?
The pApp results for the encapsulated FA materials are shown in Figure 6.7. The A>B 
movements are shown in blue and the B>A are shown in red. 
 
 
Figure 6.7 pApp of aqueous FA and NPs containing encapsulated FA (9 wt%) across the Caco-2 cell 
monolayer (A>B) (blue) and (B>A) (red) following a 4 hour incubation period.?Data shown as +/- 
standard deviation. 
 
AmG1U-p(DEA50-co-EGDMA0.9) showed the greatest increase in the A>B movement of 
FA in the series (5 x 10-6 cm s-1), although not statistically significant (P > 0.5) 
compared to the aqueous (1.44 x 10-6 cm s-1). All encapsulated FA NPs showed an 
increased (or equal) B>A movement, although also not statistically significant (P > 0.5). 
The A>B movement provides a more informative measurement compared to B>A 
movement, and is overall an underestimation of drug permeation. The drug would not 
accumulate in the B compartment in vivo, but would move with the systematic 
circulation, therefore quenching any possible equilibrium of drug concentration. 
Equally, the B>A is an overestimation compared to in vivo, as the flow of the systematic 
circulation would prevent the nano-carriers being in contact with the cells for such a 
prolonged period of time. Despite this, AmG1U-p(DEA50-co-EGDMA0.9) showed 
improved transcellular permeability properties compared to the equivalent aqueous 
preparation. 
 
In order to provide a relative indication of apparent oral administration, the pApp ratio 
(A>B)/(B>A) was calculated (Figure 6.8). The Caco-2 cell monolayer was ensured to be 
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intact throughout. The pApp ratio (A>B/B>A) (Figure 6.8A) and efflux ratio 
(B>A/A>B) (Figure 6.8B), display the relative amount of encapsulated FA NPs that is 
transported in and out of the cell respectively, compared to aqueous FA. 
 
 
Figure 6.8 A) pApp ratio A>B/B>A and B) efflux ratio B>A/A>B for FA encapsulated materials 
compared to the aqueous preparation of FA. Data shown as +/- standard deviation. 
 
The pApp ratio of encapsulated FA AmG1U-p(DEA50-co-EGDMA0.9) NPs (>0.34) 
indicates considerable A>B movement, relative to B>A movement (more movement 
from gut to blood); and the efflux ratio of encapsulated FA AmG1U-p(DEA50-co-
EGDMA0.9) NPs, indicates lessened B>A movement (>2.94) relative to A>B movement, 
suggesting less movement from blood to gut.
 
6.3.2 Cytotoxicity assays  
 
Cytotoxicity assays were deemed appropriate to ensure the nanomaterials were not toxic 
to cells. Typical cytotoxicity assays include the 3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide (MTT) assay33 and adenosine triphosphate (ATP) assay.34 
Both of these assays measure the mitochondrial function of the cells, which may result 
in an underestimated level of cytotoxicity, as cytotoxic effects experienced by the entire 
cell may go unnoticed. 
 
The MTT assay is based on the conversion of MTT to formazan crystals by 
mitochondria present in cells to determine mitochondrial activity.35 The mitochondrial 
activity is related to the number of viable living cells, therefore this assay can be used to 
assess a drug or material’s cytotoxic effects.36 The ATP assay method starts with the 
extraction of cells from the surface of cell culture flasks, in order to suspend in culture 
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media. The assay uses polypropylene plates to prevent the growth of non-neoplastic 
cells over a 5-day incubation period followed by detergent based extraction of cellular 
ATP. The cell production of ATP is a measure of the cell viability as viable cells 
produce ATP whereas dead cells do not.37 All NPs considered to not compromise the 
integrity of the monolayer were utilised in both cytotoxicity assays (Figures 6.9 and 
6.10).  
 
Figure 6.9?Caco-2 cell ATP assay, 5 day incubation: A) Aqueous FA B) DMSO C) AmG2-p(DEA50-
b-(tBuMA65-co-EGDMA0.9)) D) AmG2-p(DEA50-co-EGDMA0.9) E) AmG1U-p(DEA50-co-
EGDMA0.9).?Data shown as +/- standard deviation. 
 
Cytotoxicity of the 4 aqueous nanoprecipitates was evaluated against the Caco-2 cell 
line and no appreciable cytotoxicity was observed at achievable concentrations in assays 
assessing either ATP (Figure 6.9) or MTT turnover (Figure 6.10) as such the 
determination of an IC50 value for each polymer was not possible, indicating very low 
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cytotoxicity towards Caco-2 cells over the concentration range investigated. 
 
 
 
Figure 6.10 Caco-2 cell MTT assay, 5 day incubation: A) Aqueous FA B) DMSO C) AmG2-
p(DEA50-b-(tBuMA65-co-EGDMA0.9)) D) AmG2-p(DEA50-co-EGDMA0.9) E) AmG1U-p(DEA50-co-
EGDMA0.9).?Data shown as +/- standard deviation. 
 
Additional cytotoxicity testing was carried out on the lead nanoprecipitated 
nanomaterial, AmG1U-p(DEA50-co-EGDMA0.9) using Activated Tamm Horsfall Protein 
(ATHP-1) cells. ATHP-1 cells are monocyte-derived macrophage cells so it was 
important to ascertain the cytotoxicity of the materials with these cells, and ensure the 
NPs do not have any overt cytotoxicity to the host cell. The FA loaded sample showed 
increased cytotoxicity to ATHP-1 cells (35% (ATP) and 32% (MTT) cell viability) 
when compared with the aqueous sample of FA (76% (ATP) and 97% (MTT) cell 
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viability) during both assays over the 5 day incubation period (Figure 6.11 and 6.12). 
This may have been due to enhanced accumulation of FA in the ATHP-1 cells compared 
to the aqueous FA (cf. Caco-2 and macrophage cell accumulation studies), however, a 
cytotoxic effect or assay interference from the NPs cannot be ruled out.38 
 
Figure 6.11 ATHP-1 cell ATP assay, 5 day incubation: A) Aqueous FA B) AmG1U-p(DEA50-co-
EGDMA0.9). Data shown as +/- standard deviation. 
 
 
Figure 6.12 ATHP-1 cell MTT assay, 5 day incubation: A) Aqueous FA B) AmG1U-p(DEA50-co-
EGDMA0.9). Data shown as +/- standard deviation. 
 
6.3.3 Caco-2 and ATHP-1 cell accumulation studies 
 
AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA was utilised in 
experiments to measure the cellular accumulation ratio (CAR) in Caco-2 and ATHP-1 
cells (Figure 6.13). It is important to note, that the CAR results may also include NPs 
associated with the cell membrane, without definite confirmation of cell entry. ATHP-1 
can model accumulation of molecules in macrophages.39
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Figure 6.13 Cellular accumulation ratio for aqueous FA and AmG1U-p(DEA50-co-EGDMA0.9) 
containing encapsulated FA (9 wt%) in A) Caco-2 cells; and B) ATHP-1 cells. Data shown as +/- 
standard deviation; **, P < 0.01; and ***, P < 0.001 (ANOVA) (n=3). 
 
Figure 6.13A shows that AmG1U-p(DEA50-co-EGDMA0.9) provides an increased 
accumulation of FA in Caco-2 cells (>0.018) compared to the aqueous (>0.007). Figure 
6.13B also shows AmG1U-p(DEA50-co-EGDMA0.9) has an increased accumulation of 
FA in ATHP-1 cells (>0.024) compared to the aqueous (>0.005). The increased 
accumulation in Caco-2 cells suggests that the earlier observed permeation occurs via a 
transcellular, as opposed to paracellular, pathway. If this is the case, studies can be 
performed to understand whether it is an active or passive process through the cell. 
 
6.3.4 Endocytosis inhibition
 
Polymeric complexes can enter mammalian cells through different endocytic 
pathways.40 For efficient optimisation of the nanocarrier it is important to profile its 
cellular uptake, because this largely determines its intracellular processing and 
subsequent permeation efficiency. Most of the current information on uptake of gene-
delivery vehicles is based on data following the use of chemical inhibitors of endocytic 
pathways.41 Here, a detailed characterisation was performed using 5 commonly used 
endocytosis inhibitors: Chlorpromazine hydrochloride (Chl), Dansylcadaverine (Dan), 
Indomethacin (Ind), Genistein (Gen) and Dynasore hydrate (Dyn) on transcellular 
permeation and CAR in Caco-2 cells. 
 
Initially, the % luminescence was measured with different levels of ATP depletion in 
Caco-2 cells, relative to an untreated control, using 2-Deoxyglucose and Rotenone. This 
was the control experiment to confirm that treating Caco-2 cells with 2-deoxyglucose 
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and rotenone depletes ATP, and was used to decide what concentrations to proceed with 
(Figure 6.14). In this instance, the measurement of ATP was performed using a 
luciferin-luciferase assay in a luminometer, which measures the production of ATP.42 
Following this, cells were incubated with 2-Deoxyglucose/Rotenone for 20 min at 37oC, 
and encapsulated FA AmG1U-p(DEA50-co-EGDMA0.9) NPs were added to the well in 
order to gain an understanding of whether transport was potentially active (ATP-
dependant) or passive (non ATP-dependant). Figure 6.15 shows the Caco-2 CAR % of 
AmG1U-p(DEA50-co-EGDMA0.9) encapsulated with FA (9 wt%), indicating a reduced, 
but not significant, CAR (48%) upon ATP depletion. 
 
 
Figure 6.14 % Luminescence relative to untreated control following treatment of varying 
concentrations of 2-deoxyglucose/Rotenone. Data shown as +/- standard deviation. 
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Figure 6.15 Caco-2 CAR % of AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA (9 
wt%) with and without ATP depletion. Data shown as +/- standard deviation. 
 
Following this, the effect on transcellular permeation (pApp) in the presence of each 
inhibitor was considered (Figure 6.16). Transport across the endocytosis pathway is an 
active process43 and when these processes were inhibited, there was no significant drop 
in pApp (P > 0.5) for AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA. 
This suggests that the movement is not dependant on ATP. 
 
 
Figure 6.16 pApp of aqueous FA (blue) and AmG1U-p(DEA50-co-EGDMA0.9) (9 wt% FA) (red) with 
various endocytosis inhibitors across the Caco-2 cell monolayer following a 4 hour incubation period. 
Data shown as +/- standard deviation. 
 
 
CHAPTER 6 
 
243?
Following this, the 14C-mannitol control experiment was repeated to investigate the 
integrity of the monolayer in the presence of the inhibitors (i.e. that the passage of FA is 
transcellular and not due to a compromised monolayer). Both experiments, aqueous FA 
(Figure 6.17A) and AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA 
(Figure 6.17B), suggest the monolayer remains intact throughout the incubation with 
aqueous FA and AmG1U-p(DEA50-co-EGDMA0.9) with the selected inhibitors.  
 
 
 
Figure 6.17? pApp of 14C mannitol following 1 hour incubation, after monolayer was exposed to 
aqueous FA (A) and AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated FA (9 wt%; B) with 
various endocytosis inhibitors (red-dotted line represents threshold value). Data shown as +/- standard 
deviation. 
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6.3.5 Encapsulation of an anti-retroviral therapy drug 
 
AmG1U-p(DEA50-co-EGDMA0.9) was loaded with EFV using identical 
nanoprecipitation conditions for FA encapsulation. EFV is a non-nucleoside reverse 
transcriptase inhibitor which prevents the conversion of viral ribonucleic acid strands to 
deoxyribonucleic acid by the reverse transcriptase enzyme. EFV is considered a first-
line global therapy for new cases of HIV infection and is well-tolerated by patients. 
Side-effects of EFV administration include neuropsychiatric disturbances (which may be 
persistent), low incidence of hepatotoxicity and metabolic alterations.44,45,46,47,48 EFV 
was successfully encapsulated within the AmG1U-p(DEA50-co-EGDMA0.9) hyp-
polydendron NP dispersion at 9 wt%. This was confirmed by no observable macroscale 
precipitation of nanomaterial or drug, and a stable NP dispersion producing a 
monomodal size distribution (Figure 6.18). 
 
 
Figure 6.18 DLS size by intensity trace of blank AmG1U-p(DEA50-co-EGDMA0.9) (green), 
encapsulated FA (9 wt%; orange) and encapsulated EFV (9 wt%; blue). 
 
Table 6.3 DLS analysis of AmG1U-p(DEA50-co-EGDMA0.9) (blank) and containing encapsulated FA 
(9 wt%) or encapsulated EFV (9 wt%). 
 
pH=7.8 + FA (9 wt%) + EFV (9 wt%) 
Dz
(nm) 
PDI 
Dn
(nm) 
Dz
(nm) 
PDI 
Dn
(nm) 
Dz
(nm) 
PDI 
Dn
(nm) 
134 0.148 82 59 0.243 28 69 0.194 38 
 
The size of the encapsulated EFV NPs (Dz and Dn) was very similar to the encapsulated 
FA AmG1U-p(DEA50-co-EGDMA0.9) NPs, which were both noticeably smaller than the 
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un-encapsulated NPs (Table 6.3). This may suggest the dye or drug acts as a nucleation 
point and directs the aggregation process. Future studies for AmG1U-p(DEA50-co-
EGDMA0.9) containing encapsulated EFV should include assessing pApp, cytotoxicity 
assessment, accumulation, and the efficacy of the nanocarrier against HIV, compared to 
aqueous EFV efficacy. Furthermore, in order to reduce the likelihood of HIV becoming 
resistant to a class of anti-retroviral drugs, healthcare providers recommend that people 
infected with HIV take a combination of anti-retroviral drugs in previously mentioned 
ART. Future studies may include the encapsulation of other drugs such as the protease 
inhibitors, Lopinavir and Ritonovir.49,50 
 
6.4 Conclusions 
 
Overall, the research presented represents the study of previously synthesised materials 
within a pharmacological relevant manner. It is important to note, and issues have been 
addressed throughout, that there are limitations associated with these in vitro studies and 
how further investigations are essential to understand the behaviour of hyp-polydendron 
NPs. These results primarily suggest that the AmG1U-p(DEA50-co-EGDMA0.9) in 
particular, showed negligible cytotoxicity with a marked increase in transcellular pApp 
(A>B) without damage to the monolayer (membrane). The increased accumulation of 
encapsulated FA compared to the aqueous FA in Caco-2 and ATHP-1 cells could 
suggest uptake of the nano-carrier into primary lymphocytes and consequently, 
macrophages. This presents great advances for future developments that may allow oral 
dosing leading to circulating polymeric NPs. This may prove clinically desirable to 
many nonterminal or chronic diseases that utilise nanomedicines, but wish to avoid 
regular or repeated intravenous administration. 
?
6.5 Experimental 
 
Transcellular permeation studies: Cells were seeded at a density of 3.5 x 104 per well 
into 24 well Costar→ HTS transwell plates, with 0.33 cm2 surface area, and 3 µM pore 
size, and propagated to a monolayer over a 21 day period. Only wells with 
transepithelial electrical resistance (TEER) values >800Ω were used. 10 µM of FA hyp-
polydendron or 10 µM aqueous FA (transport buffer spiked with DMSO dissolved FA, 
DMSO final volume <0.5% of total volume), was added to the apical or basolateral 
compartment of the wells to quantify transport in both A>B and B>A directions. Plates 
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were sampled following 4 hours incubation, A and B contents were stored at -30oC prior 
to analysis. 
 
Monolayer integrity studies: To assess monolayer integrity following incubation, 100 
µL of transport buffer containing 2 µL mL-1 14C mannitol was added to the apical 
compartment and incubated for 1 hour. 4 mL of scintillation fluid was added to 100 µL 
of the sampled contents and quantified on the scintillation counter.  
 
HPLC quantification of FA: 150 µL of sample and prepared calibration for each hyp-
polydendron material, were extracted using 9 volumes of acetone, sonicated for 6 min 
and centrifuged for 3 min prior to drying at 30oC on a vacuum centrifuge. Each sample 
was reconstituted using 150 µL of 25% DMSO. Samples were run on a Dionex HPLC 
using a Fortis C18 column (100 mm x 4.6 mm i.d., 3 µm). The mobile phase consisted 
of: (A) 95% H2O; 5% ACN; 5 mM NH4FA (B) 95% ACN; 5% H2O; 5 mM NH4FA. 
Elution peaks were monitored with a fluorescence detector at; 490 (ex), 530 (em) 
(Thermo Spectrasystem FL3000) and subsequently analysed using Chromeleon v.6.8. 
software. 
 
Caco-2 and macrophage cell accumulation studies: Caco-2 cells were seeded into 6 
well plates (NunclonTM) at a density of 4 x 106 per well and incubated at 37oC 5% CO2 
for 24 hours. THP-1 cells were seeded at a density of 4 x 106 cells per well in a 6 well 
plate and allowed to differentiate to ATHP-1 cells for 7 days in 10 nM PMA 
supplemented RPMI-1640 10% FBS prior to use. Following incubation, the media was 
aspirated and cells washed twice with HBSS (37oC) and subsequently replaced with pre-
warmed (37oC) Transport Buffer containing either 10 µM (final concentration) aqueous 
FA or 10 µM (final concentration) hyp-polydendron formulated FA. Following 24 hours 
incubation at 37oC 5% CO2, 150 µL of the extracellular media was sampled. The 
remaining media was aspirated and cells were washed twice with ice cold HBSS. The 
ice cold HBSS was aspirated and replaced with 500 µL of a 50% acetone 50% water 
solution and incubated for 24 hours at -20oC, 150 µL of the lysate was subsequently 
sampled. Finally, 9 volumes of acetone was added to each intracellular and extracellular 
sample to extract FA for quantification on the HPLC as previously described. Average 
cell volumes were previously determined using a Scepter 2.0 Automated Cell Counter 
(Millipore) and used to calculate Cellular Accumulation Ratios (CAR); (Intracellular 
concentration/Volume)/(Extracellular concentration/Volume). 
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Cytotoxicity assays: Caco-2 cells were seeded into 96 well plates (NunclonTM) at a 
density of 1 x 104 per well and incubated at 37oC 5% CO2 for 24 hours. THP-1 cells 
were seeded at a density of 1 x 104 cells per well in 96 well plates and allowed to 
differentiate to ATHP-1 cells for 7 days in 10 nM PMA supplemented RPMI-1640 10% 
FBS at 37oC 5% CO2 prior to use. Following incubation, the media was aspirated and 
replaced with media containing either varying concentrations (0.1 – 15 µM) of aqueous 
or hyp-polydendron formulated FA as determined by the molarity and mass of FA 
contained in each formulation. The treated cells were then incubated for either 24 or 120 
hours at 37oC 5% CO2. All cytotoxicity analyses were determined using both ATP and 
MTT cell viability assays. 
 
ATP assays: ATP assays were conducted using CellTiter-Glo→ Reagent (Promega) in 
accordance with manufacturer’s instructions. Briefly, the plates and contents were 
initially equilibrated to room temperature. Subsequently, all but 20 µL of media was 
removed from each well and 20 µL CellTiter-Glo→ reagent was added to produce a 1:1 
ratio. The contents were then mixed for 10 minutes on an orbital shaker to induce lysis 
and allow for stabilisation of luminescence signal prior to reading on a TECAN GENios 
plate reader. MTP assay: For MTT assays, 20 µL of a 5 mg mL-1 MTT reagent was 
added to each well and incubated for 2 hours. Subsequently, 100 µL MTT lysis buffer 
(50% N-N-Dimethylformamide in water containing 20% SDS, 2.5% glacial acetic acid 
and 2.5% hydrochloric acid, pH 4.7) was added to each well and lysed overnight at 37°C 
5% CO2. Following incubation, the absorbance of each well was read using a TECAN 
GENios plate reader (560 nm). 
 
ATP depletion of Caco-2 cells using varying concentrations of 2-Deoxyglucose and 
rotenone: Caco-2 cells were incubated with varying concentrations of 2-
Deoxyglucose/rotenone (0/0, 1/50, 2/100 and 3/150 nM) as outlined for 20 min at 37oC 
5% CO2. Following incubation, ATP assays were carried out using CellTiter-GLO® kit 
as previously described to determine relative depletion of ATP compared to an untreated 
control. 
 
Apparent permeability (Papp) of fluoresceinamine encapsulated in polymeric 
nanocarrier materials: Caco-2 cell monolayers were pre-incubated for 30 min in 
transport buffer containing either: 30 µM chlorpromazine (Chl); 200 µM 
dansylcadaverine (Dan); 10 µM genistein (Gen); 150 µM dynasore (Dyn); or 150 µM 
Indomethacin (Ind) prior to washing three times with pre-warmed (37oC) HBSS. 
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Following washing, the Caco-2 monolayers were co-incubated with the various 
endocytosis inhibitors as outlined, and either aqueous (DMSO spiked; <0.1% v/v) or 
nanocarrier formulated fluoresceinamine for 4 h at 37oC 5% CO2. 
 
Statistical analysis: Data was statistically analysed using Prism 5 (GraphPad) and 
StatsDirect statistical software (version 2.7.9). 
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Synthesis and nanoprecipitation studies of biodegradable linear-dendritic 
ε-caprolactone polymer hybrids and hyp-polydendrons 
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7.1 Introduction 
7.1.1 Biodegradable nanoparticles 
 
Biodegradable nanoparticles (NPs) are strongly desirable for drug delivery applications 
due to their enhanced biocompatibility and encapsulation efficiency,1 with reported 
controlled release and decreased toxicity concerns.2 The synthesis, encapsulation, 
release studies and overall enhanced therapeutic value of drug loaded biodegradable 
NPs, over non-biodegradable nanocarriers, have been discussed in several important 
review articles.3,4 Research is ongoing, with specific investigations targeting surface 
modification, targeted delivery and control of release profiles.5 Along with encouraging 
encapsulation and stabilisation in aqueous media, the covalent modification of NPs with 
cell-targeting motifs remains a key challenge for potential drug delivery vehicles.  
 
NPs comprising p(lactic-co-glycolic acid) p(LGA) are receiving increasing attention for 
drug delivery and tissue engineering applications. Opportunities exist for NP attachment 
to cells or organs in the body,6 for example, via selectin-ligand chemistry.7 
Functionalised surfaces also offer specific attachment to scaffolds to encourage control 
over cellular interactions, or allow delivery of encapsulated moieties to target sites. This 
functionality is particularly desirable as it may reduce adverse drug side effects and 
enhance antigen delivery when considering vaccination applications. 
 
In many cases, problems have arisen during the coupling of ligands to polyester 
particles, due to the lack of functional chemical groups situated on the polymer 
backbone. This consequently hinders traditional conjugation methods and a collection of 
different methods have been developed to overcome this, including the synthesis of 
p(LGA) copolymers with either amine8 or acid9 chain-end functionality that can be 
further fabricated into particles. Alternatively, particles can be produced from polyester 
copolymers such as p(ethylene glycol) (PEG)-p(LGA), leading to the formation of 
biodegradable and biocompatible microspheres.10 Alternatively, plasma treatment of 
p(LGA) has proven to provide surface modification and introduce hydrophilic functional 
groups.11,12 Other strategies to achieve this include the inclusion of chemistries within 
the polymer backbone to render the materials more susceptible to modification. For 
example, alkyne groups have been introduced into aliphatic polyesters, via co-
polymerisation of ε-caprolactone (CL) with propargyl 3-methylpentenoate oxide, to 
allow copper catalysed azide “click” reactions.13 
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The controlled release of drugs from biodegradable materials has been demonstrated via 
tablets,14,15,16 implants,17 patches18 and injectable microspheres.19 These offer drug 
release over varying periods extending from hours to years. Lupron Depot is a p(LGA) 
matrix-type mixture containing leuprorelin acetate,20,21 administered as injectable 
microspheres to treat endometriosis and palliative care for prostate cancer. The 
component polymer, polymer molecular mass, excipients or drug loading all have an 
impact on the stability of the drug, as well as the rate of release.  
 
7.1.2 Degradable aliphatic polyesters 
 
Polyesters find utility within the field of biomedical materials due to their intrinsic 
sensitivity to water, heat and enzymatic degradation. For p(LGA), not only is it 
biodegradable but hydrolysis in physiological media results in glycolic and lactic acids, 
which are non-toxic components eliminated as carbon dioxide and water via the Krebs 
cycle.22 Commercially, the most commonly and extensively used polyester NPs are 
made from p(lactic acid) (p(LA), p(glycolic acid) p(GA), p(CL)) or p(LGA) (Figure 
7.1).  
 
 
Figure 7.1 Cyclic monomers used to produce common and extensively used polymeric biodegradable 
NPs: A) lactide; B) glycolide and C) ε-caprolactone. 
 
As mentioned above, degradable aliphatic polyesters provide the foundation for NP-
based therapeutics, with each possessing different attractive properties. The slower 
degradation of p(LGA) in comparison to p(LA) makes it particularly useful in long-term 
implantable devices. The preparation of p(CL) NPs23 have also been reported, by 
methods such as nanoprecipitation, solvent displacement and solvent evaporation. 
Polyester NPs have been shown to evade the immune phagocytic and antigen-presenting 
systems due to their ability to mimic adhesive leukocyte behaviour.7,24 Administration, 
activity and therapeutic importance of drugs within each NP system display differences, 
hence the extensive research into each nano-system. For example, the chemotherapy 
drug Taxol may be loaded into p(LGA) with a 100% encapsulation efficiency25 in 
comparison to only 20% in p(CL).26 However, the stability and therapeutic activity 
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associated with p(CL) outweighs that of p(LGA) nanomedicines. 
 
7.1.3 Ring-opening Polymerisation 
Ring-opening polymerisation (ROP) is a chain-growth polymerisation (Chapter 1, 
section 1.3), where the polymer chain end acts as the propagating centre for further 
cyclic monomers (opening the ring system) to add to the growing polymer chain. The 
ring-opening is driven by release of the bond-angle strain or steric repulsions between 
the ring atoms within the cyclic monomers.27 
 
The ROP of lactones is used worldwide to produce aliphatic polyesters for biomedical 
applications28 such as bioresorbabale devices in surgery, and drug delivery vehicles in 
therapy. Few lactones spontaneously polymerise, simply on storage or through heating,29 
and most require the presence of catalysts and initiators. Effective polymerisations have 
been performed using a range of organometallic catalysts (e.g. oxides, carboxylates, 
alkoxides), resulting in controlled ring-opening to synthesise a range of polyester 
structures;30,31 the polymerisation mechanism is dependent on the catalyst/initiator 
selected. A coordination-insertion mechanism has been proposed when using 
organometallic catalysts in combination with an alcoholic initiating species. 
 
Tin (II) 2-octanoate, Sn(Oct2), is the most commonly reported catalyst for ROP. Despite 
its toxicity, it is effective, versatile, easy to handle and soluble in common organic 
solvents and lactone monomers. The full details of the polymerisation mechanism is 
rather complex and several specific mechanisms have been proposed,32,33,34,35 including 
the well reported coordination-insertion process (Scheme 7.1).36 Within this mechanism, 
the monomer coordinates to the Lewis acidic metal centre via the exocyclic oxygen, 
rendering the carbonyl group of the lactone susceptible to nucleophilic attack.37  
 
Metal-free polymerisation approaches are attractive when targeting polyesters for 
medicinal or microelectronic devices. These methods have been achieved via 
nucleophilic, basic or bifunctional activation38,39 in a variety of systems such as 4-
aminopyridines,40 N-heterocyclic carbenes,41 thiourea/amine combinations,42,43 
guanidines,44,45 and phosphazenes.46,47 
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Scheme 7.1 Proposed ring-opening mechanisms using tin (II) 2-octanoate via co-ordination-insertion 
mechanism. 
The application of a bifunctional thiourea-amine catalyst for the ROP of lactide was 
reported in 2005,42 with no observable transesterification side reactions following 
monomer consumption. The polymerisation proceeded by monomer activation via the 
hydrogen bond-donating thiourea and by the propagating alcohol initiator through the 
hydrogen bond-accepting tertiary amine (Scheme 7.2A). Investigations revealed that 
both the hydrogen bond donor and accepter were essential for the ROP to ensue, even 
upon separation of the hydrogen-bond donating/accepting activator groups into two 
independent molecules. Despite their benefits, the thiourea-amine catalyst systems are 
noticeably slow compared to reported “superbase” systems.43 These strongly basic 
amines, specifically the commercially available 1,8-diazabicyclo[5.4.0]undec-7-ene 
(Scheme 7.2B) have successfully polymerised lactide, without the requirement of a 
hydrogen-bond donor cocatalyst.48 The “superbase” system has also displayed high 
catalytic activity with >98% lactide monomer conversion (500 eq.) within 2 hours. 
 
 
Scheme 7.2 Metal-free alternatives to metal catalyst systems for ROP. A) Proposed activation 
pathway of “supramolecular” H-bond donor and acceptor species in ROP. The monomer is activated 
by the H-bond donor group (green) and initiating/propagating system activated by the H-bond 
accepter group (blue). B) The commercially available “superbase” 1,8 diazabicyclo[5.4.0]undec-7-ene 
used in the ROP of lactide. 
 
The increasing interest in acid-catalysed ROP of (di)lactones has led investigations of 
the influence of catalyst acidity on its activity.49 This growing curiosity stems from 
reports by Kricheldorf et al.50,51 demonstrating the feasibility of trifluoromethanesulfonic 
acid (HOTf)-catalyzed ROP of lactide. In the presence of a protic initiator, HOTf 
promotes and controls the ROP of lactide at room temperature.52 This combination also 
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proved efficient for the homopolymerisation of CL and for its co-polymerisation with 
lactide.53,54 
 
Comparatively, the ROP of (di)lactones promoted by Brönsted acids has been less well 
studied. Further studies include reports from Endo and co-workers55,56 and Jérôme and 
co-workers57 reporting the polymerisation of CL using hydrochloric acid (HCl·OEt2) as 
a catalyst in the presence of an alcohol initiator. These combinations provide a well-
controlled polymerisation, but one that proceeds slowly despite the large amounts of 
acid used. Further to this, di- and tri-block copolymers of PEG and p(CL) have been 
successfully prepared via a metal-free monomer-activated mechanism in the presence of 
(HCl·OEt2).58 
 
Studies have also investigated many variants of initiator for ROP, ranging from benzyl 
alcohols59 to aluminium alkoxides.60 The facile nature of ROP has also been extended to 
include microwave preparations of p(CL), without the need for a metal catalyst using 
benzoic acid as the initiator.61 
?
7.1.4 Biodegradable linear-dendritic polymer hybrids 
 
Dendrimers have provided insights into the effect of branching on the physical and 
solution properties of macromolecules.62 Dendronised polymers and linear-dendritic 
polymer hybrids have been extensively investigated63 and shown to exhibit 
pharmacokinetic behaviour in bio-distribution studies that differs from non-dendritic 
linear materials of equivalent molecular weight.64 The synthesis of these materials is 
generally less complex than lengthy and expensive dendrimer preparation, with the 
potential utilisation of peripheral and pendant groups for drug attachment, targeting and 
enhanced solubilisation. Functionalisation of dendrons with drugs, fluorescent dyes, 
imaging moieties, targeting agents and stimuli-responsive components have all 
demonstrated a multi-valency benefit, including deoxyribonucleic acid (DNA) or protein 
binding and targeted drug delivery.65,66 
 
Fréchet and co-workers have reported combination of CL ROP with dendritic 
macromolecules containing primary alcohol functionality, derived from 3,5-
bis(benzyloxy)-benzyl alcohol, serving as initiators to produce linear-dendritic p(CL) 
polymer hybrids (Figure 7.2i).67 These ideas have been progressed further, including 
reports of new synthetic routes to produce other dendritic initiators from 2,2-
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bis(methylol)propionic acid (bis-MPA) based dendritic molecules.68 Malkoch and co-
workers have reported libraries of linear-dendritic hybrids, produced by rapid and 
efficient orthogonal click chemistry, composed of p(CL) arms attached to bis-MPA-
derived dendrimers with a linear component of PEG (Figure 7.2ii).69 Following 
successful micelle formation from these new amphiphilic dendritic structures, 
doxorubicin was encapsulated and the cellular toxicity was investigated on breast cancer 
cell lines and human macrophages.70 
 
Figure 7.2 Chemical examples of linear-dendritic biodegradable polymer hybrids that exist in the 
literature; i) Linear-dendritic CL polymer containing 3,5-bis(benzyloxy)-benzyl alcolate dendron 
chain end functionality (G4-CL); ii) Linear-dendritic PEG polymer comprised of bis-MPA dendritic 
functionality and p(CL) arms (PEG-G4-PCL). 
Aside from the biodegradability and biocompatibility associated with these linear-
dendritic polymer hybrids, they also offer distinctive hierarchical self-assembly 
behaviour, suggesting potential for stimuli-responsive nanomedicine benefits. Progress 
within this field includes linear-dendritic biodegradable block copolymer hybrids, DNA-
/protein-dendritic bio-hybrids and the considered potential applications within 
bionanotechnology.71 
 
7.1.5 Research Aims 
 
In previous work and chapters within this thesis, the successful preparation of linear-
dendritic polymer hybrids and hyperbranched polydendrons (hyp-polydendrons) has 
been presented for methacrylic monomers polymerised via atom transfer radical 
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polymerisation (ATRP). High molecular weight materials with systematic architectural 
variation and comprising a variety of different monomer compositions have undergone 
nanoprecipitation to produce NPs whose behaviour in varying pH aqueous solutions 
have been studied. The same concepts have been applied to produce highly functional, 
linear-dendritic and branched polyesters within this chapter.
 
Dendron initiators were utilised in the ROP of CL to produce a series of linear-dendritic 
polymer hybrids (Figure 7.3i), with amine-functionality incorporated within the dendron 
initiators. The co-polymerisation of cyclic and bicyclic ester monomers was carried out 
to form high molecular weight branched polyester hyp-polydendrons (Figure 7.3ii), in 
order to investigate the effect of architecture, dendron generation and pH on behaviour of 
the polymeric NPs formed from these materials. 
 
 
Figure 7.3 Diagrammatic representation of the polymerisation of CL using an amine-functionalised 
generation 2 dendron ROP initiator to produce a biodegradable linear-dendritic hybrid (i); and the co-
polymerisation of CL and 4,4’-bioxepanyl-7,7’-dione to produce a biodegradable hyp-polydendron. 
CL was chosen as the study monomer as its synthesis has been extensively studied with 
good levels of reported polymerisation control and high monomer conversions. P(CLx) is 
a highly hydrophobic polymer, ideal for the encapsulation of poorly water soluble drugs 
and it naturally degrades via non-enzymatic hydrolytic ester cleavage.72 Sn(Oct2) was 
utilised as the catalyst, as reaction conditions are well understood, it has been well 
documented in the successful production of p(CLx)73 and, unlike organic catalysts (such 
as acid catalysts), it is unlikely to interact with the dendron initiators via the amine 
functionality. 
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Hyperbranched polymers of CL have typically been produced via AB2 polycondensation 
reactions or a ring-opening multi-branching polymerisation. In the latter instance, the 
initiator is attached to the cyclic monomer ring.74 The first instance of branched p(CL) 
was reported by Hedrick and co-workers using an AB2 macromonomer derived from 
bis-MPA.75 Hedrick and co-workers extended this synthesis approach with another 
branching strategy utilising benzyl ester protected bis-MPA, Sn(Oct)2 and another AB2 
CL-based macromonomer.76 The first preparation of CL branched polymers utilising 
ROP of CL was conducted by Thurecht and co-workers;77 the solution co-
polymerisation of CL was conducted with 4,4’-bioxepanyl-7,7’-dione (BOD), in the 
presence of a reversible addition-fragmentation transfer (RAFT) agent containing a 
hydroxyl group, leading to branched p(CL) with RAFT agents at the chain ends. 
 
CL has also been polymerised in the presence of bifunctional degradable cyclic 
monomers such as BOD (Figure 7.4i) and 2,2-bis(ε-CL-4-yl)propane78 (Figure 7.4ii) in 
order to produce a range of selectively degradable cross-linked star polymers, which 
often possess improved solubility and a more globular structure with a higher density of 
functional groups, compared to linear CL polymers.79 
 
Figure 7.4 Chemical structure of bifunctional degradable cyclic monomers: i) 4,4’-bioxepanyl-7,7’-
dione and; ii) 2,2-bis(ε-caprolactone-4-yl) propane. 
In 2014, Irvine and co-workers reported the first investigations into the bulk ROP of CL 
and, in the presence of BOD, used an extension of the “Strathclyde Method” to control 
the growing polymer chains and produce high molecular weight, soluble CL polymers.80 
The concepts first discussed by Irvine and co-workers have inspired the work embodied 
within this research chapter, leading to polyester hyp-polydendrons. 
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7.2 Amine-functionalised dendron ROP initiator synthesis  
The amine-functional hyp-polydendrons discussed in previous chapters, utilised new 
dendron ATRP initiators; the formation of amine-functional polyester hyp-polydendrons 
requires the modification of this approach to form new dendron-ROP initiators. The 
initiators were designed to contain the same numbers of tertiary amine functionality as 
the linear-dendritic hybrids and hyp-polydendrons previously produced via ATRP. The 
previously synthesised ATRP initiators were synthesised after the initial production of 
dendrons containing secondary alcohol focal point functionality, and subsequent 
esterification to produce the required bromo-initiators. The analogous initiators targeted 
for ROP comprise a primary alcohol focal group as the intended initiating centre. This 
was expected to allow efficient initiation and comparisons to be drawn against benzyl 
alcohol (BnOH), a well-known initiator of bulk CL ROP in the presence of Sn(Oct2) 
catalyst. 
As previously described, the synthesis of tertiary amine-functional dendritic ROP 
initiators (AmG1’-OH and AmG2’-OH) again utilised the exhaustive Michael addition81 
of 2-(dimethylamino) ethyl acrylate (DMEA) to primary amine-containing molecules 
bearing primary hydroxyl functionality; the commercially available ethanolamine was 
used as the precursor for the synthesis of AmG1’-OH, whilst 1-[N, N-bis(2-
aminopropyl)-amino]-2-propan-1-ol (APAP’) was used to synthesise AmG2’-OH. The 
AmG0’-OH was commercially available as 2-dimethylaminoethanol (Scheme 7.3).  
 
Scheme 7.3 Diagrammatic representation of amine-functionalised the dendron ROP initiators AmG0’-
OH (green), AmG1’-OH (blue) and AmG2’-OH (red). 
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7.2.1 Synthesis of 1-[N, N-bis(2-aminopropyl)-amino]-propan-1-ol 
 
The synthesis of 1-[N, N-bis(2-aminopropyl)-amino]-propan-1-ol (APAP’) was carried 
out in four synthetic steps. [tBOC2-BAPA-G1] was previously synthesised in Chapter 2, 
by reacting tertiary butanol (Scheme 7.4 1) with 1,1’-carbonyl diimidazole (CDI) 
(Scheme 7.4 2) producing the monosubstituted imidazole carboxylic ester (Scheme 7.3 
3). This was reacted with bis(3-aminopropyl)amine (BAPA) to form [tBOC2-BAPA-G1] 
(Scheme 7.4 4),82 followed by N-alkylation to functionalise the focal point. [tBOC2-
BAPA-G1] was refluxed with 2-bromo-ethanol (Scheme 7.4 5) in 1,4-dioxane, with 
potassium carbonate as the base,83 to yield the primary alcohol functional [tBOC2-
BAPA-OH’]. Analysis by 1H and 13C nuclear magnetic resonance spectroscopy (NMR) 
and electro-spray mass spectrometry (ES-MS) are shown in the Appendix, Figures A66-
68. 
 
 
Scheme 7.4 Synthesis of 1-[N, N-bis(2-aminopropyl)-amino]-propan-1-ol. 
 
The protecting N-tertiary butoxycarbonyl (tBOC) groups were removed, as described in 
Chapter 2, to afford the tris-ammonium salt APAP’.3HCl. Finally, the salt was 
converted to the free amine AB2 branching unit APAP’, using a strong base (4M sodium 
hydroxide) and extraction of the yellow product with chloroform (CHCl3) led to the final 
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product. Characterisation of APAP’ was carried out by 1H and 13C NMR and ES-MS 
(Figure 7.5 and Appendix, Figures A69 and 70). 
 
Figure 7.5 1H NMR spectrum (CDCl3, 400 MHz) of APAP’. 
The 1H NMR spectrum (Figure 7.5) confirms the removal of the 18 tBOC protons, 
previously seen at 1.41 ppm (Appendix, Figure A66). The 13C NMR shows 5 distinct 
peaks for the 5 different carbon environments (Appendix, Figure A69) and a molecular 
ion peak of [M+H]+ = 176.2 Da was seen in the ES-MS (Appendix, Figure A70); 
calculated (C8H21N3O) m/z = 175.1 Da. 
7.2.2 Synthesis of tertiary amine functional dendron ROP initiators (AmG1’-OH 
and AmG2’-OH) 
The synthesis strategy employed the simple exhaustive Michael addition of DMEA to the 
primary amine functional groups of either ethanolamine or APAP’ (Scheme 7.3i). Three 
tertiary amine functional ROP initiators were chosen for this study, ranging from the 
zeroth to the second generation (G0-G2), with the inclusion of 2-dimethylaminoethanol as 
the AmG0’-OH initiator. 
ES-MS and 1H NMR analysis confirmed the structures and purities of the products 
through monitoring the disappearance of the two singlet signals at ~6 ppm (Figures 7.6 
and 7.7), corresponding to the protons on the double bond of the DMEA, confirming 
removal of unreacted acrylate. The 1H NMR of the AmG1’-OH confirms an integration 
ratio of 12 protons (Figure 7.6a), for the terminal tertiary amine methyl groups to 2 
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protons corresponding to the methylene neighbouring the focal point hydroxyl group 
(Figure 7.6g). The 13C NMR shows a peak at 172.7 ppm corresponding to the carbonyls 
of the ester groups of the DMEA arms (Appendix, Figure A71). A molecular peak of 
[M+H]+ m/z = 348.2 and [M+Na]+ m/z = 370.2 was seen in the ES-MS (Appendix, 
Figure A72); calculated (C16H33N3O5) m/z = 347.5 Da.
 
Figure 7.6 1H NMR spectrum (CDCl3, 400 MHz) of AmG1’-OH. 
 
The 1H NMR spectrum for the AmG2’-OH dendron initiator revealed a peak at 2.23 
ppm, integrating to 24 protons and corresponding to the tertiary amine methyl group 
protons (Figure 7.7a). The signal corresponding to the methylene neighbouring the 
primary alcohol also integrated to 2 protons (Figure 7.7j) and the 8 methylene protons 
neighbouring the oxygen of the ester bonds in the DMEA residue are seen downfield at 
4.11 ppm (Figure 7.7c). The carbonyl ester peaks are again seen at 172.6 ppm in the 13C 
NMR (Appendix, Figure A73) and an [M+H]+ molecular ion peak at m/z = 748.6 Da was 
observed in the mass spectrometric analysis; calculated (C36H73O9N7) m/z = 748.0 Da 
(Appendix, Figure A74).  
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Figure 7.7 1H NMR spectrum (CDCl3, 400 MHz) of AmG2’-OH. 
 
7.3 Ring-opening polymerisation of ε-caprolactone 
 
P(CL) was first synthesised by van Natta et al. in 1934,84 and received later recognition 
as a drug delivery vehicle in 1979 by Pitt et al.85,86 in order to investigate the controlled 
release of narcotic antagonists, steroids and the delivery of ophthalmic drugs,87 which 
are currently being developed as NPs. 
 
The polymerisation of lactones has been reported under bulk, solution (e.g. 
tetrahydrofuran (THF), dioxane and toluene), emulsion88 or dispersion89 conditions. 
Polymerisation temperatures range from 100-150°C for bulk polymerisations and 0-
25°C in solution polymerisations in order to minimize inter- and intramolecular 
transesterification reactions, but factors such as reaction time, the type and concentration 
of catalyst or initiator, and the nature of the lactone (or lactide)90 also play important 
roles.  
 
 
 
 
 
CHAPTER 7 
264
7.3.1 Linear polymerisation of ε-caprolactone using benzyl alcohol and amine-
functionalised dendron ROP initiators 
Linear polymers of CL were synthesised at 110°C in bulk, initiated by BnOH using the 
Sn(Oct2) catalyst37 at the molar ratio [initiator]:[M]:[Sn(Oct2)] = 1:30:1/350 (Scheme 
7.5). 
 
Scheme 7.5 Diagrammatic representation of the linear polymerisation of ε-caprolactone (2) initiated 
by benzyl alcohol (1) to produce the linear polymer Bn-p(CL30). 
After 24 hours at 110°C, the resulting Bn-p(CL30) was dissolved in THF and purified by 
precipitation into hexane before analysis by triple detection gel permeation 
chromatography (GPC) and 1H NMR spectroscopy. The GPC refractive index (RI) 
chromatogram of the linear polymer showed a monomodal molecular weight distribution 
(Appendix, Figure A75); however, the analysis also revealed a relatively broad 
dispersity (Đ = 1.71) (Table 7.1, entry 1). To attempt to optimise the reaction, the molar 
ratio of metal catalyst was altered from [1/350] to [1/200] relative to initiator; the 
variation of the Sn(Oct2) molar ratio within aliphatic polyester polymerisations, has 
previously allowed control over the molecular weight and the molecular weight 
distribution.91  
 
Polymerisation at this higher ratio resulted in a broader molecular weight distribution, 
and produced a polymer with a number average molecular weight (Mn) significantly 
below the targeted values (Table 7.1, entry 2; Appendix, Figure A75). The breadth of the 
initial molecular weight distribution may be a result of transesterification, therefore the 
reaction time was shortened from 24 hours to 20 hours, at a metal catalyst molar ratio of 
[1/350] relative to initiator (Table 7.1, entry 3). High monomer conversion was 
achieved, and a linear polymer with a narrower dispersity than the previous attempts was 
collected (Đ = 1.50; Figure 7.8). It is worth emphasising that reported CL polymers 
prepared in bulk are within a dispersity range Ð = 1.4-1.7 at high conversion.80 
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Table 7.1 GPC analysis of linear and linear-dendritic p(CL), branched CL-BOD copolymers and hyp-polydendrons synthesised in bulk at 110°C. 
       GPCa    
Entry Polymer [Sn(oct2)] 
Time 
(hrs) 
Conversion 
(%) Mn Theory (g mol
-1)b Mn (g mol-1) Mw (g mol-1) Đ DPnc DPnd 
1 Bn-p(CL30) 1/350 24 99 3532 3060 5420 1.77 26 - 
2 Bn-p(CL30) 1/200 24 99 3532 1780 4430 2.49 15 - 
3 Bn-p(CL30) 1/350 20 98 3532 4050 6060 1.50 35 31 
4 AmG0’-p(CL30) 1/350 24 94 3513 2780 3950 1.42 24 34 
5 AmG1’-p(CL30) 1/350 48 95 3771 3090 6050 1.96 24 26 
6 AmG2’-p(CL30) 1/350 94 94 4172 5210 11460 2.20 39 36 
7 AmG2’-p(CL30) 1/150 66 80 3487 3910 9390 2.40 28 28 
8 Bn-p(CL30-co-BOD0.6) 1/350 24 73 - 2850 4950 1.74 - 22 
9 Bn-p(CL30-co-BOD1.0) 1/350 24 96 - 5600 108560 19.39 - 14 
10 AmG0’-p(CL30-co-BOD0.6) 1/350 120 55 - 4400 8650 1.97 - 25 
11 AmG0’-p(CL30-co-BOD0.8) 1/350 192 58 - 7100 20400 2.87 - 25 
12 AmG0’-p(CL30-co-BOD1.0) 1/350 120 98 - 4540 26500 5.83 - 33 
13 AmG1’-p(CL30-co-BOD0.6) 1/350 120 68 - 5730 24600 4.29 - 22 
14 AmG1’-p(CL30-co-BOD0.8) 1/350 144 83 - 3250 92600 28.50 - 24 
15 AmG2’-p(CL30-co-BOD0.8) 1/150 72 75 - 6030 40730 6.75 - 24 
16 AmG2’-p(CL30-co-BOD1.0) 1/150 89 81 - 13450 31350 2.33 - 59 
a Triple detection GPC (THF +TEA 2% v/v); b Mn Theory = ((Mw CL)*DPn targeted) + Mw chain end; c Determined by GPC; d Determined by NMR 
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Figure 7.8 GPC RI chromatogram overlays of Bn-p(CL30) (yellow),?AmG0’-p(CL30) (green), AmG1’-
p(CL30) (blue) and AmG2’-p(CL30) (red). 
The reaction proceeded to high monomer conversion (98%) as confirmed by 1H NMR 
analysis of the crude polymerisation media. 1H NMR analysis of the purified sample 
also allowed assessment of the number average degree of polymerisation (DPn), by 
comparison of the aromatic signal attributing to the benzyl chain end group (Figure 
7.9a), with clear resonances assigned to p(CLx) proton peaks residing in the polymer 
backbone.  
 
Figure 7.9 1H NMR spectrum (CDCl3, 400 MHz) of Bn-p(CL30). 
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AmG0’-OH, AmG1’-OH and AmG2’-OH dendron ROP initiators were also used to 
polymerise CL under identical conditions (Figure 7.10) ([initiator]:[M]:[Sn(Oct2)] = 
1:30:1/350, in bulk at 110°C), with the resulting linear-dendritic polymers purified and 
analysed by GPC (Table 7.1, entries 4, 5 and 6).
 
 
Figure 7.10 Diagrammatic representation of the linear polymerisation of CL initiated by the AmG0-
G2’ dendron ROP initiators to produce the linear-dendritic p(CL) polymer hybrids, AmG0’-p(CL30), 
AmG1’-p(CL30) and AmG2’-p(CL30). 
The linear-dendritic p(CL) hybrids reached high monomer conversion (>94 %) in 
noticeably longer reaction times (Table 7.1) which increased considerably with 
increasing dendron initiator generation. The AmG0’-p(CL30) and AmG1’-p(CL30) 
possessed an Mn close to the targeted theoretical values, with the AmG0’-p(CL30) 
showing a narrower molecular weight distribution than any Bn-p(CL30) polymers 
previously produced (Figure 7.8). In comparison, the AmG1’-p(CL30) displayed a broad 
molecular weight distribution (Đ = 1.96) suggesting a lack of control and the recovered 
AmG2’-p(CL30) equally exhibited a broad distribution of molecular weights and high Mn 
values. In an attempt to establish a higher level of control, the AmG2’-OH ROP was 
carried out using an increased amount of Sn(Oct2), namely [initiator]:[M]:[Sn(Oct2)] = 
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1:30:1/150, in bulk at 110°C (Table 7.1, entry 7). An Mn closer to the theoretical value 
was obtained (3910 g mol-1), with a broader dispersity, Đ = 2.40 (Figure 7.8). The 
polymerisation only reached 80% monomer conversion within 66 hours. These initial 
studies for the production of linear-dendritic CL polymer hybrids suggest that 
improvements could be made to optimise each particular polymerisation. 
 
The AmG1’-p(CL30) 1H NMR spectrum (Figure 7.11B) shows a peak at ~2.27 ppm 
integrating to 72 (Figure 7.11 a,b,e,f,h), corresponding to the polymer protons 
neighbouring the carbonyl group and all protons neighbouring N atoms in the dendron 
chain end (22 protons). Subtraction of the dendron protons reveals a DPn=26 monomer 
units, similar to the DPn=24 monomer units predicted by GPC. The 1H NMR spectrum of 
AmG2’-p(CL30) (Figure 7.11C) allows integration of the protons residing in the dendron 
chain end. The protons neighbouring the oxygen atom within the DMEA ester arms 
integrates to 8 protons (Figure 7.11c) and the peak at ~2.23 ppm predicts a DPn=36 
monomer units, following subtraction of the 24 protons from the surface methyl groups. 
 
Previously reported kinetic studies for BnOH-initiated p(CL) synthesis, targeting chain 
lengths of DPn = 50 monomer units at 150°C in solvent free conditions, have confirmed 
controlled ROP of CL;80 similar kinetic studies were performed for the bulk linear CL 
polymerisations (target DPn  = 30 monomer units, 110°C) initiated by BnOH and the 
three dendron ROP initiators. All variants of initiator indicated first order kinetics for the 
linear polymerisation and linear evolution of Mn with conversion (Figure 7.12), at least 
within the early stages of detailed examination. Accurate dn/dc values of the final 
polymers were used to determine the earlier Mn values (Appendix, Table A3), which 
may lead to inaccuracy in reported Mn values. The Bn-p(CL30) and AmG0’-p(CL30) 
reached high monomer conversion within similar reaction times of 22 and 24 hours 
respectively (Figure 7.12A and C). The AmG1’-p(CL30) and AmG2’-p(CL30) 
polymerisations took longer to reach high monomer conversion; 48 and 94 hours for the 
AmG1’- (Figure 7.12E) and AmG2’- (Figure 7.12G). In all cases, dispersities remained 
low until reaching high monomer conversion. 
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Figure 7.11 1H NMR spectra (CDCl3, 400 MHz) of AmG0’-p(CL30) (A), AmG1’-p(CL30) (B) and 
AmG2’-p(CL30) (C). 
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Figure 7.12 Kinetic plots for linear DP30 polymers. A) and B) Bn-p(CL30), C) and D) AmG0’-
p(CL30), E) and F) AmG1’-p(CL30), G) and H) AmG2’-p(CL30). A, C, E and G) Conversion (blue 
squares), ln([M]0/[M]) (red circles); B, D, F and H) Mn (red circles) and Ð (blue lines). 
CHAPTER 7 
271
7.3.2 Co-polymerisation of CL and 4,4’-bioxepanyl-7,7’-dione using benzyl and 
AmG0-G2’ functional dendron ROP initiators 
7.3.2.1 Synthesis of BOD 
BOD has been synthesised by several research groups, with reports including its use for 
the cross-linking of lactide and CL polymerisations in order to generate selectively 
degradable star polymers.92 Further investigations have used the bicyclic ester in the 
production of selectively degradable core-crosslinked shell micelles.78 BOD is 
synthesised via the Baeyer-Villiger rearrangement (Scheme 7.6) of bis(4-
cyclohexanone) (BCH), carried out according to the method of Kirschke.93 The BCH 
(Scheme 7.7 3) is treated with a peroxy-acid, produced from urea/hydrogen peroxide 
(Scheme 7.7 2) and formic acid (Scheme 7.7 1), which inserts an oxygen next to the 
carbonyl group, to produce an ester. 
 
Scheme 7.6 Mechanism of Baeyer-Villiger reaction between bicycohexanone and peroxy-acid formed 
from urea hydrogen peroxide and formic acid. 
 
Scheme 7.7 Synthesis of BOD via the initial reaction of formic acid (1) with urea hydrogen peroxide 
(2) to produce a peroxy-acid for the subsequent reaction with bis(4-cyclohexanone) (3). 
BOD was characterised using ES-MS (Appendix, Figure A76) and 1H (Figure 7.13) and 
13C NMR (Appendix, Figure A77) spectroscopy. The protons neighbouring the oxygen 
atom of the ester group integrate to 4 protons between 4.08-4.44 ppm, and those 
neighbouring the carbonyl group are showed between 2.51-2.82 ppm. The 13C NMR 
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spectrum shows a peak at 181.3 ppm, accounting for the lactone carbonyl group amongst 
the other carbon environments. The ES-MS shows a molecular ion peak [M+NH4]+ = 
244.2 Da (calculated [M+H]+ (C12H18O4) m/z = 226.3). 
 
Figure 7.13 1H NMR spectrum (CDCl3, 400 MHz) of BOD. 
7.3.2.2 Co-polymerisation of ε-caprolactone and 4,4’-bioxepanyl-7,7’-dione 
In order to produce highly branched CL polymers in bulk, the optimal BOD 
concentration has been reported to be 0.6 equivalents of brancher per initiating species.80 
Therefore, initially, the co-polymerisation of CL and BOD was carried out at 110°C, 
using BnOH as the initiator and Sn(Oct2) catalyst in the molar ratio 
[initiator]:[BOD]:[M]:[Sn(Oct2)] = 1:0.6:30:1/350 (Scheme 7.8).  
 
Scheme 7.8 Diagrammatic representation of the co-polymerisation of CL (2) and BOD (3) initiated by 
BnOH (1) to produce the branched copolymer Bn-p(CL30-co-BOD1.0).
Upon analysis by triple detection GPC, the co-polymerisation appeared to have failed to 
produce a branched copolymer as the determined Mn and average molecular weight 
(Mw) values were not indicative of branching between chains; 2850 g mol-1 and 4950 g 
mol-1 respectively (Table 7.1, entry 8). The BOD to initiator ratio was, therefore, 
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increased to 1.0 eq. (Table 7.1, entry 9) and a highly branched p(CL30-co-BOD1.0) 
sample was generated with Mw = 108560 g mol-1; a very broad molecular weight 
distribution was also seen (Figure 7.14) and a final high monomer conversion (97%) was 
achieved. Branched p(CL) has been reported in the literature (Bn-p(CL50-co-BOD0.6)) 
possessing Mw values > 90,000 g mol-1 when prepared in bulk.80 The 1H NMR spectrum 
of the purified, branched copolymer is displayed in Figure 7.15, with identical peaks 
present compared to those observed in the Bn-p(CL30) spectrum (Figure 7.9). 
 
Figure 7.14 GPC RI chromatogram overlays of Bn-p(CL30-co-BOD0.6) (yellow-dotted) and Bn-
p(CL30-co-BOD1.0) (yellow). 
 
Figure 7.15 1H NMR (CDCl3, 400 MHz) spectrum of Bn-p(CL30-co-BOD1.0) copolymer. 
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Following the successful production of highly branched Bn-p(CL30-co-BOD1.0), the 
dendron ROP initiators were utilised in the co-polymerisation of CL and BOD (Figure 
7.16). 
 
Figure 7.16 Diagrammatic representation of the co-polymerisation of CL and BOD using AmG0-G2’ 
dendron ROP initiators. 
The AmG0’-OH and AmG1’-OH initiators were used to co-polymerise CL and BOD at 
0.6 and 0.8 molar eq. reactive to initiator, at 110°C in bulk, using identical conditions to 
those utilised in the linear polymerisations. The AmG0’-OH failed to produce highly 
branched hyp-polydendrons using either ratio of BOD:initiator (Table 7.1, entries 10 and 
11), containing only on weight average > 2 and 5 linear-dendritic chains joined together 
respectively. A highly branched hyp-polydendron, AmG1’-p(CL30-co-BOD0.8) (Table 
7.1, entry 14 and Figure 7.17) was collected.  
The BOD content was increased further to 1.0 molar equivalent, producing 
AmG0’p(CL30-co-BOD1.0) with an Mw = 26500 g mol-1 (Table 7.1, entry 12 and Figure 
7.17), but still low compared to the Mw values achieved when using BnOH and AmG1’-
OH initiators. Following failure to produce highly branched hyp-polydendrons initiated 
by AmG0’-OH and AmG1’-OH using 0.6 molar equivalents of BOD per initiator, the 
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AmG2’-OH was used to initiate the co-polymerisation of CL and BOD at 0.8 and 1.0 
molar equivalents (Table 7.1, entries 15 and 16), with the former producing a hyp-
polydendron with a Mw = 40730 g mol-1 (Figure 7.17). 
 
Figure 7.17 GPC RI chromatogram overlays of AmG0’-p(CL30-co-BOD1.0) (green), AmG1’-p(CL30-
co-BOD0.8) (blue) and AmG2’-p(CL30-co-BOD0.8) (red). 
The dendron chemistry clearly plays a role in the successful production of highly 
branched CL hyp-polydendrons. Monomer conversions were not as high as seen 
previously for ATRP hyp-polydendron synthesis (Chapter 3), which may be a limitation 
of bulk ROP polymerisation. The AmG0’-p(CL30-co-BOD1.0) achieved 98% monomer 
conversion, compared to the AmG1’-p(CL30-co-BOD0.8) reaching 83% and the AmG2’-
p(CL30-co-BOD0.8) reaching only 81% before termination of the reactions; if the 
evolution of high molecular weight structures follows the trends seen in ATRP branched 
vinyl polymerisations, very high conversions (> 90%) would be required to generate 
highly branched structures and these were not achieved for first and second generation 
polymerisations. Despite several hyp-polydendrons not reaching high monomer 
conversion, all excess monomer was successfully removed, confirmed by 1H NMR 
analysis of the final polymer following purification (Figure 7.18).  
CHAPTER 7 
276
 
Figure 7.18 1H NMR (CDCl3, 400 MHz) spectra of AmG0’-p(CL30-co-BOD1.0) (A), AmG1’-p(CL30-
co-BOD0.8) (B) and AmG2’-p(CL30-co-BOD0.8) (C) hyp-polydendrons. 
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The branched copolymer and hyp-polydendrons taken forward for nanoprecipitation 
studies contained on weight average > 18 (Bn-p(CL30-co-BOD1.0)), > 7 (AmG0’-p(CL30-
co-BOD1.0)), > 15 (AmG1’-p(CL30-co-BOD0.8)) and > 4 AmG2’-p(CL30-co-BOD0.8) 
primary polymer chains; with 7, 30 and 16 tertiary amine surface groups for the hyp-
polydendrons respectively. 
7.4 Nanoprecipitation of linear polymers, linear-dendritic hybrids, 
branched copolymers and hyp-polydendrons 
 
Stabilisation of NPs in aqueous media has been successfully achieved by two main 
strategies: (i) surface coating with hydrophilic surfactants;94 and (ii) development of 
biodegradable copolymers with hydrophilic segments, for example, PEG.95 These 
provide increased stability within the body, longer circulation times and a means to 
control the release rate of encapsulated or conjugated drugs.4 
 
The preparation of p(CL) NPs has been successfully achieved by a variety of 
nanoprecipitation, solvent displacement and solvent evaporation techniques.3 The 
encapsulation of the antihypertensive agent Isradipine within p(CLx) NPs has been 
reported via nanoprecipitation with Pluronic F68 as a stabiliser within the aqueous anti-
solvent. NPs with diameter size values in the range 110-208 nm were generated,94 
noticeably larger than NPs prepared with p(LAx) or p(LGAx) under similar conditions.3 
Results from these reports suggested potential for drug delivery via oral administration.  
 
Amphiphilic triblock copolymers, p(CLx-b-PEGy-b-CLz), have been reported in the 
literature to produce stable micelles where both PEG chains are anchored within the 
main bulk of the nano-object.95 Alteration of the block polymer lengths resulted in a 
change in micelle size, drug loading capacity, critical micelle concentrations and drug 
release behaviour. Increased p(CL) block lengths resulted in larger micelles and 
decreased drug release rates. Malkoch and co-workers have successfully produced stable 
micelles of ~100 nm from linear-dendritic polymer hybrids comprised of p(CL) arms 
and a linear PEG component. Overall, investigations into the self-assembly of linear-
dendritic biodegradable polymer hybrids to produce stable NPs are few, and the 
formation of stable nanoprecipitates from branched CL polymers are not widely 
reported. 
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Chapter 2 described the production of stable NPs in aqueous media from amine-
functionalised hyp-polydendrons comprising 2-hydroxypropyl methacrylate (HPMA) and 
ethylene glycol dimethacrylate (EGDMA) primary chains; the linear-dendritic HPMA 
hybrids only succeeded to produce nanoprecipitates in aqueous HCl due to charge-
stabilisation from protonation of the dendron groups. Nanoprecipitation studies of linear-
dendritic polymers containing 2-(diethylamino) ethyl methacrylate (DEA) revealed the 
requirement of additional charge to produce monomodal size distributions, with the 
branched p(DEA-co-EGDMA) equivalent NPs exhibiting narrow polydispersities from 
high levels of stabilisation in both neutral and acidic water, confirmed by the additional 
stability observed in physiologically-relevant media (Chapter 6).  
 
The selected linear, Bn-p(CL30), AmG0’-p(CL30), AmG1’-p(CL30) and AmG2’-p(CL30) 
and branched equivalent materials, Bn-p(CL30-co-BOD1.0), AmG0’-p(CL30-co-BOD1.0), 
AmG1’-p(CL30-co-BOD0.8) and AmG2’-p(CL30-co-BOD0.8) were dissolved in THF at a 
concentration of 5 mg mL-1. All nanoprecipitations were performed by adding the 
polymer solution (2 mL) to aqueous media (10 mL) to obtain a NP dispersion at a 
concentration of 1 mg mL-1 following evaporation of THF overnight. Analysis of the 
stable NP dispersions was conducted by dynamic light scattering (DLS) to assess NP 
hydrodynamic diameters (Dz), number average diameters (Dn) and polydispersities (PDI). 
 
All linear and linear-dendritic CL-containing polymers failed to produce stable NPs and 
underwent observable macroscale precipitation at pH = 7.8 (Table 7.2). Chapters 2 and 4 
reported the production of stable NPs from HPMA and tertiary butyl methacrylate 
(tBuMA) linear-dendritic hybrids bearing dendritic surface functionality in acidic media, 
resulting from protonation of the tertiary amines providing charge stabilisation. In an 
attempt to produce stable NPs from linear-dendritic CL-containing polymers, the 
polymer solutions were nanoprecipitated into aqueous HCl (pH = 4); successful NP 
dispersions were formed for all linear-dendritic polymer hybrids with only the Bn-
p(CL30) precipitating out of solution (Table 7.2). The linear-dendritic p(CL30) NPs 
displayed increasing size values, with narrower size distributions as the size of the 
dendron chain end decreases (Figure 7.19). The AmG2’-p(CL30) additionally, failed to 
produce a monomodal size distribution. 
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Table 7.2 DLS analysis of nanoprecipitated linear and linear-dendritic CL polymer hybrids and CL-
BOD branched copolymers and hyp-polydendrons. 
  pH=7.8a pH=4.0a 
Branched 
Polymer 
Linear  
Polymer 
Dz 
(nm) 
PDI Dn 
(nm) 
ζ 
(mV) 
Dz 
(nm) 
PDI Dn 
(nm) 
ζ 
(mV) 
- 
AmG0-
p(HPMA50) 
- - - - 581 0.280 397 +52 
- 
AmG1-
p(HPMA50) 
- - - - 246 0.193 120 +40 
- 
AmG2-
p(HPMA50) 
- - - - 491 0.165 442 +44 
- Bn-p(CL30) - - - - - - - - 
- AmG0’-p(CL30) - - - - 123 0.140 79 +84 
- AmG1’-p(CL30) - - - - 130 0.259 27 +66 
- AmG2’- p(CL30) - - - - 36 0.260 18 +20 
- 
AmG2’-
p(DEA50) 
65 0.381 12 +19 42 0.231 23 +36 
Bn-p(CL30-co-
BOD1.0) 
- - - - - - - - - 
AmG0’-
p(CL30-co-
BOD1.0) 
- - - - - 145 0.197 46 +53 
AmG1’-
p(CL30-co-
BOD0.8) 
- 151 0.081 122 +30 133 0.186 94 +48 
AmG2’-
p(CL30-co-
BOD0.8) 
- - - - - 48 0.255 19 +22 
Bn-p(CL30-co-
BOD1.0) 
Bn-p(CL30) - - - - - -  - 
AmG0’-p(CL30) - - - - 147 0.125 102 +42 
AmG1’-p(CL30) - - - - 169 0.149 111 +51 
AmG2’-p(CL30) - - - - 217 0.173 144 +71 
AmG2-p(DEA50) 182 0.118 130 +35 - - - - 
a Initial pH of water. 1 Italics indicate a bimodal size distribution measured by DLS. 
2 All co-nanoprecipitations were carried out at 90:10 wt% branched copolymer:linear-dendritic 
hybrid. 
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The observed zeta-potential (ζ) values were all highly positive (Table 7.2), with a 
decreasing trend witnessed as the size of the dendron chain end increased. This suggests 
that the AmG0’-p(CL30), that displayed the highest positive surface charge (+84 mV), 
contains the most protonated tertiary amine groups on the surface of the 
nanoprecipitates. 
 
The linear-dendritic HPMA polymers (Chapter 2), produced NPs with large Dz size 
values and an observable decreasing PDI values as the dendron size increased. The 
linear-dendritic CL hybrids formed NPs with considerably smaller sizes, with increasing 
PDI values as the dendron size increases. The surface charge decreases significantly as 
the dendron size increases, with the AmG2’-p(CL30) producing the smallest NPs with the 
smallest ζ. This is also observed in the linear-dendritic HPMA series, where the smallest 
nanoprecipitates (AmG1-p(HPMA50), Dz=246 nm) contained the smallest ζ value 
(+40 mV) and the largest nanoprecipitates (AmG0-p(HPMA50), Dz=581 nm) had the 
most positive surface potential (+52 mV). 
Figure 7.19 DLS size distribution analysis of AmG0’-p(CL30) (green), AmG1’-p(CL30) (blue) and 
AmG2’-p(CL30) (red) prepared in acidic water at a concentration of 1 mg mL-1. 
The branched copolymer Bn-p(CL30-co-BOD1.0) and hyp-polydendrons AmG0’-p(CL30-
co-BOD1.0), AmG1’-p(CL30-co-BOD0.8) and AmG2’-p(CL30-co-BOD0.8) subsequently 
underwent nanoprecipitation into deionised water. Only the AmG1’-p(CL30-co-BOD0.8) 
produced stable nanoprecipitates in neutral water (Dz=151 nm), displaying a narrow and 
monomodal size distribution (PDI = 0.081 and Figure 7.20). The branched copolymers 
and other hyp-polydendrons failed to form stable nanoprecipitates with observable 
polymer precipitation. Although it is unclear why this difference arises, there is a 
significant difference of molecular weight of the AmG1’-p(CL30-co-BOD0.8) (Mw = 
92600 g mol-1) compared to the AmG0’-p(CL30-co-BOD1.0) (Mw = 26500 g mol-1) and 
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AmG2’-p(CL30-co-BOD0.8) (Mw = 41730 g mol-1). Unpublished results from the Rannard 
group have indicated the critical nature of a small fraction of very highly branched 
polymer and this may be further supported by this anomalous result. 
To the best of our knowledge, this is the first example of stabilised p(CL) NPs in aqueous 
solution, without the need for additional stabilisers. 
 
 
Figure 7.20 DLS size distribution of AmG1’-p(CL30-co-BOD0.8) NP dispersion prepared in neutral 
water at a concentration of 1 mg mL-1. 
Following nanoprecipitation into aqueous HCl, stable NP dispersions formed for all 
three hyp-polydendrons. As the size of the dendron surface group increases, a decrease 
in Dz with concomitant increase in polydispersity and decrease in ζ values was observed; 
the AmG0’-p(CL30-co-BOD1.0) NPs were the largest with the largest positive surface 
charge; and the AmG2’-p(CL30-co-BOD0.8) produced the smallest nanoprecipitates, the 
broadest size distribution, with the lowest surface charge (Table 7.2 and Figure 7.21). 
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Figure 7.21 DLS size distribution analysis of CL-BOD hyp-polydendron NPs produced in acidic 
water at a concentration of 1 mg mL-1: AmG0’-p(CL30-co-BOD1.0) (green), AmG1’-p(CL30-co-
BOD0.8) (blue) and AmG2’-p(CL30-co-BOD0.8) (red). 
Compared to the linear-dendritic equivalents, nanoprecipitates with very similar sizes 
formed from the hyp-polydendrons (123 and 145 nm (AmG0’-) and 130 and 133 nm 
(AmG1’-)). The AmG2’-containing materials produced NPs with similar sizes and 
surface charge, due to the low molecular weight of the hyp-polydendron. Similar trends 
are noticed, with the AmG0’- particles containing the highest surface charge, with the 
AmG2’- particles displaying the highest polydispersity values. 
 
A correlation between the sizes of the hyp-polydendron nanoprecipitates in aqueous HCl 
and the surface charge was observed, a behaviour that was also noticeable within the 
NPs generated by the series of HPMA-EGDMA hyp-polydendrons. The AmG0’-p(CL30-
co-BOD1.0) produced NPs with a Dz=145 nm and a ζ=+53 mV, compared to the AmG2’-
p(CL30-co-BOD0.8) nanoprecipitates exhibiting a Dz=48 nm and a ζ=+22 mV (and the 
AmG1’-p(CL30-co-BOD0.8) residing in between with a Dz=133 nm and a ζ=+48 mV). 
Equally, the AmG1-p(HPMA50-co-EGDMA0.9) exhibited the smallest Dz (=102 nm) and 
smallest ζ (=+45 mV); and the AmG2-p(HPMA50-co-EGDMA0.9) exhibited the largest 
Dz (=196 nm) and largest ζ (=+61 mV) in aqueous HCl. 
 
7.5 Co-nanoprecipitation studies of linear and linear-dendritic 
polymers with branched, hydrophobic CL copolymers 
Previously, co-nanoprecipitated linear-dendritic HPMA-based hybrids with branched 
p(HPMA-co-EGDMA) copolymers have yielded stabilised NP dispersions (Chapter 5) in 
neutral water (pH=7.8). The co-nanoprecipitation of the linear-dendritic tBuMA polymer 
AmG2-p(tBuMA50) with EBiB-p(tBuMA50-co-EGDMA0.95) failed to produce stable NPs, 
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however, combined to form stable nanoprecipitates in aqueous HCl with the aid of 
protonation of the dendron chain ends (Chapter 5). The combination of EBiB-
p(HPMA50-co-EGDMA0.95) with AmG2-p(HPMA50) produced particles that varied 
considerably from the nanoprecipitation of AmG2-p(HPMA50-co-EGDMA0.9) alone, with 
a larger Dz (=210 nm, compared to 149 nm), a reduced size distribution (PDI=0.072, 
compared to 0.099) and identical ζ values (=-21 mV, compared to -22 mV). A similar co-
nanoprecipitation study was conducted using the linear-dendritic p(CL) hybrids and the 
branched benzyl alcohol initiated copolymer (Figure 7.22). 
 
Figure 7.22 Diagrammatic representation of the co-nanoprecipitation of linear-dendritic CL polymer 
hybrids (AmG2-p(CL30) (i)) with Bn-p(CL30-co-BOD1.0) (ii). 
7.5.1 Co-nanoprecipitation studies of amine-functionalised linear-dendritic CL 
hybrids with Bn-p(CL30-co-BOD1.0) 
The selected linear and linear-dendritic p(CL) polymers were co-nanoprecipitated with 
the branched copolymer Bn-p(CL30-co-BOD1.0) into neutral (pH = 7.8) and acidic (pH = 
4) water, in a 10:90 wt% linear polymer:branched copolymer ratio. Stable NPs formed 
for all linear-dendritic hybrid combinations in acidic water (Table 7.2), with the Bn-
p(CL30)/Bn-p(CL30-co-BOD1.0) combination resulting in macroscale precipitation.  
The AmG0’-p(CL30), AmG1’-p(CL30) and AmG2’-p(CL30) co-nanoprecipitations with 
Bn-p(CL30-co-BOD1.0) all produced monomodal size distributions (Figure 7.23). An 
increased particle size was observed as the size of the dendron increased, the opposite 
behaviour that was seen for the nanoprecipitation of the hyp-polydendrons (a decreasing 
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particle size as the dendron size increases). This additionally correlates to an increasing ζ 
as the dendron size increases, again the opposite behaviour observed when the hyp-
polydendrons were nanoprecipitated individually. This suggests that the co-
nanoprecipitation method leads to a lessened amount of dendrons situated in the main 
bulk of the nanoprecipitate during the growth stages, resulting in an increased level of 
dendron on the nanoprecipitate surface, explaining the increased zeta potential values. 
 
Figure 7.23 DLS size distribution analysis of co-nanoprecipitated NPs of Bn-p(CL30-co-BOD1.0) with 
AmG0’-p(CL30) (green), AmG1’-p(CL30) (blue) and AmG2’-p(CL30) (red). 
7.5.2 Co-nanoprecipitation and pH studies of AmG2-p(DEA50) and Bn-p(CL30-
co-BOD1.0) 
 
Following the successful production of co-nanoprecipitated NPs from linear-dendritic CL 
hybrids and Bn-p(CL30-co-BOD1.0), the co-nanoprecipitation of Bn-p(CL30-co-BOD1.0) 
with the pH-responsive linear-dendritic DEA hybrid, AmG2-p(DEA50), synthesised in 
Chapter 3, (Figure 7.24) was investigated.  
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Figure 7.24 Diagrammatic representation of the co-nanoprecipitation of Bn-p(CL30-co-BOD1.0) (ii) 
with the pH-responsive, linear-dendritic AmG2-p(DEA50) polymer hybrid (i). 
AmG2-p(DEA50) has previously been co-nanoprecipitated with EBiB-p(HPMA50-co-
EGDMA0.95) to produce NPs with a Dz=144 nm, PDI=0.102 and ζ=+52 mV (Chapter 5). 
Upon the addition of acid, the EBiB-p(HPMA50-co-EGDMA0.95) precipitated out of 
solution as large polymeric aggregates following solubilisation of the AmG2-p(DEA50). 
Additionally, AmG2-p(DEA50) was co-nanoprecipitated with EBiB-p(tBuMA50-co-
EGDMA0.95) forming stable nanoprecipitates (Dz=234 nm, PDI=0.051 and ζ=+40 mV) 
that remained stable for a short period upon acid addition, requiring further time to 
solubilise the AmG2 dendron chain end, presumably residing in the bulk of the 
nanoprecipitate. The co-nanoprecipitation of EBiB-p(tBuMA50-co-EGDMA0.95) with 
AmG2-p(DEA50) was the only example throughout this work, of a stabilised branched 
tBuMA-derived polymer NPs in neutral water. 
 
Co-nanoprecipitation of AmG2-p(DEA50) and Bn-p(CL30-co-BOD1.0) was carried out 
into acidic and neutral water (Table 7.2) at a linear-dendritic polymer:branched 
copolymer ratio of 10:90 wt%. A stable NP dispersion formed (Table 7.2) in neutral 
water, producing a monomodal size distribution (Figure 7.25), with a positive ζ
suggesting p(DEA) chains residing towards or on the nanoprecipitate surface. A stable 
NP dispersion failed to form in acidic water presumably due to solubilisation of AmG2-
p(DEA50) in pH 4. Although Chapter 4 suggested the insolubility of AmG2-p(DEA50), 
CHAPTER 7 
286
confirmed by the formation of nanoprecipitates at a concentration of 1 mg mL-1, with 
slight protonation confirmed by the positive ζ values, solubility might be possible at a 
concentration of 0.1 mg mL-1. 
 
Figure 7.25 DLS size distribution analysis of co-nanoprecipitated AmG2-p(DEA50) with Bn-p(CL30-
co-BOD1.0) prepared in neutral water at a concentration of 1 mg mL-1. 
The stabilised NPs formed from Bn-p(CL30-co-BOD1.0) and AmG2-p(DEA50) underwent 
the addition of acid to establish any pH-responsive behaviour. Upon the addition of acid, 
the NPs failed to solubilise and remained as intact nanoprecipitates, confirmed by DLS 
analysis (Dz=208 nm, PDI=0.111; Figure 7.26). The NPs were re-analysed after 7 days 
following an excess of acid addition, and continued to retain integrity (Dz=197 nm, 
PDI=0.128). This suggests dendron chain ends may be trapped within the main bulk of 
the nanoprecipitates, and the close packed nature of the co-nanoprecipitated NPs 
prevents the penetration of acid or diffusion of the trapped chains. 
 
Figure 7.26 DLS size distribution analysis of co-nanoprecipitated AmG2-p(DEA50) with Bn-p(CL30-
co-BOD1.0) (green) following acid addition (red) after 7 days (red-dotted). 
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7.6 Degradation studies of p(caprolactone) 
As previously mentioned, the hydrolysis of p(CLx) in physiological media results non-
enzymatic cleavage of the ester bonds,96,97 resulting in non-toxic components that are 
eliminated from the body as carbon dioxide and water via the Krebs cycle. A preliminary 
study was devised to study the hydrolysis of CL in phosphate buffer solution (PBS). Bn-
p(CL30) (1.00 g) was left in PBS for 8 weeks. Samples were taken after 4, 6 and 8 weeks 
and analysed by GPC to observe the break-down of the linear polymer. Figure 7.27 
shows the overlay of the initial polymer (blue), overlain with the samples after 4 (red), 6 
(green) and 8 (orange) weeks. An increasing amount of smaller material is witnessed at 
~22 mL suggesting an increasing amount of degradation over the time period. The 
samples continue to contain Bn-p(CL30), confirmed by the exact overlay of the untreated 
material eluting between 17.5-20.5 mL. 
 
Figure 7.27 GPC RI chromatograms of Bn-p(CL30) (blue) after 4 (red), 6 (green) and 8 (orange) 
weeks in PBS. 
7.7 Conclusions 
Following the synthesis of a new AB2 branching molecule, and new amine-
functionalised ROP dendron initiators, CL was successful polymerised to produce 
linear-dendritic polymer hybrids with varying dendron generation chain ends. AmG1’- 
and AmG2’-initiated polymerisations displayed broad molecular weight distributions, 
and further work needs to be done to continue optimising the ROP conditions. The effect 
of catalyst amount and reaction time demonstrated an effect on the level of control, and 
variables such as temperature and solution ROP are yet to be resolved. The 
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incorporation of BOD to produce novel biodegradable hyp-polydendrons was achieved 
for all dendron initiators, reaching Mw > 92,000 g mol-1. Again, detailed understanding 
into the branched co-polymerisation conditions are lacking, and optimisation 
improvements may be necessary to reach higher monomer conversions, and 
consequently, higher molecular weights. 
 
The formation of linear-dendritic CL NPs was achieved via nanoprecipitation into acidic 
water. Equally, the AmG0’-p(CL30-co-BOD1.0) and AmG2’-p(CL30-co-BOD0.8) required 
additional charge to produce stable nanoprecipitates; although stable AmG1’-p(CL30-co-
BOD0.8) NPs formed in neutral water. These introductory results are encouraging, 
particularly due the Bn-p(CL30) and Bn-p(CL30-co-BOD1.0) undergoing observable 
macroscale precipitation upon introduction into any aqueous media. The hyp-
polydendron structure, clearly offers benefits in terms of NP production, without the 
need for stabilisers. A preliminary degradation study suggests degradation in 
physiologically-relevant media. 
 
7.8 Experimental 
[tBOC2-BAPA-G1] – CDI (19.55 g, 0.121 mol, 2 eq.) was added to an oven-dried 
500mL 2-neck round-bottomed flask (RBF) fitted with a reflux condenser, magnetic 
stirrer and a dry N2 inlet. 350 mL of anhydrous toluene was added and the flask purged 
with N2 for 10 minutes. The solution was stirred at 60°C and tertiary butanol (17.83 g, 
23 mL, 0.241 mol, 4 eq.) added via a warm syringe. The mixture was left stirring at 
60°C for 6 hours under a positive flow of nitrogen. Bis(3-aminopropyl)amine (7.88 g, 
8.4 mL, 0.060 mol, 1 eq.) was added dropwise, and the reaction was left stirring for a 
further 18 hours at 60°C under a positive flow of nitrogen. Following this, the solution 
was allowed to cool to room temperature, and the pale yellow solution was filtered to 
remove any solid imidazole, and concentrated in vacuo. The resulting viscous oil was 
dissolved in dichloromethane (200 mL) washed with distilled water (3 x 200 mL) and 
once with brine (150 mL). The organic layer was dried with anhydrous Na2SO4, filtered, 
and concentrated in vacuo. Yield: 16.63 g, white solid, (84%). 1H NMR (400 MHz, 
CDCl3): δ = 1.43 (s, 18H), 1.63 (m, 4H), 2.64 (t, 4H), 3.20 (t, 4H), 5.19 (s, br, -NH). 13C 
NMR (100 MHz, CDCl3): δ = 28.5, 29.9, 39.0, 47.7, 79.2, 156.2. Calcd: [M+H]+ 
(C16H33N3O4) m/z = 332.3. Found: ESI-MS: [M+H]+ m/z = 332.3. Anal. Calcd for 
C16H33N3O4: C, 58.00; H, 10.00; N, 12.69. Found: C, 57.78; H, 9.92; N, 12.82. 
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[tBOC2-APAP-OH’] – [tBOC2-BAPA-G1] (15.38 g, 0.046 mol, 1 eq.), bromoethanol 
(5.81 g, 3.3 mL, 0.046 mol, 1 eq.), sodium iodide (150 mg), potassium carbonate (19.27 
g, 0.139 mol, 3 eq.) and 1,4-dioxane (150 mL) was added to a 500 mL 2-necked RBF 
fitted with a reflux condenser and magnetic stirrer. The reaction was refluxed overnight. 
After this time, water (150 mL) was added to the reaction mixture and the product was 
extracted with ethyl acetate (2 x 225 mL). The combined extracts were washed with 
water (1 x 150 mL), dried over sodium sulfate and concentrated in vacuo. The crude 
product purified by liquid chromatography (silica gel, eluting with EtOAc:MeOH, 
80:20). Yield: 7.55 g, pale yellow oil at ambient temperature, solidifying to an off white 
solid upon cooling (43 %). 1H NMR (400 MHz, CDCl3): δ = 1.41 (s, 18H), 1.62 (m, 
4H), 2.47 (t, 4H), 2.54 (t, 2H), 2.85 (s, br, OH), 3.16 (m, 4H), 3.57 (t, 2H), 5.09 (s, br, 
NH). 13C NMR (100 MHz, CDCl3): δ = 27.2, 28.4, 38.9, 51.7, 56.0, 58.9, 79.1, 156.2. 
Calcd: [M+H]+ (C18H37N3O5) m/z = 376.5. Found: ESI-MS: [M+H]+ m/z = 376.3. Anal. 
Calcd for C18H37N3O5: C, 57.52; H, 9.85; N, 11.18. Found: C, 56.97; H, 9.81; N, 11.02. 
[1-[N,N-bis (2-aminopropyl)-amino]-2-propan-1-ol (APAP’)] – To a 500 mL RBF, 
[tBOC2-APAP-OH’] (7.49 g, 0.02 mol, 1 eq.) was dissolved in ethyl acetate (80 mL), 
and had concentrated HCl (12.14 g, 10.3 mL, 36% active) added very slowly. CO2 began 
to rapidly evolve. The reaction vessel was left open to the atmosphere, heated to 50°C 
and stirred for 24 hours. After removal of ethyl acetate in vacuo, the crude oil was 
dissolved very slowly in 4M NaOH (80 mL), and reduced by approximately half its 
volume on the rotary evaporator (60°C). A yellow oily substance formed on the surface 
of the NaOH solution. The mixture was extracted with CHCl3 (2 x 80 mL), the organic 
layers combined, dried with anhydrous Na2SO4, filtered, and concentrated in vacuo. 
Yield: 2.98 g, pale yellow oil (85%). 1H NMR (400 MHz, CDCl3): δ = 1.54 (m, 4H), 
2.48 (m, 6H), 2.70 (t, 4H), 3.53 (t, 2H). 13C NMR (100 MHz, CDCl3): δ = 30.58, 40.37, 
52.01, 56.02, 59.77. Calcd: [M+H]+ (C8H21N3O) m/z = 175.05. Found: CI-MS: [M+H]+ 
m/z = 176.2. Anal. Calcd for C8H21N3O: C, 54.86; H, 12.00; N, 24.00%. Found: C, 
53.47; H, 12.06; N, 23.67%. 
AmG1’-OH – 2-(Dimethylamino)ethyl acrylate (DMEA) (6.0 g, 42 mmol, 6 eq.) was 
added to a 50 mL round 2 necked RBF containing propan-2-ol (IPA) (12 mL). The flask 
was deoxygenated under a positive N2 purge for 10 minutes. Ethanolamine (0.4266 g, 
7.0 mmol, 1 eq.) dissolved in IPA (12 mL) was added drop wise while the solution was 
stirring in an ice bath under a positive flow of N2. The final mixture was stirred for a 
further 10 minutes at 0°C before being allowed to warm to room temperature and left 
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stirring for 48 hr. The solvent was removed and the product left to dry in vacuo 
overnight. Yield: 2.33 g, yellow oil (96%). 1H NMR (400 MHz, CDCl3) δ 2.27 (s, 12H), 
2.44-2.61 (m, 10H), 2.81 (t, 4H), 3.57 (t, 2H), 4.18 (t, 4H). 13C NMR (100 MHz, 
CDCl3) δ 32.6, 45.6, 49.4, 56.2, 57.8, 59.5, 62.0, 172.7. Calcd [M+H]+ (C16H33N3O5) 
m/z = 347.5. Found: ESI-MS: [M+H]+ m/z = 348.2, [M+Na]+ m/z = 370.2. Anal. Calcd 
for C16H33N3O5: C, 55.26; H, 9.50; N, 12.09%. Found C, 57.09; H, 9.47; N, 11.02%. 
AmG2’-OH – DMEA (6.0 g, 0.042 mol, 6 eq.) was added to a 50 mL round 2 necked 
RBF containing IPA (12 mL). The flask was deoxygenated under a positive N2 purge for 
10 minutes. APAP’ (1.2222 g, 0.007 mmol, 1 eq.) dissolved in IPA (12 mL) was added 
drop wise while the solution was stirring in an ice bath under a positive flow of N2. The 
final mixture was stirred for a further 10 minutes at 0°C, allowed to warm to room 
temperature and left stirring for 48 hours. The solvent was removed and the product left 
to dry in vacuo overnight. Yield: 4.84 g, yellow oil, (93%). 1H NMR (400 MHz, CDCl3) 
δ 1.52 (m, 4H), 2.23 (s, 24H), 2.41 (m, 16H). 2.51 (t, 10H), 2.72 (t, 8H), 3.50 (t, 2H), 
4.11 (t, 8H). 13C NMR (100 MHz, CDCl3) δ 24.62, 32.24, 45.68, 48.94, 51.53, 51.89, 
55.76, 57.82, 59.48, 62.15, 172.6. Calcd [M+H]+ (C36H73O9N7) m/z = 748.01. Found: 
ESI-MS: [M+H]+ m/z = 748.6. Anal. Calcd for C36H73O9N7: C, 57.75; H, 9.76; N, 
13.10%. Found: C, 57.50; H, 9.76; N, 13.01%. 
[4,4’-bioxepanyl-7,7’-dione (BOD)] – Urea hydrogen peroxide (10 g) was added to a 
250 mL RBF containing formic acid (81.97 g, 100 mL). The solution was stirred for 2 hr 
at room temperature. The flask was then immersed in an ice bath and BCH (5 g) was 
slowly added to the solution. The reaction mixture was stirred for 4 hr. Water (100 mL) 
was then added to the mixture and the product was extracted with chloroform (3 x 100 
mL). The organic fractions were collected and washed with saturated aqueous sodium 
bicarbonate solution then dried over Na2SO4. After removing the solvent, a white 
powder was isolated and dried under vacuum overnight. Yield: 3.26 g, white solid, 
(56%). 1H NMR (400 MHz, CDCl3) δ 1.50 (m, 2H), 1.66 (m, 4H), 1.87 (m, 4H), 2.51-
2.82 (d of t, 4H), 4.08-4.44 (d of t, 4H). 13C NMR (100 MHz, CDCl3) δ 29.6, 35.9, 37.1, 
49.7, 72.4, 181.3. Calcd [M+H]+ (C12H18O4) m/z = 226.3. Found: ESI-MS: [M+H]+ m/z 
= 228.2. Anal. Calcd for C12H18O4: C, 63.64; H, 7.96%. Found: C, 61.67; H, 7.72%. 
 
[General procedure for Bn-, AmG0’-, AmG1’- and AmG2’-p(CLx)]; In a typical 
experiment, Sn(Oct2) (0.0025 g, 0.0062 mmol, 1/350 eq.) was added using a dry syringe 
to a RBF equipped with a magnetic stirrer bar flushed with dry nitrogen. Following this, 
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CL (7.39 g, 6.86 mL, 0.0648 mol, 30 eq.) was added using a dry syringe. The reaction 
mixture was degassed for a further 15 minutes and then immersed in a silicon oil bath at 
110°C. AmG2’-OH (1.62 g, 0.0022 mol, 1 eq.) was added via a dry syringe and the 
polymerisation left for 66 hr. The polymerisation was stopped by removing the reaction 
mixture from the heat and immersing it in an ice bath. The crude product was dissolved 
in 50 mL of THF and precipitated from 600 mL of hexane. The precipitated polymer 
was dried under vacuum for 24 hr. 
 
[General procedure for Bn- AmG0’-, AmG1’- and AmG2’-p(CL30-co-BODx)]; In a 
typical experiment, Sn(Oct2) (0.0018 g, 0.005 mmol, 1/350 eq.) and BOD (0.2849 g, 
0.0013 mol, 0.8 eq.) were added to a RBF equipped with a magnetic stirrer bar flushed 
with dry nitrogen. Following this, CL (5.39 g, 5 mL, 0.047 mol, 30 eq.) was added using 
a dry syringe. The reaction mixture was degassed for a further 15 minutes and then 
immersed in a silicon oil bath at 110°C. AmG1’-OH (0.5469 g, 0.0016 mol, 1 eq.) was 
added via a dry syringe and the polymerisation left for 144 hr. The polymerisation was 
stopped by removing the reaction mixture from the heat and immersing it in an ice bath. 
The crude product was dissolved in 50 mL of THF and precipitated from 600 mL of 
hexane. The precipitated polymer was dried under vacuum for 24 hr. 
 
[General procedure for aqueous nanoprecipitation of p(CL30) and p(CL30-co-
BODx)] - The materials were dissolved in THF at a concentration of 5 mg mL-1. 2 mL of 
this solution was then subjected to a rapid solvent switch through drop wise addition into 
10 mL of water, to give a final polymer concentration of 1 mg mL-1 in water after THF 
removal by evaporation overnight. 
???????????????????????????????????????? ????????????????????
1 J. D. D. A. Shaikh, V. Beniwal, D. Singh and M. N. V. Ravi Kumar, Eur. J. Pharm. Sci., 2009, 37, 
223-230. 
2 J.-C. Leroux, E. Allémann, F. D. Jaeghere, E. Doelker and R. Gurny, J. Control. Release, 1996, 36, 
339-350. 
3 A. Kumari, S. K. Yadav and S. C. Yadav, Colloid Surface B, 2010, 75, 1–18. 
4 K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni and W. E. Rudzinski, J. Control. Release, 
2001, 70, 1–20. 
5 M. L. Hans and A. M. Lowman, Curr. Opin. Solid St. M., 2002, 6, 319-327. 
6 J. Panyam and V. Labhasetwar, Adv. Drug Deliver. Rev., 2003, 55, 329–347. 
7 A. O. Eniola and D. A. Hammer, J. Control Release, 2003, 87, 15–22. 
8 E. B. Lavik J. S. Hrkach, N. Lotan R. Nazarov and R. Langer, J. Biomed. Mater. Res., 2001, 58, 
291–294. 
CHAPTER 7 
292
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
9 G. Caponetti, J. S. Hrkach, B. Kriwet, M. Poh, N. Lotan, P. Colombo and R. Langer, J. Pharm. Sci., 
1999, 88, 136–141. 
10 M. Müller, J. Vörös, G. Csucs, E. Walter, G. Danuser, H. P. Merkle, N. D. Spencer, and M. Textor, 
J. Biomed. Mater. Res., 2003, 66A, 55–61. 
11 J. Yang, Y. Wan, J. Bei and S. Wang, J. Biomed. Mater. Res., 2003, 67A, 1139–1147. 
12 Y. Wan, X. Qu, J. Lu, C. Zhu, L. Wan and J. Yang, Biomaterials, 2004, 25, 4777–4783. 
13 N. S. Teske, J. Voigt and V. Prasad Shastri, J. Am. Chem. Soc., 2014, 136, 10527−10533. 
14 B. M. Wu, S. W. Borland, R. A. Giordano, L. G. Cima, E. M. Sachs and M. J. Cima, J. Control. 
Release, 1996, 40, 77–87. 
15 W. E. Katstra, R. D. Palazzolo, C. W. Rowe, B. Giritlioglu, P. Teung and M. J. Cima, J. Control. 
Release, 2000, 66, 1–9. 
16 C. W. Rowe, W. E. Katstra, R. D. Palazzolo, B. Giritioglu, P. Teung and M. J. Cima, J. Control. 
Release, 2000, 66, 11–17. 
17 S. Prakesh and H. Brem, Cancer Control, 1998, 5, 130–137. 
18 L. Brown and R. Langer, Annu. Rev. Med., 1998, 39, 221–229. 
19 L. Murray, L. (ed.) Physicians’Desk Reference 57th edn (Thomson PDR, Montvale, New Jersey, 
2003). 
20 H. Okada, Y. Ogawa and T. Yashiki, U.S. Patent, 4, 652, 441, 1987. 
21 H. Okada, M. Yamamoto, T. Heya, Y. Inoue, S. Kamei, Y. Ogawa and S. Toguchi, J. Control. 
Release, 1994, 28, 121-129. 
22 K. Leja and G. Lewandowicz, Polish J. Environ. Stud., 2010, 19, 255-266. 
23 M. L.-L. Verger, L. Fluckiger, Y-I. Kim, M. Hoffman and P. Maincent, Eur. J. Pharm. Bio., 1998, 
46, 137–143. 
24 R. A. Jain, Biomaterials, 2000, 21, 2475–2490. 
25 L. Mu and S. S. Feng, J. Control Release, 2003, 86, 33-48. 
26 S. Y. Kim and Y. M. Lee, Biomaterials, 2001, 22, 1697–1704. 
27 C. M. Thomas, Chem. Soc. Rev., 2010, 39, 165-173. 
28 A.-C. Albertsson and I. K.Varma, Biomacromolecules, 2003, 4, 1466-1486. 
29 H. M. Colquhoun, M. G. Zolotukhin, Z. Zhu, P. Hodge and D. J. Williams, Macromol. Rapid 
Commun., 2004, 25, 808-811. 
30 D. Mecerreyes, R. Jerome and P. Dubois, Adv. Polym. Sci., 1999, 147, 1-59. 
31 D. Mecerreyes and R. Jerome, Macromol. Chem. Phys., 1999, 200, 2581-2590. 
32 J. W. Leenslag and A. J. Pennings, Makromol. Chem. 1987, 188, 1809-1814. 
33 Y. J. Du, P. J. Lemstra, A. J. Nijenhuis, H. A. M. Vanaert and C. Bastiaansen, Macromolecules, 
1995, 28, 2124-2132. 
34 A. Duda, S. Penczek, A. Kowalski, and J. Libiszowski, Macromol. Symp., 2000, 153, 41-53. 
35 A. Kowalski, A. Duda and S. Penczek, Macromolecules, 2000, 33, 689-695. 
36 J. Ling, J. Shen and T. E. Hogen-Esch, Polymer, 2009, 50, 3575-3581. 
37 A. Arbaoui and C. Redshaw, Polym. Chem., 2010, 801-826. 
38 O. Thillaye du Boullay, E. Marchal, B. Martin-Vaca, F. P. Cossio and D. Bourissou, J. Am. Chem. 
CHAPTER 7 
293
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
Soc., 2006, 128, 16442–16443. 
39 O. Thillaye du Boullay, C. Bonduelle, B. Martin-Vaca and D. Bourissou, Chem. Commun., 2008, 
1786–1788. 
40 F. Nederberg, E. F. Connor, M. Moller, T. Glauser and J. L. Hedrick, Angew. Chem., Int. Ed. Engl., 
2001, 40, 2712–2715. 
41 A. P. Dove, R. C. Pratt, B. G. G. Lohmeijer, D. A. Culkin, E. C. Hagberg, G. W. Nyce, R. M. 
Waymouth and J. L. Hedrick, Polymer, 2006, 47, 4018–4025. 
42 A. P. Dove, R. C. Pratt, B. G. G. Lohmeijer, R. M. Waymouth and J. L. Hedrick, J. Am. Chem. 
Soc., 2005, 127, 13798–13799. 
43 R. C. Pratt, B. G. G. Lohmeijer, D. A. Long, P. N. P. Lundberg, A. P. Dove, H. B. Li, C. G. Wade, 
R. Waymouth and J. L. Hedrick, Macromolecules, 2006, 39, 7863–7871. 
44 R. C. Pratt, B. G. G. Lohmeijer, D. A. Long, R. M. Waymouth and J. L. Hedrick, J. Am. Chem. 
Soc., 2006, 128, 4556–4557. 
45 B. G. G. Lohmeijer, R. C. Pratt, F. Leibfarth, J. W. Logan, D. A. Long, A. P. Dove, F. Nederberg, J. 
Choi, C. Wade, R. M. Waymouth and J. L. Hedrick, Macromolecules, 2006, 39, 8574–8583. 
46 L. Zhang, F. Nederberg, J. M. Messman, R. C. Pratt, J. L. Hedrick and C. G. Wade, J. Am. Chem. 
Soc., 2007, 129, 12610–12611. 
47 L. Zhang, F. Nederberg, R. C. Pratt, R. M. Waymouth, J. L. Hedrick and C. G. Wade, 
Macromolecules, 2007, 40, 4154–4158. 
48 S. Koeller, J. Kadota, A. Deffieux, F. Peruch, S. Massip, J. M. Léger, J. P. Desvergne and B. Bibal, 
J. Am. Chem. Soc., 2009, 131, 15088-15089. 
49 S. Gazeau-Bureau, D. Delcroix, B. Martín-Vaca, D. Bourissou, C. Navarro and S. Magnet, 
Macromolecules, 2008, 41, 3782-3784. 
50 H. R. Kricheldorf and R. Dunsing, Makromol. Chem., 1986, 187, 1611–1625.  
51 H. R. Kricheldorf and I. Kreiser, Makromol. Chem., 1987, 188, 1861–1873. 
52 D. Bourissou, B. Martin-Vaca, A. Dumitrescu, M. Graullier and F. Lacombe, Macromolecules, 
2005, 38, 9993–9998. 
53 M. Basko and P. Kubisa, J. Polym. Sci Pol. Chem., 2006, 44, 7071–7081. 
54 M. Basko and P. Kubisa, J. Polym. Sci Pol. Chem., 2007, 45, 3090–3097. 
55 Y. Shibasaki, H. Sanada, M. Yokoi, F. Sanda and T. Endo, Macromolecules, 2000, 33, 4316–4320.  
56 F. Sanda, H. Sanada, Y. Shibasaki and T. Endo, Macromolecules, 2002, 35, 680–683. 
57 X. Lou, C. Detrembleur and R. Jérôme, Macromolecules, 2002, 35, 1190–1195. 
58 M. S. Kim, K. S. Seo, G. Khang and H. B. Lee, Macromol. Rapid Comm., 2005, 26, 643–648. 
59 R. H. Platel, L. M. Hodgson and C. K. Williams, Polym. Rev., 2008, 48, 11-63. 
60 T-L. Yu, C-H. Huang, L-F. Yang, B-T. Ko and C-C. Lin, J. Chin. Chem. Soc. Taip., 2000, 47, 
1185-1190. 
61 Z. J. Yu, L. J. Liu and R. X. Zhuo, J. Polym. Sci Pol. Chem., 2003, 41, 13–21. 
62 F. Aulenta, W. Hayes and S. Rannard, Eur. Polym. J., 2003, 39, 1741–1771. 
63 D. A. Tomalia and J. M. J. Fréchet. J. Polym. Sci Pol. Chem., 2002, 40, 2719-2728. 
CHAPTER 7 
294
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
64 C. C. Lee, M. Yoshida, J. M. J. Fréchet, E. E. Dy and F. C. Szoka. Bioconjugate Chem., 2005, 16, 
535-541. 
65 F. Wurm and H. Frey. Prog. Polym. Sci., 2011, 36, 1-52. 
66 A. Sousa-Herves, R. Riguera and E. Fernandez-Megia, New J. Chem., 2012, 36, 205-210. 
67 I. Gitsov, P. T. Ivanova and J. M. J. Fréchet, Macromol. Rapid. Comm., 1994, 15, 387-393. 
68 M. Trollsås, J. L. Hedrick, D. Mecerreyes, P. Dubois, R. Jérôme, H. Ihre and A. Hult, 
Macromolecules, 1997, 30, 8508-8511. 
69 P. Lundberg, M. V. Walter, M. I.Montañez, D. Hult, A. Hult, A. Nyström and M. Malkoch, Polym. 
Chem., 2011, 2, 394-402. 
70 Z. Wu, X. Zeng, Y. Zhang, N. Feliu, P. Lundberg, B. Fadeel, M. Malkoch and A. M. Nyström, J. 
Polym. Sci. Pol. Chem., 2012, 50, 217-226. 
71 C.-M. Dong and G. Liu, Polym. Chem., 2013, 4, 46–52. 
72 K. Leja and G. Lewandowicz, Polish J. Environ. Stud., 2010, 19, 255-266. 
73 A. Kowalski, A. Duda and S. Penczek, Macromol. Rapid Comm., 1998, 19, 567-72. 
74 M. Liu, N. Vladimirov and J. M. J. Fréchet, Macromolecules, 1999, 32, 6881-6884. 
75 M. Trollsås, B. Atthoff, H. Claesson and J. L. Hedrick, Macromolecules, 1998, 31, 3439-3445. 
76 M. Trollsås and J. L. Hedrick, Macromolecules, 1998, 31, 4390-4395. 
77 Y. Zheng, W. Turner, M. Zong, D. J. Irvine, S. M. Howdle and K. J. Thurecht, Macromolecules, 
2011, 44, 1347-1354. 
78 J. T. Wiltshire and G. G. Qiao, Macromolecules, 2006, 39, 9018-9027. 
79 B. I. Voit and A. Lederer, Chem. Rev., 2009, 109, 5924-5973. 
80 N. T. Nguyen, K. J. Thurecht, S. M. Howdle and D. J. Irvine, Polym. Chem., 2014, 5, 2997-3008. 
81 K. Sarkar and P. P. Kundu, Int. J. Biol. Macromol., 2012, 51, 859-867. 
82 S. P. Rannard and N. J. Davis, Org. Lett., 2000, 2, 2117-2120. 
83 T. M. Dhar, L. A. Borden, S. Tyagarajan, K. E. Smith, T. A. Branchek, R. L. Weinshank and C. 
Gluchowski, J. Med. Chem., 1994, 37, 2334-2342. 
84 N. J. van Natta, J. W. Hill and W. H. Carothers, J. Am. Chem. Soc., 1934, 56, 455-457. 
85 C. G. Pitt, M. M. Gratzi, A. R. Jeffcot, R. Zweidinger and A.Schindler, J. Pharm. Sci., 1979, 68, 
1534-1538. 
86 C. G. Pitt, T. A. Marks and A. Schindler, Biodegradable drug delivery systems based on aliphatic 
polyesters: application to contraceptives and narcotic antagonists, in: R. Baker (Ed.), Controlled 
Release of Bioactive Materials, Academic, New York, 1980, pp. 19–43. 
87 P. Calvo, J. L. Vila-Jato and M. J. Alonso, J. Pharm. Sci., 1996, 85, 530–536. 
88 G. Sosnowski, M. Gadzinowski and S. Slomkowski, Macromolecules, 1996, 29, 4556-4564. 
89 M. Gadzinowski, S. Sosnowski and S. Slomkowski, Macromolecules, 1996, 29, 6404-6407. 
90 P. Dubois, N. Ropson, R. Jerome and P. Teyessie, Macromolecules, 1996, 29, 1965-1975. 
91 M. Trollsås, J. L. Hedrick, D. Mecerreyes, P. Dubois, R. Jérôme, H. Ihre and A. Hult, 
Macromolecules, 1998, 31, 2756-2763. 
92 A. J. Nijenhuis, D. W. Grijpman and A. J. Pennings, Polymer, 1996, 37, 2783-2791. 
93 K. Kirschke, Ger. Patent 2122598 VEB Leuna-Werke Walter Ulbricht, 1972. 
CHAPTER 7 
295
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ???????????
94 M. Leroueil-Le Verger, L. Fluckiger, Y. I. Kim, M. Hoffman and P Maincent, Eur. J. Pharm. 
Biopharm., 1998, 46, 137-143. 
95 H. Ge, Y. Hu, X. Jiang, D. Cheng, Y. Yuan, H. Bi and C. Yang, J. Pharm. Sci., 2002, 91, 1463-
1473. 
96 C. G. Pitt, M. M. Gratzl, G. L. Kimmel, J. Surles and A. Sohindler, Biomaterials, 1981, 2, 215-220. 
97 C. G. Pitt, F. I. Chasalow, Y. M. Hibionada, D. M. Klimas and A. Schindler, J. Appl. Polym. Sci., 
1981, 26, 3779-3787. 
CHAPTER 8 
296
?
?
?
?
 
Chapter 8 
 
 
 
 
 
Conclusions and Future Work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 8 
297
8.1 Conclusions 
8.1.1 Hyp-polydendron synthesis 
 
The synthesis of amine-functionalised dendron atom transfer radical polymerisation 
(ATRP) initiators was achieved, with consequent controlled formation of linear-
dendritic polymer hybrids and hyp-polydendrons. The dendron-functional 
nanoprecipitates derived from 2-hydroxypropyl methacrylate p(HPMA50) and the co-
polymerisation of HPMA and ethylene glycol dimethacrylate p(HPMA50-co-EGDMAx) 
displayed behaviour that appeared to benefit from both the presence and generation of 
the dendron end groups and the branching of the methacrylate polymer chains. The 
linear-dendritic hybrids and hyp-polydendrons exhibited varying behaviour when 
nanoprecipitated into aqueous media, presumably from a different arrangement of 
dendrons and vinyl polymer segments within the nanoprecipitates. This appears to be 
directed predominantly by the branched polymer architecture and the chemical 
dissimilarity of the charged chain-ends and the uncharged and collapsed polymer chains. 
These differences also appeared to modify the ability of the nanoparticle (NP) surfaces 
to protonate and deprotonate. 
 
Synthetic exploration of this new polymeric material class was carried out, in order to 
demonstrate the chemical and architectural versatility available. The hyp-polydendron 
structure has been altered by variation of multiple components, including the monomer 
chemistry, hyp-polydendron primary chain architecture, surface functionality, the use of 
multiple initiators and the incorporation of a new pH-sensitive brancher. This ultimately 
led to a variety of new polymer architectures including linear-dendritic polymer hybrids 
and hyp-polydendrons derived from tertiary butyl methacrylate (tBuMA) or pH-
responsive 2-(diethylamino) ethyl methacrylate (DEA); statistically copolymers of DEA 
and either HPMA or tBuMA; diblock copolymers of DEA and tBuMA with varying 
overall primary polymer chain lengths; multiple dendron/non-dendron initiators 
incorporated into the same hyp-polydendron; variation within the dendron surface and 
linker chemistry; and the incorporation of a pH-responsive brancher. Synthetically, all 
polymerisations and co-polymerisations that were monitored proceeded via first order 
kinetics. The production of linear-dendritic materials resulted in mono-modal molecular 
weight distributions, and a much broader disperse polymer distribution was observed 
when a divinyl monomer was incorporated and a branched polymer was targeted. 
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Finally, new amine-functionalised ring-opening polymerisation (ROP) dendron initiators 
were synthesised, in order to produce new caprolactone-based (CL) linear-dendritic 
polymer hybrids and hyp-polydendrons with varying generation dendron chain ends. 
These studies were conducted as a proof-of concept to extend the hyp-polydendron 
concept to polyesters and produce biodegradable linear-dendritic polymers and hyp-
polydendrons. A more detailed study and optimisation of polymerisation conditions will 
be required to enhance polymerisation control and produce materials with higher 
molecular weights. Nevertheless, an AmG1’-initiated polyester hyp-polydendron 
exhibiting an Mw > 92,000 g mol-1 was recovered. The formation of linear-dendritic CL 
NPs was achieved via nanoprecipitation into acidic water and stable AmG1’-p(CL30-co-
BOD0.8) NPs were formed in neutral water following analysis by DLS and scanning 
electron microscopy. These introductory results are encouraging, particularly due to the 
Bn-p(CL30) and Bn-p(CL30-co-BOD1.0) undergoing observable macroscale precipitation 
upon introduction into any aqueous media. The hyp-polydendron structure, clearly offers 
benefits in terms of NP production, without the need for stabilisers. Additionally, a 
preliminary degradation study was carried out, suggesting degradation in 
physiologically-relevant media. 
 
8.1.2 Nanoparticle formation and behaviour 
 
Following the synthetic exploration into the chemical and architectural variables within 
hyp-polydendron structures, the ability of these materials to form stable nanoprecipitates 
in aqueous media was investigated. Generally, the hyp-polydendrons produced stable 
nanoprecipitates with narrow size distributions, compared to the linear-dendritic hybrids 
that typically resulted in broad and bimodal size distributions. The proposed explanation 
for this behaviour includes the rapid formation of large nuclei originating from the high 
molecular weight fraction of the hyp-polydendron collapsing to form larger particles that 
contain a significant number of conjoined chains, as opposed to the linear materials 
slowly producing nuclei from much smaller structures. The inability of the statistical and 
block hyp-polydendrons derived from DEA and tBuMA to form stable NPs in neutral 
water was overcome via manipulation of the primary polymer chain length, and the 
change of precipitation media to acidic water. The inclusion of DEA within the hyp-
polydendron allowed for the stable production of nanoprecipitates via protonation of the 
tertiary amines residing in the pendant polymer groups. The pH-responsive effects of the 
DEA-containing nanoprecipitates upon the addition of acid was studied, indicating the 
existence of soluble, hydrated polymers at low pH; confirmed by observable clear 
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solutions, and noticeable decreases in particle sizes and derived count rates (DCR) 
measured by dynamic light scattering (DLS). 
 
Acid hydrolysis of the brancher within 1,4-butanediol di(methacryoyloxy)-ethyl ether 
(BDME)-containing hyp-polydendron NP dispersions, derived from DEA and statistical 
copolymers of DEA and HPMA, resulted in complete degradation of the NPs and 
component hyp-polydendrons to linear-dendritic polymer chains as confirmed by gel 
permeation chromatography (GPC) analysis displaying mono-modal molecular weight 
distributions. The AmG2-p(DEA17-b-(tBuMA33-co-BDME2.0)) failed to solubilise upon 
the addition of acid, suggesting a NP packing that prevents acid entry into the core of the 
particle. Successful encapsulation of a model dye guest molecule was achieved within 
various pH-responsive hyp-polydendron NPs, and release studies revealed a more rapid 
release rate based on modifications within the hyp-polydendron i.e. upon incorporation 
of the acid-cleavable brancher. 
 
Following the stable NP formation from nanoprecipitation of hyp-polydendrons, the co-
nanoprecipitation concept was applied to produce stabilised NPs from linear-dendritic 
polymer hybrids and branched copolymers. Overall, the co-nanoprecipitated particles 
prepared with linear-dendritic polymers produced nanoprecipitates that were noticeably 
different compared to the nanoprecipitates prepared from similarly composed hyp-
polydendrons. The facile construction of NPs via co-nanoprecipitation produces a 
hydrophobic domain, with the opportunity to introduce specific characteristics and easily 
tailored surface functionality, to provide enhanced properties and stability. 
 
8.1.3 Pharmacological assessment 
?
A selection of the nanoprecipitated and co-nanoprecipitated NP dispersions were 
progressed to pharmacological testing. A range of pharmacological evaluations were 
conducted including; passage of NPs across a model gut epithelium, predicting the 
behaviour after oral administration, studying cellular uptake and measurement of 
cytotoxicity. These were carried out in order to evaluate the potential for drug delivery 
benefits. The pharmacological experiments were carried out by Dr. Lee Tatham and 
Prof. Andrew Owen in the Department of Molecular and Clinical Pharmacology at the 
University of Liverpool.  
 
The pharmacology results suggested negligible cytotoxicity within the cell lines tested 
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with an increase in transcellular permeability, without damage to the model gut 
epithelium monolayer, for NPs comprised of AmG1U-p(DEA50-co-EGDMA0.9) 
containing the model drug molecule, fluoresceinamine (FA). The increased 
accumulation of encapsulated FA compared to the aqueous FA in Caco-2 and ATHP-1 
cells could suggest uptake of the nano-carrier into primary lymphocytes and, 
consequently, macrophages. The NPs comprising AmG1U-p(DEA50-co-EGDMA0.9), 
which exhibited the most encouraging behaviour as orally administered NPs, were also 
used to encapsulate the anti-retroviral drug, Efavirenz (EFV) (cf. Section 8.2.1), 
demonstrating the potential for therapeutic drug loading. 
 
Overall, a variety of linear-dendritic polymer hybrids and hyp-polydendrons have been 
produced, demonstrating the versatility available within the modification of chemical 
and architectural components of this new macromolecular architecture. The ability to 
produce stable nanoprecipitates has been demonstrated to depend on a variety of these 
different chemical and architectural properties, allowing modification of these structural 
properties to encourage stable NP formation. The co-nanoprecipitation method has also 
been successfully applied to produce stable NPs from linear-dendritic hybrids and 
branched copolymers. The facile construction of NPs via co-nanoprecipitation provides 
the opportunity to introduce specific characteristics and easily tailored surface 
functionality. The encouraging pharmacology data presents opportunities for future 
development that may allow oral dosing leading to circulating polymeric NPs. This may 
prove clinically desirable to many non-terminal or chronic diseases that utilise 
nanomedicines, but wish to avoid regular or repeated intravenous administration. 
 
8.2 Future Work 
 
The hyp-polydendron structure and the co-nanoprecipitation concept has revealed some 
of the impact that manipulation of the chemical and structural components has on the 
ability to form NPs, and their subsequent behaviour. Future studies may include the 
incorporation of other methacrylate or styrenic monomers using ATRP, variation of 
surface functionality for cell targeting, multiple dendron surface functionality within 
single structures or subsequent dendron functionalisation following hyp-polydendron 
synthesis. 
 
Pharmacological testing described within the thesis was carried out on a small selection 
of hyp-polydendron NPs containing encapsulated FA. In vitro studies for other 
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nanoprecipitated particles would be useful to build a database of activity; particularly 
NPs comprised of BDME-containing hyp-polydendrons and co-nanoprecipitated 
particles. In particular, the comparison of hyp-polydendron NPs containing block 
copolymers of DEA and tBuMA (and EGDMA) that showed stability in neutral water 
(Chapter 4) and the co-nanoprecipitates of EBiB-p(tBuMA50-co-EGDMA0.95):AmG2-
p(DEA50) that have showed stability in buffered media (Table 8.1) would be ideal to 
study.  
 
Table 8.1 DLS analysis of co-nanoprecipitated 10:90 wt% AmG2-p(DEA50):EBiB-p(tBuMA50-co-
EGDMA0.95) 10:90 wt% before and after the addition of transport buffer solution. 
 pH=7.8a + TBS (aq.)b 
Polymer 
Dz 
(nm) 
PDI 
Dn 
(nm) 
Dz 
(nm) 
PDI 
Dn 
(nm) 
AmG2-p(DEA50):EBiB-p(tBuMA50-co-
EGDMA0.95) 
194 0.109 155 343 0.216 253 
a Initial pH, b TBS (aq.) (1 mL) added to 10 mL (1 mg mL-1) NP dispersion  
 
In addition, the EBiB-p(DEA50-co-EGDMA0.95):AmG2-p(DEA50) 90:10 wt% co-
nanoprecipitates would provide insight into the direct comparison of in vitro studies of 
covalently-bound DEA50-co-EGDMA0.9 hyp-polydendrons that have already exhibited 
encouraging behaviour as a potential drug delivery vehicle. Future studies for the 
AmG1U-p(DEA50-co-EGDMA0.9) containing encapsulated EFV should include assessing 
apparent permeability, cytotoxicity, accumulation, and nanocarrier efficacy against 
human immunodeficiency virus (HIV), compared to EFV in an aqueous vehicle. 
Furthermore, as anti-retroviral drugs are only taken as combinations, future studies 
would require the encapsulation of other multiple drug cocktails.1,2 
 
8.2.1 pH studies on linear-dendritic polymer hybrids and hyp-polydendrons 
containing DEA, tBuMA and EGDMA 
 
The pH-responsive behaviour of statistical and block copolymer linear-dendritic polymer 
hybrids comprising DEA and tBuMA and the corresponding hyp-polydendrons (Chapter 
3) that produced stable nanoprecipitates in acidic water, has been investigated. The NP 
behaviour, size and surface charge for these materials in acidic water has already been 
discussed in Chapter 4. 
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The stable NPs containing statistical HPMA and DEA containing hyp-polydendrons 
were observed to undergo full solubilisation upon the addition of significant amounts of 
acid, therefore the response of similar materials containing tBuMA and DEA was 
studied. In this case, the NPs prepared in aqueous HCl were subjected to a further 
(rapid) addition of HCl. Due to the neutralisation during initial NP formation in acid, the 
final pH of the original aqueous dispersions was measured to vary between pH = 5.9-
7.4. Addition of 1M HCl to dispersions generated from the linear-dendritic statistical 
copolymer hybrids led to a rapid switch of pH and a noticeable decrease in the number 
size distribution (Dn) values and measured DCR (Table 8.2), consistent with dissolution 
in all cases. 
 
Table 8.2 DLS analysis of acid addition on nanoprecipitated particles prepared from statistical and 
block DEA-tBuMA linear-dendritic polymer hybrids and hyp-polydendrons 
 pH of water 
 pH = 4.0a 
(Final pH = 5.9-7.4) 
+ 1M HCl 
(Final pH = 2.6-3.1) 
Polymer Dz 
(nm) 
PDI Dn 
(nm) 
DCR 
(kcps) 
Dz 
(nm) 
PDI Dn 
(nm) 
DCR 
(kcps) 
AmG2-p(DEA33-co-tBuMA17) 44 0.167 19 10200 53 0.388 2 100 
AmG2-p(DEA25-co-tBuMA25) 37 0.181 17 7000 273 0.428 3 110 
AmG2-p(DEA17-co-tBuMA33) 65 0.172 30 42300 15 0.563 3 270 
AmG2-p(DEA33-co-tBuMA17-
co-EGDMA0.9) 
51 0.222 18 17100 144 0.452 17 1100 
AmG2-p(DEA25-co-tBuMA25-
co-EGDMA0.9) 
134 0.284 33 79700 259 0.438 11 1500 
AmG2-p(DEA17-co-tBuMA33-
co-EGDMA0.9) 
129 0.222 62 90000 141 0.293 51 17100 
AmG2-p(DEA33-b-tBuMA17) 38 0.192 19 5900 65 0.573 5 220 
AmG2-p(DEA25-b-tBuMA25) 40 0.136 24 7400 123 0.204 4 190 
AmG2-p(DEA17-b-tBuMA33) 40 0.112 25 8200 47 0.113 29 9600 
AmG2-p(DEA33-b-(tBuMA17-
co-EGDMA0.9)) 
23 0.322 12 1800 34 0.125 21 2000 
AmG2-p(DEA25-b-(tBuMA25-
co-EGDMA0.9)) 
84 0.197 44 12700 155 0.354 77 3600 
AmG2-p(DEA17-b-(tBuMA33-
co-EGDMA0.9)) 
28 0.366 13 2200 37 0.314 15 4800 
a Initial pH 
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Figure 8.1 DLS size by intensity analysis of A) AmG2-p(DEA33-co-tBuMA17) and B) AmG2-
p(DEA17-co-tBuMA33-co-EGDMA0.9) before (green) and after (red-dotted) acid addition; C) AmG2-
p(DEA25-co-tBuMA25) and D) AmG2-p(DEA25-co-tBuMA25-co-EGDMA0.9) before (orange) and after 
(red-dotted) acid addition; E) AmG2-p(DEA33-co-tBuMA17) and F) AmG2-p(DEA33-co-tBuMA17-co-
EGDMA0.9) before (red) and after (red-dotted) acid addition. 
All linear-dendritic polymer hybrids exhibited Dn values representative of fully solvated, 
individual linear polymer chains at this low pH. The hyp-polydendrons did not fully 
solubilise, particularly the AmG2-p(DEA17-co-tBuMA33-co-EGDMA0.9), where the Dz 
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and Dn values remained relatively high, although the PDI and the Dz did increase for two 
of the materials with higher DEA content. This is relatively surprising as all linear-
dendritic hybrids dissolved under these conditions. AmG2-p(DEA17-co-tBuMA33-co-
EGDMA0.9) contained the greatest hydrophobic monomer content, which may prevent 
complete solubilisation at low pH. Alternatively, this could imply a hyp-polydendron 
arrangement during nanoprecipitation and aggregation, with a compact assembly of 
branched material that prevents acid access to the pH-responsive primary chains within 
the main bulk of the nanoprecipitate (Figure 8.1). 
 
The linear-dendritic block copolymer hybrid and block copolymer hyp-polydendron 
nanoprecipitates prepared in aqueous HCl, where studied in similar experiments to those 
used to evaluate the statistical copolymer architectures; namely rapid addition of acid to 
the aqueous NP dispersions initially produced in acid environments (Table 8.2). After 
the pH change, the NP dispersions prepared from the AmG2-p(DEA33-b-tBuMA17) and 
AmG2-p(DEA25-b-tBuMA25) linear-dendritic block copolymer hybrids ceased to exist as 
stabilised nanoprecipitates, becoming solvated chains at low pH as confirmed by the 
dramatic decrease in DCR and reduction in Dn values (5 and 4 nm respectively) (Table 
8.2); the AmG2-p(DEA33-b-tBuMA17) and AmG2-p(DEA25-b-tBuMA25) linear-dendritic 
polymer hybrids contain the highest DEA content. The other linear-dendritic polymer, 
AmG2-p(DEA17-b-tBuMA33), was stable even at such a low pH. A limited swelling was 
seen, accounting for the small increase in Dz and Dn values, and corresponding increase 
in DCR, presumably due to additional polymer/dendron protonation occurring at the NP 
surface (Figure 8.2).  
 
The AmG2-p(DEA33-b-(tBuMA17-co-EGDMA0.9)) and AmG2-p(DEA17-b-(tBuMA33-co-
EGDMA0.9)) hyp-polydendrons initially nanoprecipitated into aqueous media at pH = 4, 
generated bimodal NP distributions measured by DLS. Following acid addition, these 
distributions coalesced into single NP populations (Figure 8.2B and F) and no obvious 
dissolution was seen. 
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Figure 8.2 DLS size by intensity analysis of A) AmG2-p(DEA33-b-tBuMA17) and B) AmG2-
p(DEA17-b-(tBuMA33-co-EGDMA0.9)) before (green) and after (red-dotted) acid addition; C) AmG2-
p(DEA25-b-tBuMA25) and D) AmG2-p(DEA25-b-(tBuMA25-co-EGDMA0.9)) before (orange) and after 
(red-dotted) acid addition; E) AmG2-p(DEA33-b-tBuMA17) and F) AmG2-p(DEA33-b-(tBuMA17-co-
EGDMA0.9)) before (red) and after (red-dotted) acid addition. 
 
As mentioned above, the hyp-polydendron nanoprecipitates failed to fully solubilise 
under the very low pH conditions. The AmG2-p(DEA33-b-(tBuMA17-co-EGDMA0.9)) 
increased in Dn and DCR values, potentially as the increased levels of protonation led to 
solvated polymer chains extending from the NP surface. The AmG2-p(DEA25-b-
(tBuMA25-co-EGDMA0.9)) DCR values decreased significantly, resembling a value 
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more similar to the other block hyp-polydendron nanoprecipitates. The AmG2-p(DEA17-
b-(tBuMA33-co-EGDMA0.9)) also increased in Dn and DCR values, suggesting a lack of 
solubilisation, potentially requiring further aggregation in order to maintain a stabilised 
NP dispersion. These observations suggest collapsed and closely packed polymeric 
nanoprecipitates that prevent acid penetration into the main bulk of the NP. This 
behaviour was also observed for the AmG2-p(DEA17-co-tBuMA33-co-EGDMA0.9) 
nanoprecipitates, where the high content of hydrophobic tBuMA led to a lack of 
solubilisation. 
 
Further investigations could include increasing the primary polymer chain length across 
the range of these materials, in attempts to produce stable NPs in neutral water. This has 
initially been demonstrated for the AmG2-p(DEA50-co-(tBuMA65-b-EGDMA0.9)), which 
not only formed stable NPs, but retained stability in transport buffering vehicle media 
(Chapter 6). 
 
8.2.2 Preliminary co-nanoprecipitation studies of linear-dendritic CL polymer 
hybrids of varying DPn with Bn-p(CL30-co-BOD1.0) 
 
The co-nanoprecipitation method has produced a variety of stabilised NPs from a range 
of differently-composed linear and branched polymers at 10:90 wt%. All the linear-
dendritic polymers p(HPMA50), p(DEA50) and p(tBuMA50) and branched copolymers, 
p(HPMA50-co-EGDMA0.95), p(DEA50-co-EGDMA0.95) and p(tBuMA50-co-EGDMA0.95) 
prepared by ATRP contained targeted number average degrees of polymerisation (DPn) 
= 50 monomer units. The co-nanoprecipitation process could be extended to include 
linear-dendritic hybrids of varying DPn. This was preliminarily studied using linear-
dendritic CL polymer hybrids of DPn = 20, 30 and 50 monomer units: AmG0’-p(CL20), 
AmG0’-p(CL30), AmG0’-p(CL50), AmG1’-p(CL20), AmG1’-p(CL30), AmG1’-p(CL50), 
AmG2’-p(CL20), AmG2’-p(CL30) and AmG2’-p(CL50). Co-nanoprecipitation was 
conducted with Bn-p(CL30-co-BOD1.0) previously synthesised in Chapter 7.  
 
All materials were dissolved in tetrahydrofuran (THF) at a concentration of 5 mg mL-1. 
The linear-dendritic polymer solution (0.2 mL, 1 mg polymer) was combined with the 
Bn-p(CL30-co-BOD1.0) polymer solution (1.8 mL, 9 mg polymer) prior to co-
nanoprecipitation into acidic (pH=4) and neutral (pH=7.8) water (10 mL) to produce a 
final NP dispersion with a concentration of 1 mg mL-1 following THF evaporation 
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overnight and subsequent analysis by DLS. 
 
Figure 8.3 Diagrammatic representation of AmG0’-p(CL20), AmG0’-p(CL30), AmG0’-p(CL50), 
AmG1’-p(CL20), AmG1’-p(CL30), AmG1’-p(CL50), AmG2’-p(CL20), AmG2’-p(CL30) and AmG2’-
p(CL50).
 
The AmG0’-initiated linear-dendritic polymers produced stable NPs, exhibiting a 
decreasing Dz value as the polymer chain length increases. The AmG0’-p(CL20) 
produced NPs with the broadest size distribution (Table 8.3), suggesting a reduced level 
of controlled NP aggregation with the polymer containing the lowest DPn. This could be 
due to the longer polymer chains aggregating less to achieve stabilisation. The AmG1’-
initiated polymers all produced NPs of similar sizes, with the DP50 linear-dendritic 
hybrid displaying an increased level of controlled assembly suggested by the narrowest 
PDI (0.148). Across the co-nanoprecipitation of the DP20 series of linear-dendritic CL 
NPs, a decreasing NP diameter with narrower size distributions are witnessed as the size 
of the dendron chain end decreases (Figure 8.4). Contrastingly, the co-nanoprecipitated 
particles prepared using the DP50 linear-dendritic hybrids (AmG0’-p(CL50) and AmG1’-
p(CL50)) showed increasing sizes with narrowing polydispersities as the dendron size 
increases; the AmG2’-p(CL50) failed to produce stabilised nanoprecipitates. 
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Table 8.3 DLS analysis of nanoprecipitated linear and linear-dendritic CL polymer hybrids and co-
nanoprecipitated linear-dendritic CL polymer hybrids with Bn-p(CL30-co-BOD1.0) 10:90 wt% linear-
dendritic hybrid:branched copolymer. 
  pH=7.8a pH=4.0a 
 
Polymer 
Dz 
(nm) 
PDI 
ζ 
(mV) 
Dz 
(nm) 
PDI 
ζ 
(mV) 
 Bn-p(CL30) - - - - - - 
 AmG0’-p(CL20) - - - 133 0.307 +48 
 AmG0’-p(CL30) - - - 123 0.140 +84 
 AmG0’-p(CL50) - - - 97 0.184 +51 
 AmG1’-p(CL20) - - - 121 0.241 +68 
 AmG1’-p(CL30) - - - 130 0.259 +66 
 AmG1’-p(CL50) - - - 122 0.148 +62 
 AmG2’- p(CL20) - - - 37 0.301 +27 
 AmG2’- p(CL30) - - - 36 0.260 +20 
 AmG2’- p(CL50) - - - - - - 
Bn-p(CL30-co-BOD1.0) 
AmG0’-p(CL20) - - - 181 0.155 +81 
AmG0’-p(CL30) - - - 160 0.126 +42 
AmG0’-p(CL50) - - - 141 0.138 +35 
AmG1’-p(CL20) - - - 177 0.167 +69 
AmG1’-p(CL30) - - - 169 0.149 +51 
AmG1’-p(CL50) - - - 137 0.127 +40 
AmG2’- p(CL20) - - - 235 0.212 +82 
AmG2’- p(CL30) - - - 217 0.173 +71 
AmG2’- p(CL50) - - - 192 0.148 +79 
a Initial pH of water 
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Figure 8.4 DLS size distribution analysis of co-nanoprecipitated Bn-p(CL30-co-BOD1.0) with A) 
AmG0’-p(CL20) (yellow), AmG0’-p(CL30) (orange), AmG0’-p(CL50) (brown); B) AmG1’-p(CL20) 
(yellow), AmG1’-p(CL30) (orange), AmG1’-p(CL50) (brown); and C) AmG2’-p(CL20) (yellow), 
AmG2’-p(CL30) (orange), AmG2’-p(CL50) (brown) prepared in acidic water at a concentration of 1 
mg mL-1 at a ratio of 10:90 wt% linear-dendritic hybrid:branched copolymer. 
 
Further studies involving CL NPs could include the co-nanoprecipitation of linear-
dendritic polymers of varying DPn with branched copolymers of varying DPn; and the 
stability of these biodegradable NPs in a physiologically-relevant media. The 
degradation of these materials could be investigated further to include the degradation of 
co-nanoprecipitated particles compared to the degradation rates when the polymers are 
covalently-bound. Furthermore, investigations of the clearance and interaction within the 
body of the hydrolysed products for these materials, and for the pH-responsive materials 
could be studied. 
 
8.2.3 Synthesis and applications of CL copolymers 
 
The composition and architecture of polyesters has been explored in various literature 
reports to include a range of statistical and block co-polyesters in the hopes of improved 
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mechanical properties, degradability and hydrophilicity. Copolymers of CL include the 
production of macroinitiators via ROP, followed by polymerisation techniques such as 
reversible-addition fragmentation chain transfer3 and ATRP. The latter has been 
successfully reported with the synthesis of A-B-A triblock copolymers with pH-
responsive di(methylamino)ethyl methacrylate A blocks polymerised from a 
bifunctional p(CL) macroinitiator.4 A range of selectively degradable core cross-linked 
star polymers has been reported5 via a two-step process, where the linear polymers are 
able to further polymerise due to their active terminal functionality. These are capable of 
initiating polymerisation of monofunctional and bifunctional monomers in such a way 
that the active linear polymers are coupled together, forming a star-shaped polymer held 
together by the branched polymer core. In this particular instance, the core cross-linked 
polymers were designed so that either the arm or the core was degradable, allowing for 
polymers with a selective target degradation profile, either by initial linear ROP and 
subsequent ATRP or initial linear ATRP and subsequent ROP. 
 
These strategies could be utilised to produce linear-dendritic CL polymer arms, 
following by conversion of the hydroxyl chain end of the polyester into an ATRP 
initiator by a facile esterification reaction. This macroinitiator could then be used to 
initiate DEA or DEA and EGDMA to produce block hyp-polydendrons composed of 
biodegradable and pH-responsive polymers (Figure 8.5). 
 
Figure 8.5 Diagrammatic representation of the proposed ROP of CL using a dendron initiator, 
followed by the ATRP of DEA/DEA and EGDMA using the CL macroinitiator. 
 
8.2.4 Preliminary studies of thermo-responsive hyp-polydendrons 
 
The range of methacrylic and styrenic monomers on offer for utilisation in ATRP is 
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vast, and, as already demonstrated, the hyp-polydendron structure has included HPMA, 
DEA and tBuMA within the polymer core. The polymerisation of oligo ethylene glycol 
methyl ether methacrylate (OEG) provides opportunity for the production of a thermo-
responsive hyp-polydendron. Thermo-responsive polymers are considered as one of the 
most widely utilised stimuli-responsive polymers, as they are easy to apply both in vitro
and in vivo.6,7,8,9,10,11 The EBiB and AmG1U-Br ATRP initiators were used to co-
polymerise OEG and EGDMA (Figure 8.6) at 20°C in isopropanol using CuCl/bpy as 
the catalyst system in the molar ratio [Initiator]:[M]:[CuCl]:[bpy]=1:50:1:2. Both 
polymers were purified by passing through a basic alumina column to remove the 
catalytic system, followed by precipitation from THF into cold hexane before analysis 
by GPC (Table 8.4). 
 
 
 
Figure 8.6 Diagrammatic representation of the co-polymerisation of OEG and EGDMA initiated by 
EBiB and AmG1U dendron ATRP initiators. 
 
 
 
 
 
 
 
CHAPTER 8 
312
Table 8.4 GPC analysis of p(OEG50-co-EGDMAx) branched copolymer and hyp-polydendron. 
 GPCa 
Polymer Mn  
(g mol-1) 
Mw  
(g mol-1) 
Đ 
EBiB-p(OEG50-co-EGDMA0.95) 33600 170800 5.09 
AmG1U-p(OEG50-co-EGDMA0.9) 82940 208650 2.52 
a Triple detection using THF/TEA (2% v/v) eluent 
 
A high molecular weight branched copolymer, EBiB-p(OEG50-co-EGDMA0.95) and hyp-
polydendron AmG1U-p(OEG50-co-EGDMA0.9) were successfully collected containing 
broad size distributions typical of branched polymers, with Mw values of 170,800 and 
208,650 g mol-1 respectively. 
 
The EBiB-p(OEG50-co-EGDMA0.95) and AmG1U-p(OEG50-co-EGDMA0.9) were 
dissolved in THF at 5 mg mL-1 and nanoprecipitated into neutral water (pH=7.8) to 
produce an end concentration of 1 mg mL-1 after evaporation of THF overnight. Both 
branched polymers existed as solubilised objects in aqueous media, confirmed by the 
very low Dn values and low derived count rates (Table 8.5). Upon heating to 70°C, large 
stabilised nanoprecipitate aggregations formed with narrow size distributions (Table 8.4 
and Figure 8.7).  
 
Table 8.5 DLS analysis of p(OEG50-co-EGDMAx) branched copolymer and hyp-polydendron in 
different temperature conditions in neutral water (pH=7.8). 
 Temperature 
 25°C 70°C 
Polymer 
Dz 
(nm) 
PDI 
Dn 
(nm) 
DCR 
(kcps) 
Dz 
(nm) 
PDI 
Dn 
(nm) 
DCR 
(kcps) 
EBiB-p(OEG50-co-EGDMA0.95) 19 0.368 6 794 625 0.113 564 634790 
AmG1U-p(OEG50-co-EGDMA0.9) 50 0.512 9 2150 222 0.119 193 451460 
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Figure 8.7 DLS size by intensity analysis of p(OEG50-co-EGDMAx). A) EBiB-p(OEG50-co-
EGDMA0.95) at 25°C (blue) and 70°C (red); B) AmG1U-p(OEG50-co-EGDMA0.9) at 25°C (blue) and 
70°C (red). 
 
The volume phase transition occurs because of competing hydrogen-bonding properties 
depending on whether the intra- and intermolecular hydrogen bonding within the 
polymer is more favourable than the water-polymer interaction. The solubility in water 
arises when the interactions between the water and polymer are preferred. Once again, a 
difference in NP size is witnessed between the branched copolymer and hyp-
polydendron, establishing different NP behaviour as a consequence of the surface 
functionality; the AmG1U-p(OEG50-co-EGDMA0.9) produced smaller NPs, suggesting 
less aggregation is required to achieve stabilisation. 
 
Further work could include the co-polymerisation of DEA and OEG to produce a series 
of dual-responsive hyp-polydendrons (Figure 8.8), for NP behaviour in different pH and 
temperatures. Equally, the co-nanoprecipitation of AmG2-p(DEA50):EBiB-p(OEG50-co-
EGDMA0.95) could be conducted. 
 
Figure 8.8 Proposed diagrammatic representation of dual-responsive hyp-polydendrons containing 
varying amounts of OEG and DEA. 
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8.3 Experimental 
 
Typical synthesis of branched copolymer and hyperbranched polydendron utilising 
the co-polymerisation of OEG and EGDMA, (EBiB- and AmG1U-p(OEG50-co-
EGDMAx)) – In a typical synthesis, targeting a DPn = 50 monomer units (p(OEG50-co-
EGDMA0.9)), bpy (83.3 mg, 0.5333 mmol, 2 eq.), OEG (4 g, 13.3 mmol, 50 eq.), 
EGDMA (47.6 mg, 0.2401 mmol, 0.9 eq.) and IPA/H2O (33.3% v/v based on OEG) 
were placed into a 25 mL round-bottomed flask. The solution was stirred and 
deoxygenated using a N2 purge for 15 minutes. Cu(I)Cl (26.4 mg, 0.2667 mmol, 1 eq.) 
was added to the flask and left to purge for a further 5 minutes. AmG1U-Br (0.1590 g, 
0.2667 mmol, 1 eq.) was added to the flask under a positive flow of N2 and the solution 
was left to polymerise at 20°C. Reactions were terminated when >99 % conversion was 
reached, as judged by 1H nuclear magnetic resonance spectroscopy, by exposure to 
oxygen and addition of THF. The catalyst residues were removed by passing the mixture 
over a basic alumina column. THF was removed under vacuum to concentrate the 
sample before precipitation into cold hexane.  
?
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Chapter 2 – Synthesis and nanoprecipitation studies of 2-
hydroxypropyl methacrylate linear-dendritic polymer hybrids and 
hyperbranched polydendrons 
?
Figure A1 1H NMR (CDCl3, 400 MHz) spectrum of [tBOC2-BAPA-G1] 
?
Figure A2 13C NMR (CDCl3, 100 MHz) spectrum of [tBOC2-BAPA-G1] 
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?
?
Figure A3 ES-MS of [tBOC2-BAPA-G1] 
?
?
Figure A4 1H NMR (CDCl3, 400 MHz) spectrum of [tBOC2-BAPA-OH] 
?
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Figure A5 13C NMR (CDCl3, 100 MHz) spectrum of [tBOC2-BAPA-OH] 
?
?
?
Figure A6 ES-MS of [tBOC2-BAPA-OH] 
?
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Figure A7 13C NMR (CDCl3, 100 MHz) spectrum of APAP 
?
?
Figure A8 ES-MS of APAP 
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?
Figure A9 13C NMR (CDCl3, 100 MHz) spectrum of AmG1-OH 
?
Figure A10 ES-MS of AmG1-OH 
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?
Figure A11 13C NMR (CDCl3, 100 MHz) spectrum of AmG2-OH 
?
?
Figure A12 ES-MS of AmG2-OH 
?
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?
Figure A13 13C NMR (CDCl3, 100 MHz) spectrum of AmG0-Br 
?
?
Figure A14 ES-MS of AmG0-Br?
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Figure A15 13C NMR (CDCl3, 100 MHz) spectrum of AmG1-Br 
 
?
Figure A16 13C NMR (CDCl3, 100 MHz) spectrum of AmG2-Br 
?
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Figure A17 ES-MS of AmG1-Br 
?
?
?
Figure A18 ES-MS of AmG2-Br 
?
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?
Figure A19 1H NMR (MeOD, 400 MHz) spectrum of EBiB-p(HPMA50). 
 
?
Figure A20 1H NMR (MeOD, 400 MHz) spectrum of AmG0-p(HPMA50). 
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?
Figure A21 1H NMR (DMSO, 400 MHz) spectrum of AmG1-p(HPMA50).?
 
 
Figure A22 1H NMR (MeOD, 400 MHz) spectrum of EBiB-p(HPMA50-co-EGDMA0.95). 
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?
Figure A23 1H NMR (MeOD, 400 MHz) spectrum of AmG0-p(HPMA50-co-EGDMA0.9). 
 
?
Figure A24 1H NMR (MeOD, 400 MHz) spectrum of AmG1-p(HPMA50-co-EGDMA0.9). 
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?
Figure A25 AmG2-p(HPMA50) aggregated in water (pH=2) 
?
Chapter 3 – Linear polymer, linear-dendritic polymer hybrid, 
branched copolymer and hyp-polydendron synthesis 
 
 
Figure A26 1H NMR (MeOD, 400 MHz) spectrum of EBiB-p(DEA50). 
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Figure A27 1H NMR (MeOD, 400 MHz) spectrum of AmG0-p(DEA50). 
 
 
Figure A28 1H NMR (MeOD, 400 MHz) spectrum of AmG1-p(DEA50). 
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Table A1 Average dn/dc values of p(DEA50) linear/linear-dendritic polymers and p(DEA50-co-
EGDMAx) copolymer/hyp-polydendrons 
 
Target polymer dn/dca 
EBiB-p(DEA50) 0.0705 
AmG0-p(DEA50) 0.0812 
AmG1-p(DEA50) 0.0710 
AmG2-p(DEA50) 0.0713 
AmG1U-p(DEA50) 0.0897 
a THF eluent containing 2% TEA (v/v) 
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Figure A29 Kinetic plots for branched DP50 polymers. A) and B) EBiB-p(DEA50-co-
EGDMA0.95), C) and D) AmG1-p(DEA50-co-EGDMA0.9), E) and F) AmG2-p(DEA50-co-
EGDMA0.9). A, C and E) Conversion (blue squares), ln([M]0/[M]) (red circles); B, D and F) Mn 
(red circles) and Ð (blue lines), Mw (black diamonds). 
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Figure A30 Kinetic plots for linear EBiB-p(DEA50). A) Conversion (blue squares), ln([M]0/[M]) 
(red circles); B) Mn (red circles) and Ð (blue lines). 
 
 
 
Figure A31 1H NMR (MeOD, 400 MHz) spectrum of EBiB-p(DEA50-co-EGDMA0.95). 
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Figure A32 1H NMR (MeOD, 400 MHz) spectrum of AmG0-p(DEA50-co-EGDMA0.9). 
 
 
Figure A33 1H NMR (MeOD, 400 MHz) spectrum of AmG1-p(DEA50-co-EGDMA0.9). 
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Figure A34 1H NMR (MeOD, 400 MHz) spectrum of EBiB-p(tBuMA50). 
 
 
Figure A35 1H NMR (MeOD, 400 MHz) spectrum of EBiB-p(tBuMA50-co-EGDMA0.95). 
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Figure A36 Kinetic plots for linear EBiB-p(tBuMA50) and branched EBiB-p(tBuMA50-co-
EGDMA0.95). A and C) Conversion (blue squares), ln([M]0/[M]) (red circles); B and D) Mn (red 
circles) and Ð (blue lines), Mw (black diamonds). 
Table A2 Average dn/dc values of EBiB and amine-functionalised tBuMA linear polymer, linear-
dendritic polymer hybrid, branched co-polymer and hyp-polydendron. 
Target polymer dn/dca 
EBiB-p(tBuMA50) 0.0589 
AmG2-p(tBuMA50) 0.0708 
EBiB-p(tBuMA50-co-EGDMA0.95) 0.0541 
AmG2-p(tBuMA50-co-EGDMA0.9) 0.0568 
a THF eluent containing 2% TEA (v/v) 
?
?
APPENDIX 
336
?
Figure A37 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA25-co-HPMA25). 
 
 
Figure A38 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA17-co-HPMA33). 
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Figure A39 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA33-co-HPMA17-co-
EGDMA0.9). 
 
Figure A40 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA17-co-HPMA33-co-
EGDMA0.9). 
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Figure A41 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA33-co-tBuMA17). 
 
 
Figure A42 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA25-co-tBuMA25). 
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Figure A43 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA25-co-tBuMA25-co-
EGDMA0.9). 
 
 
Figure A44 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA17-co-tBuMA33-co-
EGDMA0.9). 
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Figure A45 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA33-b-tBuMA17). 
 
Figure A46 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA17-b-tBuMA33). 
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Figure A47 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA33-b-(tBuMA17-co-
EGDMA0.9)). 
 
Figure A48 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA17-b-(tBuMA33-co-
EGDMA0.9)). 
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Figure A49 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA50-b-(tBuMA65-co-
EGDMA0.9)). 
?
?
Figure A50 13C NMR (CDCl3, 100 MHz) spectrum of AmG1U-OH 
?
?
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?
Figure A51 ES-MS of AmG1U-OH 
?
?
Figure A52 13C NMR (CDCl3, 100 MHz) spectrum of AmG1U-Br 
?
?
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?
Figure A53 ES-MS of AmG1U-Br 
?
?
?
Figure A54 13C NMR (CDCl3, 100 MHz) spectrum of BnG2-OH 
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?
Figure A55 ES-MS of BnG2-OH 
?
?
Figure A56 13C NMR (CDCl3, 100 MHz) spectrum of BnG2-Br 
?
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?
Figure A57 ES-MS of BnG2-Br 
 
 
 
Figure A58 1H NMR spectrum (MeOD, 400 MHz) of AmG1U-p(DEA50). 
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Figure A59 1H NMR spectrum (MeOD, 400 MHz) of AmG1U-p(DEA50-co-EGDMA0.9). 
 
 
 
Figure A60 1H NMR (MeOD, 400 MHz) spectrum of EBiB0.9-(AmG2)0.1-p(tBuMA50-co-
EGDMA0.95).
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Figure A61 13C NMR (CDCl3, 100 MHz) spectrum of BDME. 
 
Figure A62 ES-MS of BDME 
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Figure A63 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA33-co-HPMA17-co-
BDME2.0). 
Figure A64 1H NMR spectrum (MeOD, 400 MHz) of AmG2-p(DEA17-b-(tBuMA33-co-
BDME2.0)) 
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Chapter 4 – Nanoprecipitation and pH studies of linear polymers, 
linear-dendritic hybrids, branched copolymers, terpolymers and hyp-
polydendrons 
 
?
Figure A65 Calibration curve for FA in acidic water. 
?
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Chapter 7 – Synthesis and nanoprecipitation studies of 
biodegradable linear-dendritic ε-caprolactone polymer hybrids and 
hyp-polydendrons 
?
?
?
Figure A66 1H NMR (CDCl3, 400 MHz) spectrum of [tBOC2-BAPA-OH’] 
?
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Figure A67 13C NMR (CDCl3, 100 MHz) spectrum of [tBOC2-BAPA-OH’] 
?
?
?
Figure A68 ES-MS of [tBOC2-BAPA-OH’]?
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?
Figure A69 13C NMR (CDCl3, 100 MHz) spectrum of APAP’ 
?
?
Figure A70 ES-MS of APAP’ 
?
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Figure A71 13C NMR (CDCl3, 100 MHz) spectrum of AmG1’-OH. 
 
 
 
Figure A72 ES-MS of AmG1’-OH 
?
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?
Figure A73 13C NMR (CDCl3, 100 MHz) spectrum of AmG2’-OH 
?
?
?
Figure A74 ES-MS of AmG2’-OH 
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Figure A75 GPC RI chromatogram overlays of Bn-p(CL30) polymerised in 24 hours (black) and using 
[1/200] molar ratio of Sn(Oct2) (brown).?
 
Table A3 Dn/dc values of p(CL30) linear/linear-dendritic polymers. 
Target polymer dn/dca 
Bn-p(CL30) 0.0825 
AmG0’-p(CL30) 0.0776 
AmG1’-p(CL30) 0.0798 
AmG2’-p(CL30) 0.0711 
a THF eluent containing 2% TEA (v/v) 
 
?
Figure A76 ES-MS of BOD 
?
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?
Figure A77 13C NMR (CDCl3, 400 MHz) spectrum of BOD 
